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Background: The quality of care for people with dementia in care homes is of concern. Interventions that
can improve care outcomes are required.
Objective: To investigate the clinical effectiveness and cost-effectiveness of Dementia Care Mapping™
(DCM) for reducing agitation and improving care outcomes for people living with dementia in care homes,
versus usual care.
Design: A pragmatic, cluster randomised controlled trial with an open-cohort design, follow-up at 6 and
16 months, integrated cost-effectiveness analysis and process evaluation. Clusters were not blinded to
allocation. The primary end point was completed by staff proxy and independent assessors.
Setting: Stratified randomisation of 50 care homes to the intervention and control groups on a 3 : 2 ratio
by type, size, staff exposure to dementia training and recruiting hub.
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Participants: Fifty care homes were randomised (intervention, n = 31; control, n = 19), with 726 residents
recruited at baseline and a further 261 recruited after 16 months. Care homes were eligible if they recruited
a minimum of 10 residents, were not subject to improvement notices, had not used DCM in the previous
18 months and were not participating in conflicting research. Residents were eligible if they lived there
permanently, had a formal diagnosis of dementia or a score of 4+ on the Functional Assessment Staging
Test of Alzheimer’s Disease, were proficient in English and were not terminally ill or permanently cared for
in bed. All homes were audited on the delivery of dementia and person-centred care awareness training.
Those not reaching a minimum standard were provided training ahead of randomisation. Eighteen homes
took part in the process evaluation.
Intervention: Two staff members from each intervention home were trained to use DCM and were asked
to carry out three DCM cycles; the first was supported by an external expert.
Main outcome measures: The primary outcome was agitation (Cohen-Mansfield Agitation Inventory),
measured at 16 months. Secondary outcomes included resident behaviours and quality of life.
Results: There were 675 residents in the final analysis (intervention, n = 388; control, n = 287). There was no
evidence of a difference in agitation levels between the treatment arms. The adjusted mean difference in
Cohen-Mansfield Agitation Inventory score was –2.11 points, being lower in the intervention group than in
the control (95% confidence interval –4.66 to 0.44; p = 0.104; adjusted intracluster correlation coefficient:
control = 0, intervention = 0.001). The sensitivity analyses results supported the primary analysis. No differences
were detected in any of the secondary outcomes. The health economic analyses indicated that DCM was not
cost-effective. Intervention adherence was problematic; only 26% of homes completed more than their first
DCM cycle. Impacts, barriers to and facilitators of DCM implementation were identified.
Limitations: The primary completion of resident outcomes was by staff proxy, owing to self-report
difficulties for residents with advanced dementia. Clusters were not blinded to allocation, although
supportive analyses suggested that any reporting bias was not clinically important.
Conclusions: There was no benefit of DCM over control for any outcomes. The implementation of DCM
by care home staff was suboptimal compared with the protocol in the majority of homes.
Future work: Alternative models of DCM implementation should be considered that do not rely solely on
leadership by care home staff.
Trial registration: Current Controlled Trials ISRCTN82288852.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 16.
See the NIHR Journals Library website for further project information.
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Glossary
Agency staff Temporary staff who are provided by an external organisation (an agency) to cover staff
shortages/absences when these cannot be met by the care home’s own staff pool.
Bank staff A pool of staff employed by the care home on non-substantive contracts and who are drawn
on when the care home is unable to cover absences or shortages with staff who have contracted hours.
DCM expert mapper An experienced user of DCM appointed by the trial to support trial mappers in
completing cycle 1 of DCM in each intervention home.
DCM intervention lead A member of the trial team who is responsible for oversight and leadership of
DCM implementation across the intervention care homes and co-ordination of the DCM expert mappers.
Independent researcher A member of the research team who is independent of the care home by virtue
of not having previously collected any outcomes data there.
Mapper A member of care home staff trained to use DCM.
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Awareness and Person-Centred
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BPSD behavioural and psychological
symptoms of dementia
BSC behaviours that staff may find
challenging to support
CACE complier-average causal effect
CCA complete-case analysis
CDR Clinical Dementia Rating
CEAC cost-effectiveness acceptability
curve
CI confidence interval
CMAI Cohen-Mansfield Agitation
Inventory
CMAI-O Cohen-Mansfield Agitation
Inventory Observational
CONSORT Consolidated Standards of
Reporting Trials
CQC Care Quality Commission
CRF case report form
CTRU Clinical Trials Research Unit
DCM™ Dementia Care Mapping
DEMQOL Dementia Quality of Life
DEMQOL-proxy Dementia Quality of Life –
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EAT Environmental Audit Tool
EPIC Enhancing Person-centred
care In Care homes
EQ-5D-5L EuroQol-5 Dimensions,
five-level version
EQ-5D-5L-proxy EuroQol-5 Dimensions, five-level
version, proxy version
FAST Functional Assessment Staging
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FITS focused intervention for
training staff
GEE generalised estimating
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GHQ-12 General Health Questionnaire-12
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GP general practitioner
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LAG Lay Advisory Group
MAR missing at random
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MI multiple imputation
MICE multiple imputations by chained
equations
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NICE National Institute for Health
and Care Excellence
NMB net monetary benefit
NPI Neuropsychiatric Inventory
NPI-NH Neuropsychiatric Inventory –
nursing home version
PAS Pittsburgh Agitation Scale
PCCT person-centred care training
PPI patient and public involvement
PRN pro re nata (as required)
PSSRU Personal Social Services
Research Unit
QALY quality-adjusted life-year
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
xxi
QoL quality of life
QOL-AD Quality of Life in Alzheimer’s
Disease
QUALID Quality of Life in Late-Stage
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Plain English summary
Agitation is common in care home residents and may result from care that does not meet individualneeds. Dementia Care Mapping™ (DCM) is a tool used within care homes to improve the delivery of
person-centred care, which may help reduce agitation. This randomised controlled trial aimed to understand
whether or not DCM is better than usual care at reducing resident agitation, behaviours that staff may find
difficult to support and the use of antipsychotic medicines, as well as at improving residents’ quality of life
and staff communication. It also assessed its value for money.
We recruited 726 residents with dementia from 50 care homes. After initial data collection, care homes
were randomly assigned to DCM (31/50) or told to continue with usual care (19/50) and data were
collected again after 6 and 16 months. A further 261 residents were recruited after 16 months. We also
interviewed staff, relatives and residents about the use of DCM after the final data collection had taken
place.
Two staff members in each DCM home were trained to use DCM and were helped by an expert to use it
for the first time. They were asked to use it again a further two times without support. Results showed
that DCM was no better than usual care in relation to any of the outcomes. It was also not shown to be
value for money. Only one-quarter of care homes used DCM more than once. The care staff who were
interviewed said that the benefits of using DCM included reduced resident boredom and increased staff
confidence. There were also many challenges, including the time needed to complete DCM, a lack of
managerial support and problems with staffing levels.
Putting DCM into practice in care homes was difficult, even with expert support, and most care homes did
not complete three DCM cycles. Future research should explore models of implementing DCM that do not
rely on care home staff to lead them.
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Scientific summary
Background
At least 80% of people living in care homes have dementia. Concerns have consistently been raised about
care home quality, and improvement in this area has been a UK-wide government research and practice-
development priority for over a decade. Poor-quality care is associated with poor outcomes for people
with dementia, including an increase in behaviours that staff may find challenging to support (with the
most common of these being agitation), reduced resident quality of life and increased prescribing and
administration of antipsychotic and other tranquillising medications. Person-centred care is a recommended
approach to the delivery of good-quality care.
Dementia Care Mapping™ (DCM) is a whole-home, practice development intervention that has been
widely used in health and social care settings, nationally and internationally, to support the embedding
of person-centred care in practice. There is good evidence of its use in practice settings as a quality audit
and improvement tool. This trial was designed to provide robust evidence on the clinical effectiveness and
cost-effectiveness of DCM as an intervention to support care homes in sustainably transferring the learning
gained from person-centred care training into care practice. The trial aimed to determine whether or not
DCM could provide a solution for achieving widespread implementation of an approach to training and
practice development that is practical for use in routine health and social care and that improves care
quality and outcomes for people living with dementia.
Objectives
The primary objective of the DCM Enhancing Person-centred care In Care homes (EPIC) trial was to
determine whether or not the intervention was more clinically effective in reducing agitation in residents with
dementia, as measured by the total Cohen-Mansfield Agitation Inventory score, and more cost-effective than
the control (usual care) 16 months after randomisation. The secondary objectives were to determine whether
or not the intervention was more clinically effective than the control at reducing behaviours that staff may
find challenging to support and the use of antipsychotic and other psychotropic drugs and at improving the
mood and quality of life of residents with dementia, care home staff well-being and role efficacy, and the
quality of staff–resident interactions at 6 months and at 16 months.
Other aspects that the trial sought to explore included the safety profile of the intervention, any differential
predictors of the effects of the intervention, and the process, challenges, benefits and impact of implementing
the intervention.
Methods
Design
The DCM EPIC study was a pragmatic, multicentre, cluster randomised controlled trial utilising an open-cohort
design with embedded cost-effectiveness and process-evaluation analyses.
Setting
Fifty residential, nursing and dementia care homes across West Yorkshire, Oxfordshire and South London,
providing care for people with dementia, were recruited using a random sampling method. Homes were
eligible if they could recruit a minimum of 10 residents to the trial, had no improvement notices and were
not taking part in any conflicting research.
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Participants
The residents recruited at baseline were registered after care home recruitment, confirmation of eligibility,
informed consent and collection of baseline data, but prior to care home randomisation. At baseline,
residents were eligible for the trial if they were a permanent resident in the care home, had a formal
diagnosis of dementia or a score of 4+ on the Functional Assessment Staging Test of Alzheimer’s Disease
and had sufficient proficiency in English to understand what the research involved, if able to do so.
Residents were not eligible if they were known to be terminally ill, permanently bed-bound or cared for in
bed, or if they were taking part in other conflicting research.
Following a change from a closed-cohort to an open-cohort design, owing to a greater than expected loss
to follow-up among residents, further residents were recruited at 16 months. In addition to the baseline
eligibility criteria, residents recruited at 16 months were not eligible if they had declined to participate in
the trial at baseline or had moved into the home or participating unit less than 3 months prior to screening.
Randomisation
Care homes were randomised on a ratio of 3 : 2 to the intervention or control group. Treatment arms were
balanced for home or unit type (i.e. general residential or nursing home vs. specialist dementia care home),
size (large ≥ 40 beds vs. medium or small < 40 beds), the provision of dementia awareness training by
research team (yes or no) and the recruiting hub (West Yorkshire, London or Oxford).
Intervention
The intervention followed standard procedures as set out in the DCM manual and guidance. Two staff
members from each intervention care home were trained to use DCM, followed by implementation of
three standard DCM cycles (each comprising briefing; observation; data analysis, reporting and feedback;
and action-planning). The first cycle was supported by an external DCM expert mapper provided by the
research team, who attended the first cycle and provided additional support remotely. This is a higher
degree of support than what mappers would usually receive post training, but it was required to support
standardised intervention implementation across all intervention care homes. To support intervention
fidelity and its measurement, care homes were provided with guidelines that included standardised
templates for recording attendance at briefing and feedback sessions and for DCM reporting and
action-planning. Additional mechanisms for supporting intervention adherence included sending short
message service (SMS) reminders and hard copies of all paperwork to mappers ahead of each cycle and
telephone support provided by the DCM intervention lead. Intervention homes were asked to complete
DCM alongside usual care.
Control
Control homes were asked to continue with usual care.
Outcome measures
The primary outcome was agitation at 16 months, measured by the Cohen-Mansfield Agitation Inventory.
Other resident outcomes included BSC and mood measured by the Neuropsychiatric Inventory (NPI); quality
of life measured with the Quality of Life in Late-Stage Dementia (QUALID) scale, Quality of Life Alzheimer’s
Disease (QOL-AD) measure, Dementia Quality of Life (DEMQOL) measure, DEMQOL-proxy, EuroQol-5
Dimensions, five-level version (EQ-5D-5L), and EQ-5D-5L-proxy; and prescribed and administered medications
and safety data (e.g. hospitalisations and deaths). The staff outcomes were the sense of competence gained
in caring for people with dementia measured using the Sense of Competence in Dementia Care Staff
(SCIDS) scale. The care home outcomes were the quality of staff interactions with residents measured using
the Quality of Interactions Schedule (QUIS).
Sample size
The sample size was calculated to detect a moderate standardised effect size of 0.4 on the primary outcome:
the between-arm difference in mean Cohen-Mansfield Agitation Inventory scores at 16 months. Fifty care
homes, each recruiting 15 participants, provided 90% power at a 5% significance level to detect a clinically
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important difference of 3 points (standard deviation 7.5 points), assuming 25% loss to follow-up and an
inflation factor of 2.0 (i.e. a cluster size of 11 participants available for analysis after loss to follow-up) and
an intracluster correlation coefficient of no greater than 0.1. As the intracluster correlation coefficient was
expected to be higher in the intervention arm, an allocation ratio of 3 : 2 was used, giving 30 (450) and 20
(300) care homes (residents) in the intervention and control arms, respectively, equating to 50 (750) care
homes (residents) overall.
During the trial, the loss to follow-up was higher than the anticipated maximum of 25%, mainly owing to
death rates. To maintain a statistical power close to 90% and to preserve our ability to detect a moderate
standardised effect size of 0.4, to maintain validity and to increase the generalisability of the trial, we
recruited additional, newly eligible, consenting residents from the randomised care homes 16 months after
randomisation and performed a cross-sectional analysis of the data.
Results
Out of 335 screened care homes, 241 randomly sampled care homes were approached; 94 formally
expressed interest and were assessed for eligibility. Of the 63 eligible care homes, 50 consented to take
part, were able to recruit a minimum of 10 resident participants and were randomised into the trial:
19 were placed in the control group and 31 in the intervention group.
At baseline, a total of 1564 residents were screened for eligibility; 1069 were eligible, 781 consented,
743 registered for the trial and 726 were registered at the point of care home randomisation. Following
the approved design change, a further 1444 residents were screened from 48 care homes 16 months
after randomisation. Of those, 421 were eligible, 266 consented and 261 residents were subsequently
registered (intervention, n = 162; control, n = 99).
Overall, at 16 months, a total of 675 residents were included in the cross-sectional sample: 414 residents
from the original cohort who reached 16 months and 261 additionally recruited residents.
A primary analysis was conducted on the cross-sectional sample. All 675 residents in the cross-sectional
sample at 16 months were included in the primary analysis, 666 of which had complete data. No evidence
of a clinical or statistical difference was found between treatment arms in the primary outcome of agitation
at 16 months. The adjusted mean difference in total Cohen-Mansfield Agitation Inventory score was
–2.11 points, being lower in the intervention arm than in the control (adjusted means: 45.47 points in control,
43.35 points in intervention; 95% confidence interval –4.66 to 0.44 points; p = 0.104). The adjusted intracluster
correlation coefficient was zero in the control and 0.001 in the intervention arm.
A complier-average causal effect analysis of the cross-sectional sample, comparing care homes in the
intervention arm that completed at least one cycle to an acceptable level with care homes that would have
completed at least one cycle to an acceptable level had the intervention been offered to them, gave a mean
difference in Cohen-Mansfield Agitation Inventory score at 16 months of –2.5 points (95% confidence
interval –5.4 to 0.4 points; p = 0.089), being lower in ‘compliers’ than in ‘non-compliers’.
The sensitivity analyses and the complier-average causal effect analysis supported the results found in the
primary analysis, namely that the intervention is not superior to the control.
Analyses of behaviours that staff may find challenging to support, mood, quality of life, pro re nata/as required
(PRN) prescription medications and quality of staff interactions were conducted on a closed cohort at 6 months,
and on the cross-sectional sample (primary) and a closed cohort (supportive) at 16 months. No statistically
significant differences were found in the closed cohort between arms on any resident-level or care home-level
secondary outcome at 6 months. Although no statistically significant differences were found between arms in
the primary cross-sectional sample at 16 months, trends in favour of the intervention as regards behaviours
that staff may find challenging to support and mood were found in the closed cohort at 16 months.
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There were no reported unexpected serious adverse events.
In the health economic base-case cost–utility analysis, the intervention was more costly (by £1479) and
more clinically effective (by 0.024 quality-adjusted life-years) than the control. This yielded an incremental
cost-effectiveness ratio of £60,627, well above the £20,000 National Institute for Health and Care Excellence
threshold, indicating that DCM is not cost-effective. The cost-effectiveness analyses based on improvement
in Cohen-Mansfield Agitation Inventory score indicated that, although the intervention was more costly,
it was also more clinically effective than the control. The incremental cost per unit improvement in Cohen-
Mansfield Agitation Inventory score was £289 for the intervention versus £67 for the control, for the
imputed and complete-case samples, respectively. However, all cost-effectiveness plane simulations lie above
the willingness-to-pay threshold suggesting that, using the base-case analysis, DCM is unlikely to be
cost-effective. The cost-effectiveness acceptability curve confirmed this and indicated that, when λ = £20,000,
there is a very low probability that the intervention will be cost-effective.
The process evaluation identified that DCM implementation was poorer than expected, with 22.6%
(n = 7) of care homes not completing one full cycle, 51.6% (n = 16) of homes completing only their first
cycle supported by an expert mapper, 12.9% (n = 4) completing two full cycles and only 12.9% (n = 4)
completing the three full, per-protocol cycles to an acceptable level. The mappers, managers, residents,
relatives and staff interviewed were able to identify a range of benefits of using DCM for residents, staff
and care home practices, including improved communication, staff being better able to identify resident
needs and the provision of more activities. A range of care home-level (context, manager support, staff
motivation and engagement, mapper skills and qualities), intervention-level (understanding of tool and
process, complexity and time demands) and trial-level (expectations of DCM and the trial, expert mapper
support) barriers to and facilitators of implementation were also identified.
Conclusions
This trial indicates that, as an intervention led by care home staff, DCM is not clinically effective or
cost-effective at reducing agitation or improving quality of life and other care outcomes for residents with
dementia living in care home settings. This outcome may be associated with the poor intervention fidelity
we experienced during the trial, despite efforts to support implementation, which went beyond standard
DCM practice/implementation structures. This suggests that the majority of care homes may not provide
the right conditions for a costly intervention such as DCM and that externally led models may provide a
more practical and resource-effective method of implementation. However, further research is needed to
evaluate this. Future research should more carefully consider the conditions needed for effective psychosocial
intervention implementation and appropriate models for delivering interventions, given the available resources
and cultural and organisational challenges of implementing complex interventions in care home settings.
Trial registration
This trial is registered as ISRCTN82288852.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 24, No. 16.
See the NIHR Journals Library website for further project information.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxviii
Chapter 1 Introduction
Scientific background
Of those living with dementia in the UK, 38% reside in a care home,1 and at least 80% of people living
in care homes have dementia.2 In 2017, over 16,000 care homes were registered in England, around
11,900 residential homes and 4500 nursing homes,3 the majority of which provide care for older people.
Concerns have consistently been raised about care home quality.4,5 Improvement in care quality and in staff
knowledge and skills has been a consistent UK government research and practice development priority for
nearly a decade.6–9 Poor-quality care is associated with poor outcomes for people with dementia, including
an increase in behaviours that staff may find challenging to support (BSC).10,11 Developing an informed
and effective care home workforce is a strategic component of improving care quality;6,12 however, there
remains limited robust evidence regarding effective evidence-based staff training and practice development
interventions for care homes providing care for people with dementia.13,14 Furthermore, it is often difficult
to achieve widespread implementation into real-world practice of evidence-based training interventions
developed in the context of research.14,15
Dementia Care Mapping™ (DCM)16,17 is a whole-home, practice development intervention that has been
widely used in health and social care settings, nationally18 and internationally,19 to support the embedding
of person-centred care in practice. There is good evidence of its use in practice settings as a quality audit
and improvement tool.20–29 This trial was designed to provide robust evidence on the clinical effectiveness
and cost-effectiveness of DCM as an intervention to support care homes in sustainably transferring the
learning gained from person-centred care training (PCCT) into care practice. The trial aimed to determine
whether or not DCM could provide a solution for achieving widespread implementation of an approach to
training and practice development that is practical for use in routine health and social care.
Behaviours that staff may find challenging to support
The behaviours that may be expressed by people with dementia in care home settings, such as agitation,
aggression, restlessness, hallucinations, delusions, depression, anxiety and apathy, may be considered by
staff as challenging to support.30 These BSC are also known as ‘neuropsychiatric’ symptoms or ‘behavioural
and psychological symptoms of dementia’ (BPSD). We have chosen to use the term BSC rather than BPSD,
as the former reflects a more person-centred terminology that better emphasises the biopsychosocial causes
of such behaviours. It also represents the terminology used by relatives and staff in care home settings.
Up to 90% of people living with dementia experience one or more of these behaviours during the course
of their condition30 and BSC are reported in up to 79% of care home residents at any one time.31 BSC also
cause distress to the people with dementia experiencing them,32 are associated with reduced quality of life33,34
and have a negative impact on the well-being of other residents.35 BSC also have significant associated
costs,36,37 including increased risk of hospitalisation,38,39 higher accident and emergency use37 and the
production of excess disability, whereby the functional abilities of people decline more quickly than is
otherwise expected.37 Therefore, reducing BSC has the potential to improve the quality of life of people
with dementia living in care homes and to reduce the costs of providing care to this group.
Agitation is the most common,31,40 the most distressing to the person with dementia32 and the most
difficult to manage41 of all BSC in care home settings. Agitation includes aggressive behaviours, physically
non-aggressive behaviours and verbal agitation,42 including pacing, spitting, verbal aggression, constant
requests for attention, hitting, kicking, pushing, throwing things, screaming, biting, scratching, intentional
falling, hurting oneself and/or others, making sexual advances and restlessness.43 The presence of these
behaviours puts the person who is agitated at risk of triggering aggressive responses from other residents44
and causes distress for other residents, the person’s family and staff. Rates of > 60% are reported of
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nursing-home residents with dementia displaying agitation,45,46 making it an extremely common BSC and
potentially harmful for the people experiencing it, other residents and staff.
The presence of agitation is reported as highly challenging compared with other BSC in terms of clinical
management.41 Agitation places an increased burden on care staff,47,48 who feel less confident in dealing with
situations in which residents are agitated than in their management of other BSC.49 There is an association
between a person with dementia experiencing agitation and fewer visits from relatives, experiencing social
isolation48 and poorer quality of life.33 The frequency of agitated behaviours, the difficulties staff have in
managing these behaviours and the potential risks they pose to the person, other residents and staff mean
that drug treatments such as antipsychotics and other psychotropic medications are frequently prescribed as a
first-line management approach. However, antipsychotics are linked to stroke and excess deaths,50 which
means that their reduced use is an ongoing priority.4,9 There is a concern that the mandated reduction in
antipsychotic prescribing may in turn lead to the prescription of other psychotropic drugs as an alternative,51,52
despite a lack of evidence of their efficacy. Investigating psychosocial approaches to reducing the incidence of
agitation and supporting staff with BSC management is therefore a research priority.5
Agitation and other BSC are not an inevitable consequence of dementia. Agitation is often exacerbated
by poor care practices and a poor surrounding environment of the person with dementia,53 as well as by
poorly managed physical health and pain.41,54 Such behaviours often reflect an expression of unmet needs
by a person with dementia in response to staff members’ inadequate understanding of a person’s needs
or poor-quality care.4,54,55 This is often related to a lack of stimulation of and engagement with the person
with dementia.56 For example, Brodaty et al.57 found significant variability between care homes in terms
of the proportions of residents within each setting who displayed BSC, indicating a care home-level effect
that may include both admissions criteria and care practices. Likewise, Weber et al.58 reported a significant
reduction in BSC when people with dementia attended a therapeutic day hospital programme compared
with when they were at home, again indicating the impact of the psychosocial environment. The presence
of agitation within individuals with dementia in care home settings is, therefore, likely to be associated
with organisational aspects of care and the care culture.54 Therefore, the use of psychosocial interventions
that address the quality of care practice4,59–61 are recommended, with agitation being a key treatment
target area for people with dementia in care homes.62
Person-centred care
Person-centred care is an effective psychosocial approach in dementia care63 that is considered a best-practice
approach to reducing agitation and other BSC.59 Person-centred care means providing a supportive social
environment within a care setting in which people with dementia are valued and treated as individuals and
staff are encouraged to see the world from their perspective.59,64 Person-centred care, therefore, involves
evaluating and responding to the unique needs of each person with dementia and offering an individualised
approach. The National Institute for Health and Care Excellence (NICE) and Social Care Institute for Excellence
(SCIE) dementia guideline59 recommends individualised, holistic or person-centred assessment and care
planning, with regular review and individually tailored and monitored psychosocial interventions for BSC.
The delivery of care that is person centred is associated with a reduction in agitated behaviours,65 and in
BSC more generally,61 and with reduced use of antipsychotics.63,66,67 Bird et al.68 found that multifaceted,
individualised interventions lead to significant reductions in BSC. Therefore, the most useful interventions to
effect change identify individual causes of BSC and suggest appropriate person-centred solutions.68–70 This
approach is reliant on staff having the required knowledge, skills and confidence to deliver person-centred
care. The provision of person-centred support is an element of the common induction standards71 for all
social care workers in England. The provision of at least basic training to staff on person-centred care is
expected within all care homes in England59 and is a regulatory requirement.72 Currently, there are no
widely implemented quality criteria for PCCT and the content, approaches, quality and efficacy of PCCT
vary considerably across the sector.73 Effective PCCT can produce immediate practice benefits;65,67 however,
owing to the variability of the amount, content and quality of PCCT that staff receive across the sector,
the knowledge, skills and staff confidence levels in relation to delivery of person-centred care remain a
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concern.49,74 Research indicates that standardising PCCT is unlikely to address these issues14 and, therefore,
evidence-based approaches to help staff sustainably embed PCCT into practice are required.15
Although effective PCCT can produce immediate practice benefits, evidence suggests that PCCT alone
might not sustain change over time13,65,67,75 and that PCCT needs to be accompanied by an additional
intervention to support ongoing change.66,76 For example, Fossey et al.66 employed PCCT alongside a
comprehensive 10-month focused intervention for training staff (FITS), including ongoing staff training
and support. At post test, antipsychotic medication use had decreased by > 40% in the intervention
group. Chenoweth et al.63 provided PCCT to two staff members who then disseminated person-centred
care practice across the site. Researchers provided additional individualised care planning and ongoing
telephone support during a 4-month intervention period. Ten months after randomisation, agitation levels
were significantly lower than in the usual-care control sites. A limitation of both of these studies is that
it is unclear whether PCCT, additional support or both caused the effect. Evidence of the efficacy of
PCCT after a longer follow-up period is limited;13 however, Moniz-Cook et al.67 found that the benefits
of PCCT alone were not sustained after 1 year. The PCCT programmes evaluated thus far indicate that
embedding additional support into the training intervention is required to produce sustained benefits.15,77,78
Implementing evidence-based health-care interventions in real-world practice is a recognised challenge,
with barriers to implementation of research-designed interventions reported across all areas of practice.79–81
Current successful interventions that combine staff training with ongoing support, such as the FITS,66 are
resource intensive, requiring regular ongoing input from a specialist practitioner, and it has not yet been
possible to implement them widely in everyday practice.82 Interventions are required that provide staff with
knowledge to support BSC management and that are cost-effective and feasible to implement. Any such
intervention will need to accommodate the varying amounts, content and quality of PCCT that is a feature
of the sector. DCM is an intervention that may address this issue.
Dementia Care Mapping™
This tool, DCM,16,17 is an established, routine care home/NHS practice development intervention that is
recommended in the NICE/SCIE dementia guideline59 and is regularly used for ensuring that a systematic
approach is used in the provision of individualised person-centred care. DCM is an observational tool set
within a practice development cycle that is used to support the sustained implementation of PCCT in
dementia care practice.83 Following initial formal training of care staff to use the tool, its application includes
five phases: briefing, observation, data analysis and reporting, feedback and action-planning. A detailed
overview of the DCM intervention is provided in Chapter 2, Dementia Care Mapping™ (intervention arm).
This cycle is repeated every 4–6 months to monitor and revise action plans. DCM implementation, therefore,
requires no external input over the long term and is thus potentially less resource intensive and more closely
aligned with real-world dementia practice than other interventions aiming to address BSC.66
Although DCM has been used in dementia care for nearly 20 years, including in care home settings,25,84–87
and has strong face validity within the practice field,88 there is limited robust evidence of its effectiveness
in relation to clinical outcomes such as the reduction of BSC. Reported benefits of DCM include the
improvement of well-being in people with dementia,22,27,89 helping staff consider care delivery from the
point of view of the person with dementia and the production of evidence to underpin action-planning
that in turn motivates staff and increases their confidence to deliver person-centred care.87,88
Evidence of the effects of Dementia Care Mapping™
Only six published studies have examined the benefits of using DCM for improving clinical outcomes in care
homes: two pilot studies employing a pre-test/post-test design,90,91 one quasi-experimental controlled trial92
and three cluster randomised controlled trials (RCTs).63,93,94 None of these was carried out in the UK. At the
time of submission of the grant application for this trial, only the two pilot studies90,91 and one of the RCTs
had been published.63
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A pilot study conducted in the Netherlands91 utilising a one-group pre-test/post-test design found that
DCM, used alone, reduced verbal agitation and anxiety in people with dementia. It also improved care
staff’s feelings of connection with their clients. A pre-test/post-test design pilot study90 conducted in
three Australian care homes found that DCM led to improvements in the quality of staff interactions
and reductions in agitation and depression, compared with three control homes. A quasi-experimental
controlled trial conducted in Germany92 compared outcomes at 6 and at 16 months with baseline. Nine
nursing homes units, located in nine nursing homes owned by the same group, were allocated not at
random to one of three arms: a no-intervention control group (n = 3), a DCM-experienced intervention
group (n = 3) and a DCM intervention group (n = 3). The DCM-experienced group had been exposed to
two externally delivered DCM cycles annually over a number of years. The DCM intervention group had no
previous exposure to DCM, but had expressed an interest in undertaking the method. Two staff members
from both intervention groups received DCM training and were requested to implement three DCM cycles
over 18 months. The control group received an intervention based on training staff about quality of life
(QoL), followed by QoL assessment, using a standardised tool, of all care home residents at least every
6 months. The study found no significant difference between the two intervention groups and the control,
and no difference between the two intervention groups, as regards QoL or BSC.
The first cluster RCT evaluating the efficacy of DCM was conducted in Australia63 in 15 care homes
randomised equally between three arms [usual care (control), PCCT and DCM] and included 289 people
with dementia (18% loss to follow-up at 10 months). The trial found that 10 months after randomisation,
DCM, when used alone, was associated with significantly reduced agitation and falls in people with
dementia compared with the control and PCCT groups, and with reduced staff feelings of burnout.95
A three-arm cluster RCT93 was also conducted in 15 care homes in Norway, randomising equally between
a control group, person-centred care framework implementation and DCM. The study recruited 446
people with dementia (29% loss to follow-up at 10 months). It found significant reductions in overall
neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI), significant reductions in
agitation and psychosis as measured by the NPI subscales and a significant improvement in QoL compared
with the usual-care control. Both trials had explanatory designs involving researcher-led cycles of DCM
with variable degrees of input from trained care home staff, which restricted the generalisability of the
results, as the usual implementation of DCM is practitioner led. A Dutch cluster RCT conducted in 34 units
across 11 care homes compared DCM with a usual-care control.94 It recruited 434 residents (35% loss to
follow-up at 12 months) and found no difference in residents’ agitation between the DCM intervention
and control homes. Positive staff outcomes were found in the intervention group, including significantly
fewer reported negative emotional reactions and significantly more positive reactions towards people
with dementia than in the control group. The trial authors identified potential DCM intervention fidelity
issues, finding less than desirable implementation in some clusters. All three RCTs were exploratory and
each included only two full cycles of DCM before the final follow-up, with follow-up periods of only
10–12 months post randomisation, reducing the time for any potential change or impacts to be seen.
The results of these existing studies are mixed in terms of the reported efficacy of DCM. The studies that
included researcher-led cycles of DCM (Australia and Norway) showed efficacy for some outcomes, whereas
studies with cycles of DCM led by care home staff have shown no benefits of DCM (the Netherlands and
Germany). A recent systematic review of DCM implementation96 found limited research in this area, with
implementation found to be challenging across a number of the published studies. There was some consensus
that appropriate mapper selection, preparation and ongoing support during DCM implementation, alongside
effective leadership for DCM within an organisational context of commitment to the delivery of person-
centred care, could support better implementation.
In summary, the limitations of the existing studies include:
l a relatively small number of clusters (Australia and Germany) or small numbers of care homes
containing multiple clusters (the Netherlands and Norway)
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l the use of DCM alone, rather than alongside PCCT in accordance with UK best-practice guidelines83
(Australia and the Netherlands), which reflects the context within each country at the time of the trial,
for example in Australia, where PCCT was the exception rather than assumed good practice
l only two full cycles of DCM before the final follow-up, which limited the potential for impacts
to be seen, owing to the length of time that changes within care home practice can take to
implement, and thus limited the demonstration of potential resident benefits (Australia, Norway
and the Netherlands)
l a follow-up period of no more than 12 months after randomisation, reducing the time for potential
changes and impacts to be seen (Australia and Norway)
l explanatory trial designs (Australia and Norway) involving researcher-led cycles of DCM with variable
degrees of input from trained care home staff, potentially limiting staff ownership of the DCM process,
the implementation of any action plans and the longer-term sustainability of DCM use; this also restricts
the generalisability of the results, as the usual implementation of DCM in care practice is practitioner led
l no formal, published process evaluation (Australia and Norway)
l the studies were conducted in Australia, Norway, Germany and the Netherlands, where care funding,
policy, context, regulations and processes are different from those of the UK.
Despite promising results on the potential efficacy of DCM in care home settings, the conduct of these trials
in countries where usual-care practices, funding and systems are different from the UK and where DCM
was implemented differently from its use in the UK means that their results cannot be directly transferred.
A definitive RCT evaluating the clinical effectiveness and cost-effectiveness of DCM for helping staff to
implement person-centred care in UK care home settings, building on this previous work, is therefore
needed to inform future UK care home practice.
Rationale for the research
The knowledge intended to be gained from this trial, beyond that gained within the existing RCTs, was:
l Previous trials used explanatory designs. By contrast, in this trial, a pragmatic trial design reflecting the
conditions of DCM implementation in usual practice in UK care home settings would be used. In particular,
trained care home staff, rather than researchers, led the cycles of DCM implementation. The trial design,
size and statistical power allowed definitive conclusions to be drawn regarding the effectiveness of DCM as
an intervention in usual practice within UK care home settings.
l Previous RCTs had conducted only one or two DCM cycles with a follow-up period of a maximum of
12 months. In this trial, it was intended that care homes would implement three cycles of the DCM
intervention with follow-up over a period of 16 months. This is beneficial because some anticipated
practice changes, for example to the underlying care culture, are likely to take time to implement.
In addition, given the annual staff turnover rates of around 30%97 in care homes, which may potentially
lead to longer-term implementation challenges, a longer follow-up period was necessary to investigate
whether or not longer-term effects and sustainability could be achieved within this context.
l A full economic evaluation within this pragmatic trial design was included, offering a definitive position
on cost-effectiveness. Only one of the previous trials conducted an economic evaluation and, given its
explanatory design and conduct in a funding system different from that of the UK, the findings cannot
be confidently generalised.
The design of this trial built on existing explanatory trials to offer a definitive assessment of the clinical
effectiveness and cost-effectiveness of DCM as a standard clinical intervention in care home settings.
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Aims and objectives
The aim of the DCM Enhancing Person-centred care In Care homes (EPIC) cluster RCT was to evaluate the
clinical effectiveness and cost-effectiveness of DCM implemented in addition to usual care (intervention),
compared with the usual care (control) for people with dementia living in care homes in the UK.
It aimed to answer the following primary and secondary research questions.
Primary research questions
At 16 months after the randomisation of care homes, is the intervention:
l more effective than the control in reducing agitation in residents with dementia as measured by the
total Cohen-Mansfield Agitation Inventory (CMAI) score?
l more cost-effective than the control?
Secondary research questions
Is the intervention more effective than the control at 6 and at 16 months after randomisation in:
l reducing BSC in people with dementia over time?
l reducing the use of antipsychotics and other psychotropic drugs in residents with dementia?
l improving mood and QoL in residents with dementia?
l improving care home staff well-being and role efficacy?
l improving the quality of staff–resident interactions over time?
Other questions the trial sought to explore related to:
l the safety profile of the intervention as assessed by the number and types of adverse events
l any differential predictors of the effects of the intervention
l the process, challenges, benefits and impact of implementing the intervention.
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Chapter 2 Trial design and methods
Trial design
This section outlines the trial design and procedures at the commencement of trial recruitment. The original
trial protocol is published elsewhere.98 Subsequent amendments to the original trial protocol, after trial
commencement, are highlighted throughout this section and then reported in detail in Summary of changes
to project protocol.
This trial was a pragmatic, multicentre, cluster RCT of DCM plus usual care (intervention) versus usual care
alone (control) in residential, nursing and dementia care homes across West Yorkshire, Oxfordshire and
South London for people with dementia.
Owing to greater than expected loss to follow-up during the trial, a design change was approved to move
from a closed-cohort to an open-cohort design, with additional residents recruited at the 16-month follow-up
and the cross-sectional sample of residents used within the primary analysis (see Summary of changes to
project protocol). The cross-sectional sample of residents was used in the primary statistical analysis (and a
secondary health economic analysis), defined at baseline and at 16 months, respectively, as all residents
registered at care home randomisation and at 16 months. The closed-cohort sample of residents was used in
the primary health economic analysis (a supportive statistical analysis and all analyses of 6-month outcomes),
defined simply as all residents registered at care home randomisation.
As the aim of DCM is to change practice across the whole care home setting and it is not possible to limit
the potential effects to the care provided to only a sample of people with dementia living in the care home,
a cluster design was justified. This influenced the decision to consider two important sources of clustering:
cluster randomisation and DCM treatment provision, with care homes nested within treatment arms. Owing
to this, we anticipated that the clustering effect would vary across arms, with a higher intracluster correlation
coefficient (ICC) in the intervention arm. Therefore, an unequal allocation of care homes on a ratio of 3 : 2 to
intervention and control groups, respectively, was implemented. An integral cost-effectiveness analysis and a
nested qualitative process evaluation were included.
Ethics approval, research governance and study oversight
Ethics approval for the study was granted by National Research Ethics Service (NRES) Committee Yorkshire
and the Humber – Bradford Leeds on 14 February 2013, Research Ethics Committee (REC) reference number:
13/YH/0016. Care home insurance and indemnity applied to trained mappers who implemented the
intervention within the care home setting. Appropriate site-specific approvals were obtained from the three
participating hubs: Yorkshire (Bradford Teaching Hospitals NHS Foundation Trust), Oxford (Oxford Health
NHS Foundation Trust) and London (Guy’s and St Thomas’ NHS Foundation Trust). The trial was registered
with the International Standard Randomised Controlled Trial Register (ISRCTN) reference 82288852.
Day-to-day management of the trial was undertaken by a Trial Management Group (TMG) comprising the
co-applicants, trials researchers and staff, as well as a patient and public involvement (PPI) representative.
This group met twice before the official start of the project, monthly during trial set-up and then bi-monthly
or quarterly. Updates on trial progress were provided by e-mail between meetings. A Lay Advisory Group was
established and contributed to TMG decisions (see Patient and public involvement).
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Trial Steering Committee
The trial was overseen by a Trial Steering Committee (TSC) comprising five independent members
(three academic members, one PPI representative and one care home representative). The TSC monitored
trial recruitment, retention, timelines, intervention adherence, data return and quality and considered
new issues. It also provided advice and approval for changes to the protocol or trial procedures. It met
approximately every 6 months throughout the trial.
Data Monitoring and Ethics Committee
An independent Data Monitoring and Ethics Committee (DMEC), comprising four academic members,
met approximately every 6 months during the trial. It reviewed unblinded data, recruitment, retention,
intervention implementation and safety by group. The DMEC also undertook an annual review of any
serious adverse events (SAEs).
Participants
It was intended that 750 residents with dementia from a random sample of 50 care homes would be
recruited, along with participants’ relatives and care home staff.
Care home eligibility, recruitment and consent
Care home eligibility
To be eligible for the trial, a care home was required to:
l have a sufficient number of permanent residents with dementia [based on a formal diagnosis or
Functional Assessment Staging Test of Alzheimer’s Disease (FAST) score of 4+] eligible to participate,
achieving a minimum of 10 residents registered to the trial prior to care home randomisation
l have a manager or nominated person agreeing to sign up to the trial protocol as the research lead for
the duration of the project
l have agreed to release staff for DCM training and subsequent mapping processes
l be within the trial catchment area.
Care homes were not eligible for the trial if they:
l were subject to Care Quality Commission (CQC) enforcement notices, admission bans or relevant
moderate or major CQC compliance breaches
l were receiving other special support for specific quality concerns, such as being currently subject to,
or having pending, any serious safeguarding investigations, or receiving voluntary or compulsory
admission bans or local commissioning special support, owing to quality concerns
l had used DCM as a practice development tool within the 18 months prior to randomisation or were
planning to use DCM over the course of trial involvement
l were currently in, had recently taken part in or were planning to take part in another trial that
conflicted with DCM or data collection.
If a care home was a large multisite or multifloor establishment, the one or two units with the largest
percentage of residents with dementia, or in which the manager felt that DCM implementation would be
most beneficial, were selected to participate as one home.
Care home recruitment
Catchment areas for each recruitment hub (Leeds Beckett University, King’s College London and Oxfordshire
Health NHS Trust) were established based on postcode districts/boroughs in West Yorkshire, South London
and Oxfordshire, respectively. All care homes in the catchment areas were identified and screened for initial
eligibility via publicly available information (home type, number of beds and CQC status). Care homes that
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were deemed eligible were randomly ordered within catchment areas and divided into batches. The first
batch of homes from each hub were sent the care home information sheet [see www.journalslibrary.nihr.ac.
uk/programmes/hta/111513/#/ (accessed July 2019)] by post. A researcher then contacted the care homes
by telephone within 1 to 3 weeks to determine their interest in taking part. If a care home expressed interest
in taking part, the researcher conducted initial eligibility screening ahead of visiting to determine full
eligibility and to initiate care home consent and management permissions [see www.journalslibrary.nihr.ac.
uk/programmes/hta/111513/#/ (accessed July 2019)]. If the researcher was unable to make contact with the
care home following several attempts, a decision was made to cease attempting to contact. Once all care
homes within a batch had been contacted, or deemed uncontactable, the next batch was approached until
sufficient homes were recruited.
Dementia training audit and provision of dementia awareness training
As person-centred care is considered best practice within UK care homes,59 it was expected that homes
would have routinely provided staff with appropriate PCCT.72 As the quality of PCCT is variable across
the sector in the UK, to ensure that each care home met at least minimum dementia awareness training
standards, a training audit was developed by the research team (its content and the minimum standards
required in the trial are reported elsewhere).99 The training audit was completed in each care home prior to
baseline data collection. The researcher completed this by reviewing training records and having discussions
with home managers and/or other relevant staff (e.g. the training lead). When homes fell below the
minimum standard, they received a half-day dementia awareness course modified in consultation with
service users from an existing resource developed by Bupa Care Services and the University of Bradford.100
The course was delivered by an experienced trainer/mentor who coached a member of the care home staff
to be able to deliver the course to additional staff. Care homes were expected to deliver the training to
at least 20% of permanent direct care staff prior to baseline data collection and to complete paperwork
detailing how many staff members received the training and when. Based on CQC data,101 we expected up
to 20% of homes to require this dementia awareness package.
Resident eligibility, recruitment and consent
Residents were recruited to the trial at baseline, prior to care home randomisation. Additional residents
were recruited 16 months after a design change to the study, owing to larger than anticipated loss to
follow-up (see Design change).
Resident eligibility
At baseline, residents were eligible for the trial if they:
l were a permanent resident in the care home and not present for receipt of respite or day care
l had a formal diagnosis of dementia or a score of 4+ on the FAST102 (indicating mild to severe dementia)
as rated by the home manager or another experienced member of staff
l were appropriately consented (in accordance with the Mental Capacity Act 2005103 and clinical trials
guidance on informed consent104,105)
l had an allocated member of staff willing to provide proxy data
l had sufficient proficiency in English to contribute to the data collection required for the research.
At baseline, residents were not eligible for the trial if they were:
l known by the care home manager and/or relevant senior staff member to be terminally ill (e.g. formally
admitted to an end-of-life care pathway)
l permanently bed-bound/cared for in bed
l currently in, had recently taken part in or were planning to take part in another trial that conflicted with
DCM or with the data collected in the trial.
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Resident screening
The researcher, along with the care home manager and/or a relevant member of senior staff, screened all
care home residents to identify eligible people with dementia to be approached to take part in the trial.
The basic demographics of all residents and their eligibility or reasons for ineligibility at screening were
recorded, using only the screening number.
Resident informed consent
In accordance with the Mental Capacity Act 2005,103 all eligible residents were assumed to have capacity
to consent unless assessed otherwise. The manager/senior staff member approached each eligible resident
and sought their permission for the researcher to speak with them. If the resident had capacity and gave
verbal consent to speak to the researcher, this was documented and the researcher approached them to
discuss the study. If the resident was deemed to lack the capacity to make this decision, then the process
for appointing a consultee was followed (see Consent for those without capacity).
The researcher approached each resident who had capacity and agreed to speak to them, explaining the
trial using the appropriate documentation and undertaking a further documented assessment of capacity
to give informed consent. The resident was provided with the resident information sheet [see www.
journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)] and, at least 24 hours later,
they were given the opportunity to ask any further questions and then, for those with capacity, formal
consent to participate in the trial was sought. If the resident was deemed by the researcher at any point to
lack the capacity to consent, the process for appointing a consultee was followed (see Consent for those
without capacity).
Consent for those with capacity
Residents who were able to give informed consent were asked to sign, or make a mark on, the trial
consent form [see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)].
For those who were not able to sign, a witness confirmed that informed consent had been given. Given
the progressive nature of dementia, a further capacity assessment was conducted at each data collection
point by the researcher to assess continued capacity. In the case of residents who lost capacity during
the trial, appropriate guidance on consent in the light of changed capacity was followed,106 involving the
appointment of a consultee (see Consent for those without capacity). When a resident had capacity and
consented to taking part in the trial, consent to approach his or her main carer (relative/friend) was sought
regarding their participation as a proxy informant.
Consent for those without capacity
When a resident was assessed and found to lack the capacity to give informed consent, a ‘Personal
Consultee’ was appointed to give advice on the resident’s wishes. This was usually a relative or a close
friend. When the resident had no close family or friends able or willing to act as Personal Consultee,
a member of staff in the care home who knew them well but who was not actively involved in any
elements of the research process (e.g. as a mapper or in giving proxy data on the resident) was
appointed as a ‘Nominated Consultee’.
If the proposed Personal Consultee was present in the care home, they were approached by the researcher
and given all of the appropriate documentation [see www.journalslibrary.nihr.ac.uk/programmes/hta/
111513/#/ (accessed July 2019)] in person and asked for written consent to hold their personal details to
enable the researcher to directly contact them thereafter. The proposed Personal Consultee was given at
least 24 hours to talk to the resident and other relatives/friends about the resident’s wishes. The Personal
Consultee was then asked to return the declaration form by post, within a week, expressing their advice
on the resident’s wishes regarding taking part in the trial. If the Personal Consultee was not present in the
care home, the documentation was sent to them by post, via the care home, on the researcher’s behalf.
Details were provided on how to contact the researcher should they wish to discuss the role. For both
methods of approach, if the declaration form had not been returned after 1 week, a follow-up reminder
was sent by post by the researcher informing the Personal Consultee that a Nominated Consultee would
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be identified if no response was received within 1 week. If, after a further week, the declaration form had
not been returned, the process of appointing a Nominated Consultee was followed.
A Nominated Consultee identified by the manager was approached using the appropriate documentation
[see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)] to discuss the potential
involvement in the trial with the resident, other staff members who knew them well and any relatives/friends.
The Nominated Consultee was then asked to complete the declaration form, providing advice on the
resident’s wishes.
Personal and Nominated Consultees were advised that they could approach the researchers at any time to
indicate if they felt that the person they were representing had changed their mind about participating in
the trial and to withdraw them from participation. Given the potential frailty of those serving as Personal
Consultees, a review of Personal Consultees’ capacity was undertaken by the researcher via the care home
manager at 6- and 16-month follow-ups, where feasible.
Staff roles, eligibility, recruitment and consent
Staff roles
There were five staff roles within the trial, some of which were mutually exclusive (Table 1):
1. to act as a Nominated Consultee for residents (see Consent for those without capacity)
2. to provide data on standardised measures relating to their role (see Staff measures)
3. to provide proxy informant data on residents they know well (see Proxy informant eligibility, recruitment
and consent)
4. to become a trained DCM mapper (see Mapper identification, eligibility and consent)
5. to participate in the trial’s process evaluation (see Process evaluation and assessment of treatment
implementation).
Staff measures
To be eligible to complete a staff measures booklet, staff were required to be a permanent, contracted,
agency or bank member of staff at the time of data collection and have sufficient proficiency in English.
Consent to participate in this role was assumed through staff return of the booklet. The staff measures
booklets and accompanying information sheets [see www.journalslibrary.nihr.ac.uk/programmes/hta/
111513/#/ (accessed July 2019)] were distributed to all eligible staff members at each data collection visit,
by either the researcher or the care home manager. Booklets were returned anonymously by the staff
member either via a sealed envelope to a locked box located within the care home or posted directly to
the research office in the stamped return envelope provided.
Proxy informant eligibility, recruitment and consent
To be eligible to act as a proxy informant and to provide proxy data on a resident, staff had to be a permanent
or contracted member of staff who knew the resident well. Bank or agency staff were not eligible for this
role. Potential proxy informants were identified by the care home manager/senior member of staff using the
TABLE 1 Role summary
Staff roles Nominated Consultee DCM mapper Proxy informant
Nominated Consultee ✗ ✗
Staff measures ✗ ✓ ✓
Proxy informant ✗ ✗
DCM mapper ✗ ✗
Process evaluation ✗ ✓ ✓
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appropriate trial documentation [see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed
July 2019)]. Where possible, the same proxy informant was used for each resident throughout the trial,
although this was not always possible owing to staff turnover, annual leave and shift patterns.
Relative/friend eligibility, recruitment and consent
Where possible, a relative or friend who visited the care home regularly was identified for each participating
resident to provide proxy data. The relative/friend proxy was identified in discussion with either the resident
or the care home manager/senior member of staff. They could also act in the role of Personal Consultee.
To be eligible to provide proxy data, relatives/friends were required to have visited the resident at least once
per week over the previous month, be willing to provide data by either telephone or post during the data
collection week and have sufficient proficiency in English to contribute to the data collection required.
Relatives/friends were approached either in person by the care home manager or researcher or by post,
depending on visiting patterns and times, using the appropriate trial documentation [see www.
journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)].
Relative/friend recruitment took place at baseline and continued at the 6-month follow-up in some homes
until December 2015, when the decision to cease further recruitment was made owing to low overall
relative/friend recruitment. Data continued to be collected from consented relatives/friends throughout the
trial. Their continuing eligibility for participation was reassessed at each subsequent data collection point
because of changing patterns of visiting over time. When relative/friend proxies withdrew from the trial,
additional participant relatives/friends were not recruited.
Registration, randomisation and blinding
Registration of residents
Residents recruited at baseline were registered with the Clinical Trials Research Unit (CTRU) at the University of
Leeds following care home recruitment, training review (see Dementia training audit and provision of dementia
awareness training), eligibility confirmation, obtaining informed consent and resident-level baseline data
collection, but prior to care home randomisation. Following a design change (see Summary of changes to
project protocol), additional residents were recruited at 16 months and were registered with the CTRU after
confirmation of eligibility, informed consent and collection of their resident-level data.
Randomisation, stratification and blinding
Immediately following baseline, once all residents, staff and relatives/friends were recruited and registration
was complete, care homes were randomised using the 24-hour automated randomisation system at the
CTRU. Care homes fulfilling eligibility criteria were randomised on a 3 : 2 basis to either the intervention or
the control group, respectively. A computer-generated minimisation programme was used,107 incorporating
a random element to ensure that the arms were balanced for the following care home characteristics:
l home/unit type (general residential/nursing or specialist dementia care)
l size (large, ≥ 40 beds; or medium/small, < 40 beds)
l provision of dementia awareness training by research team (yes or no)
l recruiting hub (West Yorkshire, London or Oxford).
To maintain blinding of trial researchers collecting data within care homes, randomisation was performed
by the CTRU Data Management team, who were therefore not blind to treatment allocation. Following
randomisation, the CTRU informed the care home manager of the treatment allocation, by telephone call
or e-mail. The intervention lead was notified of homes allocated to the intervention, so that arrangements
could be confirmed for training with consented mappers and contact with the DCM expert mapper could
be initiated. Researchers were not informed of treatment allocation and agreed procedures were applied
to maintain blinding throughout the trial. Other CTRU staff were informed of treatment allocation only if
TRIAL DESIGN AND METHODS
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this was required to undertake their role. All occurrences of unblinding and the reasons for and method
of unblinding were recorded.
Because researchers were blinded, they were unaware of the identity of trained mappers. Therefore, a text
message was sent to mappers in the intervention homes by CTRU trial management staff, ahead of data
collection at 6 and at 16 months, to remind them not to provide proxy informant data if requested to do so.
Procedure
Usual care (both arms)
Usual care was defined as the care routinely delivered within the setting and was continued in all participating
care homes with no restrictions imposed on current practices or on homes undertaking additional development
or training. The exception was that control-arm homes were required not to implement DCM during the trial
period. Details regarding any changes in usual-care practice during the course of the trial (e.g. new staff roles,
change of ownership, new practice initiatives or training programmes) were documented by the researcher at
follow-up visits.
To facilitate a person-centred primary care response to BSC in case care homes sought support, all general
practitioners (GPs) who served each care home were provided with generic best-practice guidance about
the implementation of person-centred care and managing BSC, irrespective of whether or not the residents
they provided services to were participating in the trial. We did not inform individual GPs about which
residents were participating in the trial.
Dementia Care Mapping™ (intervention arm)
The intervention followed standard procedures as set out in the DCM manual and guidance.17,108 Two
staff members from each intervention care home were trained to use DCM, followed by implementation
of (ideally) three standard DCM cycles (each comprising briefing; observation; data analysis, reporting
and feedback; and action-planning), in accordance with the British Standard best-practice guideline.83
In addition, care homes were provided with fidelity guidelines, which included standardised templates
for recording attendance at briefing and feedback sessions and for DCM reporting and action-planning.
Other mechanisms for ensuring adherence to the intervention and for supporting mapper engagement
were implemented, including support from a DCM expert mapper during cycle 1 (see Expert mapper
support for cycle 1) and sending short message service (SMS) reminders to mappers ahead of each cycle.
Mapper identification, eligibility and consent
Two staff members in each home were identified by the manager as suitable to be trained in the use of
DCM (mappers). To ensure timely progression from care home randomisation to DCM training, and to
avoid selection bias, two mappers were identified in every consenting home at care home recruitment
and their informed consent to undertake the mapper role was gained. To be eligible, staff had to be a
permanent or contracted staff member, had to have the right skills and qualities as assessed by the home
manager against a mapper role descriptor provided by the research team [see www.journalslibrary.nihr.ac.
uk/programmes/hta/111513/#/ (accessed July 2019)], had to agree to implement DCM per protocol and
had to take part in the process evaluation, if required.
Potential mappers were initially approached by the manager with reference to the written mapper role
description. Once verbal consent was obtained, the researcher discussed the role and responsibilities of
mappers again with reference to the role descriptor and mapper information sheet, before gaining their written
informed consent [see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)]. If a
mapper withdrew or left the care home before the end of the trial, where feasible, another suitable member
of staff was identified, consented and trained using a similar procedure, to ensure continuity of DCM
implementation in the home.
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Training
Following randomisation, care homes allocated to the intervention group received DCM training as soon as
their mappers were able, depending in part on the course schedule.
All trial mappers attended a standard 4-day DCM training course held in Bradford or London and provided
by the University of Bradford. It included an assessment of competency in the use of DCM. One additional
attempt at the assessment was permitted for those attendees who failed to achieve a pass mark at the first
attempt. The course trainers were informed in advance of which attendees were EPIC trial mappers. They
provided data on which mappers had successfully completed and passed the course.
Implementation
Following completion of the formal assessed training course, implementation of DCM commenced,
comprising a practice development cycle of briefing the staff team; observation over a number of hours;
data analysis, reporting and feedback to the staff team; and action-planning. Re-mapping at regular
intervals forms part of the standard process to monitor progress and to set new action plans. Intervention
homes were scheduled to complete their first cycle 3 months after randomisation (or as soon as practicable),
their second cycle at 8 months and their final cycle at 13 months. Ahead of each mapping cycle, the trial
manager at the CTRU contacted mappers individually via SMS to remind them of the upcoming cycle.
Paper documents were posted to them to prompt completion of the cycle.
Briefing
Mappers were asked to run at least one briefing session 1–2 weeks prior to undertaking the mapping
observations. Briefing sessions informed the care home staff about DCM and the process of implementation,
and provided an opportunity for staff to ask questions and for mappers to address any staff concerns.
Observation
Mappers used the standard DCM procedure. They were asked to observe as many individuals as they felt
confident to, up to a total of five, for up to 6 consecutive hours on a single day if possible. Alternatively,
they could observe for as long as possible on consecutive days up to a total of 6 hours. A detailed
description of the DCM tool is published elsewhere83,109 and summarised here: every 5 minutes, the
mapper records two pieces of information about each person they are observing, namely a behaviour
category code (BCC) and a mood/engagement (ME) value. There are 23 possible BCCs for the mapper to
choose from and they capture what the person with dementia is doing within that 5-minute period. The
ME value encapsulates the associated mood and engagement level of the person with dementia and is
chosen from a six-point scale (+5, +3, +1, –1, –3, –5). A set of rules is used to determine which BCC and
ME value to choose. The mapper also records instances when a person with dementia is ‘put down’ by a
care worker, known as personal detractions, and examples of excellent care, called personal enhancers.
These are recorded as and when they occur. As DCM is grounded in person-centred care, for reasons
of privacy and dignity, observations take place only in communal living areas, such as the lounge, the
dining room and corridors. Mappers do not observe in bedrooms or bathrooms.
Data analysis, reporting and feedback
For the purposes of trial data analysis, reporting and feedback were considered as a single phase, rather
than as the two separate phases of implementation described in the DCM literature. Once the data had
been collected, they were analysed by the mappers and presented in a standardised report format for the
purposes of feedback to the care team. In the trial, a standard template for DCM reporting was given to the
mappers by the research team [see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed
July 2019)]. DCM feedback sessions provided an opportunity for mappers to share their observations with
the staff team and for collective discussion about good care practices and areas for improvement. In the
trial, mappers were requested to run one or more feedback sessions with as many members of the staff
team as possible within 1 month of conducting the observations.
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Action-planning
Action plans of ways to improve care were then produced. As part of the feedback session, or in a subsequent
meeting, staff and mappers were asked to jointly develop agreed, achievable group (care home-level) and
individual resident-level action plans containing short-, medium- and longer-term goals that they wished to
implement. Mappers were asked to monitor progress on these actions during the next mapping cycle.
Resident consent for mapping
Prior to mapping, residents were selected to be mapped through discussions between the care team and
mappers, during the briefing session or on the day of mapping. Mappers followed DCM guidance, which
states that residents may be selected for observation because they display a range of abilities or have
particular care needs that staff members have difficulties meeting or understanding. Residents selected
for mapping observations did not need to be consenting trial participants, as DCM was implemented as
a whole-home intervention. Consent was gained verbally by the mappers, either from the resident or
in discussion with their relative prior to observations taking place, in accordance with the usual consent
process utilised in DCM. Any resident data collected as part of the DCM process, which was subsequently
used for monitoring intervention fidelity or for any other purposes in the trial, was anonymised by the
mappers before being sent to the research team.
Expert mapper support for cycle 1
This pragmatic trial aimed to ensure that DCM implementation reflected what is possible in a typical UK
care home, maximising relevance to practice. However, the first cycle of mapping was supported by an
expert in the use of DCM (a DCM expert mapper), who was assigned by the research team. This is not
standard practice, as trained mappers would usually engage in DCM without further support following
training completion. However, it was implemented in the trial to support implementation fidelity across
clusters (see Process evaluation and assessment of treatment implementation), provide coaching for
care home mappers, encourage implementation and support establishment of inter-rater reliability of
DCM coding between trained mappers in each care home. The DCM expert mapper worked alongside the
mappers during their first DCM cycle, spending 3 days in the care home supporting the establishment of
inter-rater reliability on DCM coding frames, briefing, mapping observations and delivery of the feedback
and action-planning session. Two additional days of desk-based support were provided on the preparation
of briefing documentation, the feedback report and action plans. Telephone and e-mail support for DCM
implementation from the DCM intervention lead was available to all intervention homes thereafter, if required.
Outcomes
Primary end point
The primary end point was agitation at 16 months following randomisation, measured by the CMAI, as
rated by staff proxy. The Pittsburgh Agitation Scale (PAS) and a modified observational CMAI (CMAI-O),
rated by independent researchers, provided a means of assessing concurrent validity, addressing the issue
of potential detection bias owing to the inability to blind staff to intervention allocation status.
Health economic end points
The primary health economic end point was cost per quality-adjusted life-year (QALY) at 16 months. A
secondary end point was cost per unit of improvement in CMAI score at 16 months. Both of these adopted
the health and personal social service provider perspective.
Secondary end points
Secondary end points relating to residents were:
l BSC (NPI)
l mood (NPI)
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l QoL [Quality of Life in Late-Stage Dementia (QUALID) scale, Quality of Life in Alzheimer’s Disease
(QOL-AD) measure, Dementia Quality of Life (DEMQOL) measure and EuroQol-5 Dimensions, five-level
version (EQ-5D-5L)]
l prescribed medication
l safety (SAEs and safeguarding).
Secondary end points relating to staff were:
l the Sense of Competence in Dementia Care Staff (SCIDS) scale.
Secondary end points relating to homes were:
l the Quality of Interactions Schedule (QUIS).
Furthermore, intervention fidelity was assessed. All other data are potential mediators or moderators of the
treatment effect. Measures, collection time points and methods of completion are summarised in Table 2.
To ensure that a consistent data set was available for each resident at each time point, the main informant
for the primary outcome and for proxy-completed secondary outcomes was a staff proxy informant. These
data were supplemented, where possible, by information provided by the resident (when able) and by their
relative/friend (when available).
Resident measures
Primary outcome measure: Cohen-Mansfield Agitation Inventory42,43
The CMAI measures 29 agitated or aggressive behaviours.110 The frequency of each symptom is rated on
a seven-point scale (1–7) ranging from ‘never’ to ‘several times an hour’, based on observations over the
previous 2 weeks. A total score is obtained by summing the individual frequency scores, yielding a total
score ranging from 29 to 203. The CMAI has good psychometric properties111 when used in a care home
setting. Data from previous similar studies provide an expected points change to inform the sample size
calculation. The CMAI was completed via researcher interview with the staff proxy informant, in accordance
with the CMAI manual.43
As blinding staff to intervention allocation was not possible, two independent observational measures
of agitation were collected to assess potential bias in completion of the CMAI by staff proxy informants
[see Agitation measures (supportive outcomes)]. Observation scales have been shown to have good
convergence with informant measures of agitation.112 Observations were completed by an independent
blinded researcher who was not involved in any other data collection in the care home.
Agitation measures (supportive outcomes)
Cohen-Mansfield Agitation Inventory – Observational113
The CMAI-O was developed by the trial team, with the permission of the CMAI’s author, to provide
an observational measure of agitation. It is rated on a four-point scale (1–4) ranging from ‘never’ to
‘several times an hour’, based on observations over 1 day. The CMAI-O data collection was completed on
participating trial residents in communal areas between approximately 10.00–12.00 and 14.00–17.00
(dependent on meal times in each care home). A copy is available from the authors on request.
Pittsburgh Agitation Scale114
The PAS is an established observational rating of agitation. The scale has good reported reliability and
validity.114 Observations are conducted for between 1 and 8 hours. PAS data were collected on participating
trial residents in communal areas between 10.00 and 12.00 and between 14.00 and 17.00.
TRIAL DESIGN AND METHODS
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TABLE 2 Summary of data collected
Assessment
Method of completion
(completed with/on) Purpose Level
Timeline
Screening Baseline 6 months 16 months
Resident demographics Researcher assessment (CM, CR) Individual ✗ ✗ ✗
CMAI Researcher interview (SP) Primary end point Individual ✗ ✗ ✗
CMAI-O Independent researcher observations (R) Independent assessment of
concurrent validity of CMAI for
detection of potential bias
Individual ✗ ✗ ✗
PAS Independent researcher observations (R) Independent assessment of
concurrent validity of CMAI for
detection of potential bias
Individual ✗ ✗ ✗
NPI – nursing home version Researcher interview (SP) Secondary end point Individual ✗ ✗ ✗
DEMQOL measure – proxy version Researcher interview (SP, RF) Health economics end point Individual ✗ ✗ ✗
EQ-5D-5L/EQ-5D-5L – proxy version Researcher interview (R, RF, SP) Health economics end point Individual ✗ ✗ ✗
QUALID scale Researcher interview (SP, RF) Secondary end point Individual ✗ ✗ ✗
QOL-AD measure (care home) Researcher interview (R) Secondary end point Individual ✗ ✗ ✗
Health-care resource use Researcher assessment (CR) Health economics end point Individual ✗ ✗ ✗
Prescription medications Researcher assessment (CR) Secondary end point Individual ✗ ✗ ✗
Resident comorbidities Researcher assessment (CR) Individual ✗ ✗ ✗
Clinical Dementia Rating scale Researcher interview (SP) Process measure Individual ✗ ✗ ✗
FAST Researcher interview (SP) Individual ✗ ✗ ✗
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TABLE 2 Summary of data collected (continued )
Assessment
Method of completion
(completed with/on) Purpose Level
Timeline
Screening Baseline 6 months 16 months
General Health Questionnaire – 12 itemsa Self-completed (S) Secondary end point ✗ ✗
SCIDS scale Self-completed (S) Secondary end point ✗ ✗ ✗
QUIS Researcher observations (R, S) Process measure Cluster ✗ ✗ ✗
Care home demographics Researcher interview (CM) Cluster ✗ ✗ ✗
Environmental Audit Tool Researcher observations (CH) Process measure Cluster ✗ ✗ ✗
Group Living Home Characteristics
questionnaire
Researcher assessment (CH) Secondary end point Cluster ✗ ✗ ✗
Assessment of Dementia Awareness and
Person-Centred Care Training audit
Researcher assessment (CM, CR) Pre-baseline benchmarking for
provision of additional person-
centred dementia awareness
training and usual-care
monitoring
Cluster ✗ ✗ ✗
Safety reporting Researcher assessment (CM) Safety Monthly following randomisation
Reporting unexpected SAEs Researcher assessment (CM) Safety As highlighted
CH, care home observations; CM, care home manager; CR, care home records; R, resident; RF, relative/friend proxy informant; S, staff; SP, staff proxy informant.
a Collection of General Health Questionnaire data from staff was ceased during the trial (see Summary of changes to project protocol).
TRIA
L
D
ESIG
N
A
N
D
M
ETH
O
D
S
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
18
Neuropsychiatric Inventory – nursing home version115
The Neuropsychiatric Inventory – nursing home version (NPI-NH) records a broader range of BSC including
delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/
indifference, disinhibition, irritability/lability, aberrant motor behaviour, sleep and night-time behaviour
disorders and appetite/eating disorders. The NPI-NH is a 12-item version designed for use with nursing-
home/care home populations and has good reported reliability and validity.115
Quality of life
Dementia Quality of Life measure proxy version116
The DEMQOL measure proxy version (DEMQOL-proxy) is a QoL questionnaire designed specifically for use
in people with dementia. It has 32 items covering mood, behavioural symptoms, cognition and memory,
physical and social functioning, and general health. It is administered by interview with a carer (formal
or family) of the person with dementia. The DEMQOL-proxy has acceptable psychometric properties for
measuring QoL in dementia117 and is modelled to enable the derivation of preference-based indices
(utility values), with the latter employed in the secondary cost–utility analyses.118
EuroQol-5 Dimensions, five-level version – self-report and proxy versions119
The EQ-5D-5L is an accepted standardised, five-item measure of health outcomes that provides a single
index value for health status120 covering usual activities, self-care, mobility, pain and anxiety/depression,
each with five response options (no problems, slight problems, moderate problems, severe problems and
unable to do the task). Both the self-report and the proxy versions were used in the trial.
Quality of Life in Late Stage Dementia121
The QUALID scale is an 11-item scale that rates the presence and frequency of QoL indicators over the
previous 7 days using proxy report. It is a reliable and valid scale for rating QoL in people with moderate
to severe dementia and has good internal consistency, test–retest reliability and inter-rater reliability.121
Quality of Life in Alzheimer’s Disease (care home)122
The QOL-AD measure is a 13-item self-report measure of QoL with good reported internal reliability,
test–retest reliability and convergent validity.122 It is reported to be reliable in use with people with mild to
severe dementia.123–125 The adapted version of the QOL-AD measure126 is a 15-item questionnaire developed
for use in care homes and it uses simple language and a four-response answer that is consistent across all
questions (poor, fair, good or excellent). It includes minor changes to the standard QOL-AD measure to
ensure relevance to those living in long-term care (e.g. an amendment of the wording of existing items, the
removal of questions on management of money and marriage status, and the addition of questions relating
to relationships with staff, one’s ability to take care of oneself, one’s ability to live with others and one’s
ability to make choices). It has good reported internal consistency.126
Demographics, health and health-care resource use
Resident demographics
Standardised demographic information (sex, date of birth, etc.) was collected by the researcher via interview
with the care home manager or other senior member of staff and a review of the resident’s care records.
Health-care resource use
This measure was adapted from one developed for a care home feasibility trial.127 The measure captured
the use of primary and secondary care, including hospital-based care [e.g. hospital and accident and
emergency (A&E) visits and stays], community-based care (e.g. GP visits and contact with other health-care
professionals such as physiotherapists and psychiatrists) and other costs (e.g. adapted beds and other aids)
incurred during the previous 3 months.
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Prescription medications
The prescription of medications within categories of interest (e.g. antipsychotic, benzodiazepine,
non-benzodiazepine anxiolytic, non-benzodiazepine antipsychotic, memantine, antidepressant,
cholinesterase inhibitor, anticonvulsant, mood stabiliser and pain relief), and the administration of these if
prescribed on an as required (PRN) basis, was recorded on a standardised case report form (CRF). This was
completed by the researcher through a review of residents’ medication records for the previous month.
Resident comorbidities
These were collected by the researcher using a standardised CRF through a review of residents’ care
records.
Dementia severity
Clinical Dementia Rating scale128
The Clinical Dementia Rating (CDR) scale is a well-utilised, standardised scale for rating the severity of
dementia, ranging from no cognitive impairment to severe or advanced dementia.129 Impairment on six
cognitive categories is rated and an algorithm is used to calculate the overall severity rating. Severity is
rated by a trained assessor via informal interview/conversation with the person, or with a proxy who knows
the person well. In this study, the CDR scale was completed by the researcher through interview with a
staff proxy who knew the resident well.
Functional Assessment Staging Test102
The FAST is a scale designed to record the functional severity of dementia. Scores range from 1 (no dementia)
to 7 (severe dementia) with levels 6 and 7 each having five sublevels. It is designed for use particularly in more
moderate to severe dementia. It is completed by proxy report from a caregiver.102
Staff measures
Staff work stress
General Health Questionnaire – 12 items130
The General Health Questionnaire – 12 items (GHQ-12) is a measure of stress/psychological well-being
used in the general population. It has good reported psychometric properties.131 It contains 12 items
related to mental health, each scored on a four-point scale of the frequency of symptoms or behaviours
(‘less than usual’ to ‘much more than usual’). Owing to poor return rates, the collection of GHQ-12 data
ceased during the trial (see Summary of changes to project protocol for further details).
Job or role efficacy
Sense of Competence in Dementia Care Staff scale132
The SCIDS scale is a user-friendly, self-complete, 17-item scale measuring staff members’ competence
in caring for people with dementia across four subscales (professionalism, building relationships, care
challenges and sustaining personhood). Each item is rated on a four-point scale of confidence (‘not at all’
to ‘very much’). It has acceptable internal consistency and test–retest reliability.132
Organisational measures
Care quality
Quality of Interactions Schedule133
The QUIS is an observational measure of the quality and quantity of staff interactions with residents during
care delivery, at the care home level. It records five types of interactions (positive social, positive care,
neutral, negative protective and negative restrictive) and has reported adequate inter-rater reliability and
TRIAL DESIGN AND METHODS
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sensitivity.134 The QUIS was completed via researcher observation, using a time-sampling technique in each
setting. In accordance with QUIS guidelines,133,135 observations of interactions at 5-minute intervals were
conducted in communal areas in the care home and recorded, then summarised into 15-minute intervals.
One-hour observations were completed at two time points (a.m. and p.m.) over 2 days within the same
week (7-day period) in line with care home activities (e.g. morning coffee break) in the most populated
communal area in the home. For the purposes of analysis in this trial, the proportion of interactions that
were positive (positive social and positive care) was used.
Care home environment and characteristics
Care home demographics questionnaire
This questionnaire, designed by the study team, collected organisational data regarding each care home
(size, type, ownership, geography, staff turnover, staff ratios, resident demographics, etc.) and its manager
(qualifications, length of time in post, leadership style, etc.).
Environmental Audit Tool136
The Environmental Audit Tool (EAT) is an instrument with reported adequate reliability and validity used to
differentiate between the quality of the physical environment in various types of dementia care facilities.136
It was completed by the researcher with the assistance of a staff member if required.
Group Living Home Characteristics questionnaire137
The Group Living Home Characteristics (GLHC) questionnaire is a measure of the style of care being
delivered in the care home. It examines how ‘home-like’ care delivered is. It includes four subscales (physical
environment, residents, relatives/other visitors and staff), each containing at least three related statements
answered according to a five-point scale (‘never’ to ‘always’). It was completed by the researcher.
Assessment of Dementia Awareness and Person-Centred Care Training audit99
For information on the Assessment of Dementia Awareness and Person-Centred Care Training (ADAPT)
audit, see Dementia training audit and provision of dementia awareness training.
Safety reporting and reported unexpected serious adverse events
For information, see Resident safety.
Sample size
The sample size was calculated to detect a moderate standardised effect size of 0.4 on the primary outcome:
the between-group difference in mean CMAI scores at 16 months. We assumed that the standard deviation
(SD) would be similar to that observed in a recently completed trial in UK care homes (7.5 points).66 The
moderate effect size translated into a minimum difference of 3 points. If greater variation in CMAI scores
was observed (SDs ranging from 15 to 20 points as reported by Zuidema et al.138) then, for the same effect
size, a difference of 6 to 8 points could be detected, respectively. A difference of 8 points on the CMAI score
is seen as indicative of real behavioural change.138 Fifty care homes, each recruiting 15 participants, provide
90% power at a 5% significance level to detect a clinically important difference of 3 points (SD 7.5 points),
assuming 25% loss to follow-up (as seen in Chenoweth et al.63) and an inflation factor of 2.0 (i.e. a cluster
size of 11 participants available for analysis after loss to follow-up and an ICC no greater than 0.166).
As provision of care is a further source of clustering and because the ICC was anticipated to be higher in
the intervention arm (based on clinical opinion), an allocation ratio of 3 : 2 was used, resulting in there
being 30 (450) and 20 (300) care homes (residents) in the intervention and control arms, respectively,
namely 50 (750) care homes (residents) overall.
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During the trial, the TMG, DMEC and TSC monitored loss to follow-up. This was higher than the anticipated
maximum of 25%, mainly owing to death rates. To maintain a statistical power close to 90% and to preserve
our ability to detect an effect size of 0.4 SDs, to maintain validity and to increase the generalisability of the
trial, we recruited additional, newly eligible, consenting residents from the randomised care homes 16 months
after randomisation and performed a cross-sectional analysis of the data (see Summary of changes to project
protocol).
Statistical and health economic methods
A comprehensive statistical and health economic analysis plan was developed and approved following
the approval of the design change. All analyses were performed once at final analysis in SAS® v9.4 (SAS
Institute Inc., Cary, NC, USA; SAS and all other SAS Institute Inc. product or service names are registered
trademarks or trademarks of SAS Institute Inc. in the USA and other countries.® indicates USA registration.)
or Stata® v14 (StataCorp LP, College Station, TX, USA).
A Consolidated Standards of Reporting Trials (CONSORT) flow diagram has been used to display care home
and resident pathways from registration to final follow-up (see Chapter 3, Recruitment and randomisation).
Analysis populations
The principal analyses were intention to treat (ITT), including all randomised care homes and all registered
residents, regardless of whether or not they received or adhered to their allocated intervention. A further
supportive analysis was planned of ‘compliers’, defined as care homes that would have received at least
one cycle of DCM to an acceptable level (with all components of the cycle completed) had it been offered
to them. Other thresholds of compliance that we considered were exploratory. Safety was summarised
on the closed-cohort sample of residents, as we were unable to obtain timely NHS Digital data on the
cross-sectional sample. The samples of staff and relatives/friends providing data (other than staff proxy
data) were so small that analyses based on them are descriptive and provided in the appendices only
(see Appendix 1, Table 31).
Missing data
In general, if there were no instructions in the manual on how to handle missing items (for the PAS,
NPI-NH, QUALID scale, SCIDS scale and EAT), prorating was used if < 25% of items were missing (based
on adopting a more conservative approach than that proposed by Staquet et al.139), otherwise the score
was assigned as missing. As the proportion of residents with notable missing primary outcomes was low,
we prorated for simplicity, despite assumptions underlying prorating not always being met.
The primary intended method for handling missing scale data in the cross-sectional analyses was to analyse
complete cases, under the assumption that data are missing completely at random (MCAR). For completeness,
we also report a sensitivity analysis using multiple imputation (MI), under the assumption that cross-sectional
data are missing at random (MAR). If the MCAR assumption were found not to hold true, then the primary
analysis would use the multiple-imputed data, assuming that data are MAR. The proportion of residents
missing in analyses of the closed-cohort sample was sizeable at 6 months and substantial at 16 months. As
death and moving care home were expected to be the most important predictors of missing closed-cohort
data, we expected that these data would be missing not at random (MNAR). We considered a range of
approaches to handling missing closed-cohort data (see Tables 9, 47 and 48), but report a tipping point
analysis140 for the primary analysis, which indicates the assumptions that would be required about the missing
data to change the conclusions.
For completeness, we also report an analysis using MI, under the assumption that closed-cohort data are
MAR, which assumes that residents registered at care home randomisation do not die during the duration
of the trial. The same variables were included in the imputation models, apart from the baseline questionnaire
scores: the baseline questionnaire score used in the imputation model was always the same as the outcome
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questionnaire score. The imputation model was done separately for different analysis populations: in the cross-
sectional analysis, baseline variables were care home summaries, whereas, in the closed cohort, individual-level
baseline information was used.
Screening, baseline, treatment and outcome summaries
The numbers of care homes approached, screened, eligible, consenting and participating, along with the
numbers of residents in the closed-cohort sample and the cross-sectional sample, were summarised in a
CONSORT flow diagram. Reasons for exclusion and the characteristics of screened residents were also
presented overall and across samples.
Baseline characteristics of care homes, care home managers and residents (closed-cohort and cross-sectional
samples) were summarised overall and for the intervention and control groups. In accordance with the
TIDieR checklist,141 summaries of treatment receipt were given by intervention component for DCM and by
parallel-group for usual care.
Baseline, 6- and 16-month outcomes were summarised for the intervention and control groups and
additionally for residents in the closed-cohort and cross-sectional samples at 16 months.
Primary effectiveness analysis
The continuous primary outcome of agitation (CMAI score) was analysed on the cross-sectional sample of
residents using a linear two-level heteroscedastic regression model that allowed the cluster and resident-level
random effects to vary by arm. The model adjusted for minimisation factors (care home type, size, provision
of dementia awareness training and recruiting hub) and average care home-level baseline characteristics
(dementia severity via CDR scale, age and CMAI score) as fixed effects. These variables were prespecified in
the protocol and age was added as an additional covariate. Unadjusted and adjusted ICCs, estimates and
corresponding 95% confidence intervals (CIs) were presented, by arm. A negative mean difference in
outcome favours the intervention. The primary analysis model was decided a priori in the statistical analysis
plan (SAP) before the data were unblinded and without reference to the data. It was consistent with/
followed on from the trial design.
Sensitivity effectiveness analyses
The robustness of the conclusions of the primary effectiveness analysis was assessed via a number of sensitivity
analyses. The primary effectiveness analysis was repeated:
l with an additional covariate categorising care homes by whether they were recruited before or after the
eligibility criteria change
l including care home size as a continuous covariate
l assuming that clustering is homogeneous across arms
l using CMAI-O and PAS scores in place of the CMAI
l using the closed-cohort sample in place of the cross-sectional sample, allowing dementia severity,
age and CMAI score to be included as covariates at the resident level.
Supportive effectiveness analyses
The treatment effect among ‘compliers’ was estimated using a series of complier-average causal effect
(CACE) models. Our main supportive analysis defined ‘compliers’ as care homes that would have received
at least one cycle of DCM to an acceptable level if it had been offered. Other thresholds were exploratory.
CACE treatment estimates were obtained from two-stage least squares instrumental variable regressions
(using the Stata command ‘ivreg’), using robust standard errors to allow for clustering effects. The model
adjusted for the same baseline variables as the primary analysis model, with the addition of the binary
variable ‘treatment received’ (number of DCM cycles received to a prespecified level).
For our mediation analysis, we used a parametric causal mediation approach to allow for interactions
between mediators and treatments, which the typical Baron and Kenny142 approach does not. We reported
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the natural indirect effect, which is the effect on outcomes of having the mediator present compared with
it not being present, for a number of prespecified intermediate variables (potential mediators). Analysis was
done on an ITT basis on the cross-sectional cohort. Each mediator was analysed separately assuming that
there was no unobserved confounding in treatment–outcome, mediator–outcome and treatment–mediator
relationships and that any mediator–outcome relationship confounders were not affected by treatment
allocation. We used parametric regression models using the Stata command ‘paramed’. A linear regression
model was fitted for the outcome variable. Logistic regression was used for the mediator variable.
In the MI, we also included the potential mediators.
In our moderator analyses, we explored whether or not the treatment effect differed depending on
prespecified baseline characteristics of either the care home or the resident. The primary analysis was
repeated, including each potential moderator, alongside the interaction between treatment and the
potential moderator. Analyses were performed on the ITT cross-sectional sample, subject to the availability
of data for each potential moderator.
Secondary effectiveness analyses
Secondary analyses were undertaken using the same principles as the analysis of the primary outcome.
For secondary outcomes (BSC, use of antipsychotic drugs and other psychotropic drugs, mood, resident
QoL, staff role efficacy, care quality and the quality of staff–resident interactions), three analyses were
performed:
1. cross-sectional analysis at 16 months
2. closed-cohort analysis at 6 months
3. closed-cohort analysis at 16 months.
The same covariates were included as for the primary analysis (for closed-cohort analyses, individual
resident-level covariates were used as appropriate). Cluster-specific linear two-level heteroscedastic
regressions were fitted in which outcomes were continuous (resident QoL). Population-average logistic
regressions were fitted, using generalised estimating equations (GEE), in which outcomes were binary
(BSC, use of antipsychotic drugs and mood).
Safety analysis
The number and proportion of residents in the closed cohort who died from any cause between randomisation
and 16 months was summarised by arm. The cause and place of death were also reported. The number of
hospital admissions per resident, the mean number of hospital admissions per resident, the average length of
hospital admission, the overall number of hospital admissions reported and the admissions by ward type were
summarised by arm and overall. No formal statistical comparison was undertaken between arms.
Health economic analysis
The economic evaluation was a within-trial analysis. We chose not to develop a decision-analytic model
for the evaluation. Although a model may have been useful in extrapolating any costs and health benefits
beyond the end of the trial, we felt that the measure of future effectiveness would be highly uncertain
and would require additional assumptions (e.g. about the duration of effect). The analysis followed the
reference case guidance for technology appraisals set out by NICE.143 The primary analysis was a cost–utility
analysis and it presented outcomes as QALYs using a health and personal social service provider perspective
(although some of these costs might, in practice, be paid for by residents themselves, this was not accounted
for in the analysis because it was deemed not to have any impact on the incremental costs of the DCM
intervention). A secondary cost-effectiveness analysis based on cost per unit of improvement in CMAI score
was also conducted.
Deviations from the statistical analysis plan
The following deviations from the SAP were decided on during data analysis. The primary health economic
analysis assumed that the Local Authority pays for the provision of care for residents (NHS and social care
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perspective). We had planned to conduct an analysis in which we assumed that some proportion of residents
paid for their own care home stay. Following further discussions with the research team, it was decided that
this element would be removed. The justification for this was that care homes are paid even when residents
are hospitalised and hence the source of payments for residency would not have an impact on the results.
In the SAP we stated that: ‘The validity of reports will be assessed by correlating scores between EQ-5D-5L and
those on the alternative measures (QUALID, QOL-AD) and by exploring the ability of the measure to distinguish
between known groups (for example, based on CDR)’ (Holloway I, Walwyn REA, Martin A, Meads D, Farrin A,
Surr C. Statistical and Health Economic Analysis Plan, University of Leeds, 2017). This was not included as
part of the required analysis within the original grant application. This analysis is still planned as additional
methodological research. For the trial analysis, we took the pragmatic approach and based the primary analysis
on staff proxy measures, as this was by some margin the most complete data.
Resource use and costs
Unit costs for health service staff and resources were obtained from national sources such as the Personal
Social Services Research Unit (PSSRU),144 the eMIT national database145 and the NHS reference cost database146
(see Appendix 1, Table 66, for a summary of unit costs).
Cost of intervention
The DCM intervention consisted of two components: (1) delivery and receipt of DCM training and
(2) implementation of the DCM process in care homes.
It was assumed that both components would require DCMmappers in the trial (two per intervention site) to take
dedicated time away from their usual care duties during the working day. The amount of time required for the
DCM training course was 4 days. The estimated amount of time required for the DCM process is reported in
existing DCM guidelines,83 based on the experiences of experts using DCM in practice settings. Data were also
collected during the trial to assess the validity of these estimates and, when this was shown to exceed the
assumed average, the impact of any additional staff time was assessed in sensitivity analyses. It was assumed that
additional time was not required for other care home staff to attend DCM briefing and feedback sessions, but
that these were arranged at handover and other convenient times for staff to attend as part of their usual duties.
To calculate the total cost of staff time, an hourly wage was estimated for a typical DCM mapper. This
incorporated data from the trial on the proportion of DCM mappers in particular roles (e.g. a care home
worker and a care home manager) and data published by the PSSRU on the hourly wages (or annual salaries
converted to hourly wages using standard methods) of workers in these roles. When relevant wage data
were not available from the PSSRU, we reviewed alternative sources, including recent job advertisements.
Additional costs of the delivery and receipt of DCM training included the course fees, training materials,
accommodation, meals, subsistence and travel. These were estimated using information from the DCM
course provider and data on the costs incurred in running the trial. A further additional cost of implementing
the DCM process in care homes was the consultancy fees, travel and subsistence expenses incurred through
employment of external DCM expert mappers to support the intervention implementation and fidelity
during the first DCM mapping cycle in each of the intervention sites. The primary analysis assumed that the
intervention was delivered as planned and that all cycles were implemented and costed. A sensitivity analysis
costed only the cycles that had been partially or fully implemented.
The primary analysis assumed that the Local Authority paid for the provision of care home care for residents.
As such, these costs were included in the health-care provider (NHS) and social care cost perspective.
Health-care resource use
Data on health-care resource use incurred during the previous 3 months were collected for each resident
at baseline, at 6 months and at 16 months. Medication use during the past month was captured at the
same time points (see Demographics, health and health-care resource use).
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Quality of life/utility
Quality of life was measured in the trial at baseline, at 6 months and at 16 months using the EQ-5D-5L,
completed by care home residents, and the EQ-5D-5L-proxy, completed by staff and relatives.120 A recently
generated UK general population tariff147 was used to calculate the utility scores and a (5L to 3L) mapping
algorithm was used as a sensitivity analysis.148
Utility values were also calculated using the DEMQOL-proxy tool (DEMQOL-proxy-U), which was completed
by staff and relatives. A UK population tariff was used to calculate utility scores.118 The main cost–utility
analyses were based on the EQ-5D-5L utility, but sensitivity analyses were conducted based on DEMQOL-
proxy-U.
Taking a pragmatic approach, we elected to base the primary analysis on EQ-5D-5L data from the staff proxy
at all three time points, as this represented the most complete set of responses. However, we conducted
a sensitivity analysis employing resident-completed EQ-5D-5L data when they were available at all three time
points. When such data were not available, we used data from relative proxies (if available at all three time
points) and, finally, when this was unavailable, from staff proxies.
Analysis
The primary economic analysis was a cost–utility analysis over 16 months presenting incremental cost-
effectiveness ratios (ICERs) for intervention versus control, with effects expressed in terms of QALYs.
As the clinical efficacy analyses used agitation as the primary end point, a secondary cost-effectiveness
analysis based on change in CMAI score over 16 months was also conducted.
Total QALYs were calculated using an area under the curve approach between adjacent utility measure
completions using EQ-5D-5L and DEMQOL-proxy utilities captured at baseline, at 6 months and at
16 months. If residents died, their utility value was assumed to be zero and their data were retained in
the analyses. Quality of life was assumed to change from last completion value to zero in a linear fashion.
Total costs were estimated using the resource use questionnaires at 6 and 16 months. It was assumed
that reported resource use during a 1-month (for medications) or 3-month (other costs) period remained
constant between time points in the trial (e.g. the 10-month period between follow-up at 6 and 16 months).
To capture the costs incurred prior to death, a daily cost was estimated based on each resident’s previous
resource consumption (at baseline or at 6 months) and applied until the date of death.
Incremental costs and QALYs (or CMAI scores) were estimated using a seemingly unrelated regression
(SUR) approach, which consisted of a system of regression equations that can recognise the correlation
between individual costs and outcomes:
Model 1 (cost):
TotalCosti = αi + β RandTrtch + εi. (1)
Model 1A (cost-sensitivity analysis):
TotalCosti = αi + β1 RandTrtch + β2 T0_Costsi + β3 T0_CDRi + β4 T0_Agei + εi. (2)
Model 2 (QALYs):
TotalQALY i = αi + β1 RandTrtch + β2 T0_QALYi + β3 T0_CDRi + β4 T0_Agei + εi, (3)
where T0 = baseline and CDR = CDR score.
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So that the economic analysis was consistent with the statistical analysis, age and baseline CDR scores
were included in the regression model, in addition to baseline QALYs (Model 2 above). Although costs
were not significantly different at baseline, these same baseline characteristics were included in the SUR for
costs in a sensitivity analysis.
Incremental cost-effectiveness ratios were calculated for both cost per QALY gain and cost per unit
improvement in CMAI score. We used the NICE willingness-to-pay per incremental QALY threshold
[£20,000 = lambda (λ)] to determine whether or not the intervention was cost-effective. Interventions
with an ICER under £20,000 per QALY are generally considered cost-effective. There is no such
willingness-to-pay threshold to aid the interpretation of changes in CMAI score, but we framed this
in the context of other study results.
Discounting at the NICE preferred rate of 3.5% per annum for costs and effects was conducted for values
after 12 months (i.e. for the final 4 months of the trial).
Net-benefit analysis
A net-benefit regression framework was also employed to allow parametric analysis of the incremental
costs and benefits of the intervention. Net monetary benefit (NMB) is calculated using individual-level total
costs, total QALYs and the cost-effectiveness threshold (λ = £20,000):
NMB = (λ × QALYs)− costs. (4)
Linear regression models were used to regress treatment allocation on individual-level (‘i’ for individuals in
the trial) estimates of NMB, while controlling for other observable trial-arm imbalances (e.g. dementia
severity, agitation levels or sociodemographics):
NMBi = αi + βRandTrti + δ Xi + εi, (5)
where RandTrt is the treatment allocation and X is a vector of observable characteristics.
We examined heterogeneity in the treatment effect by compliance in a multilevel model accounting for
clustering at the care home level:
NMBi = αi + βRandTrti.Ci + δ Xi + εi, (6)
where C is a categorical variable representing care home compliance with the intervention as measured by
the number of cycles in which all four DCM components were completed to an ‘acceptable’ level (at the
care home level): zero, one, or two to three cycles.
Control-arm care homes were in the reference category, with the coefficient (β) being a measure of
incremental net benefit.
To be consistent with the statistical analysis, we also conducted a CACE analysis on NMB, which is designed
to account for the potential endogeneity of compliance using a two-stage least squares instrumental
variables approach.
Missing data
We ran the resident-level analysis on complete cases [complete-case analysis (CCA)] initially, which required
data on total QALYs (based on various EQ-5D-5L or DEMQOL measures, depending on the analysis) and total
costs. However, owing to the extent of missing data, the primary analysis was based on data for which missing
values were imputed using MI. This assumed that the data were MAR. The first stage of the imputation
process used mean imputations to estimate the baseline values of each EQ-5D-5L, DEMQOL-proxy measures,
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CMAI score and time-invariant characteristics (age/date of birth at baseline), following guidance in a paper by
Faria et al.149
Second, MIs by chained equations (MICE) was used to impute missing EQ-5D-5L, DEMQOL-proxy
measure (index values rather than individual items) and CMAI score at 6 months and at 16 months, and
individual components of total costs at all three time points. The number of individual components of total
costs (n = 15) used in the imputation process was decided, taking a pragmatic approach. As a general rule,
at each time point, high-cost and common resource items (e.g. hospital visits and stays) were imputed
individually and less common items were imputed on a bundled basis.
The number of imputations (n = 48) reflected the ratio of missing to complete data. We accounted for
clustering within care homes. Rubin’s150 rules were used to combine parameter estimates of the MIs.
Cross-sectional cohort analysis
The change in the trial to an open-cohort design meant that additional data for some residents were available
at 16 months, despite them not being in the trial at baseline or at the 6-month follow-up. For the primary
analysis, we used data only from those residents consented into the trial at baseline (the original cohort).
However, to be consistent with the statistical analysis, an additional analysis was conducted incorporating
the costs and QALYs for those residents providing data only at 16 months (the cross-sectional cohort).
When data on both costs and EQ-5D-5L were available only at 16 months in the cross-sectional cohort,
we imputed the total cumulative costs and total QALYs for the whole trial period using a two-stage
imputation process. First, mean values of the total costs and total QALYs generated in the imputations
described above (n = 48) were used to replace the missing data on total costs and total QALYs in the
closed cohort. Second, data on total costs and total QALYs for each individual in the closed cohort
(n = 726) (including the values that had been imputed in the first stage) were used to impute the total
costs and QALY data for all individuals in the cross-sectional cohort, using the MICE method and Rubin’s
rules described above, accounting for recorded data at 16 months, including costs and QoL. This enabled
calculation of an ICER for the cross-sectional cohort. As this approach relied on an unusual two-stage
imputation process for individuals who had no recorded data at baseline, the results should be considered
illustrative only and be treated with due caution. This approach also relied on an assumption that survival
was independent of the intervention and the time spent in the care home, as residents providing data only
at 16 months would have survived until 16 months had they been in the care home for that duration.
Sensitivity analyses
Deterministic sensitivity analysis of the ICER was undertaken to test the robustness of the results to
changes in the analytical approach and to assumptions made. For example, we re-ran analyses exploring
the impact on results of different approaches to costing, of handling missing data and of employing
alternative utility capture methods.
A non-parametric bootstrapping analysis was also conducted to determine the level of sampling uncertainty
around the ICER estimates by generating 10,000 estimates of incremental costs and benefits, using the
combined estimates of the multiple-imputed data sets (n = 48) using Rubin’s150 rules, and accounting for
clustering in care homes. The bootstrapped estimates were used to generate the cost-effectiveness plane
and the cost-effectiveness acceptability curve (CEAC).151
Process evaluation and assessment of treatment implementation
Aims and research questions
The process evaluation was designed to examine the process, challenges, benefits and impacts of the trial
to identify the processes and factors associated with degrees of successful and unsuccessful intervention
implementation.
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The aims of the process evaluation included:
l describing adherence to the required components of the intervention and the quality (or fidelity) of
intervention delivery
l understanding staff members’, residents’ and relatives’ perceptions of the impacts of the intervention
l understanding the barriers to and facilitators of implementing DCM in practice.
The process evaluation answered research questions aligned to the Medical Research Council guidelines on
process evaluations152 and included implementation, mechanisms of impact and context.
l What was implemented?
¢ What was the process of setting up the intervention in each care home?
¢ Did this differ, and, if so, how did it differ, from the intended process as outlined in the protocol?
¢ How many cycles of DCM were delivered in each care home? (Dose + Reach)
¢ To what extent did each cycle in each care home meet the planned delivery as set out in the
protocol? (Fidelity + Reach)
¢ Did care homes deviate from the delivery of the intervention as set out in the protocol and, if so, how?
l How did participants react to the intervention?
¢ What were mappers’, managers’, residents’, relatives’ and staff members’ experiences of the
intervention and its implementation?
¢ What were mappers’, managers’, residents’, relatives’ and staff members’ perceptions of the impact
of the intervention?
¢ Did the intervention have any perceived or unexpected impacts or consequences?
¢ For the perceived impacts, through what mediators/processes did each group perceive the
intervention to have operated?
¢ Did the intervention or its mechanisms of impact operate in any unexpected ways?
l What contextual factors shaped if, and how, the intervention was implemented or worked?
¢ What were the perceived barriers to and facilitators of intervention implementation, mechanisms of
impact and the perceived impact from the perspective of mappers, DCM expert mappers, managers,
staff members, residents and relatives?
¢ How did care homes that demonstrated different degrees of intervention implementation manage
and address barriers to and facilitators of intervention implementation?
The process evaluation and implementation assessment was intended to support the refinement and
improvement of intervention efficacy and the sustainable implementation of the intervention over time,
if the intervention was found to be effective.153
Design of the process evaluation
A mixed-methods approach to data collection was used, involving quantitative and qualitative components
to embed the process evaluation as part of the main trial data set.
The quantitative data set included an assessment of the levels of adherence and fidelity in each care home,
utilising data provided by the mappers from each care home at each cycle. These data included details
on the ‘dose’ and quality of DCM use in relation to briefing (the number of briefing sessions held and the
proportion of care home staff receiving briefing), mapping cycles (the number of mapping sessions, the
number of residents observed, the length of the mapping period and the number of mappers taking part),
feedback sessions (the number of feedback sessions held and the proportion of care home staff receiving
feedback) and DCM and action-planning documentation (successful completion of standard mapping
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documents during each cycle using the standard templates provided and the number of action plans
developed per resident and at the home level).
The qualitative data were collected from a subset of 18 intervention homes using semistructured interviews
with residents, the care home manager, mappers, staff members, relatives and residents. Homes that had
achieved varying degrees of success with DCM implementation (no full cycles, at least one full cycle, two or
more full cycles) were purposefully selected to explore the factors associated with successful and unsuccessful
implementation. Although the selection of care homes took place before the final follow-up data collection
point, the process-evaluation interviews took place after all outcome data had been collected in each home
(i.e. at the end of the 16-month follow-up data collection). Semistructured interviews were also conducted
with the DCM expert mappers to explore their experience of supporting the implementation of DCM
within the intervention homes. To enable links between the qualitative and quantitative data, researchers
undertaking the qualitative data collection were provided with implementation data by the CTRU from the
first two cycles in the home prior to the interviews.
Sampling for the quantitative and qualitative data collection
For the quantitative data analysis, frequency data from the mapping cycles in all intervention homes
were used to assess dose, adherence and fidelity, and to understand the variation in the levels of DCM
implementation across homes.
For the qualitative data collection, purposive sampling was used to select a subset of 18 homes that
had achieved varying degrees of success with DCM implementation in order to explore factors associated
with this in greater detail. Owing to the staggered recruitment of care homes and the need to set up the
process-evaluation data collection dates with home managers ahead of time, participating homes had
to be identified before all three cycles of mapping were due to have been completed. These homes
were stratified into three equal groups (six per group) according to if they were considered likely to be
‘successful implementers’ (more than two cycles completed), ‘partial implementers’ (one or two cycles
completed) or ‘unsuccessful implementers’ (fewer than one cycle completed) of DCM.
Homes that differed according to key characteristics with the potential to affect DCM implementation,
including location (six from each hub), size (large ≥ 40 beds vs. medium or small < 40 beds) and type of
home (nursing, dementia or general residential), were also accounted for in the sampling.
Participant eligibility
Residents from homes taking part in the process evaluation were eligible if they were deemed to have the
capacity to consent and were able to take part in a brief interview. Staff were eligible to take part if they
were a permanent or contracted member of staff. Relatives/friends were eligible if they had visited the care
home at least once a month during the trial.
Identifying staff and relatives/friends to approach was undertaken in conjunction with the home manager
and included identification of the staff members who had played a key role in intervention delivery.
All potential participants were provided with verbal and written information about the interview, were
given time to consider taking part and signed a consent form if they were willing to participate [see
www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed July 2019)]. Mappers had already
provided consent to take part in the process evaluation as part of their initial consent to become mappers.
Data collection, transcription and storage
All researchers were trained in qualitative interviewing ahead of data collection to ensure consistency in
the approach. Resident interviews were brief, using a conversational style informed by a flexible interview
schedule. Staff and relative/friend interviews were conducted using a semistructured format informed by a
topic guide. The interviews focused on experiences of DCM implementation, with prompts to encourage
interviewees to discuss the various stages of DCM implementation, the successes, challenges and impacts
of implementation, and any changes required to improve DCM implementation or impact in the care
TRIAL DESIGN AND METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
30
home, as well as future plans for DCM within the care home. Mappers who had left the home during the
trial were not interviewed. Relatives/friends of resident participants who had died during the trial were not
contacted regarding the process-evaluation interviews. Interviews were conducted within the care homes,
in a private room with no other individuals present, and an alternative method of telephone interviews was
offered to all relatives/friends [see www.journalslibrary.nihr.ac.uk/programmes/hta/111513/#/ (accessed
July 2019) for copies of interview topic guides].
The interviews were audio-recorded using a digital audio-recording device and were professionally
transcribed by a researcher independent to the study. Any potentially identifying information about the
participants was anonymised or removed during transcription. Audio files were securely transferred in
encrypted format and stored securely on computers in university offices.
Data analysis
Data analysis utilised a framework analysis approach.154 The initial data analysis by all researchers involved
in data collection informed the development of a coding matrix, which guided and created a structure for
further data analysis. The focus of the coding matrix (and therefore of the data analysis) was on experiences
of utilising and implementing DCM, particularly on identifying patterns and variations in implementation,
barriers to and facilitators of implementation, and the impacts of DCM implementation. The coding matrix
helped to assimilate the development of coding categories between the team of researchers that undertook
the analysis. Each transcript was independently analysed by two researchers to ensure that key themes were
identified. Development of the coding categories continued throughout the data analysis, informed by
the emerging themes and analytic thoughts of the researchers. Codes and themes were compared and
contrasted across homes and between different types of respondents to develop an in-depth, nuanced and
contextualised understanding of the implementation and the impacts of DCM.
The quantitative data that informed the process evaluation (measures of adherence and fidelity in each home)
were collected and analysed as part of the main trial data set (as described in Screening, baseline, treatment
and outcome summaries). Findings from the quantitative data were integrated with the qualitative data to
provide an in-depth understanding of DCM implementation and the issues surrounding implementation.
Measurement of adherence
Adherence to the prescribed processes for intervention delivery was monitored from randomisation to
check that both mappers attended DCM training on time and passed the assessment. At each expected
round of mapping, adherence to the processes was monitored to check that mappers delivered all
components of the DCM cycle as intended and to the required quality (fidelity) and delivered three full
cycles (dose). Anonymised copies of all observation data collection sheets, feedback reports and action
plans were collected to assess fidelity. Data were also collected from the DCM expert mapper about cycle
1 completion, following their support of mappers through their first cycle of mapping. For the purposes
of the trial, DCM was considered as comprising four required components: (1) briefing, (2) observation,
(3) data analysis, reporting and feedback and (4) action-planning.
Care homes were classified according to their compliance with the intervention at each cycle, namely as
‘acceptable’, ‘partial’ or ‘none’.
For a cycle to be classified as:
l acceptable, the care home must have completed all four components
l partial, the care home must have completed one to three components
l none, the care home must have completed none of the components.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
If paperwork was not received for specific components and the researchers had been unable to ascertain
verbally from mappers if particular cycle components had been completed, the following rules were used
to determine whether a component had been completed:
l If there was paper documentation for observation, it was assumed that briefing had also taken place
(at least two components were completed).
l If there was paper documentation for feedback, it was assumed that briefing and observation had
taken place (at least three components were completed).
l If there was paper documentation for action-planning, it was assumed that briefing, observation and
feedback had taken place (all components were completed).
An assessment of the quality of each component was also conducted when paperwork had been returned,
including whether or not all of the required DCM coding frames and accompanying qualitative notes had
been used during mapping; if the standard feedback report format had been used and all parts of this
had been completed (group data summary and individual data summary for each resident); and whether
or not the standard action-planning template had been used, and if there were action plans developed at
the care home level and for each resident mapped.
Summary of changes to project protocol
Ten substantial amendments to the protocol and associated trial documentation were made during the trial.
Internal pilot
Initially, two homes were recruited to the study early to allow internal piloting and review of trial processes,
procedures, measures and tools ahead of recruitment of further care homes. Data from these homes were
included in the trial. Changes to the original project protocol, implemented following this pilot, are reported
in detail in the published protocol,98 in Table 3 and Appendix 2.
Design change
Our original sample size estimation, to detect a clinically important difference of 3 points (SD 7.5 points)
in the primary end point of agitation using the CMAI questionnaire, assumed a 25% loss to follow-up
16 months after care home randomisation. If loss to follow-up was higher than anticipated (but no greater
than 35%), our intended sample size of 750 residents still provided more than 85% power at a two-sided
5% significance level to detect a moderate effect size, equating to 0.4 SDs.
Through monitoring loss to follow-up within the trial, we determined by November 2015 that the rate would
exceed our lower limit of 25%. Using data from care homes randomised into the trial up to 27 November 2015,
we predicted that loss to follow-up at 16 months would be in the range of 32% to 48% (see Appendix 3,
Figures 10 and 11). As such, continuing the trial as planned would not provide sufficient power for statistical
analysis of the primary end point. An amendment to the trial design was required to ensure that the results
of the trial were robust and generalisable. After considering all of the available options, we proposed
recruiting additional residents at follow-up (i.e. a move to an open-cohort design) (see Appendix 3). All those
consenting to take part (residents already participating in the trial and consented at baseline, as well as
additional residents consenting at 16 months) provided data at 16 months.
The key impact of this design change was to increase the size of the cohort at follow-up to maintain the
power of the trial and its ability to detect the effect size of 0.4 with 90% power (see Appendix 3, Table 67).
Sample size calculations
With an estimated 48% loss to follow-up, we expected to lose 360 residents before the 16-month follow-up,
resulting in data at all three time points from 388 residents. All of the other parameters (significance level,
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two-sided test and an ICC of 0.1) remained the same. Consideration was given to recruiting only a proportion
of eligible residents at each home at 16 months.
Three possible scenarios of additional recruitment were considered (an average of three additional residents
per care home, recruiting 35% of residents lost to follow-up in each care home or replacing only 25% of
residents lost to follow-up in each care home) and all provided sufficient power to detect the effect size
of 0.4 (89%, 91% and 90% power, respectively). The TMG, the oversight committees (TSC and DMEC) and
the funder agreed that imposing a recruitment ceiling at 16 months would be open to selection bias and
that statistical power and the ability to generalise could be limited. Recruitment processes could also be
protracted as a result of allowing time for decision-making via a Personal Consultee (i.e. should this be
a refusal to take part, further resident–consultee dyads would then need to be approached, thereby
considerably lengthening the recruitment process, researcher workload and thus cost).
Researchers were therefore instructed to recruit as many residents as possible to minimise bias. Numbers
were monitored to ensure that at least three extra residents from each remaining care home were recruited.
TABLE 3 Summary of substantial amendments to the protocol and associated trial documentation
Amendment
number Date Summary of amendment
SA1 10 January 2014 Modification to method and content of health resource data to be collected,
including from medical records and NHS Digital (previously Health and Social Care
Information Centre)
SA2 22 April 2014 Modifications to care home information sheet to improve clarity and provide
additional information following review by the PPI panel
SA3 26 June 2014 Modifications to care home recruitment process; resident, staff and relative eligibility
criteria; screening of proxy informants; translation of trial documentation; process
for completion of independent assessments; monitoring of DCM implementation;
relative/friend withdrawal; resident safety monitoring; and information included on
participant information sheets and consent forms (for mappers, staff proxy and
residents including consultees). In addition, clarification of mutually exclusive staff
roles, amendment of assessment measures to be used, establishment of a DMEC
and development of a short form of the resident information sheet
SA4 10 September 2014 Personal Consultee introductory letter and reminder letter, and relative/friend proxy
informant introductory letter approved
SA5 15 January 2015 GP letter to accompany guidance on antipsychotic prescribing approved
SA6 15 January 2015 Change of sponsor, modification to care home eligibility criteria, modification to
resident eligibility criteria and modification to randomisation stratification criteria
SA7 22 October 2015 Modification to requirements for witnessing resident consent, addition of SMS
reminders for mappers and modifications to participant information sheets and
consent forms
SA8 4 February 2016 Detail added to the protocol on conduct of the process evaluation, modifications to
staff measures booklet, modification to continued attempts to recruit relative/friend
proxy informants post baseline and modifications to participant information sheets
SA9 15 April 2016 Change to open-cohort design, with additional recruitment of resident participants
at the 16-month follow-up and associated changes to trial documentation
approved; modification to staff proxy informant consent processes; modification
regarding requirements to check care home indemnity insurance; introduction/
modification of documents to support process evaluation and to proposed process
evaluation methods and processes; and modification to process for assessing
ongoing capacity of Personal Consultees
SA10 25 July 2016 Modification to data collected during process evaluation and additional text
messages to remind mappers about mutually exclusive staff roles
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The benefits of the design change were:
l An ability to detect intervention effects at the care home level (as the intervention is aimed at the whole
care home).
l Conclusions could be generalised to a broader population of residents (i.e. not just to those still residing
in the care home 16 months following randomisation).
l We would be able to analyse the data for a cross-sectional (i.e. open-cohort) and closed-cohort
(longitudinal) design.
l We minimised selection bias by providing an objective criterion for inclusion (all eligible consenting
residents).
l Recruitment processes were resource-efficient, as all eligible residents were approached to participate at
a single time point.
l We would be less reliant on assumptions regarding imputation for missing data.
As well as maintaining power and increasing generalisability, the agreed design change incurred minimal
additional cost.
Three of the authors (RW, AF and CS) have since secured additional funding from the Medical Research
Council155 to conduct a methodology ‘bolt on’ to the EPIC trial regarding the use of open-cohort designs in
clinical trials. This recognises the importance of considering alternative trial designs for the conduct of
studies in populations with potential large loss to follow-up rates.
Resident eligibility (16 months after randomisation)
The following inclusion criteria were applied for additional residents recruited at the 16-month follow-up:
l a permanent resident within the care home or unit(s) taking part in the trial
l a formal diagnosis of dementia or a score of 4+ on the FAST,102 rated by the home manager or another
experienced member of staff
l sufficient proficiency in English to contribute to the data collection required for the research.
Residents were not eligible if they:
l were already a DCM EPIC trial participant
l declined (personally or via their Personal or Nominated Consultee) to participate in the trial at baseline
l moved to the care home (or participating EPIC unit) fewer than 3 months prior to screening
l were known by the care home manager and/or relevant senior staff member to be terminally ill
(e.g. formally admitted to an end-of-life care pathway)
l were permanently bed-bound/cared for in bed
l were taking part in or had recently taken part in another trial that conflicted with the DCM intervention
or with data collection for the DCM EPIC trial.
Resident safety
Given that the intervention was at the care home level, was very low risk and was non-invasive, and that
trial consent was for data collection, minimal reporting of safety data was required. Given that the trial
population was care home residents with dementia, adverse events were expected as part of usual care
and, therefore, data on SAEs were collected only on consented trial residents.
A SAE was defined as an untoward event that resulted in death, was life-threatening, required or prolonged
existing hospitalisation, was significantly or permanently disabling or incapacitating, or was otherwise
considered medically significant by a clinician. It was expected that residents would be admitted to hospital
in the event of a SAE; therefore, the safety reporting form collected information on hospitalisation, including
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the reason, the duration and the outcome. All deaths occurring from the date of consent to the final data
collection visit were recorded on a trial death form and reported electronically to the CTRU within 1 working
day of becoming aware. These data were collected by the researcher monthly, via a telephone call to the care
home manager/research lead, from the point of randomisation to the completion of the 16-month follow-up.
Summaries of SAEs were reviewed annually by the trial DMEC.
Any SAE occurring to a resident that, in the opinion of the care home manager/lead and chief investigator,
was related to research procedures and was unexpected needed to be reported to the main REC.
Safeguarding
It was possible that the researchers might observe poor or potentially abusive practice while visiting care
homes participating in the trial. The definition of abuse detailed in the Department of Health156 guidance
was utilised. In the case of observing suspected abuse, the relevant Local Authority ‘Safeguarding Adults’
processes were followed after a discussion of the incident between the researcher and the recruitment
centre lead/chief investigator.
Patient and public involvement
Patient and public involvement was embedded in both the design and the conduct of the trial through lay
advisors on the investigator team and a Lay Advisory Group (LAG). The main focus was ensuring that PPI
input was meaningful and that a PPI strategy was written at the beginning of the trial to outline how their
contribution was envisaged.
Lay advisors
Three dedicated lay advisors were part of the investigator team: one individual as a member of the TSC
and two as members of the TMG (one of whom was also a co-applicant). These individuals provided a
user perspective on the design and conduct of the trial. They attended regular meetings throughout the
trial and ensured that the TMG considered issues of importance to people living with dementia, their families
and people working in care homes. Examples of advice included simplification of participant information and
provision of assistance to the researchers to do this, and a suggestion that a short, pictorial version of the
resident information sheet was developed. These individuals also reviewed newsletters before they were
circulated, making suggestions such as increased font size to improve the accessibility of these documents to
the families of people living in care homes. The lay advisors collaborated on the development and writing of
a trial summary that was prepared for care home managers. They also supported the preparation of this
section on PPI.
Lay Advisory Group
The LAG was recruited through a partnership agreement with the Alzheimer’s Society, which hosted the
LAG meetings. The LAG consisted of eight members: a person living with dementia, relatives of people
living with dementia, the manager of a care home, a person working for a care organisation and a
representative from the Alzheimer’s Society. The LAG met three times during the trial to discuss progress,
initial results and dissemination strategies. A fourth meeting was held to discuss final trial outputs in
February 2018, following completion of the trial in December 2017.
Alongside attendance at LAG meetings, individuals reviewed trial documents such as information sheets
and consent forms prior to ethics approval being sought. Individuals from the group also reviewed the
intervention protocols. All trial newsletters were reviewed by the LAG prior to distribution. Members of
the LAG had the opportunity to review the publication plan and be involved with all publications arising
from the study. The decision on whether or not to be involved in each publication was based on if, as a
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group, members considered that it would be beneficial for a PPI representative to be involved and if it was
relevant for them to provide input.
The LAG was responsible for devising the non-academic dissemination strategy for the trial. Such avenues for
dissemination included practitioner articles, a lay article for the Alzheimer’s Society magazine, infographics
and radio interviews, as well as dissemination on social media. The LAG will continue to be involved in
the design and dissemination of these publications, including the design of the trial results summaries,
as well as posters for care homes and for individual trial participants (i.e. residents, relatives/friends, staff
members, etc.).
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Chapter 3 Results
Recruitment and randomisation
Cluster recruitment
The numbers of care homes randomised and residents registered are summarised in Figure 1 by treatment
arm, at baseline, at 6 months and at 16 months following randomisation for the original cohort and for
the cross-sectional sample.
A total of 335 care homes were screened for entry into the trial. Of these, 241 randomly sampled care
homes were approached and 94 homes expressing interest were formally assessed using the eligibility
criteria. Of the 63 eligible care homes, 51 consented to take part and, following one consent withdrawal,
50 care homes were randomised into the trial (21 from Yorkshire, 15 from London and 14 from Oxford;
see Appendix 1, Table 26). Nineteen care homes (38.0%) were randomised to the control group and 31
(62.0%) to the intervention group. Care homes were randomised over 16 months, from October 2014 to
January 2016.
Resident participant flow and recruitment
Original cohort
A total of 1564 residents were screened for eligibility from consenting care homes, of whom 1069 (68.4%)
were eligible. Of those who were eligible, 781 (73.1%) were consented and, of those, 743 (95.1%)
were registered. Finally, of those registered, 726 (97.7%) were consented and registered at the point of
care home randomisation. The reasons for exclusion from the trial are summarised overall and by hub in
Appendix 1, Table 27. Residents in the original cohort were registered over 15 months, from October 2014
to December 2015.
Additional resident recruitment at 16 months
Following the approved design change, a further 1444 residents were screened from 48 care homes
16 months after randomisation (see Appendix 1, Table 27). This included all residents already participating
and those who had declined to take part when approached at baseline, who were then recorded as
ineligible, alongside participants failing to meet other eligibility criteria. The first two care homes randomised
did not screen additional residents, as agreement for the design change was received after these care homes
had completed the 16-month follow-up. Of the 1444 residents, 421 were eligible, 266 consented and
261 residents were subsequently registered (99 residents in control homes and 162 in intervention homes).
A lower proportion of residents in London were ineligible as a result of being permanently bed-bound or
terminally ill.
There was a higher proportion of ineligible residents of those screened (owing to not having a formal diagnosis
of dementia) and of consent refusals in the intervention arm than in the control arm (see Appendix 1, Table 28).
The additional residents were screened over 12 months, from June 2016 to May 2017.
Cross-sectional sample
Overall, at 16 months, a total of 675 residents were included in the cross-sectional sample: 414 residents
from the original cohort who reached 16 months, and 261 additionally recruited residents. There were
regional differences between hubs in resident ethnicity and funding type, with London reporting the
lowest proportion of white residents and Oxford reporting the highest proportion of Local Authority
funding (see Appendix 1, Table 29).
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Baseline
• Residents died, n = 55
• Residents withdrawn, n = 0
• Residents moved out, n = 7
• No CMAI score at 6 months, n = 2
• Residents died, n = 54
• Residents withdrawn, n = 1
• Residents moved out, n = 6
• No CMAI score at 16 months, n = 0
• Residents died, n = 65
• Residents withdrawn, n = 1
• Residents moved out, n = 16
• No CMAI score at 6 months, n = 2
Care homes screened
(n = 335)Care homes not approached, as sufficient
number reached in area
(n = 37; 11.0% of screened) 
Approached
(n = 241/335, 71.9%)
No response
(n = 40; 16.6% of approached)
(Several attempts at contact failed)
Not interested
(n = 107; 44.4% of approached)
• Not interested in research, n = 29 (27.1%)
• Organisation declined, n = 27 (25.2%)
• No/new manager, n = 11 (10.3%)
• Too busy, n = 10 (9.3%)
• Care home closed, n = 6 (5.6%)
• Taking part in other research, n = 4 (3.7%)
• Ineligible, n = 4 (3.7%)
• Not interested in intervention, n = 4 (3.7%)    
• Other, n = 2 (1.9%)
• Reason not known, n = 10 (9.3%) 
Interested
(n = 94/241, 39.0%) Not eligible
(n = 31; 33.0% of interested)
• Insufficient number of residents with dementia,
   n = 22 (71.0%)
• Had used DCM™ in last 18 months, n = 5 (16.1%)
• Not suitable for participation (i.e. CQC status,
   admissions ban), n = 2 (6.5%)
• Staff unavailable to attend DCM™ training, n = 1
   (3.2%)
• Involved in conflicting research, n = 1 (3.2%)
Eligible
(n = 63/94, 67.0%)
Not consented
(n = 12; 19.0% of eligible)
• Staffing issues, n = 4 (33.3%)
• Declined, n = 3 (25.0%)
• Care home being sold, n = 1 (8.3%)
• Care home under administration, n = 1
   (8.3%) 
• No response from care home, n = 1 (8.3%) 
• Care home not required; sufficient
   number reached in area, n = 1 (8.3%)
• Could not recruit minimum
   number of residents, n = 1 (8.3%)
Consented
(n = 51/63, 80.9%)
Randomised
50 care homes and
726 residents registered
at randomisation 
Withdrawn prior to randomisation
(n = 1, 2.0%)
• Staffing issues, n = 1 (100%)
No longer eligible
(n = 57; 17.0% of screened)
• CQC status, n = 36 (63.2%)
• Insufficient number of residents with dementia,
   n = 14 (24.6%)
• Insufficient number of permanent residents,
   n = 2 (3.5%)
• Participating in conflicting trial, n = 1 (1.8%)
• Other, n = 4 (7.0%)
Residents screened
(n = 1564)
• Eligible, n = 1069/1564 (68.4%)
• Consented, n = 781/1069 (73.1%)
• Registered, n = 743/781 (95.1%)
Control
Care homes
(n = 19)
• Assessed residents, n = 308
• Median residents/home (min., max.) = 14 (9, 36)
Intervention
Care homes
(n = 31)
• Assessed residents, n = 418
• Median residents/home (min., max.) = 13 (8, 21)
Care homes
(n = 19)
• Assessed residents (closed cohort), n = 244
• Median residents/home (min., max.) = 11 (5, 25)
Care homes
(n = 31)
• Assessed residents (closed cohort), n = 334
• Median residents/home (min., max.) = 10 (5, 19)
6-month
follow-up
16-month
follow-up
(primary)
Care homes withdrawn from intervention
(n = 0)
• Residents died, n = 92
• Residents withdrawn, n = 0
• Residents moved out, n = 22
• No CMAI score at 16 months, n = 2
Care homes withdrawn from intervention
(n = 2)
Care homes
(n = 19)
• Assessed residents (closed cohort), n = 185
• Median residents/home (min., max.) = 9 (4, 19)
• Registered residents (additional), n = 99 and
   registered residents (cross-section), n = 287 
• Median residents/home (min., max.) = 12 (4, 34)
• Assessed residents (cross-section), n = 284
Care homes
(n = 31)
• Assessed residents (closed cohort), n = 220
• Median residents/home (min., max.) = 7 (1, 12)
• Registered residents (additional), n = 162 and
   registered residents (cross-section), n = 388
• Median residents/home (min., max.) = 12 (5, 24)
• Assessed residents (cross-section), n = 382
FIGURE 1 Care home and resident CONSORT flow diagram. Max., maximum; min., minimum.
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Investigation into potential recruitment bias of additional residents
As the additional residents for the cross-sectional sample were recruited following care home randomisation,
age, gender, ethnicity, length of stay in care home and funding type were compared for all screened and
registered residents (Table 4). Overall, there was a shorter length of stay in the additional cohort than
in the original cohort, as was expected. Of the 726 residents included in the original cohort, 145 (20.0%)
consented themselves, 263 (36.2%) were consented by a Personal Consultee and 318 (43.8%) were
consented by a Nominated Consultee (see Appendix 1, Table 30). By contrast, of the 261 residents recruited
at 16 months, 58 (22.2%) consented themselves, 73 (28.0%) were consented by a Personal Consultee and
130 (59.8%) were consented by a Nominated Consultee. There was no difference by arm in the proportion
of residents who consented themselves, but a higher proportion were consented by Nominated Consultees
in the intervention arm (n = 87, 53.7%) than in the control arm (n = 43, 43.4%).
Staff recruitment
There was a very poor return rate of staff questionnaire booklets (see Appendix 1, Table 31), despite the
changes made to encourage return rates [i.e. removal of the GHQ-12 and personal data (see Chapter 2,
Summary of changes to project protocol)]. Following consultation with oversight committees, it was agreed
that persistence with obtaining staff data was important, as the intervention was designed to effect a
‘whole-home’ change. However, owing to low return rates, planned statistical analyses could not be
conducted.
Relative/friend recruitment
At baseline, 197 relatives/friends were registered to the trial, with 96 in the control arm and 101 in the
intervention arm. This reflects a larger proportion in the control arm, given the 2 : 3 randomisation allocation.
The total number of relatives/friends registered to the trial reduced at 6 months (N = 170; control, n = 85;
intervention, n = 85) and 16 months (N = 118; control, n = 63; intervention, n = 55) (see Appendix 1, Table 32),
as might be expected with the high loss to follow-up rates. It was agreed by the oversight committees that,
given the low percentage of data received, these data would not be useful when undertaking statistical
analyses, with the exception of some of the health economic analyses (see Chapter 2, Health economic
analysis). New relative/friend informants were therefore not identified at follow-up. When relatives/friends
agreed to take part at baseline, we continued to request their follow-up data.
Baseline data
Care home characteristics
At baseline, on average, the intervention-arm homes were larger than the control-arm homes. However,
the average proportion of permanent residents with dementia was higher in the control arm. Care home
managers had similar work experience and training across both arms (Table 5).
A slightly higher than anticipated number of care homes (n = 13, 26%)99 needed PCCT ahead of baseline
data collection, owing to not meeting minimum criteria on the ADAPT audit tool.
Resident characteristics
In the closed-cohort sample, the mean resident age at randomisation was similar between intervention and
control arms (85.3 years in control, 86.0 years in intervention) (Table 6). A higher proportion of residents in
the intervention arm were male (n = 126, 30.1%) than in the control arm (n = 64, 20.8%) and the median
number of comorbidities was two in both arms, with the proportion of residents with no comorbidities
similar across arms.
In the cross-sectional sample, control residents were slightly younger than intervention residents (83.7 and
85.2 years, respectively). There was a higher proportion of residents with no reported comorbidities in the
control arm than in the intervention arm. Similar levels of dementia severity were observed in both arms,
as measured with the FAST, although a lower proportion of residents had moderately severe to severe
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TABLE 4 Characteristics of screened residents overall and by arm
Characteristic
Original cohort Additional residents
Screened Registered Screeneda Registered
Total
(N= 1564)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 275)
Intervention
(N= 602)
Total
(N= 877)
Control
(N= 99)
Intervention
(N= 162)
Total
(N= 261)
Age at registration (years),
mean (SD)
85.1 (8.18) 85.2 (7.37) 85.9 (7.83) 85.6 (7.64) 85.1 (7.51) 85.1 (8.36) 85.1 (8.10) 84.6 (7.69) 85.9 (8.09) 85.4 (7.95)
Length of stay in care home
(years), mean (SD)
2.3 (2.48) 2.3 (2.14) 2.4 (2.47) 2.3 (2.34) 1.3 (1.84) 1.7 (2.29) 1.6 (2.17) 1.2 (1.01) 1.5 (1.72) 1.4 (1.50)
Sex, number of
females (%)
1140 (72.9) 244 (79.2) 292 (69.9) 536 (73.8) 202 (73.5) 423 (70.3) 625 (71.3) 68 (68.7) 118 (72.8) 186 (71.3)
Ethnicity, n (%) missing data
White 1483 (94.8) 26 302 (98.1) 400 (95.7) 702 (96.7) 271 (98.5) 2 575 (95.5) 4 846 (96.5) 6 99 (100.0) 158 (97.5) 257 (98.5)
Other 55 (3.5) 6 (1.9) 18 (4.3) 24 (3.3) 2 (0.7) 23 (3.8) 25 (2.9) 0 (0.0) 4 (2.5) 4 (1.5)
Funding type, n (%)
Local Authority 741 (47.4) 128 (41.6) 224 (53.6) 352 (48.5) 113 (41.1) 291 (48.3) 404 (46.1) 52 (52.5) 74 (45.7) 126 (48.3)
Continuing health care 115 (7.4) 28 (9.1) 20 (4.8) 48 (6.6) 5 (1.8) 16 (2.7) 21 (2.4) 1 (1.0) 1 (0.6) 2 (0.8)
Self-funded 555 (35.5) 133 (43.2) 156 (37.3) 289 (39.8) 94 (34.2) 224 (37.2) 318 (36.3) 33 (33.3) 75 (46.3) 108 (41.4)
Local Authority and
self-funded
69 (4.4) 17 (5.5) 17 (4.1) 34 (4.7) 26 (9.5) 42 (7.0) 68 (7.8) 13 (13.1) 12 (7.4) 25 (9.6)
Missing 84 (5.4) 2 (0.6) 1 (0.2) 3 (0.4) 37 (13.5) 29 (4.8) 66 (7.5) 0 (0.0) 0 (0.0) 0 (0.0)
a Excluding those already participating in an EPIC trial or those that were screened at baseline but refused consent.
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TABLE 5 Baseline care home and care home manager characteristics
Characteristic Control (N= 19) Intervention (N= 31) Total (N= 50)
Unit type, n (%) missing data
General residential/nursing home 11 (57.9) 0 20 (64.5) 0 31 (62) 0
Specialist dementia care home/unit 8 (42.1) 0 11 (35.5) 0 19 (38) 0
Care home
More than one unit, n (%) missing data 3 (15.8) 0 3 (9.7) 0 6 (12) 0
DCM used between 18 months and 5 years,
n (%) missing data
11 (57.9) 0 20 (64.5) 0 31 (62) 0
Residents’ meeting held within the last 6 months,
n (%) missing data
17 (89.5) 0 30 (100) 1 47 (95.9) 1
Relatives’ meeting held within the last 6 months,
n (%) missing data
18 (94.7) 0 29 (96.7) 1 47 (95.9) 1
Number of beds in the care home, mean (SD)
missing data
28.8 (8.97) 2 36.8 (14.28) 1 33.9 (13.1) 3
Number of permanent residents, mean (SD)
missing data
30 (11.27) 0 32.9 (14.02) 1 31.8 (12.98) 1
Percentage of permanent residents with dementia,
mean (SD) missing data
83.1 (21.21) 0 74.2 (22.48) 1 77.7 (22.21) 1
Percentage of self-funded residents, mean (SD)
missing data
52.8 (28.12) 0 37.9 (21.12) 1 43.7 (24.89) 1
Cost of a self-funded place per year (£), mean (SD)
missing data
44,553 (13,291) 0 41,638 (13,003) 1 42,768 (13,056) 1
Number of residents per staff member (daytime),
median (range) missing data
5.2 (3.0–8.8) 0 4.7 (2.5–10.5) 1 4.8 (2.5–10.5) 1
Number of residents per staff member (night-time),
median (range) missing data
9.5 (3.3–17.5) 0 9.7 (2.9–15.3) 1 9.7 (2.9–17.5) 1
Care home manager
Time in current role (years), median (range) 2.5 (0.3–37.0) 2.9 (0.3–25.0) 2.6 (0.3–37.0)
Length of time working in care homes, n (%)
Up to 10 years 3 (15.8) 7 (22.6) 10 (20.0)
More than 10 years 16 (84.2) 24 (77.4) 40 (80.0)
Length of time in a manager role, n (%)
Up to 2 years 3 (15.8) 7 (22.6) 10 (20.0)
Up to 5 years 5 (26.3) 4 (12.9) 9 (18.0)
Up to 10 years 2 (10.5) 5 (16.1) 7 (14.0)
More than 10 years 9 (47.4) 15 (48.4) 24 (48.0)
Manager dementia training/education, n (%)
Previously trained as a dementia care mapper by
University of Bradford
3 (15.8) 4 (12.9) 7 (14.0)
Dementia-specific qualification 4 (21.1) 10 (32.3) 14 (28.0)
Dementia covered in one part of a qualification 10 (52.6) 18 (58.1) 28 (56.0)
Attended a dementia-specific training course 19 (100.0) 31 (100.0) 50 (100.0)
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TABLE 6 Resident characteristics
Original cohort at baseline Control (N= 308) Intervention (N= 418) Total (N= 726)
Age at randomisation (years), mean (SD)
missing data
85.3 (7.38) 0 86 (7.83) 0 85.7 (7.64) 0
Sex, number of males (%) 64 (20.8) 126 (30.1) 190 (26.2)
Number of comorbidities per resident,
median (range)
2 (0–10) 2 (0–14) 2 (0–14)
Selected comorbidities,a n (%)
Anxiety 34 (11.0) 23 (5.5) 57 (7.9)
Depression 62 (20.1) 55 (13.2) 117 (16.1)
Psychosis 16 (5.2) 24 (5.7) 40 (5.5)
Sleep disturbance 6 (1.9) 7 (1.7) 13 (1.8)
Delirium 3 (1.0) 2 (0.5) 5 (0.7)
FAST stage (out of completed scores), n (%) (N = 306) (N = 391) (N = 697)
1 2 (0.7) 0 (0.0) 2 (0.3)
2 2 (0.7) 0 (0.0) 2 (0.3)
3 1 (0.3) 1 (0.3) 2 (0.3)
4 39 (12.7) 56 (14.3) 95 (13.6)
5 26 (8.5) 48 (12.3) 74 (10.6)
6 166 (54.2) 214 (54.7) 380 (54.5)
7 70 (22.9) 72 (18.4) 142 (20.4)
Cross-section at 16 months Control (N= 287) Intervention (N= 388) Total (N= 675)
Age at randomisation (years), mean (SD)
missing data
83.7 (7.77) 0 85.2 (7.79) 0 84.6 (7.81) 0
Gender, number of males (%) 71 (24.7) 110 (28.4) 181 (26.8)
Number of comorbidities per resident,
median (range)
2 (0–7) 3 (0–12) 2 (0–12)
Selected comorbidities,a n (%)
Anxiety 26 (9.1) 27 (7.0) 53 (7.9)
Depression 64 (22.3) 66 (17.0) 130 (19.3)
Psychosis 11 (3.8) 21 (5.4) 32 (4.7)
Sleep disturbance 2 (0.7) 5 (1.3) 7 (1.0)
Delirium 2 (0.7) 2 (0.5) 4 (0.6)
FAST stage (out of completed scores), n (%) (N = 284) (N = 384) (N = 668)
4 22 (7.7) 35 (9.1) 57 (8.5)
5 20 (7.0) 21 (5.5) 41 (6.1)
6 168 (59.2) 238 (62.0) 406 (60.8)
7 74 (26.1) 90 (23.4) 164 (24.6)
a Not mutually exclusive.
Reproduced from Meads et al.157 © The Author(s) 2019. This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The table
includes minor additions and formatting changes to the original table.
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dementia (FAST stages 6 or 7) in the closed cohort (74.9%) than in the cross-sectional sample (85.4%),
owing to the worsening of dementia of residents in the closed cohort over time.
Treatment summaries
Control
Organisational and staff changes reflecting usual care at a care home level are summarised in Table 7 for
both arms, each compared with the previous time point. A higher proportion of care homes had experienced
management changes in the intervention arm than in the control arm at 6 months, and a higher proportion of
care homes had new staff roles introduced in the unit in the intervention arm than in the control arm. At both
follow-up points, a higher proportion of intervention care homes achieved or completed standard quality
assessments than control-arm homes. Compared with control homes, a smaller proportion of intervention care
homes reported having staff with higher-level dementia-specific qualifications at 6 months but, by 16 months,
a higher proportion of intervention homes reported having staff with higher-level dementia-specific
qualifications.
Intervention
Adherence to the intervention is reported by cycle and number of components completed (i.e. briefing;
observation; analysis, reporting and feedback; and action-planning) in Figure 2 (see Appendix 1, Table 33,
for further details on adherence by care home), with the furthest reported component through the DCM
cycle presented when the full cycle was not completed. Intervention fidelity is also reported in detail
elsewhere.169 Based on documented evidence, 16 care homes (51.6%) in the intervention arm completed
only one cycle to an acceptable level, four (12.9%) completed two cycles to an acceptable level and four
(12.9%) completed all three cycles to an acceptable level. Seven care homes (22.6%) did not complete a
full intervention cycle, with three (9.7%) of these not completing any of the intervention components.
Additional intervention component summaries can be found in Appendix 1 (see Tables 34–40 and Figure 7).
Owing to challenges in a complete set of adherence data being received from care homes, it was not
possible to ascertain how many care home staff had engaged with the DCM process during each cycle and
thus to assess intervention ‘dose’ in terms of reach.
TABLE 7 Summary of changes in usual care
Change
At 6 months (from baseline),
n (%) number unknown
At 16 months (from 6 months),
n (%) number unknown
Control
(N= 19)
Intervention
(N= 31)
Total
(N= 50)
Control
(N= 19)
Intervention
(N= 31)
Total
(N= 50)
Any organisational changes 4 (21.1) 0 6 (19.4) 0 10 (20.0) 0 4 (21.1) 0 6 (19.4) 0 10 (20.0) 0
Any care home management
changes
5 (26.3) 0 12 (38.7) 0 17 (34.0) 0 8 (42.1) 0 13 (41.9) 0 21 (42.0) 0
Any new staff roles 1 (5.3) 0 6 (19.4) 0 7 (14.0) 0 3 (15.8) 0 7 (22.6) 0 10 (20.0) 0
Any new projects or initiatives 5 (26.3) 0 9 (29.0) 0 14 (28.0) 0 6 (31.6) 0 12 (38.7) 0 18 (36.0) 0
Any new voluntary measures to
improve standards
1 (5.3) 0 3 (9.7) 0 4 (8.0) 0 0 (0.0) 0 3 (9.7) 0 3 (6.0) 0
Any standard quality
assessments achieved
3 (15.8) 0 9 (29.0) 0 12 (24.0) 0 2 (10.5) 0 6 (19.4) 0 8 (16.0) 0
Currently subject to any CQC
notifications
2 (10.5) 0 6 (19.4) 0 8 (16.0) 0 1 (5.3) 0 1 (3.2) 0 2 (4.0) 0
PCCT available in unit 18 (94.7) 0 29 (93.5) 0 47 (94.0) 0 16 (84.2) 1 31 (100.0) 0 47 (94.0) 1
Staff with higher-level
dementia-specific qualification
10 (52.6) 0 12 (38.7) 1 22 (44.0) 1 10 (52.6) 0 20 (64.5) 0 30 (60.0) 0
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Losses and exclusions after randomisation
Withdrawals
Two care homes in the intervention arm withdrew from further trial treatment but not from further data
collection: one in month 11 and one in month 12. One resident from the closed cohort withdrew consent
for all data collection in the intervention arm (withdrawn by Personal Consultee in month 2). There were
four staff-proxy withdrawals, one in each arm at each of the the 6- and 16-month follow-ups. There were
four relative/friend withdrawals, one in the control arm (at the 16-month follow-up) and three in the
intervention arm (one at the 6-month and two after the 16-month follow-up).
Protocol violations
There were two care home eligibility violations identified and reported in the first 2 months following
randomisation (one in each arm). Both related to changed CQC status between recruitment and randomisation.
In both cases, the chief investigator agreed to the care homes continuing in the trial and so they were included
in the ITT analysis. Five staff eligibility violations were reported in the intervention arm, involving individuals who
undertook both mapper and staff-proxy roles.
Resident deaths in closed cohort
Seventeen residents died between care home registration and randomisation (see Appendix 1, Table 41);
the remaining 726 residents constituted the original cohort. Overall, there were 272 (37.5%) deaths
reported between randomisation and the end of the 16-month follow-up in the original cohort, 111 (36.0%)
in the control arm and 161 (38.5%) in the intervention arm [primary outcome data were available for two
residents who died (1.8%) in the control arm and for four residents who died (2.5%) in the intervention arm].
The majority of these deaths occurred in the care home [224/272, 82%: 89/111 (80.2%) in the control arm
and 135/161 (83.9%) in the intervention arm]. The mean proportion of deaths per care home in the control
arm was 0.36 (SD 0.12) and in the intervention arm it was 0.39 (SD 0.14).
Clinical effectiveness of the intervention
Analyses of the primary outcome
Analyses were conducted on the cross-sectional sample (primary) and the closed cohort. Unadjusted
scores are presented in Table 8 for the primary outcome (staff proxy-completed CMAI), and the change
in unadjusted scores from baseline is presented graphically in Appendix 1, Figures 8 and 9. At baseline,
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FIGURE 2 Completion of intervention components by cycle. Reproduced from Surr et al.158 This article is distributed
under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/)
which permits any use, reproduction and distribution of the work without further permission provided the original work
is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
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the mean total CMAI score was higher in the control arm (48.4 points) than in the intervention homes
(45.4 points). In the closed cohort at 6 months, the gap had closed, with the mean total CMAI scores
being 44.9 points and 43.6 points, respectively, in control and intervention homes [however, 148/726
(20.4%) residents were lost to follow-up]. By 16 months, the gap had widened again in the closed cohort
[although, by this time, 321/726 (44.2%) residents were lost to follow-up], with mean total CMAI scores
of 46.4 points and 41.4 points, respectively, in control and intervention care homes. The gap was slightly
narrower in the cross-sectional sample [9/675 (1.3%) lost to follow-up], with mean total CMAI scores of
46.1 points and 42.8 points in the control and intervention homes, respectively. Differences in mean total
CMAI scores between the control and intervention homes are therefore small in both resident samples,
largely arising from changes carried through from baseline.
TABLE 8 Unadjusted CMAI scoresa by resident sample and time point
Closed cohort
Control (n= 308),
mean (SD) missing data
Intervention (n= 418),
mean (SD) missing data Total (n= 726)
Baseline total score 48.4 (19.53) 2 45.4 (15.95) 2 46.7 (17.6) 4
Subscales
Aggressive behaviour 14.3 (8.10) 2 12.6 (6.28) 2 13.3 (7.16) 4
Physically non-aggressive 11.6 (6.47) 8 11.3 (6.08) 10 11.4 (6.25) 18
Verbally agitated 10.4 (6.23) 5 9.9 (5.94) 2 10.1 (6.06) 7
Other 12 (4.58) 0 11.5 (3.73) 2 11.7 (4.12) 2
6-month total score 44.9 (16.75) 64 43.6 (14.32) 84 44.2 (15.39) 148
Subscales
Aggressive behaviour 13.3 (7.21) 64 12.4 (6.14) 84 12.8 (6.62) 148
Physically non-aggressive 10.5 (5.88) 68 10.6 (5.28) 100 10.6 (5.54) 168
Verbally agitated 9.4 (5.42) 64 9.6 (5.42) 87 9.5 (5.42) 151
Other 11.7 (3.95) 64 11 (3.26) 84 11.3 (3.58) 148
16-month total score 46.4 (16.54) 123 41.4 (14.73) 198 43.7 (15.76) 321
Subscales
Aggressive behaviour 14 (7.66) 123 12.3 (5.9) 196 13 (6.8) 319
Physically non-aggressive 11 (5.82) 124 9.2 (4.85) 205 10 (5.38) 329
Verbally agitated 9.7 (5.55) 123 9 (5.63) 197 9.3 (5.60) 320
Other 11.8 (4.05) 123 10.8 (3.08) 199 11.3 (3.59) 322
Cross-section
Control (n= 287),
mean (SD) missing data
Intervention (n= 388),
mean (SD) missing data Total (n= 675)
16-month total score 46.1 (16.78) 3 42.8 (15.79) 6 44.2 (16.29) 9
Subscales
Aggressive behaviour 13.7 (7.93) 3 12.2 (5.87) 4 12.9 (6.86) 7
Physically non-aggressive 11 (6.01) 4 9.9 (5.36) 15 10.4 (5.67) 19
Verbally agitated 9.8 (5.79) 3 9.7 (6.16) 5 9.7 (6.00) 8
Other 11.5 (3.73) 3 11 (3.49) 7 11.2 (3.60) 0
a CMAI score overall range: 29–203. A higher score indicates a higher frequency of agitated behaviour. CMAI subscales:
aggressive behaviour (range 9–63), physically non-aggressive behaviour (range 6–42), verbally agitated behaviour
(range 5–35) and other behaviour (range 9–63).
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All 675 residents in the cross-sectional sample at 16 months were included in the primary analysis, of whom
complete data were available for 666. There was no evidence of a difference in agitation levels between
arms. The mean difference in total CMAI score from the two-level heteroscedastic linear regression model
fitted to the multiply imputed data (assuming that data were MAR) was –2.11 points, being lower in the
intervention arm than in the control arm (adjusted means: 45.47 points in the control arm and 43.35 points
in the intervention arm; 95% CI –4.66 to 0.44 points; p = 0.104). The unadjusted ICC was 0 in the control
and 0.058 in the intervention arm, but the adjusted ICC was 0 in the control and 0.001 in the intervention
arm, indicating that between-cluster heterogeneity in the intervention arm was explained by the covariates in
the model. Using the complete cases, the mean difference was –2.19 points, being lower in the intervention
arm than in the control homes (95% CI –4.81 to 0.43 points), and the adjusted ICC was zero in both
treatment arms, indicating that the treatment effect was neither clinically meaningful nor statistically
significant at the 5% level (p = 0.099) (see Appendix 1, Table 45). The primary analysis is summarised in
Table 9.
Supportive and sensitivity analyses
Unadjusted scores for the CMAI-O and PAS outcomes, which were used in place of the CMAI, by resident
sample and time point, are presented in Table 10 (cross-section) and in Appendix 1, Tables 42 (closed cohort)
and 43 and 46 and 47 (complete cases). A similar pattern of differences was found for these supportive
outcomes completed by the blinded independent researcher. The mean CMAI-O scores were consistently very
slightly higher in the afternoon than in the morning. The same is the case for PAS scores. Loss to follow-up
was higher for these supportive outcomes [about 276/726 (38.0%) at baseline, 358/726 (49.3%) at 6 months
and 495/726 (68.2%) and 310/675 (45.9%) at 16 months in the closed cohort and cross-section, respectively]
than for the primary outcome.
The sensitivity and supportive analyses are summarised in Table 9 and Appendix 1, Table 44, respectively.
The key sensitivity analysis simplified the model fitted to ensure complete convergence and was added
post hoc. Sensitivity analyses on the CMAI score for the subset of residents included in the analyses of the
CMAI-O and PAS were also added post hoc. The equivalent analyses on the complete cases are provided
in Appendix 1, Tables 18–20. The key sensitivity analysis and the first three planned sensitivity analyses
supported the results found in the primary analysis.
Sensitivity analyses of the CMAI-O and the PAS indicated a potential overestimation of the treatment effect
from the primary analysis, as the mean differences are reduced when a blinded independent observation is
made (see the analyses in rows 4a and 4c in Table 9). However, we would expect the CMAI-O and PAS to
potentially underestimate agitation levels, as they are conducted over only two observation periods in a
single week, in public areas of the home, during restricted daytime hours. The staff-proxy rating is made over
2 weeks and includes consideration of agitation during personal care in the evening and at night-time. The
sensitivity analysis conducted on the closed cohort gave a mean difference of –3.25 (95% CI –6.13 to –0.37;
p = 0.027), apparently contradicting the conclusion of the primary analysis. However, the sensitivity analysis
is not robust, as it relies on multiply-imputed data for 45% of the sample. It has a different interpretation
too, as this is the treatment effect estimated for residents who remain in the care home from baseline to
16 months. A sensitivity analysis on the closed cohort assumed that data are MNAR. This explores the impact
of assumptions about the missing data, looking at a range of plausible and potentially implausible scenarios
in which there was a shift in the CMAI score at 16 months of up to 40 points either way for residents that
died, withdrew or moved away. This assumes that the scores for all residents with missing data would have
shifted by the same number of points. The conclusions of the closed-cohort analysis remain unchanged for
shifts of –40 to 5 points from the average CMAI score at 16 months for those who died, and any shift for
those who withdrew (see Appendix 1, Table 48).
Supportive analyses of the closed cohort at 6 and 16 months (see Appendix 1, Table 44) indicate that there
were no differences in CMAI, CMAI-O or PAS scores at 6 months and no differences in CMAI-O and PAS
scores at 16 months. Overall, these analyses confirm that the intervention is not superior to the control.
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TABLE 9 Primary and sensitivity analyses assuming that missing data are MAR: cross-sectional sample
Analysis
Adjusted mean
in control arm
Adjusted mean in
intervention arm
Estimated mean
difference 95% CI p-value
Adjusted ICC for
intervention arm
Adjusted ICC
for control arm n
Primary analysis, CMAI score on ITT sample 45.47 43.35 –2.11 –4.66 to 0.44 0.104 0.001 0.000 675
Sensitivity analyses
Key sensitivity analysis (hub omitted from
the model), CMAI score on ITT sample
46.02 43.78 –2.24 –4.91 to 0.42 0.099 0.010 675
1. Adjusting for before–after eligibility
change,a CMAI score on ITT sample
44.82 42.69 –2.13 –4.71 to 0.45 0.105 0.002 0.000 675
2. Care home size as a continuous variable,
CMAI score on ITT sample
45.59 43.21 –2.38 –5.00 to 0.25 0.076 0.000 0.000 675
3. Homogeneous clustering across arms,
CMAI score on ITT sample
45.41 43.32 –2.09 –4.61 to 0.44 0.105 0.001 675
4a. CMAI-O score (a.m.) 31.00 30.41 –0.58 –1.62 to 0.45 0.269 0.215 0.006 675
4b. CMAI score on subset with CMAI-O
(a.m.)
47.49 43.43 –4.06 –7.55 to –0.57 0.023 0.016 0.001 365
4c. CMAI-O score (p.m.) 31.34 31.11 –0.22 –1.52 to 1.08 0.737 0.220 0.013 675
4d. CMAI score on subset with CMAI-O
(p.m.)
47.49 43.43 –4.06 –7.55 to –0.57 0.023 0.016 0.001 365
4e. PAS score (a.m.) 0.93 0.73 –0.20 –0.67 to 0.27 0.402 0.166 0.011 675
4f. CMAI score on subset with PAS (a.m.) 47.49 43.43 –4.06 –7.55 to –0.57 0.023 0.016 0.001 365
4g. PAS score (p.m.) 1.17 0.89 –0.28 –0.96 to 0.41 0.429 0.299 0.018 675
4h. CMAI score on subset with PAS (p.m.) 47.49 43.43 –4.06 –7.55 to –0.57 0.023 0.016 0.001 365
5. CMAI score at 16 months (closed cohort) 46.4 43.16 –3.25 –6.13 to –0.37 0.027 0.013 0.001 726
a Eligibility changed in December 2014 after the first two care homes were randomised.
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A CACE analysis of the cross-sectional sample, comparing care homes in the intervention arm that
completed at least one cycle to an acceptable level with care homes that would have completed at least
one cycle had the intervention been offered to them, gave a mean difference in CMAI score at 16 months
of –2.5 points (95% CI –5.4 to 0.4 points; p = 0.089). This indicates that the ITT estimate from the primary
analysis is not dissimilar to the effect of completing at least one cycle to an acceptable level. The 95% CIs
are wider than in the primary analysis and the CACE estimate is not statistically significant at the 5% level
(p = 0.089) (Table 11). The exploratory CACE analyses using other definitions of adherence indicate that
the treatment effect may increase if care homes complete at least two DCM cycles to an acceptable level,
compared with completing only one cycle. Although these analyses are suggestive of a dose–response
relationship in which supporting adherence to the second and third cycles might result in a clinically
meaningful effect, this would need to be confirmed by further research.
The change in unadjusted CMAI scores for the care homes between baseline and 16 months is presented
by intervention adherence (the number of cycles completed to an acceptable level) in Figure 3. There was
considerable variation in CMAI score changes between care homes completing zero, one, two and three
acceptable cycles.
TABLE 11 The CACE analysis using various scenarios
Analyses Model
Treatment effect
(standard error) 95% CI p-value
CACE analyses (documented
and expert evidence), MI
At least one cycle to an acceptable level –2.5 (1.5) –5.4 to 0.4 0.089
At least one cycle to a partial level –2.2 (1.3) –4.8 to 0.3 0.087
One cycle only to an acceptable level –3.6 (2.2) –7.9 to 0.8 0.106
At least two cycles to an acceptable level –8.5 (5.3) –18.9 to 2.0 0.112
Complete-case CACE
analyses, sensitivity analyses
At least one cycle to an acceptable level
At least two cycles to an acceptable level –2.6 (1.4) –5.4 to 0.2 0.068
At least one cycle to a partial level –2.2 (1.3) –4.8 to 0.3 0.087
TABLE 10 Unadjusted CMAI-Oa and PASb scores by time point: cross-sectional cohort
Outcome
a.m., mean (SD) number completed p.m., mean (SD) number completed
Control
(n= 287)
Intervention
(n= 388)
Total
(n= 675)
Control
(n= 287)
Intervention
(n= 388)
Total
(n= 675)
16-month CMAI-O
total score
31.1 (3.8) 156 30.5 (3.3) 209 30.8 (3.5) 365 31.4 (3.8) 148 31.1 (3.9) 206 31.2 (3.9) 354
Subscales
Aggressive
behaviour
9.3 (0.9) 156 9.3 (1.0) 209 9.3 (1.0) 365 9.3 (1.1) 148 9.3 (1.2) 206 9.3 (1.1) 354
Physically
non-aggressive
6.7 (1.4) 156 6.5 (1.5) 209 6.6 (1.4) 365 6.9 (1.5) 148 6.8 (1.9) 206 6.9 (1.8) 354
Verbally agitated 5.8 (2.2) 156 5.5 (1.5) 209 5.6 (1.8) 365 5.8 (1.9) 148 5.7 (1.7) 206 5.7 (1.8) 354
Other 9.3 (1.0) 156 9.2 (0.7) 209 9.2 (0.8) 365 9.3 (0.9) 148 9.3 (0.9) 206 9.3 (0.9) 354
16-month PAS score 1.1 (1.9) 156 0.8 (1.7) 209 0.9 (1.8) 365 1.2 (1.9) 148 0.9 (1.8) 205 1.0 (1.8) 353
a CMAI-O score overall range: 29–116. A higher score indicates more frequent agitated behaviour.
b PAS score range: 0–16. A higher score represents higher levels of agitation.
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Analyses of the secondary outcomes
Analyses of the NPI-NH, PRN prescription medications, QoL and quality of staff interactions were conducted
on the closed cohort at 6 months and on the cross-sectional sample (primary) and the closed cohort
(supportive) at 16 months. Unadjusted scores are presented in Tables 12–15 by resident sample and time
point and in Appendix 1, Tables 49–60.
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FIGURE 3 Change in CMAI score between baseline and 16 months by adherence to the intervention.
TABLE 12 Unadjusted NPI-NH scores and BSC by resident sample and time point
Closed cohort
Total NPIa scores, mean (SD) missing data
Number experiencing BSC, n (%) number
completed
Control
(n= 308)
Intervention
(n= 418) Total (n= 726)
Control
(n= 308)
Intervention
(n= 418) Total (n= 726)
Baseline 13 (13.95) 0 11.7 (12.35) 0 12.2 (13.06) 0 236 (76.6) 308 325 (77.8) 418 561 (77.3) 726
Subscalesb
Agitation/
aggression
5.0 (2.85) 2 4.7 (2.86) 0 4.8 (2.85) 2 145 (47.1) 308 192 (46.0) 417 337 (46.5) 725
Depression/
dysphoria
4.1 (2.77) 0 3.6 (2.63) 2 3.8 (2.70) 2 92 (30.0) 307 129 (30.9) 418 221 (30.5) 725
Anxiety 5.2 (3.16) 2 3.9 (2.32) 3 4.5 (2.80) 5 80 (26.0) 308 98 (23.5) 417 178 (24.6) 725
Apathy/
indifference
5.4 (3.30) 1 5.2 (3.07) 1 5.3 (3.16) 2 91 (29.5) 308 130 (31.2) 417 221 (30.5) 725
Disinhibition 5.0 (3.29) 0 3.8 (2.62) 0 4.3 (2.97) 0 51 (16.6) 308 65 (15.6) 416 116 (16.0) 724
Irritability/lability 5.3 (3.16) 3 4.4 (2.85) 0 4.8 (3.01) 3 117 (38.0) 308 153 (36.7) 417 270 (37.2) 725
continued
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
49
TABLE 12 Unadjusted NPI-NH scores and BSC by resident sample and time point (continued )
Closed cohort
Total NPIa scores, mean (SD) missing data
Number experiencing BSC, n (%) number
completed
Control
(n= 308)
Intervention
(n= 418) Total (n= 726)
Control
(n= 308)
Intervention
(n= 418) Total (n= 726)
6 months 11.3 (12.35) 0 9.7 (10.14) 0 10.4 (11.17) 0 186 (76.2) 244 238 (74.4) 320 424 (75.2) 564
Subscalesb
Agitation/
aggression
5.4 (3.24) 0 4.4 (2.62) 0 4.9 (2.98) 0 120 (49.0) 245 125 (39.2) 319 245 (43.4) 564
Depression/
dysphoria
3.7 (2.66) 0 3.5 (2.35) 1 3.6 (2.47) 1 63 (26.0) 242 101 (31.6) 320 164 (29.2) 562
Anxiety 4.6 (2.92) 2 4.0 (2.71) 1 4.3 (2.81) 3 47 (19.3) 244 57 (17.9) 319 104 (18.5) 563
Apathy/
indifference
5.7 (3.39) 1 4.3 (2.91) 1 4.9 (3.16) 2 73 (29.9) 244 116 (36.3) 320 189 (33.5) 564
Disinhibition 4.9 (3.08) 0 5.3 (3.44) 0 5.1 (3.23) 0 35 (14.3) 244 30 (9.4) 320 65 (11.5) 564
Irritability/lability 4.5 (3.12) 0 4.4 (2.89) 0 4.5 (2.99) 0 83 (33.9) 245 99 (30.9) 320 182 (32.2) 565
16 months 10.4 (9.25) 0 7.7 (9.36) 0 8.9 (9.4) 0 146 (78.9) 185 154 (69.4) 222 300 (73.7) 407
Subscalesb
Agitation/
aggression
4.5 (2.30) 0 4.5 (3.00) 0 4.5 (2.65) 0 82 (44.3) 185 76 (34.2) 222 158 (38.8) 407
Depression/
dysphoria
3.5 (2.09) 1 3.1 (1.87) 1 3.3 (1.99) 2 63 (34.1) 185 55 (24.8) 222 118 (29.0) 407
Anxiety 4.5 (2.28) 0 4.4 (2.83) 1 4.4 (2.56) 1 29 (15.7) 185 34 (15.3) 222 63 (15.5) 407
Apathy/
indifference
5.5 (3.33) 0 5.2 (3.40) 0 5.3 (3.36) 0 73 (39.5) 185 62 (27.9) 222 135 (33.2) 407
Disinhibition 3.6 (2.43) 1 3.6 (2.59) 0 3.6 (2.48) 1 24 (13.0) 185 24 (10.8) 222 48 (11.8) 407
Irritability/lability 4.5 (2.30) 0 4.0 (2.83) 0 4.2 (2.58) 0 65 (35.1) 185 66 (29.7) 222 131 (32.2) 407
Cross-section
Control
(n= 287)
Intervention
(n= 388) Total (n= 675)
Control
(n= 287)
Intervention
(n= 388) Total (n= 675)
16 months 10 (10.46) 0 8.4 (10.25) 0 9.1 (10.36) 0 219 (77.1) 284 269 (70.1) 384 488 (73.1) 668
Subscalesb
Agitation/
aggression
4.7 (2.48) 0 4.7 (2.67) 2 4.7 (2.58) 2 116 (40.8) 284 141 (36.7) 384 257 (38.5) 668
Depression/
dysphoria
3.5 (2.35) 2 3.2 (2.03) 1 3.3 (2.19) 3 95 (33.5) 284 105 (27.3) 384 200 (29.9) 668
Anxiety 4.0 (2.45) 0 4.0 (2.57) 2 4.0 (2.51) 2 48 (17.0) 283 72 (18.8) 384 120 (18.0) 667
Apathy/
indifference
5.5 (3.41) 0 4.6 (3.06) 0 5.0 (3.25) 0 95 (33.5) 284 108 (28.1) 384 203 (30.4) 668
Disinhibition 3.8 (2.70) 1 4.4 (3.22) 0 4.1 (2.99) 1 35 (12.3) 284 42 (10.9) 384 77 (11.5) 668
Irritability/lability 4.5 (2.44) 0 4.0 (2.66) 1 4.2 (2.58) 1 94 (33.1) 284 127 (33.1) 384 221 (33.1) 668
a The total NPI score is calculated by summing the total score for the first 10 domains (excluding the sleep and appetite
domains), with the total NPI score ranging from 0 to 120. Higher scores on the NPI are indicative of the resident
exhibiting more BSC.
b The number experiencing BSC refers to experiences of any of the behaviours from the listed subscale.
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As can be seen in Table 12, at baseline, the proportions of residents experiencing BSC (defined as the
following behaviours in the NPI-NH: agitation/aggression, depression/dysphoria, anxiety, apathy/indifference,
disinhibition or irritability/lability) were similar across the intervention and control arms. However, the average
NPI-NH score was higher in the control than in the intervention arm. Agitation/aggression was experienced
by the highest proportion of residents across all time points and in both samples. At 16 months, the
proportion of residents experiencing BSC was smaller in the intervention arm than in the control arm for
both the cross-sectional and the closed-cohort samples. The average NPI-NH score was similar in both arms
for both samples, having reduced more in the control arm than in the intervention arm from baseline.
The percentage of residents prescribed antipsychotics on a PRN basis was low across time points, at less
than 1.6% (see Table 13), making it difficult to detect any differences between the arms. QoL was primarily
measured using the staff-proxy QUALID scale. Data are presented on the resident-rated QOL-AD measure
and the relative-proxy QUALID scale; however, this is for comparison only, owing to the poor completion
rates (see Table 14). There are no notable differences in the QUALID scores provided by staff proxies at
baseline, 6 months or 16 months in either resident sample. This pattern is supported by the resident-rated
QOL-AD measure and the relative-proxy QUALID scale.
The proportion of positive interactions as measured by the QUIS (see Table 15) differed between arms at
baseline and at 6 months, with a higher proportion of interactions experienced in the intervention arm
than in the control arm; this difference in proportions was not evident at 16 months.
TABLE 13 Unadjusted PRN prescription medications by resident sample and time point
Closed cohort
Control (n= 308),
number prescribed (%)
Intervention (n= 418),
number prescribed (%)
Total (n= 726),
number prescribed (%)
Baseline
Antipsychotic 5 (1.6) 5 (1.2) 10 (1.4)
Non-benzodiazepine hypnotic 2 (0.6) 4 (1.0) 6 (0.8)
Pain relief 109 (35.4) 123 (29.4) 232 (32.0)
6 months
Antipsychotic 4 (1.3) 2 (0.5) 6 (0.8)
Non-benzodiazepine hypnotic 1 (0.3) 3 (0.7) 4 (0.6)
Pain relief 89 (28.9) 132 (31.6) 221 (30.4)
16 months
Antipsychotic 2 (0.6) 2 (0.5) 4 (0.6)
Non-benzodiazepine hypnotic 4 (1.3) 3 (0.7) 7 (1.0)
Pain relief 59 (19.2) 83 (19.9) 142 (19.6)
Cross-section
Control (n= 287),
number prescribed (%)
number completed
Intervention (n= 388),
number prescribed (%)
number completed
Total (n= 675),
number prescribed (%)
number completed
16 months
Antipsychotic 2 (0.7) 4 (1.0) 6 (0.9)
Non-benzodiazepine hypnotic 6 (2.1) 3 (0.8) 9 (1.3)
Pain relief 90 (31.4) 138 (35.6) 228 (33.8)
The frequencies given are those of the samples in question, assuming that the missing data reflect no prescriptions. No PRN
anticonvulsants, no PRN mood stabilisers and no PRN non-benzodiazepine anxiolytics were prescribed for any residents at
any time points.
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All 726 residents in the closed cohort were included in analyses of the resident-level secondary outcomes at
6 months; all 49 care homes in which the QUIS was completed were included in the analysis at 6 months
(Table 16). The odds ratio for the presence versus absence of one or more of the six domains of the NPI-NH
describing BSC is 0.95 (95% CI 0.61 to 1.48), indicating that there was no difference in the odds of residents
experiencing these domains across arms (at a population or cluster-specific level). The odds of residents
being prescribed antipsychotics on a PRN basis in the intervention arm was 0.46 times the odds in the
control arm. However, the 95% CI (0.09 to 2.24) was wide, which reflects uncertainty from the small
number of prescriptions made. The odds of experiencing depression/dysphoria and apathy/indifference in
the intervention arm were both approximately 1.32 times the odds in the control arm; however, the 95% CIs
both overlapped one (0.87 to 2.0 and 0.85 to 2.07, respectively), so the differences are not statistically
significant. The odds ratio for the presence or absence of anxiety was 1.01 (95% CI 0.62 to 1.66), indicating
that there was no difference in the odds of residents experiencing anxiety across arms.
TABLE 14 Unadjusted QoL scores by resident sample and time point
Time point
Control, mean
score (SD) n
Intervention, mean
score (SD) n
Total, mean
score (SD) n
Closed cohort (N = 308) (N = 418) (N = 726)
Baseline
QUALIDa staff proxy 20.9 (7.19) 308 20.1 (6.76) 418 20.5 (6.95) 726
QUALID relative proxy 22.5 (7.49) 82 21.6 (6.86) 81 22.0 (7.18) 163
QOL-ADb resident 42.7 (5.13) 155 41.7 (7.11) 189 42.1 (6.31) 344
6 months
QUALID staff proxy 20.7 (6.88) 245 19.3 (6.04) 319 19.9 (6.45) 564
QUALID relative proxy 21.6 (7.18) 62 22.1 (8.89) 65 21.8 (8.07) 127
QOL-AD resident 43.0 (5.09) 92 41.3 (5.97) 137 42.0 (5.68) 229
16 months
QUALID staff proxy 19.9 (6.38) 185 19.5 (6.06) 222 19.7 (6.20) 407
QUALID relative proxy 23.0 (6.24) 38 23.1 (8.41) 31 23.0 (7.24) 69
QOL-AD resident 43.2 (6.17) 65 42.8 (5.47) 81 43.0 (5.77) 146
Cross-section (N = 287) (N = 388) (N = 675)
16 months
QUALID staff proxy 19.5 (6.44) 284 19.5 (6.20) 384 19.5 (6.30) 668
QUALID relative proxy 23.0 (6.15) 39 23.1 (8.41) 31 23.0 (7.18) 70
QOL-AD resident 43.4 (5.69) 113 42.2 (6.61) 156 42.7 (6.25) 269
a QUALID score range: 11 to 55; 11 represents the highest QoL.
b QOL-AD score range: 13 to 52; higher scores reflect greater QoL.
TABLE 15 Unadjusted QUIS interactions by resident sample and time point
Total interactions
(% positive) missing data Control (n= 19) Intervention (n= 31) Total (n= 50)
Baseline 2065 (74.9) 0 2405 (81.7) 1 4470 (78.6) 1
6 months 1766 (81.7) 0 2291 (88.6) 0 4057 (85.6) 0
16 months 1578 (83.7) 0 2320 (83.7) 0 3898 (83.7) 0
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The mean QUALID staff-proxy score was 0.74 points lower in the intervention arm than in the control arm
(95% CI –1.91 to 0.43 points), indicating no difference in QoL between arms. Therefore, no statistically
significant differences were found in the closed cohort between arms on any resident-level secondary
outcome at 6 months. Similarly, there was insufficient evidence that proportions of positive staff
interactions with residents, observed using the QUIS, differed by treatment arm.
All 675 residents in the cross-sectional sample were included in the primary analyses and all 726 residents
in the closed cohort were included in the supportive analyses of the resident-level secondary outcomes at
16 months. All 49 care homes in which the QUIS was completed were included in its analysis at 16 months
(Table 17). In the cross-sectional sample, the odds of residents experiencing one or more of the six domains
of the NPI-NH describing BSC in the intervention arm were 0.72 (95% CI 0.48 to 1.08) times the odds in the
control arm, indicating that, although there was no statistically significant difference in the odds of residents
experiencing these domains across arms (at a population or cluster-specific level), the trend was in favour
of the intervention. In the closed cohort, the odds in the intervention arm were 0.57 (95% CI 0.34 to 0.95)
times the odds in the control arm, a result that is statistically significant (at a population or cluster-specific
level) at the 5% level.
In the individual domains, in the cross-sectional sample, the odds that residents experienced depression/
dysphoria or apathy/indifference in the intervention arm were both around 0.76 times the odds in the
control arm (95% CIs 0.51 to 1.12 and 0.53 to 1.25, respectively), but this was not statistically significant.
In the closed cohort, however, the odds in the intervention were both around 0.59 times the odds in the
control (95% CIs 0.37 to 0.95 and 0.38 to 0.95, respectively), which were statistically significant at the 5%
TABLE 16 Secondary outcomes at 6 months (closed cohort)
Secondary outcome Analysis
Treatment effect
(intervention –
control) 95% CI p-value n
Resident related
BSC Population-average logistic
model (GEE)
0.950 0.612 to 1.476 0.820 726
Cluster-specific logistic model
(REML)
0.951 0.584 to 1.547 0.838 726
Antipsychotic medication Population-average logistic
model (GEE)
0.455 0.093 to 2.236 0.331 726
Mood (NPI domain)
Depression/dysphoria Population-average logistic
model (GEE)
1.320 0.872 to 1.999 0.190 726
Anxiety Population-average logistic
model (GEE)
1.011 0.617 to 1.656 0.967 726
Apathy/indifference Population-average logistic
model (GEE)
1.330 0.853 to 2.073 0.208 726
Quality of life
QUALID (staff proxy) Linear model (REML) –0.740 –1.910 to 0.430 0.214 726
Care home related
Quality of staff interactions
QUIS: proportion of positive
interactions
Linear regression 0.039 –0.023 to 0.101 0.210 49
REML, restricted maximum likelihood.
Odds ratio < 1 favours intervention.
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level in favour of the intervention. Like at 6 months, the odds ratios for the presence or absence of anxiety
were close to 1 in both the cross-sectional and the closed-cohort samples, indicating no difference across
arms. Overall, although no statistically significant differences were found between arms in the primary
cross-sectional sample at 16 months, trends in favour of the intervention in BSC and mood were found in
the closed cohort.
TABLE 17 Secondary outcomes at 16 months by resident sample
Secondary outcome Analysis
Treatment effect
(intervention –
control) 95% CI p-value n
Cross-section: resident related
BSC Population-average logistic
model (GEE)
0.720 0.479 to 1.083 0.115 675
Cluster-specific logistic model
(REML)
0.681 0.400 to 1.158 0.156 675
Antipsychotic medication Population-average logistic
model (GEE)
1.191 0.216 to 6.559 0.841 675
Mood (NPI domain)
Depression/dysphoria Population-average logistic
model (GEE)
0.757 0.511 to 1.123 0.167 675
Anxiety Population-average logistic
model (GEE)
1.133 0.670 to 1.916 0.642 675
Apathy/indifference Population-average logistic
model (GEE)
0.810 0.525 to 1.249 0.340 675
Quality of life
QUALID (staff proxy) Linear model (REML) –0.050 –1.120 to 1.020 0.922 675
Closed cohort: resident related
BSC Population-average logistic
model (GEE)
0.570 0.343 to 0.948 0.031 726
Cluster-specific logistic model
(REML)
0.577 0.334 to 0.996 0.048 726
Antipsychotic medication Population-average logistic
model (GEE)a
0.783 0.114 to 5.368 0.802 726
Mood (NPI domain)
Depression/dysphoria Population-average logistic
model (GEE)
0.592 0.369 to 0.950 0.030 726
Anxiety Population-average logistic
model (GEE)
1.037 0.588 to 1.830 0.900 726
Apathy/indifference Population-average logistic
model (GEE)
0.601 0.380 to 0.952 0.030 726
Quality of life
QUALID (staff proxy) Linear model (REML) –0.070 –1.260 to 1.110 0.902 726
Closed cohort: care home related
Quality of staff interactions
QUIS: proportion of positive
interactions
Linear regression –0.001 –0.081 to 0.078 0.972 49
REML, restricted maximum likelihood.
a Model fitted without adjusting for hub and stratification factors to ensure convergence.
Odds ratio < 1 favours intervention.
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On the staff proxy-completed QUALID scale, there was no difference in mean scores between arms,
indicating no difference in QoL at 16 months. There was no evidence of a difference between treatment
arms in the proportion of positive staff interactions with residents, observed using the QUIS.
The CIs for residents being prescribed antipsychotics on a PRN basis in the cross-sectional and closed-cohort
samples were wide, making them difficult to interpret (see Tables 16 and 17).
Additional summaries of secondary outcomes can be found in Appendix 1, Tables 49–52 and 61 (unadjusted
scores), Tables 26–30 (output from additional models) and Tables 58–60 (summary of medications).
Analyses of safety
There were no reported unexpected serious adverse events (RUSAE). The majority of care home residents
in the closed cohort did not have any hospital admissions: 231 (75.0%) in the control arm and 308 (73.7%)
in the intervention arm (Table 18). On average, hospital admissions lasted 3.7 days in the control arm and
2.9 days in the intervention arm. The majority of hospital admissions were to general wards.
Deaths are reported in Resident deaths in closed cohort and in Appendix 1, Table 41.
TABLE 18 Hospital admissions in the closed cohort
Admissions Control (N= 308) Intervention (N= 418) Total (N= 726)
Number of hospital admissions per resident, n (%)
0 231 (75) 308 (73.7) 539 (74.2)
1 64 (20.8) 77 (18.4) 141 (19.4)
2 11 (3.6) 25 (6) 36 (5)
3 2 (0.6) 7 (1.7) 9 (1.2)
Number of hospital admissions per resident, mean (SD) 0.3 (0.57) 0.4 (0.71) 0.3 (0.65)
Length of hospital admission (days), mean (SD) 3.7 (12.33) 2.9 (9.65) 3.2 (10.86)
Overall number of hospital admissions reported, n (%) 92 (25) 153 (26.3) 245 (25.8)
Admission ward type, n (%)
General 77 (83.7) 132 (86.3) 209 (85.3)
Intensive care unit 2 (2.2) 4 (2.6) 6 (0.2)
High-dependency unit 0 (0) 0 (0) 0 (0)
Other 9 (9.8) 11 (7.2) 20 (8.2)
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Chapter 4 Cost-effectiveness
Missing data
Figure 4 outlines the data available for the economic evaluation and the level of MI conducted. Data from
389 (intervention, n = 214; control, n = 175) residents were available for the original cohort CCA and from
726 (intervention, n = 418; control, n = 308) residents were available for the imputed data set (and the
primary analysis sample).
Costs
The costs of the DCM intervention and the assumptions behind this are described in Table 19. These were
agreed with the research team and cover the DCM training and implementation. The total cost of the DCM
intervention was estimated to be £421.07 per resident (£9290.30 per care home). Control-arm costs were
assumed to be zero.
Table 65 in Appendix 1 includes descriptive statistics on resource use across time points and by trial arm,
based on data taken from resident care plans and care home records. Owing to changes to the consent
requirements to access NHS Digital data between baseline recruitment and the request for a data download
at 16 months, we were unable to receive the data and thus were unable to use it to check the accuracy of
the data on hospital admissions obtained from the care home records. The health-care resource costs are
Baseline Month 6 Month 16
Staff-completed
EQ-5D-5L
(n = 575)
Staff-completed
EQ-5D-5L
(n = 404)
Resource
use
(n = 498)
Resource
use
(n = 378)
Missing
(n = 3)
Missing
(n = 129)
Dead
(n = 99)
Missing
(n = 52)
Dead
(n = 99)
Missing
(n = 103)
Dead
(n = 245)
Missing
(n = 77)
Dead
(n = 245)
Complete data on resource and EQ-5D-5L
(including patients who died, for whom value = 0)
Baseline and month 6 (n = 487)
Baseline, month 6 and month 16 (n = 389)
Staff-completed
EQ-5D-5L
(n = 723)
FIGURE 4 Data completion rates for the complete-case sample (baseline resource use not required for CCA).
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described in Table 20. Costs are presented in GBP (2017 prices). Total costs were £3539.00 and £2059.58,
on average, per resident in the intervention and control arms, respectively. The t-tests suggest that these
costs were significantly different for the imputed (p < 0.001) and complete-case (p < 0.05) samples.
Primary care costs were similar across arms while secondary care costs were noticeably higher in the
intervention arm. The intervention arm included a few high-cost individuals. There were six residents in the
control arm whose costs exceeded the maximum, with long periods of hospital stays or one-to-one care;
these were excluded, along with seven other high-cost individuals (generated in the imputation) in a
sensitivity analysis.
TABLE 19 Costs of DCM intervention
Description of costs Cost (£) Key assumptions and sources
Training course fee 975.00 DCM course booking form.159 Inclusive of lunch, refreshments and course
materials
Accommodation (4 nights) 300.00 Based on review of DCM EPIC trial records
Meals/other subsistence 70.00 Based on review of DCM EPIC trial records
Travel to/from the course 100.00 Based on review of DCM EPIC trial records
Staff time 434.77 Assumed that there are four categories of care staff (hourly wage and
proportion of staff in each category shown in brackets): care home worker
(£7.38, 20%) and senior care home worker (£8.20, 25%) (hourly wages
reported in PSSRU 2016144), nurse (£12.45, 20%) (based on £25,902 annual
salary for band-5 nurse reported in PSSRU 2016144 and converted to hourly
rate) and care home manager (£21.63, 35%) (assumed median annual salary
of £45,000, based on a review of recent job advertisements)
The proportion of staff in each category was based on a review of DCM EPIC
trial records. Assumed that course participation required 4 full working days
(8 hours per day)
Delivery and receipt of training
(for each DCM mapper)
1879.77 Assumed that two staff were trained in each intervention home and that
there were no staff in the trial who did not require training (e.g. because they
had previously received it)
Assumed that there were no last minute cancellations (which may have
incurred additional costs if rebooking)
Staff time per mapping cycle
for DCM mapper
543.46 Using data on the cost of staff time listed above and assuming that each
mapping cycle required 5 full working days (based on DCM mapper guidance
document83 and some verification using DCM EPIC trial data)
Implementation costs
(for each DCM mapper)
1630.38 Assumed that there were three mapping cycles per DCM mapper (conducted
in accordance with DCM mapper guidance based on published standards83)
and that additional time was not required for other staff to attend DCM
briefing and feedback sessions, but that these were arranged at handover or
at other convenient times as part of usual duties (as per protocol)
Consultancy fees for external
DCM expert
2100.00 To support intervention implementation and fidelity in the first cycle of DCM
mapping, assumed to be for 5 days (£420.00 per day)
Travel and subsistence
expenses for DCM expert
mapper
170.00 Based on review of DCM EPIC trial data
Implementation costs
(for each DCM expert mapper)
2270.00 Assumed that each care home received one full cycle of DCM supported by
the expert mapper
Total costs
Per care home 9290.30 Assumed that there were two DCM mappers and one external DCM expert
per care home
Per resident 421.07 Assumed that there were 22.06 residents per care home (calculation based on
DCM EPIC trial data)
All costs are reported at 2016/17 prices.
COST-EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
58
Utility
Staff proxies represented the greatest proportion of completed QoL measures (n = 453; 62%). This was
followed by relative/friend proxies (n = 176; 24%) and resident self-report (n = 168; 23%). Table 21
includes the utility values (with MI) for each trial arm across assessment mode and questionnaire.
The primary analysis was based on the utility values reported in the top row of Table 21 (i.e. the imputed
EQ-5D-5L completed by staff proxies and scored using the standard UK tariff). Other analyses presented in
this study used the alternative utility values reported in other rows of Table 21. The first four rows of this
table show the imputed utility scores for EQ-5D-5L (rows 1–3) and DEMQOL (row 4), whereas the final two
rows report the utilities that were used in the CCA (i.e. prior to MI).
In the primary analysis, there was a slight baseline imbalance, with the control arm having marginally
higher QoL. As we might anticipate, mean EQ-5D-5L scores declined during the trial over 16 months with
resident longevity. There was a trend apparent in most of the approaches, namely that the decline in QoL
was greater in the control arm than in the intervention arm. Using all approaches, QoL was higher in the
intervention arm than in the control arm at 16 months.
The baseline imbalance in QoL was a relatively consistent finding across assessments and scoring methods.
Adjustment for this was made in the calculation of QALYs.
Cost-effectiveness
The cost-effectiveness results are also published in Meads et al.157 © The Author(s) 2019. This article is
distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The text below
includes minor additions and formatting changes to the original text.
Table 22 includes the ICERs for the primary and secondary analyses and for the various sensitivity analyses.
In the base-case cost–utility analysis, the intervention was more costly (by £1479) and more effective
TABLE 20 Health-care resource costs in base-case analysisa
Costs (£)
Intervention (n= 418) Control (n= 308)
Mean
Standard
error Minimum Maximum Mean
Standard
error Minimum Maximum
Intervention
costs
421.07 N/A N/A N/A 0.00 N/A N/A N/A
Primary care
costs
1522.32 81.37 0.00 19,559.93 1568.13 85.58 0.00 8544.83
Secondary
care costs
1547.34 315.41 0.00 67,346.67 436.96 99.98 0.00 14,220.38
Medication
costs
46.40 3.64 0.00 405.38 53.67 4.76 0.00 459.25
Total cost 3539.00 337.00 421.00 73,944.00 2059.58 146.71 0.66 18,032.06
N/A, not applicable.
a Discounted, closed-cohort, EQ-5D-5L, staff completed, with imputation. These values are unadjusted to reflect the true
range of costs.
Reproduced from Meads et al.157 © The Author(s) 2019. This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any
noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The table
includes minor additions and formatting changes to the original table.
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TABLE 21 Utility values
Assessment
Baseline 6 months 16 months
Intervention Control Intervention Control Intervention Control
n Mean
Standard
error n Mean
Standard
error n Mean
Standard
error n Mean
Standard
error n Mean
Standard
error n Mean
Standard
error
EQ-5D-5La – staff MI; primary analysis 418 0.663 0.011 308 0.676 0.011 418 0.573 0.015 308 0.569 0.019 418 0.421 0.018 308 0.395 0.019
EQ-5D-5L – staff MI; death not recoded 418 0.663 0.011 308 0.676 0.011 366 0.654 0.013 261 0.672 0.015 277 0.636 0.017 204 0.596 0.017
EQ-5D-5La – staff MI mapped to 3L 418 0.435 0.016 308 0.469 0.019 418 0.363 0.018 308 0.374 0.020 418 0.262 0.019 308 0.229 0.017
DEMQOLa – staff MI 418 0.759 0.006 308 0.746 0.007 418 0.669 0.013 308 0.623 0.016 418 0.746 0.018 308 0.736 0.021
EQ-5D-5La – staff CCAb 214 0.663 0.016 175 0.682 0.018 214 0.554 0.021 175 0.531 0.025 214 0.364 0.025 175 0.349 0.025
EQ-5D-5La – patient/relative or staff CCA 215 0.702 0.016 176 0.716 0.019 215 0.596 0.022 176 0.555 0.026 215 0.383 0.025 176 0.370 0.027
a In these cases, deaths were coded as zero.
b Only those with completions at all three time points.
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TABLE 22 Cost-effectiveness
Analysisa
Costs (£) QALYs/benefits
ICERn Intervention n Control Incremental n Intervention n Control Incremental
Base case
EQ-5D-5L – staff MI 418 3539 308 2060 1479 418 0.718 308 0.708 0.024 £60,627
CMAI MI 219 3318 185 2345 974 219 –1.767 185 –0.557 –3.37 £288.88b
Sensitivity analyses
EQ-5D-5L CCAb 214 3380 175 2073 1307 214 0.682 175 0.665 0.029 £45,674
EQ-5D-5L – staff MI, implemented cycle costs 418 3463 308 2060 1403 418 0.718 308 0.708 0.024 £57,509
EQ-5D-5L – staff MI, excluding intervention cost outliers in
the imputations
412 3046 308 2060 533 412 0.722 308 0.708 0.027 £36,371
EQ-5D-5L CCA excluding intervention cost outliersb 208 2437 175 2073 364 208 0.688 175 0.665 0.033 £10,975
EQ-5D-5L – staff MI mapped to 3L 418 3539 308 2060 1479 418 0.457 308 0.459 0.026 £57,208
DEMQOL – staff MI 418 3539 308 2060 1479 418 0.836 308 0.799 0.032 £45,918
EQ-5D-5L – staff MI open cohortc 523 2830 394 1608 1222 523 0.577 394 0.548 0.028 £42,953
DEMQOL – staff MI open cohortc 523 2830 394 1608 1222 523 0.665 394 0.629 0.036 £34,234
EQ-5D-5L – staff MI (intervention arm; only those who
completed at least two DCM cycles to an acceptable level)
100 2856 308 2060 796 100 0.734 308 0.708 0.026 £30,447
EQ-5D-5L – staff MI (intervention arm; only those who
completed at least one DCM cycle to an acceptable level)d
328 3833 308 2060 1774 328 0.744 308 0.708 0.044 £40,062
CMAI CCA 129 2768 101 2424 344 129 –1.78 101 1.06 –5.12 £67.20b
EQ-5D-5L – staff MI, with adjustment for baseline costs 262 3366 225 1924 1464 262 0.732 225 0.692 0.061 £24,139
a All costs and benefits (with the exception of the CMAI) that occurred in the final 4 months are discounted.
b Cost per unit change in CMAI score; no adjustment for baseline costs except where shown.
c Unadjusted, as baseline data not collected.
d Residents residing in care homes in the intervention arm that did not complete any cycles to an acceptable level of compliance were excluded from the analysis.
Reproduced from Meads et al.157 © The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The table includes minor additions and formatting changes to the original table.
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(0.024 QALYs) than the control. This yielded an ICER of £60,627, well above the £20,000 NICE threshold,
indicating that DCM is not cost-effective. The CCA had similar costs to the imputed sample but higher
incremental QALYs for the intervention than for the control. With the exception of the analyses that
excluded high-cost outliers, the ICERs from various sensitivity analyses [including those that restricted the
intervention sample to intervention-compliant care homes (i.e. those completing at least one cycle)] also
all exceeded £20,000. These analyses included additional costs associated with the intervention of over
£1600 and an incremental benefit ranging from 0.024 to 0.036. The cross-sectional cohort analysis yielded
lower incremental costs and higher incremental benefits for the intervention than those found in the
imputed sample.
In the sensitivity analyses that excluded the high-cost outliers in the intervention arm (six were excluded from
the CCA and prior to conducting MIs for an analysis using MI data), incremental costs reduced dramatically
and the ICER approached the cost-effectiveness threshold (£36,371/QALY) in the base case and fell below
it in the complete-case scenario (£10,975/QALY). The ICER also decreased in line with greater intervention
compliance. An analysis adjusting for baseline costs yielded an ICER below £25,000, but this was based on
a dramatically reduced sample and cannot be considered a robust estimate.
The cost-effectiveness analyses based on improvement in CMAI score indicate that, although the intervention
was more costly, it was also more clinically effective. Incremental cost per unit improvement in CMAI score
was £289 and £67 for the intervention and control arms, for the imputed and complete-case samples,
respectively.
Figures 5 and 6 are the cost-effectiveness plane and the CEAC, respectively, for the base-case cost–utility
analysis. The plane indicates that the greatest uncertainty lies in the benefits of the intervention. All of the
simulations lie above the willingness-to-pay threshold, suggesting that, using the base-case analysis, DCM
is unlikely to be cost-effective. The CEAC confirms this and indicates that, when λ = £20,000, there is a
very low probability that the intervention will be cost-effective.
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FIGURE 5 Cost-effectiveness plane. Reproduced from Meads et al.157 © The Author(s) 2019. This article is
distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons license, and indicate if changes were made. The figure includes minor
additions and formatting changes to the original figure.
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Table 23 reports the outcomes from the net-benefit regression model including the covariates employed
in the main statistical model and an interaction between trial-arm and compliance indicator variables.
The only significant predictors of net benefit were baseline EQ-5D-5L (a higher QoL leads to a higher net
benefit) and CDR score (lower values lead to a higher net benefit). In this model, neither the intervention
nor the compliance × intervention interaction terms are statistically significant. The CACE analysis yielded
similar results in that the active treatment variable including only intervention care homes that complied
with the intervention (having completed at least one acceptable cycle) was not statistically significant.
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FIGURE 6 Cost-effectiveness acceptability curve. Reproduced from Meads et al.157 © The Author(s) 2019. This article
is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction
in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made. The figure includes minor additions and formatting
changes to the original figure.
TABLE 23 Net-benefit regression
Variable Coefficient
Robust standard
error p-value
Lower confidence
limit
Upper confidence
limit
Treatment × compliance = 0 –1617.88 840.149 0.061 –3311.72 75.96
Treatment × compliance = 1 –1427.81 1159.62 0.225 –3762.80 907.18
Treatment × compliance = 2 177.53 1139.85 0.88 –2117.28 2472.34
Date of birth 0.16 0.09 0.115 –0.04 0.35
Baseline EQ-5D-5L score 14,628.21 1381.11 0.000* 11,847.35 17,409.07
Baseline CDR score –807.31 389.57 0.044* –1592.07 –22.56
Care home type –463.22 835.22 0.582 –2144.57 1218.125
Care home size 856.64 1032.51 0.411 –1221.49 2934.77
Care home training 353.93 1107.15 0.751 –1874.86 2582.727
Care home hub = 2 23.62 1359.16 0.986 –2713.0556 2760.31
Care home hub = 3 –1152.31 1215.883 0.348 –3599.056 1294.44
Constant 5282.33 1726.75 0.004 1802.20 8762.46
*p < 0.05.
Note
n = 726. Prob > F = 0.0000.
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Chapter 5 Process evaluation
Participants
In total, 75 interviews were conducted. Of these interviews, 67 were with staff members, who had
undertaken various roles during the trial. Interviews took place with 17 managers, 25 mappers (two of
whom were also managers) and 27 ‘other’ members of staff, who reflected a range of roles in the care
home and varying degrees of involvement with the intervention. Owing to the high losses to follow-up
and the requirement of having to be able to provide informed consent to participate in an interview, only
two residents participated. Six relatives agreed to participate in interviews. Interviews ranged greatly in
duration (from 3 to 38 minutes) depending on the interviewee’s knowledge and awareness of the
intervention.
What was implemented?
Each care home was asked to implement DCM as set out in the protocol and described above (see
Chapter 3, Intervention). There was considerable variation in implementation across the 31 intervention
homes, as well as variable compliance with returning the required trial documentation to provide evidence
of DCM implementation. A range of approaches was used to increase return rates of trial documentation,
including multiple telephone and e-mail reminders from the intervention lead and CTRU staff and, in some
cases, through unblinded researchers attending the care home to collect copies of documentation. In some
care homes, documented evidence of all components of intervention completion (e.g. attendance sheets
for briefing and feedback sessions, mapping data, feedback reports and action plans) were not always
available, even though mappers or managers reported that a cycle of mapping had occurred. We made the
assumption that undocumented earlier phases of a DCM cycle (e.g. briefing session) had been completed if
documentation for later phases was provided (e.g. mapping data or feedback report). We also recorded a
component of a cycle as complete only if we had documentary evidence for completion of it or for a later
stage of the process. In some cases, mappers reported verbally to the intervention lead or CTRU staff that a
DCM cycle or components of it had been completed, but failed to provide documentary evidence of this.
Therefore, our final compliance data may be subject to inaccuracies of both under- and over-reporting of
the components of each cycle that actually occurred.
Mapper training and retention
Mapper training was delivered per protocol (within 2 months of randomisation) in 21 out of 31 (68%)
homes. There were delays in training mappers from nine care homes (29%), and in one home (3%) no
mappers were trained. In two homes (6%), only one mapper was trained, rather than the stipulated two.
Withdrawal of one or both of the mappers occurred in 17 homes (55%). The reasons for withdrawal were
resignation from the care home, ill-health/long-term sickness and maternity leave and, in one home, both
mappers withdrew because of a lack of management support to mapping. At the 16-month follow-up,
14 homes (45%) had two trained mappers still in post, seven homes had one mapper (23%) and 10 homes
(32%) had no mappers. Although there was funding to train additional mappers, this occurred in only one
home, owing to insufficient time before the end of the trial to train further mappers, being unable to
identify a suitable replacement mapper or the consented mapper being unable to attend scheduled DCM
training for personal or organisational reasons.
Mapping cycles
As is reported in Chapter 3, Resident characteristics, DCM implementation was considerably less than that
required, namely three per-protocol acceptable cycles, in the majority of the 31 intervention homes, with
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only four homes completing three full cycles. The first cycle of mapping was commenced per protocol
(within 3 months of randomisation) in 22 out of 31 homes (71%). The DCM expert mappers reported
spending considerable time contacting care homes to rearrange mapping dates following cancellations
by the care home and in prompting the production of feedback reports and action plans during the first
supported cycle.
How did participants react to the intervention?
Experiences of the intervention
As was the case in the implementation of the intervention, experiences of the intervention and its success
varied between homes and also between stakeholder groups (e.g. mappers, managers, staff, relatives and
residents). The discussion about experiences of the intervention predominantly focused on the impacts of
DCM and the challenging and facilitating factors experienced when implementing DCM. Experiences of
the intervention are therefore explored under these two broad themes: Perceptions of intervention impact
focuses on the perceptions of DCM’s impact and What were the perceived barriers to and facilitators of
intervention implementation, the mechanisms of impact and the perceived impacts from the perspective
of mappers, DCM expert mappers, managers, staff, residents and relatives? focuses on the barriers to and
the facilitators of DCM implementation and its impact.
Perceptions of intervention impact
In keeping with the findings of the statistical analyses (see Chapter 3, Clinical effectiveness of the intervention),
which identified a variability in impacts between care homes, the process evaluation identified variability in
how much participants felt that DCM had an impact within their care home. In the following sections,
examples of positive impacts are first considered, before moving on to consider examples of when DCM was
felt to have variable or little impact.
Perceptions of impacts for people with dementia
A range of impacts of DCM were identified for people with dementia at both an individual and a home
level, as indicated in the key themes below.
Improved responses to individuals’ needs, personalities and interests
A repeated positive experience was the ability of DCM, and the observational element in particular, to help
staff to identify, and so respond to, residents’ individual needs, personalities and interests:
One of our gentleman that we did the observation on, we found that he made his own well-being
by playing with food and chucking it. So then I could go to the chef and say . . . ‘This gentleman
plays with his food, what can we do?’ We saw him doing it before but because of the mapping it
makes you look into it a bit more . . . He was happier, he’d have a lot more things that he could
play with.
Mapper 50028/10394
When you’re mapping somebody and you see that they’re not joining the group activities you, we
thought, right, let’s just try and see if we can do an activity that’s just for her.
Manager/mapper 50069/10475
Dementia Care Mapping was repeatedly cited as enabling individualised tailoring of care and activities,
which helped staff to better meet residents’ preferences, needs and interests. This ability to better identify
individual needs extended to groups of residents that staff could find more difficult to care for, as discussed
in the following sections.
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Improved anticipation and understanding, and prevention of complex behaviours
Examples of better identification of individual needs were related to BSC, which included agitation
(the primary trial outcome measure), aggression and distress:
I’m finding this really interesting because we can just observe all of the behaves of our residents, and
then we can just think about this, what can we change? How can we make them more happy? . . .
How can we reduce of their really low behaves, which make them distract or distressed?
Mapper 50028/10637
In terms of challenging behaviours . . . it became predictable, but then it is preventable through your
interventions. The mapping itself helped us identify the individual needs and once that is identified we
tried to set up plans and how to deal with or approach the challenge, the behaviour that is challenging.
Mapper 50011/10160
Participants repeatedly described how mapping helped to identify, and so to anticipate, preventable patterns
of challenging behaviour by recognising antecedents, warning signs and early points of intervention.
This supports the trial’s hypothesis that DCM would have an impact on agitation, although the preceding
quotations suggest that reducing agitation would have been a focus only for residents who were identified
by staff or mappers as being agitated, rather than a blanket intervention for all residents.
Increased quality and quantity of interactions
Alongside impacts at an individual level, staff also spoke of impacts for all residents at the care home level.
The impact most frequently referred to was improvements in the quantity and quality of staff–resident and
resident–resident interactions:
You know, they [staff] try and engage with people more.
Staff 50010/10095
We’ve got another lady who’s end-stage dementia who’s just by people chatting with her: she’s
actually started speaking again! Now, whether that would have happened anyway I don’t know,
but she’s not spoken for ever such a long time, but now odd words are coming out.
Manager 58930/40001
Increases in staff–resident interactions were repeatedly cited, as in the previous example, as having a visible
impact on the person’s mood:
Sometimes even one little smile to residents, one little joke, or one interaction can make a big change,
for the rest of the day even . . . It’s like our lunchtimes there is around 30 something residents plus six
carers in one room, and how someone can still feel lonely, and one interaction can change that.
Mapper 50028/10637
One of our care staff, he just went to her [lady with dementia] with a bright smile and started joking
and how that changed her mood! . . . She was much more brighter, she was much more involved in
all the situation.
Mapper 50028/10637
These and other quotations included throughout the process-evaluation results suggest a potential link
between increased interaction and activity as a result of DCM implementation, and improved well-being
for residents in intervention homes.
Increased provision of activities and occupation
Alongside improvements in resident interaction, increased provision of social and therapeutic activities and
meaningful occupation was another common impact of the DCM process. These activities were typically
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instigated in response to recognition from mapping observations that residents were spending large
proportions of their time without these types of stimuli:
My activities budget is off the scale! But at least I know if I do a map now on a particular day I know
that there’s going to be stuff going on, and I know that if I’m sat there I’m not going to be bored silly.
Manager/mapper 50069/10475
Now we introduce lots of sensory activities . . . all the residents have got some sort of activities . . .
because we’ve been observing . . . and we’ve been thinking about what could improve their well-being.
Mapper and manager/mapper 50018/10268 and 10277
In the 2 years that we’ve been here . . . the level of stimulus, activities, has grown.
Relative 58747/40007
Dementia Care Mapping highlighted the importance of providing care that addressed not only the physical
needs of residents, but also their social and emotional needs and well-being:
I have to say, that first map I was bored silly, and that made me think we are not doing anywhere
near enough for these residents. Yes, we’re ticking all the boxes in terms of care, they’re well looked
after, you know, everything is up to date in terms of that person, but what are we doing here to keep
their well-being sort of on a good level?
Manager/mapper 50069/10475
This quotation again suggests a link between increased occupation for residents as a result of DCM and
improvements in well-being.
Improved responses to the needs of particular groups of residents
Some staff perceived that DCM had a greater impact on certain subgroups of residents. Residents with more
advanced dementia or with more limited verbal communication abilities were considered, by some staff,
to be more likely to benefit from DCM, as it provided a useful method of identifying their unique needs:
Especially those with end-stage dementia, I think they do tend to get more attention possibly than they
did before. I think staff are more considerate towards them and give them a bit more empathy . . .
A lot of the residents we have that can still interact . . . they seem to be already getting quite a lot of
attention . . . I think it has had more impact on the residents that weren’t getting the attention, possibly.
Mapper 59830/40002
So many of our residents have severe dementia and, you know, their comprehension is very limited so
[mapper X] helped us in there to make changes.
Manager/mapper 50069/10475
Residents who were included in DCM mapping were another group that staff considered as gaining
particular benefit from DCM participation, as their involvement in mapping provided a focus on identifying
their care needs.
Other impacts for people with dementia
Other impacts for people with dementia that were reported by staff included giving people with dementia
a voice, enhancements to the environment and improvements to the equipment to better meet residents’
needs at an individual or a care home level:
As we observe them [people with dementia], it gives them a lot of chance and opportunity to
express themselves.
Mapper 50011/10160
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One lady, she couldn’t lift up the cup and we decided to change from a plastic beaker to two handles,
which has helped her a lot.
Mapper 58747/10447
We changed many things, even changed the place where they sit. We try to make them comfortable;
those who are watching TV switch off the radio when the TV’s on, because the first time [first mapping]
it was kind of noisy. So we try to make it better.
Mapper 58747/10447
These examples collectively illustrate how DCM gave staff the ability to understand experiences within
the care home from the perspective of residents with dementia, and so to identify how those experiences
might be improved. The ability of DCM to uncover the ‘emic’ perspective of residents is explored further in
Perceptions of impacts for staff.
Summary
As the previous examples show, the impacts of DCM for people with dementia reported by staff at both
an individual and a care home level indicate that DCM could lead to an increase in staff–resident and
resident–resident interactions, an increase in meaningful resident occupation and an improvement in
staff identification of individual residents’ needs. Some staff reported that impacts were more likely for
particular groups of residents, namely those with more advanced dementia or communication difficulties,
or residents who underwent DCM mapping.
Perceptions of impacts for staff
The perceived impacts of DCM for managers, mappers and other care home staff included increased
awareness of residents’ needs, of communication of these needs and of care quality, as well as greater
confidence among staff in caring for residents with dementia.
Improved awareness and understanding of residents’ needs and care quality
Impacts on staff predominantly related to an improved understanding of the residents under their care
and, as a result, improved awareness of the quality of care being provided in the home:
You don’t realise what you’re doing sometimes and it makes you look at things to say I wouldn’t like
that type of thing.
Staff 58930/40005
I think the benefits were just along the lines of highlighting to staff a little bit more about the needs of
dementia clients.
Manager 50013/60005
Numerous references were made to DCM helping staff to better understand and respond to the needs
and behaviours of people with dementia, indicating that this was a key impact for staff. DCM also allowed
staff to see the perspectives and experiences of residents with dementia and provided a powerful reminder
of the importance of understanding these:
Sometimes you just forget about, you know, the actual person. And to sit in that lounge and that
dining room for 6 hours, you go through what they go through every day. If that isn’t the message of
Dementia Care Mapping, I don’t know what is.
Manager/mapper 50069/10475
We were looking at it from the residents’ point of view, so we could see what they like, what they
didn’t like.
Mapper 50031/10456
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Comments from other staff members echoed these suggestions that, prior to DCM implementation, staff
were less cognisant of residents’ experiences of care in the home.
Improved understanding of embodied communication
An improved understanding of embodied communication was a repeatedly cited impact. Staff, managers
and mappers all referred to an increased awareness of, and response to, non-verbal cues and
communication from residents with dementia as a result of DCM:
We’re more attuned to looking for non-verbal cues and very small changes.
Manager 58930/40001
It’s like offering somebody a drink and then, when you are observing it, actually they’re wanting to do
it for themselves. So it’s about watching that hand movement isn’t it, and making carers aware.
Mapper 50019/10181
. . . by holding hands or by touch, there is, you can see the difference. The person will be quiet, or
they needed that attention.
Mapper and manager/mapper 50018/10268 and 10277
Staff recognition of non-verbal cues of residents’ needs was important, as they helped the staff to identify the
resident’s unique personality, abilities, preferences and requirements. Improving embodied communication
was therefore particularly important for residents who rarely or never communicated verbally.
Increased confidence and positive feedback for staff
Staff were often reported to feel more confident in their care practices as a result of DCM taking place in
the home:
They’re more confident now than they were.
Manager 50019/10195
Care assistants are now confident about doing things with the residents in there . . . I think they’re
enjoying their jobs more, I think they’re enjoying being in that unit more.
Manager 50167/10711
Increases in confidence appeared to stem from several sources. These included feedback from the DCM
process about the needs of residents, examples of the positive impact on residents when their needs were
well met and DCM providing an opportunity to celebrate the sometimes overlooked positive actions of staff:
Sometimes even though you’re seeing the staff are doing very good things to the residents, sometimes
you don’t appreciate . . . you don’t get the time to do that . . . but this was the time that we could be
able to appreciate the staff.
Mapper and manager/mapper 50018/10268 and 10277
Increases in staff confidence and knowledge could also result from having staff who have been trained
as mappers available in the home, as they are a perceived source of expertise and support in relation to
problems and approaches to caring for residents with dementia:
After talking with the mappers it presents a greater awareness of what you need to do with and for
your clients.
Staff 50010/40010
She’s [mapper] got that extra knowledge that she’ll go, well, it could be this, or it could be that.
Staff 10666/40015
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The potential increases in staff confidence and knowledge that could arise from having access to the expertise
of a mapper within the home suggests that some impact may have been possible in intervention homes that
did not actually implement any DCM cycles. However, this is not borne out in the main trial results.
Summary
The most commonly cited impacts of DCM on staff were an increased awareness and understanding of
the needs of residents with dementia, including the embodied communication of residents with limited
verbal communication, and increased confidence among staff in providing care for people with dementia.
Changes in care practices and culture
Related to impacts on staff were wider changes in the practice and culture of care across the home. The
magnitude of the changes referred to could vary greatly, from small changes in staff behaviours to more
significant changes that could require managerial or financial support.
Smaller, achievable changes to care practices and culture
Relatively small, and therefore achievable, changes in staff behaviour were often considered by participants
to make a big difference, despite the relatively little time, cost or effort that they took to implement:
Just tiny little things, for instance, when a staff member walked through the foyer . . . and acknowledged
the residents, their faces lit up. That split second, and even a smile, it made a lot of difference to
the residents.
Mapper 50031/10456
Now if I’m dealing with anybody, I have a conversation while I’m washing and dressing them. And
that way I’m finding out little bits about them . . . about their likes and dislikes, what they used to do
in their past life.
Staff 50018/60002
Examples of these small, achievable changes often involved staff making better use of the opportunities
available to them to interact with residents, for example as they undertook care tasks or were passing
through the home. Despite these examples signifying relatively small changes to practice, they were felt
by staff, especially if collectively adopted, to have a significant impact on residents:
It doesn’t have to be a major functional change of the home, these [changes spoken of] are all really,
really small things but, holistically and collectively, they make a massive difference.
Manager 50011/10611
The little things can make a big difference for someone who is just, who is not involved in the
situation, even in the big group where they are sitting.
Mapper 50028/10637
The significance attached to such changes was also an example of the low levels of baseline interaction
seen in some homes during the QUIS observations, in which residents could spend long periods of time
with no one to interact with.
Larger, formal changes to care practices and culture
Larger changes to more formal care practices and processes were also reported, such as changes to staff
inductions, ‘in-house’ training and care planning approaches. These changes required more effort to
implement and could necessitate support at a managerial level or agreement across multiple care homes:
We have made it into a holistic type of care planning, wherein again we have brought in
person-centred care.
Mapper 50011/10160
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The main difference that it’s had so far is altering our training, ‘X’ does our dementia training across
both homes, and we also do dignity training between both homes. And we’ve changed those courses
quite a lot, so that it delivers a lot more of the language we learnt across Dementia Care Mapping.
Mapper and manager/mapper 50018/10268 and 10277
Changes to care home culture requiring managerial support were also spoken about, for example in
relation to changing the previously held assumptions at a home level that talking to residents did not
constitute ‘proper work’:
There’s this culture shift where it’s OK to sit down and have a chat with them [residents], it’s OK
to be seen to do that . . . If she [care home owner] saw a carer sitting down [before DCM] it would
be like ‘What the hell are you doing? You’re being lazy!’. And actually there’s a massive shift now,
if you walk in and see a carer sitting and joking around with residents, that’s a really good
responsive service.
Manager 50011/10611
This final example indicates the importance of having senior management that understands and supports
the need to change care practices and culture in the home.
A tool for identifying and evaluating changes to care practices and culture
Many of the preceding responses indicate that DCM was used as a tool to identify areas for improvement
across a range of care home practices and processes, including training needs, the quantity and quality of
interactions with residents and care planning. Managers were particularly aware of the potential benefits
of DCM as a structured tool for identifying and providing evidence for practice improvements:
Whereas before we would try to improve but we didn’t really know how, so it was a bit like running
around headless . . . I think one of the most positive things about mapping is that it gives you a
structure to sort of put dementia and dementia care in . . . So before [DCM], you sort of, you want to
improve but it’s very difficult to know how to improve.
Mapper and manager/mapper 50018/10268 and 10277
From the cycles that the girls have done, they’ve identified and can share information with the rest of
the employees, to actually improve in any way we can the care that’s delivered.
Manager 50031/11187
Dementia Care Mapping was also used as a means of providing evidence of the impact of improvements
to care practices, and thus provided a means of both motivating and maintaining changes to the practice
and culture of care:
Until you’ve sat there for a few hours and actually seen someone gain enjoyment from just holding
something, it’s something that’s very easy to ignore because it’s very small. So it [DCM] meant we
could actually start making small changes, people could see the difference.
Mapper and manager/mapper 50018/10268 and 10277
I’ve always said it’s [sitting and chatting with residents] a legitimate activity, but it is, now it’s been
pointed out to them that it actually does have an impact on that person’s health and well-being,
then, you know, it’s done more.
Manager 58930/40001
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Having managers who were also mappers facilitated the process of getting senior staff to understand, and
to provide financial support for, any changes required to care practices in the home. In some instances,
significant changes were made to care practices as a result of DCM implementation:
That whole unit is light years away from before it was, before you started doing the mapping, before
we started the project.
Manager 50167/10711
Summary
The DCM intervention enabled care homes to achieve change in some of the daily care practices of their
staff, most noticeably in relation to the level of interactions with residents. Changes were also noted to
formal care practices such as approaches to care planning and staff induction and training. DCM was
perceived to be a useful tool through which the need for these changes was identified, with managerial or
across-site support required for changes to be made at a care home level.
Impacts on relatives
Some impacts from DCM were noted for relatives of residents in the home. The most common impacts
cited for relatives were an increased involvement in the home and better provision of information by staff
to relatives about their family member’s care:
It has involved not just the home staff; it has involved families.
Manager 50010/10755
I found it really interesting for the residents that we mapped to let their families know what we’d
noticed . . . This is what we found when we were doing [DCM], and this is what we’re going to do.
Manager/mapper 50069/10475
There is a suggestion here that impacts may be greater for residents who were mapped, and also for their
relatives. It should, however, be noted that these perceived impacts were reported by staff and not by
relatives who, as discussed previously in Impacts on relatives, could struggle to identify the impacts of
DCM on themselves:
I don’t know, it’s really hard to say . . . Overall I’m really happy so I can’t say there’s been anything
specific that I’ve noticed that’s any different.
Relative 50010/40009
Examples of limited impacts
Although many participants identified positive impacts resulting from the implementation of DCM within
their home, they sometimes struggled to provide examples or identify specific ways in which change
had occurred:
I do think there is an impact there generally yes.
Manager 50010/10755
When the interviewer asked ‘Can you give us any examples of specific action plans that came from the
first cycle, which was a while ago?’, manager 50011/10611 responded ‘It was ages ago, erm . . . I can’t
specifically’.
In addition, some participants considered that DCM had asserted little influence over care practices in the
home or over the experiences of residents. When the interviewer asked ‘Has there been any impact, there
might not have been, on the residents do you think as the result of mapping?’, mapper 50010/10096
responded ‘No. No I don’t think so’.
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In addition, when the interviewer asked ‘Has there been anything for staff; have they changed kind of
their routines at all?’, manager/mapper 50069/10475 responded ‘Erm, not as a whole, no’.
It might be expected that staff from homes who implemented fewer cycles of DCM would struggle to
identify impacts as a result. This tendency is supported to a degree by the previous quotations, all of which
came from homes that experienced problems with DCM implementation and completed only one or two
cycles of DCM as a result. However, some participants from homes completing three cycles still struggled
to identify definitive impacts from the implementation of DCM:
I must admit I have seen some improvement but I’m not here every day.
Mapper 58930/40002
When the interviewer followed up with ‘Have you seen improvement for the residents’ quality of life as
well, do you think?’, this participant responded ‘I think so, yeah. Especially those with end-stage dementia,
I think they do tend to get more attention possibly than they did before’.
I suppose I haven’t necessarily seen any real changes, but I was happy in the first place.
Relative 50018/20107
Collectively, and in line with the main trial results, these quotations suggest that implementing DCM did
not uniformly lead to positive impacts for care home residents or for staff. Issues were also experienced
with unexpected, and sometimes negative, impacts and with maintaining positive impacts over time, as is
explored next.
Unexpected impacts or consequences
A small number of potentially unexpected, and sometimes negative, impacts or inappropriate uses of DCM
were identified during the interviews.
Conflict among staff
Disagreements over the findings of mapping sessions were reported to lead to conflict among staff in one
home, although these differences were subsequently resolved:
There was arguments as well, because you know they say sometimes that you don’t see the residents
and how they are being . . . and we cleared everything and they did take it in a positive way eventually!
Mapper and manager/mapper 50018/10268 and 10277
Although this was the only reference made to arguments, some other homes also reported initially
negative responses from staff to DCM feedback, highlighting the importance of ensuring that staff
understand the DCM process and the importance of providing feedback that celebrates positive examples
of care as well as highlighting areas for care improvement.
Fear of scrutiny from past negative experiences
As a result of a home beginning to use DCM, some staff felt scrutinised and fearful, predominantly
because of past negative experiences of other forms of care scrutiny, such as CQC inspections:
In most cases when it [feedback on care] happens it’s a negative experience because there’s inspectors
from various organisations, so I think it wasn’t until we started giving feedback and there was quite a
bit of positives in there that the staff really engaged with the process.
Mapper and manager/mapper 50018/10268 and 10277
The staff . . . it didn’t matter how much time we spent explaining that it wasn’t about spying on them,
that’s how they felt about it.
Mapper 50019/10181
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It was like being spied on.
Staff 50010/40010
These feelings appeared to be more common in staff members who did not fully understand the purposes
or processes of DCM. Such feelings typically, but not always, lessened or went away as the processes
involved in implementing DCM became more familiar to staff and better understood.
Inappropriate use of Dementia Care Mapping
Some misunderstandings about the purpose of DCM also appeared to lead to it being used in ways that
appeared to be inappropriate or not in line with its recommended use. One home reported using evidence
from DCM to assess potential new members of staff and as part of a fee review to provide evidence that a
resident’s needs had changed and their fee should be increased:
We ask all new members of staff to come in for training where we dementia map them . . . We also
use it [DCM] for fee review, so if we have someone whose needs have really drastically increased
I can go to them and say she needs X amount of day care hours a week and there is the evidence.
Manager 50011/10611
In addition, in another home, DCM was perceived as a method for staff to highlight errors in each other’s
care practices:
The idea is that if one carer’s working with another they can turn to them and say you shouldn’t have
done that you should do this.
Mapper and manager/mapper 50018/10268 and 10277
It is potentially relevant that both these examples came from managers who had not been trained in DCM
and appeared, from the content of their interviews, to not fully appreciate the purpose of DCM. This
reconfirms the importance of ensuring that care home staff who hold key leadership roles, such as
managers, have a clear understanding of DCM for it to be implemented appropriately and effectively.
Summary
In summary, some unexpected and negative consequences of DCM implementation were also identified,
including conflict between staff over the results of mapping sessions, fear of being scrutinised and
inappropriate uses of DCM. These undesirable consequences were noted more frequently among homes
and staff (and particularly managers) for which DCM was poorly understood. In addition, the impacts of
DCM were not always easy to identify nor uniformly positive. Some participants struggled to identify any
impacts as a result of DCM implementation or to definitively attribute any impacts they did identify to
DCM implementation. Participants who could not identify or attribute impacts were often, but not always,
from homes that had struggled or failed to implement the trial’s recommended dose of DCM.
What contextual factors shaped if and how the intervention was
implemented or worked?
What were the perceived barriers to and facilitators of intervention implementation,
the mechanisms of impact and the perceived impacts from the perspective of mappers,
expert mappers, managers, staff, residents and relatives?
The data indicated that implementing DCM in care homes is complex and that there are many factors that
may facilitate or prevent successful implementation. Barriers and facilitators were identified by managers,
mappers, expert mappers and staff members and related to three main themes: care home-level barriers
and facilitators, intervention barriers and facilitators, and trial barriers and facilitators.160
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Care home-level barriers and facilitators
Care home context
Contextual features of care homes affected the degree to which DCM was implemented within each care
home. This included broad issues, such as the type of setting and staffing levels or losses, and more specific
issues, such as the availability of computers in the home and funds to support implementation.
The type of care home may have influenced implementation, with additional complications present in
nursing homes. However, the value of DCM in more complex settings was acknowledged:
I think it’s just the workload, really. The amount of work there is sometimes, and with it being a
nursing home – the intensity of the workload. Obviously, we have a lot of very poorly people
sometimes.
Mapper 58930/40002
Managers of residential homes felt that they were disadvantaged by a lack of qualified staff members with
the expertise to help to facilitate implementation:
Because we are only a residential home, erm, y’know, we haven’t got nurses and stuff so my staff
aren’t that confident anyway . . . I’m glad we got involved because we got a lot out of it, I’m just
disappointed that we weren’t able to continue.
Manager 10666/10722
Larger care homes that were well staffed were able to build time for DCM into their rotas, whereas smaller
care homes with fewer staff members could struggle to accommodate the cover required to facilitate
DCM:
That’s the reason we pulled out, because they [mappers] couldn’t carry on doing their deputy
manager role, or senior care role, and be a mapper with the amount of reports . . . So I think it’s
just a bit unrealistic.
Manager 50011/10611
Across all care home settings, high levels of staff turnover were an issue. A level of consistency in staff
involvement is needed for understanding the change over time for residents and also to implement
changes as a result of DCM:
Care homes are really, really busy. Turnover of staff in care homes can be quite dramatic at times,
and the realities are there’s other pressures on them isn’t there. But that’s, that’s it though isn’t it.
That’s the reality of anywhere though I suppose.
DCM expert 70005
Particularly important in relation to the staffing of care homes was the turnover of mappers. Not only did
this lead to delays in implementing DCM while additional mappers were recruited and trained, but this
also had an impact on the confidence of the remaining mappers, leaving some feeling overwhelmed by
what was required of them:
I think where I struggled and like with the report and things was because I was the only mapper, they
were like ‘I need you to map three people’. And it was like ‘ahh . . . my first map’. And I’m mapping
three people whereas if there was somebody with me, then we could’ve both done that together.
Mapper 50028/10394
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Care homes with limited access to computers experienced difficulties in completing the computer-based
elements of DCM:
We’re not always the most IT literate in care homes. Having access to computers and time to analyse
can be quite difficult.
Mapper and manager/mapper 50018/10268 and 10277
Some care homes also had high workloads or competing priorities at the time, such as CQC reports or
problems with staffing levels:
It was mainly the home, the crisis that the home was in . . . Knowing the staff we had at the time and
the difficulties we had . . . I struggled just to get them to do the health and safety training, the basics.
Manager/mapper 50009/10104
These findings suggest that DCM implementation may be easier in larger nursing or dementia-specific care
homes with greater numbers of qualified staff, where there may be greater access to computers and to
funds and larger staffing pools to provide cover for mappers to undertake DCM.
Manager
The care home manager was a key individual in the success of DCM. Although managers were not always
involved in the implementation of DCM, as they generally were responsible for rotas, allocating staff
workloads and supervising the mappers, their engagement either ensured that it ran efficiently or created
barriers for the mappers:
I think management support, you know, it can either be amazing when it’s amazing or it can be a real
difficulty if the manager isn’t supportive.
DCM expert 70006
Generally, there was thought to be a lack of support from managers. Managers needed to have awareness
of the time required for their mappers to be involved and willing to support this process:
The managers delegated all aspects – all of it – to the mappers, and didn’t take any responsibility for
ensuring the process. I think the odd manager was supportive, again from the office, but not really
understanding about making time.
DCM expert 70004
When there were difficulties in the relationship between managers and mappers, issues arose for mappers,
particularly at the feedback stage. The hierarchical nature of care homes sometimes acted as a barrier in
the process, meaning that mappers were unwilling or felt unable to challenge the care home manager:
It’s mainly from a confidence perspective, [mappers] were clearly not confident to challenge a manager
who was not supporting.
DCM expert 70003
Conversely, when managers were engaged with DCM, this facilitated the process and helped mappers to
make changes based on what was observed during the cycles. Furthermore, when managers valued DCM,
they could see clear benefits from implementing it. For example, one manager believed that it was a key
tool in helping to improve the CQC rating of the care home:
They were very clear that they thought DCM was fantastic, because they saw it as a way of improving
the quality of their care to take their home CQC rating from good to outstanding.
DCM expert 70004
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Managers referred to the adaptations required to make DCM fit into their home. This included suggested
or actual adaptations to the process of DCM itself, such as shorter maps, and hypothetical or actual
adaptations to the work of staff, such as changes to rotas and over time:
We’re going to be having to change shifts so they can be on shift at the same time every month
because we can do some mapping.
Manager 50010/10755
These findings suggest that managers are key in the implementation of DCM and can act as either a
barrier or a facilitator. A good relationship between the manager and the mappers is crucial to successful
implementation.
Motivation and enthusiasm for Dementia Care Mapping
Motivation and enthusiasm were key factors when implementing DCM. Expert mappers emphasised that,
when managers and staff teams were motivated to be involved in the DCM process, mappers were more
likely to implement DCM within the home:
The manager would come in and, you know, be really enthusiastic. They came to the briefing; everybody
was at the briefing, the whole home, the manager of the home, do you know what I mean. The company
really bought, really bought in to DCM. And the two girls, the two mappers were just really enthusiastic
about it . . . and really, really tried their hardest.
DCM expert 70005
To capitalise on this motivation and confidence, some care homes undertook the first cycle of DCM soon
after the training session, and this appeared to have benefits, with greater difficulties experienced if mapping
was undertaken or attempted a while after attendance at the training session:
They went for that training down in London then there was a gap and I kind of think if they had just
gone straight in and done the mapping, they might have done it. But I feel that when a few weeks
passed, they were struggling to say how we do this . . . maybe they didn’t have the confidence,
you know what, to roll it out.
Manager 10666/10722
The motivation of mappers was sometimes overshadowed by the time constraints within care homes,
meaning that the mappers were able to complete the mapping hours, but often struggled to find the time
to discuss what had been observed:
When I was actually there we had lots of, you know, creative really, very inspiring conversations about
care practice. But it’s trying to nab them, it’s almost like it’s impossible to nab, sit the person down
and really discuss what’s going on.
DCM expert 70002
In summary, having motivation and enthusiasm for making changes to practice was key in the success of
DCM. However, the challenges faced, such as time constraints, sometimes overshadowed the motivation
of individuals.
Staff engagement
As DCM is a home-level intervention, effective engagement with care home staff influenced the extent to
which DCM was implemented. Particularly important was having staff who were open to feedback based
on the observations and were willing to contribute towards formulating action plans. In some care homes,
the mappers were able to engage a large proportion of staff in feedback sessions, which was seen as
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positive by the DCM experts. Mappers who were in more senior roles may have found it easier to
encourage staff to attend feedback sessions, owing to their status within the home:
I was so impressed how they just gathered people up, at busy times as well. And they really saw the
worth of that, and great discussion. I was, and that was the first home, so I thought wow this
really works.
DCM expert 70002
To implement a care home-level intervention, the involvement of all staff roles was crucial. The importance
of staff members in a range of roles attending feedback sessions was highlighted:
There was a really big crowd actually, and it did include lots of different disciplines of staff, including
the painter and decorator and maintenance man, which was great.
DCM expert 70002
The degree of engagement of the wider care home staff with DCM influenced the implementation of
DCM. High levels of engagement with staff led to more of a ‘whole home’ approach to considering DCM
feedback and agreeing on action plans:
You really have to get quite a few people across the organisation thinking in the same way to sort of
drive that change.
Mapper and manager/mapper 50018/10268 and 10277
Staff engagement was achieved through multiple strategies. These included providing feedback in staff
meetings to ensure good coverage; a focus on ensuring that staff understood DCM, its purpose and the
outputs of mapping; and a focus on providing positive, as well as negative, feedback. The latter strategy,
in particular, helped to ensure that staff were engaged and that the benefits of DCM were demonstrated:
We sort of ended up picking two or three very small examples of people who were very happy or very
sad and just focusing on those, describing in laymen’s terms . . . They did take it in a positive way
because they’d been, initially we said it’s for all our residents’ well-being.
Mapper and manager/mapper 50018/10268 and 10277
The selection of mappers influenced how engaged the staff team were. When mappers were not seen to
be popular staff members or people to be respected, it was difficult for them to engage with the staff
team to implement change:
The second time around we held a meeting and nobody came . . . We did try like, you know, individual
[meetings], a few minutes at a time, but I don’t think they took it seriously enough, do you know what
I mean?
Mapper 50010/10096
However, when mappers were respected, engagement was facilitated by the fact that implementation and
feedback were peer led, as opposed to being conducted by an external person:
It’s people that you know and peer-led, it’s, you know, it’s not like somebody from outside coming
and talking with them, it engages the staff.
Manager 58930/40001
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In one home, there was a division in the work environment between staff who did and staff who did not
support the mapper, which made feedback sessions particularly difficult. This led to further difficulties in
implementing DCM, as staff were not willing to make changes to practice. This may have been reflective
of the culture in the care home, highlighting underlying issues that existed prior to involvement in the trial:
I would say in that home there’s two very definite groups of staff: the ones who want to see progress,
who would support the mapper, who would want to encourage her and make it work, and there was
also a very strong group of people who say, you know, ‘what does she think she’s telling us’.
DCM expert 70001
Negative attitudes towards DCM from both staff and managers also acted as a barrier to engagement with
DCM. If DCM was not perceived to be a priority, staff often did not take the time to learn about and
understand the process:
I felt that the ways that people had been working prior to that, the culture of the place, whilst there
was a lot about it which I would really commend it for, there were definitely some things that needed
to be looked at. And I felt that there was a reluctance to look at that. And there was quite a lot of
defensive response.
DCM expert 70001
Some staff questioned the validity of DCM when the presentation of residents was changeable or they
considered that DCM did not suit the residents they provided care for:
. . . some of our residents are quite, quite poorly so it doesn’t work for them, it just depends how well
they are.
Staff 58747/40008
However, gathering together to collectively reflect on DCM feedback sometimes made staff feel a part of
the process and helped to break down potential barriers and mistrust, for example in relation to being
observed and receiving feedback, of which staff may have had past negative experiences:
In most cases when it happens, it’s a negative experience because there’s inspectors from various
organisations, so I think it wasn’t until we started giving feedback and there was quite a bit of
positives in there that the staff really got engaged with the process.
Mapper and manager/mapper 50018/10268 and 10277
In summary, staff engagement was crucial to the implementation of DCM. Without the support of the
staff team, mappers struggled to make practice changes. The mappers needed to be respected by the staff
team for DCM to have any influence in the care home. The importance of receiving feedback from peers
rather than from external individuals was highlighted.
Mapper qualities
The choice of mappers, including whether or not they had the required qualities, was a key indicator of
implementation success. The qualities valued in mappers, namely those qualities considered by managers to
facilitate DCM implementation, included confidence in undertaking the mapping and feedback sessions,
leadership skills to motivate and influence action-planning in the home, pragmatism, dedication, an interest
in and an enthusiasm for DCM and improving the care of people with dementia, and a keenness to learn.
Managers were asked to select mappers; this was done based on the skills required to become a mapper
but also based on the staff members that were available to choose from in each home, who were deemed
likely to remain working at the home for the duration of the trial:
Two team leaders stuck out as being really passionate about people living with dementia.
Manager 50019/10611
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Attending the training and implementing DCM improved the confidence of some mappers:
I never thought I’d be able to do it, but when we got back here, and after the training we actually put
it into practice . . . It all made sense.
Mapper 50031/10456
Mappers having the motivation to improve the quality of care for people with dementia helped facilitate
the implementation of DCM. However, for one mapper, the challenges of implementing DCM over-ruled
her motivation and she became disengaged with the process:
I think it impacted on how they felt about it. It became a chore and one lady I can think of in particular
was very excited and motivated about it, and became less so because of the challenges. And that’s
really sad to see. Someone who had that real passion to just go ‘do you know, it’s just too hard’,
but initially is like ‘I’m happy to come in on my day off because I think it’s marvellous’, but when
you’re not then getting that support it, you know, wears you out really. Wears you down.
DCM expert 70003
Certain skills and abilities were also perceived as being central to enabling mappers to undertake the
various processes involved in implementing DCM. These skills and abilities included computer literacy,
writing high-quality reports, fluency in English and sufficient academic ability to undertake the more
complex components. Conversely, mappers who did not possess some of the aforementioned qualities or
skills, despite the trial processes used to identify and recruit mappers with the required skills, could struggle
to implement DCM. In particular, a lack of IT skills, low confidence levels and insufficient fluency in English
were cited as barriers to DCM implementation:
For me it was quite difficult because English is not my native language.
Mapper 58930/40002
The selection of mappers in senior roles was perceived to have both positive and negative impacts on DCM
implementation. Although senior staff could possess academic, writing and leadership skills that facilitated
DCM implementation, it was more difficult to free up staff in these roles to undertake mapping and they
could be subject to multiple competing demands on their time, which challenged their ability to implement
DCM:
[I chose] two quite strong team leaders that I knew would be able to get staff on their side and would
be able to manage the feedback, because they can be quite difficult sometimes.
Manager 50019/10611
I was disappointed that my staff couldn’t continue with the mapping, but I think I made the error in
the staff I chose . . . their level of responsibility in the home was too high, so it didn’t enable them to
have enough time.
Manager 50167/10711
Although the qualities and skills mentioned previously were identified as important, in reality it could be
difficult for managers to identify staff members who possessed many or all of the skills required to
implement DCM in a care home context:
If I look at the whole team there are few other people who would have been possible, academically
capable of completing that project. And that’s a difficulty.
Manager 50167/10711
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An important component of mapper choice was commitment from the potential mapper. Agreement was
not, however, always forthcoming, given the length of the DCM course and the often distant geographical
locations in which the courses were held. These were logistical issues that were especially problematic for
staff with caring or other commitments:
We need someone who would agree to do it, and promise that when they come back they’re going
to get the job done.
Manager 50021/11082
Furthermore, although managers recognised the qualities that were important for mappers to possess,
in reality the choice of mapper often came down to who was willing and available to undertake the 4-day
course, particularly if this would involve staying in another area:
When we found out they would have to do 4 days’ training in London, [mapper initially chosen]
wasn’t able to do that. And because we found out almost at the last minute, we just had to grab
somebody else that was free really.
Manager 10666/10722
A further example of availability being prioritised above ability was seen in another care home in which,
following a mapper leaving, the manager did not pick a staff member to attend DCM training based on
their abilities. Instead, the new mapper was selected based on their availability to attend the course:
I think when in one case where a manager . . . didn’t have a clue about who to nominate, she was
just, she was looking at the off-duty and sort of picking names off the off-duty.
DCM expert 70005
Mappers who were less qualified or experienced found it harder to implement DCM. The DCM process
asked mappers who were care assistants to develop and utilise skills that they were not familiar with using.
Having the skills to ask questions as part of feedback sessions, which allowed staff members to give
opinions rather than just yes or no responses, was particularly challenging for some mappers:
It was about time, it was about access, it was about computer literacy. And the, for some of the care
workers, writing anything was a real challenge. You know, they’re just not, not used to putting
descriptions down, let alone sort of feedback-type questions to ask.
DCM expert 70002
There were many conflicting priorities placed on mappers, particularly if they were staff with additional
responsibilities, such as completing the medication rounds or conducting assessments for potential new
residents. This had an impact on the time available to complete the stages of DCM:
Well it was all just such a squeeze in the day, you know, and I remember being at one home where
one of the mappers was late, one of the other mappers was busy doing the drugs, you know, and
that was quite a familiar scenario.
DCM expert 70004
In summary, the selection of mappers had a significant impact on the delivery of DCM as an intervention.
Recruiting mappers with the appropriate skills facilitates the delivery of DCM, as difficulties with stages of
the mapping process, such as analysis and report writing, can result in much more time than anticipated
needing to be dedicated to the completion of cycles. For mappers to undertake the DCM cycles, a degree
of effort, commitment and time was needed that some mappers had not anticipated or appreciated when
agreeing to take on the role. The amount of time that staff would need to be away from their usual roles
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to undertake DCM meant that it was not viewed by some, in its current form, as a tenable intervention in
a care home setting. Ensuring that managers understand what skills are particularly important for mappers
helps to reduce the likelihood of these acting as a barrier to the delivery of DCM.
Intervention barriers and facilitators
A number of barriers to and facilitators of the DCM intervention itself were identified.
Understanding Dementia Care Mapping
The extent to which mappers, managers and staff valued and understood the benefits of DCM influenced
whether or not it was successfully implemented or facilitated. When DCM was perceived as a tool and a
process that could improve the quality of care being delivered, managers and mappers were more engaged.
In care homes in which DCM was not understood, particularly in terms of the time commitments required,
there were issues with the completion of cycles:
The manager that clearly didn’t get it, I think was just so busy with everything else. Absolutely,
you know, I did see her running around like this, yeah.
DCM expert 70003
An understanding of the DCM process and its potential for changing the care delivered in care homes is
crucial to successful implementation. When some of the trained mappers did not fully understand the
process, they struggled to explain it to others:
The trouble is, when they came back [from the training], they weren’t able to explain properly what
they had to do. So, you know, they were trying to explain it to us and we were finding difficulty
understanding what was actually involved.
Manager 10666/10722
As a result of a lack of understanding of DCM, managers and staff did not always engage with the
process:
I still don’t understand it . . . no one has been able to explain it to me fully . . . Every time I asked them
[the mappers] to explain they were struggling. So I never got a full grasp of what it was all about.
Manager 10666/10722
When managers did not understand the process or value of DCM, it was perceived as a distraction and it
became particularly difficult for mappers to be released from their duties:
I would say the challenges outweigh everything else really.
Manager/mapper 50009/10104
However, for the majority of mappers, the value of DCM was clear and easily understood, even when this
was not clear to the managers:
You can see a big difference. You can actually see what goes on through their [the residents’] eyes.
When you sit there and watch them for about 3 hours.
Mapper 50019/10180
These findings indicate the importance of mappers, managers and staff having a clear understanding of
the DCM process before attempting to implement it. Without this understanding, mappers are unable to
be released from their duties to complete mapping tasks, as it is not seen as a priority or a valuable tool
within the care home.
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Complexity and time demands of Dementia Care Mapping
Dementia Care Mapping was felt to be complex and time-consuming by some participants, with the
nature of DCM felt by these participants to be a barrier to its implementation in a care home context.
Various aspects of DCM were felt to be too complex, including the observation phase and associated
coding, the report writing and the language used:
So the report writing, yeah, was horrific to be honest. Very time-consuming. Obviously we both had
different roles at that point so quite demanding, so getting time, and it’s not a very quick process. Like
I say it took quite a lengthy period of time. So that were quite bad to be honest, it was very demanding.
Mapper 50069/10476
Particular components of the process were identified as time-consuming or overly onerous, including the
length of the training course and the paperwork and report-writing requirements:
Some of the things that certainly I picked up on, some of the things they found more difficult, was around
the kind of data analysis and report writing. That was the area that people seemed to find most difficult.
DCM expert 70006
For some mappers, there were delays between them attending the training course and completing their first
cycle of DCM, which might have led to them forgetting some of the more detailed parts of the process,
such as the observational coding framework. The DCM experts had to give additional, unexpected time to
help mappers ‘revise’ some parts of their training before starting the mapping cycle:
I mean one person I worked with, we did our first IRR [inter-rater reliability], our first kind of check of
her accuracy and I think we got, our agreement was kind of in the 40s. Like it was very, very low.
And that was mapping one person for an hour.
DCM expert 70006
The time required to undertake DCM meant that mappers had to be taken away from their usual roles
and defined as ‘off the floor’ and were therefore removed from the core business of care delivery in the
case of direct care staff:
The mappers were also carers and nurses and had, you know, activities and tasks and jobs to do as
well as the mapping. Yeah, I think they found it quite overwhelming.
Manager 58930/40001
In addition, some managers felt that once the training course was completed they were then left to
implement DCM on their own, although in reality every home had access to a DCM expert for 5 days to
support implementation of their first cycle. Such views raise questions about the fit of DCM for care homes
and suggest the need to consider adapting standard DCM processes for care home staff in the future
development of the tool.
Trial barriers and facilitators
Expectations of Dementia Care Mapping and the trial
Expectations of the trial and of what was required to support the implementation of DCM did not meet
the realities experienced by participants. In particular, the time and costs exceeded those expected by the
managers and mappers. This had an impact on the schedules in place for each care home and led to the
expert mappers having to consistently renegotiate schedules:
But from start to finish, although we renegotiated, kind of, schedules for me going down there,
it was difficult, I think they would say that they weren’t aware of the time commitments to it.
DCM expert 70005
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Some managers were not aware that the mappers could not be included as members in the staff team
and thus could not provide direct care on the days when they were mapping. These managers did not
appreciate that the mappers were unable to stop mapping to assist residents with any care needs that they
had during the mapping process. This led to tensions between some managers, mappers and expert mappers:
They were definitely not aware of that because they were not normally on the part of the numbers,
so they didn’t realise that they would have to be off the numbers to do the, you know, preparing the
map, for the mapping, for the map itself and to do the rest of their work.
DCM expert 70005
The range of processes and tasks involved in participation in the trial, as well as those involved in implementing
DCM, such as the completion of trial and DCM paperwork, seeking consents, undertaking interviews and
identification of staff participants, were not anticipated by managers or mappers prior to taking part:
They struggled with the copious amounts of paperwork, they told me that if they knew what was
involved that wouldn’t have gone for it.
Manager 50019/10195
In summary, the conduct of the trial may have negatively influenced perceptions of the tenability of
implementing DCM in care home settings, with the combined burden of trial and DCM participation proving
difficult for some care homes to manage. Mismatches occurred between the expectations of what the DCM
intervention entailed and the additional work that was required by managers and staff during the trial,
despite having been provided with detailed written and verbal explanations of the processes and the time
involved by the research team. Care home managers and mappers were not fully aware of the expectations
of them during the trial, particularly in relation to the time involved in each stage and component of the
trial, and the requirement of mappers to focus on all aspects of the DCM intervention while in the mapper
role, with the consequence being that they were unable to attend to their usual care work at these times.
This had a negative impact on the ability of mappers to implement DCM, as they were frequently not
released from the staff roster to complete the DCM procedures.
Expert mapper support
Expert mappers viewed themselves as incredibly valuable to the implementation of DCM, suggesting that,
without their input and support, DCM would not have been successfully implemented in the majority of
care homes:
If the expectations had remained the same, I don’t think it would have worked without the
expert mappers.
DCM expert 70006
However, two DCM experts felt that the mappers would have completed the cycles regardless of whether
they supported the mappers or not. They thought, instead, that the observation data or the implementation
process would have been of a lower quality without the support they provided to the mappers:
I think some of the classic mistakes that can be made in DCM would’ve been made . . . and if they
hadn’t been picked up and supported or changed, it can have a really devastating effect on DCM.
DCM expert 70002
Support provided by the expert mappers helped to clarify any uncertainties and alleviate mapper doubts:
It is nice to have somebody sat with you whilst you’re actually doing it practically, to be able to say
‘Am I using this code or that code?’, ‘Am I observing this right?’
Mapper 58930/40002
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When DCM expert mapper support was delivered flexibly and with a friendly manner, it was valued by
care homes. There were, however, also times when support was perceived as problematic:
The expert mapper was a little full on. Knew her subject, very passionate, but very, erm, timescale
orientated. Which kind of pushed, I think, added to the stress.
Manager 58930/40001
The DCM expert mappers believed that they went above and beyond their expected roles to provide support
within care homes. They were allocated 5 days of time to support each care home; however, they felt that
much more time than this was required. Certain situations led to an increased need for DCM expert mapper
support, such as a care home having only one mapper, or tensions in the relationship between mappers:
I’ve tried to support her individually because the other mapper hasn’t supported her in the individual
care summaries. So I’ve tried to support her extra by phone and do that, but I don’t think she was,
she had the skills to do that by herself.
DCM expert 70005
Despite support from the DCM expert mapper being provided to all homes during the first cycle of DCM,
not all homes felt supported:
I feel as if we were, had the training and then left to our own devices really.
Mapper 50024/10349
Conversely, some mappers felt that they did not need the support and that, as they knew the residents
well, they had a better insight into the residents than the DCM expert:
When you learn anything really you just want to go and do it on your own don’t you. You don’t want
someone looking over your shoulder going ‘yeah, yeah you’ve not done that right’ or ‘I didn’t get
that’ or ‘why did you put that’ . . . well I know that resident and I know.
Mapper 50069/10476
For other homes, the mappers benefited from DCM expert mapper support during the first cycle, but felt
that they required more than what was provided to continue to undertake DCM cycles:
When she’d gone the support had gone.
Mapper 50010/10096
One DCM expert mapper suggested that, for future DCM research, research assistants should support
mappers in completing DCM paperwork. However, this does not represent the standard use of DCM
within care homes and thus the pragmatic trial design employed in the present trial:
I think you would’ve really struggled if they hadn’t had someone going in. Be that an expert mapper
or be that a research assistant, to go in and support them with doing the paperwork and completing
that, which obviously would unblind the researchers. But they would need some kind of support to be
able to engage with the research.
DCM expert 70006
These findings suggest that DCM expert mappers felt that their influence had a positive impact on DCM
delivery and resulted in substantially more cycles being completed than would have been without their
input. However, this support was not always appreciated by the mappers. The implementation data,
which show only 26% of intervention homes completed further acceptable DCM cycles after the first cycle
supported by the expert, highlight the value of expert mappers’ input in supporting DCM implementation
in care home settings.
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Summary
There were many barriers to and facilitators of implementing DCM, owing to the complex nature both of
the intervention and of care home settings. The selection of appropriate staff as mappers was key, as it was
important to ensure that they had the necessary skills to implement all aspects of DCM, including suitable
language skills, the time to undertake all aspects of DCM within their day-to-day role, being well respected
by the staff team and having leadership capabilities and influence among the staff. It was crucial that the
expectations of DCM were understood by both care home managers and mappers before training was
completed. Implementation was easier in larger care homes, where there was a larger staff budget to allow
mappers to be released from their usual roles. The support of expert mappers was felt to be particularly
important in the beginning to implement DCM. Although this is not a standard component of DCM, unless
purchased as an addition to standard training, it was a necessary feature of mapper support during the trial.
These findings have implications for considering the way that mappers are currently trained and the support
that may be required to implement DCM in practice (i.e. to fully engage mappers in the four phases of a
DCM practice development cycle).
Specific barriers to and facilitators of identifying, achieving or maintaining impacts
Alongside the barriers to intervention implementation (and so to impacts) identified in the previous section,
there were some specific barriers to and facilitators of identifying, achieving or maintaining impacts from DCM.
Barriers to identifying impacts
Challenges to identifying impacts arose primarily from the perceived difficulties in accurately identifying the
impacts of any care improvements on people with dementia. For example, some staff and relatives felt that
people with dementia would not be able to recognise the impact of any changes made, and some relatives
(who may have been involved in completing outcome measures) felt that it was difficult for them to
identify changes in their family member, owing to the infrequency of their contact with the resident:
They [people with dementia] will not acknowledge it [DCM] as having an impact on them.
Mapper 50011/10160
I think their life has perhaps been improved by it, but I don’t know whether they would be able to
express that or realise that.
Manager 58930/40001
I think it’s amazing and probably essential, and you know, it’s hard to get data because . . . the
residents themselves aren’t particularly reliable.
Relative 50016/20114
Barriers to achieving positive impacts
Interviewees spoke of multiple challenges to achieving positive impacts from DCM. Some of the more
predictable barriers included staffing, the costs of making changes and competing priorities for staff,
such as high workloads or emergencies. For example, if competing priorities meant that action plans
were not always carried out, then the potential impacts from DCM were not always realised:
You are trying to carry action plans out, but the day-to-day everything means that you can’t carry them
out as much as you’d like to because, like I say, you end up with short staff, you end up with emergencies.
Mapper 59830/40002
The understanding and perceptions of DCM (e.g. of its purpose, quality and reliability) and the perceptions
of the current quality of care in the home appeared to shape the degree to which the outputs of mapping
sessions were attended to or seen as indicating a need for change:
They [staff] don’t understand what it is.
Mapper 50010/10095
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The main issues [with DCM] are, some of the things we got on the feedback were, well, you were
looking at so and so, they hadn’t slept last night so that’s why they’ve been nodding off the whole
time. So even for that resident it sometimes doesn’t give you an accurate picture.
Mapper and manager/mapper 50018/10268 and 10277
[Answering a question about whether changes to care have occurred] No I don’t think so, because
they’re all pretty good anyway. The staff here are pretty good. So we do sort of pride ourselves on
person-centred care.
Mapper 50031/10456
Additional barriers to achieving positive impacts included staff who were not open to change and a lack of
managerial or financial support for changes proposed as a result of DCM cycles:
Obviously you always get a few who don’t want to take on board anything.
Mapper 58930/40002
When we do the briefing we, let’s say, decide to do some things a different way, and they agree.
But later on they found some difficulties, like I said, to change the chairs or something. And then
maybe that’s cost then.
Mapper 58757/10446
Barriers to maintaining positive impacts
Some care homes experienced challenges in maintaining positive impacts from DCM over time. These
challenges included difficulties in maintaining staff engagement with the DCM process, in particular with
the feedback and action-planning sessions, and difficulties maintaining momentum as staffing teams
changed over time:
People stopped turning up . . . The first time around . . . we had maybe eight or something in here,
and they did, you know, we had a good meeting. But then the second time around we held a meeting
and no one came . . . we put posters up all over and we let everyone know that we were doing these
feedback sessions . . . and nobody turned up.
Mapper 50010/10095
I think sustained changes certainly from the staff who were here then, but the staff who haven’t
actually had that form of training, the momentum has waned actually.
Mapper 50024/10349
Of note in relation to achieving and then maintaining positive impacts for care home residents generally
is the fact that many examples of impacts for residents were specific to the individuals who had been
mapped. These findings suggest that the impacts of DCM may be greater for mapped individuals than for
residents who were not involved in mapping:
The ones that we mapped, I’d like to think are more gainfully employed with their time.
Manager/mapper 50069/10475
We have observed a resident then we have made a care plan specific to that resident’s needs.
Mapper 50011/10160
As mapped individuals were a small minority of the trial sample, producing and maintaining a positive
effect on residents more generally may have been difficult for those homes that focused predominantly
on action-planning for mapped individuals and focused less on the development of home-level action
plans. Given that mappers could select any care home residents to be observed during DCM cycles, those
mapped were not necessarily trial participants. In addition, a focus in some homes on addressing the needs
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of mapped individuals may have reduced the longer-term impact of DCM, as the high rates of death and
transfer to other care settings made it likely that many mapped individuals were no longer residing in the
homes at follow-up:
Even to be observed, for them [mapped individuals], was kind of benefitting . . . but unfortunately
most of them are not here anymore . . . so we can’t say ‘oh it’s brilliant, working . . .’
Mapper 58747/10446
Action plans and impacts for mapped residents were not necessarily transferable to other residents, or
were not viewed as such by staff, which may have affected the degree to which positive impacts from
DCM were able to be maintained over time.
Facilitators of achieving and maintaining impacts
As well as identifying challenges to achieving positive outcomes from DCM, interviewees reported a
number of factors that facilitated the achievement or maintenance of impacts. Changing staff perceptions
of the quality of care they were providing and/or their perceptions of people with dementia and their
needs was a key impact facilitator:
You don’t realise, when you’re walking through the room, that you’ve passed 10 people and you
haven’t even spoke to them.
Mapper 50010/10095
It encourages the staff to think more of them as people . . . because obviously they [people with more
advanced dementia] don’t respond as much . . . so it has helped in that way, to make them more
aware that they still have to have the same contact, the same explanations for them.
Mapper 58930/40002
As creating change in care practices was dependent on staff recognising the need for change, mappers
needed to clearly demonstrate the issues with the current care for these to be recognised and addressed
by staff:
It’s really tempting to go in gung-ho and start talking about PEs [personal enhancers] and the different
codes, and it’s like trying to sit the staff down and talk about trigonometry. It’s not something interesting
that makes much sense to them . . . We sort of ended up picking two or three very small examples of
people who were very happy or very sad and just focusing on those, describing it in layman’s terms.
Mapper and manager/mapper 50018/10268 and 10277
It was good and clear to see, you know, which areas we really needed to improve on.
Manager/mapper 50069/10475
Making DCM feedback accessible helped staff to understand the need for changes in their care practices,
and the purpose and value of DCM, a lack of understanding of which was identified as a barrier to impacts.
Creating a shared understanding of the need for improvements was felt to be an important driver for change:
You really have to get quite a few people across the organisation thinking in the same way to sort of
drive that change.
Mapper and manager/mapper 50018/10268 and 10277
One thing I am more aware of is how staff, certain staff, sometimes talk to residents . . . in the
inductions now that we do, we make it really clear about what we want a new member of staff,
how we want them to interact, how we want them to speak . . . I go through how I would like
people to speak to residents.
Manager/mapper 50069/10475
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Embedding DCM data, feedback and action plans into the work of the care home, through their inclusion
in care plans, handovers and staff meetings, and engaging staff across the home in identifying care
improvements were strategies through which mappers tried to ensure a home-level approach to care
improvement:
We implemented it in our handovers as well as through all the team leaders.
Mapper 50019/10181
Putting together a dementia group which has carers, cleaners, people across the organisation,
and you talk to them and try and actually get them on board. You try and sort of instil in them
what person-centred care looks like.
Mapper and manager/mapper 50018/10268 and 10277
So then I could . . . say to the chef ‘This gentleman plays with food, what can we do?’
Mapper 50028/10394
Some of these actions to embed DCM into usual-care practice also helped to ensure that changes were
maintained. In addition, the identification of achievable changes, such as when staff were encouraged to
interact more with residents on a routine basis, was considered by participants as a good strategy for
facilitating impact.
Summary
Multiple barriers to and facilitators of identifying, achieving and maintaining impacts were identified
by participants. These included difficulties in measuring impacts for people with dementia; competing
care priorities; levels of managerial, financial and home-level support for change; and staff members’
understanding and perceptions of DCM, of current care quality, of the need for change and of people
with dementia. A focus on care improvements for mapped individuals can limit impacts for other residents
and the maintenance of impacts over time.
Mechanisms of action
In this section, we have drawn on the available evidence to assess if the anticipated mechanisms of action
or logic models through which we expected DCM to have an impact on outcomes were present.
Ancillary analyses (moderator/mediator analyses)
Complete cases of the cross-sectional sample were included in the analysis of care home-level moderators
identified a priori (Table 24). Moderators were measured at baseline and were assessed by including an
interaction between the treatment arm and the moderator variable in the primary analysis of CMAI score,
one at a time. There was no evidence of moderation of any prespecified baseline characteristics on CMAI
score at 16 months. The results are exploratory and should be treated with caution.
All 675 residents in the cross-sectional sample were included in the exploratory analyses of care home-level
mediators of the randomised effect of intervention versus control on CMAI score at 16 months. The ‘natural
indirect’ or mediated effects of each potential mediator (and their 95% CIs) are given in Table 25, adjusted
for all of the covariates included in the primary analysis of CMAI score. It can be seen that no potential
mediator was found to dominate the mediation of the effect of randomised treatment on the primary
outcome, and none of the mediated effects was statistically significant at the 5% level. Additional analyses
are planned (outside the scope of the final analyses reported) to explore whether or not our a priori
potential mediators have a clearer role in mediating the treatment received on the primary outcome.
Unadjusted scores of predictive and process measures are given in Appendix 1, Tables 62–64.
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TABLE 24 Assessment of moderators of treatment effect at 16 months: cross-sectional sample, complete cases –
adjusted estimates
Moderator
Unadjusted CMAI score at 16 months (95% CI)
p-value for
interactionaControl Intervention
1. Care home size 0.7672
< 40 residents 45.1 (42.54 to 47.63) 42.8 (40.71 to 44.98)
≥ 40 residents 47.0 (44.06 to 50.03) 42.9 (40.45 to 45.26)
2. Care home type 0.8713
Independent 46.9 (42.68 to 51.20) 40.9 (38.67 to 43.12)
Chain 45.8 (43.58 to 48.01) 44.4 (42.16 to 46.61)
3. Agency staff use 0.1815
Below or equal to median 45.5 (42.15 to 48.94) 42.2 (40.19 to 44.16)
Above median 46.3 (43.89 to 48.69) 43.7 (41.13 to 46.34)
4. Bank staff use 0.2249
Below or equal to median 48.3 (45.19 to 51.38) 42.0 (40.01 to 43.96)
Above median 44.3 (41.81 to 46.83) 43.8 (41.25 to 46.33)
5. Self-funding (proportion of self-funded places)
(continuous)
0.8230
Below or equal to mean 46.1 (43.52 to 48.68) 42.6 (40.68 to 44.51)
Above mean 46.1 (43.04 to 49.05) 43.3 (40.42 to 46.11)
6. Care home facilities (EAT score) (continuous) 0.4339
Below or equal to mean 45.0 (42.11 to 47.92) 41.9 (39.80 to 43.98)
Above mean 47.0 (44.29 to 49.64) 44.0 (41.58 to 46.47)
7. GLHC score (continuous) 0.9756
Below or equal to mean 45.3 (42.67 to 47.87) 42.4 (40.38 to 44.43)
Above mean 47.1 (44.09 to 50.12) 43.4 (40.85 to 45.93)
8. Care home manager’s experience
(length of time in care home) (continuous)
0.9961
Below or equal to mean 45.9 (43.79 to 48.06) 44.2 (42.21 to 46.18)
Above mean 46.8 (41.72 to 51.78) 39.8 (37.22 to 42.30)
9. QUIS (proportion of positive interactions) 0.0737
Below or equal to mean 46.8 (43.85 to 49.81) 44.4 (41.67 to 47.11)
Above mean 45.4 (42.79 to 48.02) 41.7 (39.83 to 43.65)
10. Staff-to-resident ratio (continuous) 0.3592
Below or equal to mean 48.0 (45.03 to 50.90) 44.5 (42.41 to 46.48)
Above mean 44.2 (41.64 to 46.85) 39.4 (37.07 to 41.82)
11. Average baseline CDR score (continuous) 0.3601
Below or equal to mean 44.3 (41.58 to 46.95) 39.9 (37.71 to 42.12)
Above mean 47.8 (44.99 to 50.69) 44.9 (42.69 to 47.06)
12. Average baseline CMAI score (continuous) 0.7150
Below or equal to mean 42.8 (40.43 to 45.07) 40.3 (38.21 to 42.32)
Above mean 49.5 (46.40 to 52.61) 45.8 (43.37 to 48.19)
a The same variables in the model as in the primary analysis with the added moderator and interaction term
moderator × treatment.
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Interview data
Drawing on interviewees’ perceptions of the DCM implementation process and its impacts, alongside the
quantitative trial data, we had intended to propose a model for the intervention’s mechanisms of impact.
This model was intended to set out the processes through which the implementation of DCM may lead to
change, and the barriers and facilitators that may enable or inhibit the achievement and maintenance of
those changes. Although the results set out some of the contextual features required to facilitate DCM
implementation and the challenges that need to be overcome to implement DCM effectively, given the
negative trial result and the great variability in DCM implementation observed, we have been unable to
come to any conclusions about potential mechanisms of action. Specific potential barriers to mechanisms
of action included poor implementation of DCM, particularly beyond the first supported mapping cycle,
which meant that exposure to DCM over the trial period was limited to one or fewer cycles over the
15-month period for three-quarters of the intervention homes.
TABLE 25 Causal mediators analyses based on MIs
Potential mediator
Adjusted natural indirect
effect (standard error) 95% CI
Potential care home-level mediators (at 6 months)
Change in care home manager (yes/no) 0.27 (0.22) –0.16 to 0.70
QUIS (proportion of positive interactions) 0.18 (0.34) –0.48 to 0.84
Improved EAT score in privacy and community (yes/no) 0.21 (0.39) –0.56 to 0.98
Improved EAT score in community links (yes/no) 0.00 (0.37) –0.72 to 0.73
Improved EAT score in domestic activity (yes/no) 0.39 (0.27) –0.13 to 0.91
Improved GLHC score (yes/no) –0.67 (0.55) –1.75 to 0.41
Potential care home-level mediators (at 16 months)
Change in care home manager (yes/no) –0.00 (0.11) –0.23 to 0.22
QUIS (proportion of positive interactions) 0.00 (0.06) –0.11 to 0.11
Improved EAT score in privacy and community (yes/no) 0.12 (0.23) –0.34 to 0.58
Improved EAT score in community links (yes/no) – –
Improved EAT score in domestic activity (yes/no) 0.15 (0.17) –0.18 to 0.47
Improved GLHC score (yes/no) –0.67 (0.42) –1.49 to 0.16
Mediator analysis did not account for clustering.
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Chapter 6 Discussion
Key findings
The DCM EPIC trial was a pragmatic, multicentre, cluster RCT of DCM’s clinical effectiveness and cost-
effectiveness compared with a usual-care control in UK care home settings. The trial evaluated whether
or not DCM led to reductions in agitation, other BSC and PRN antipsychotic and other tranquilliser use
and to improved QoL for care home residents with dementia and improved quality of staff interactions
with residents. It also sought to determine whether or not DCM was cost-effective. Thirty-one care
homes were randomised to the DCM intervention arm and 19 were randomised to the control arm.
A total of 987 residents were recruited and registered: 726 at baseline (308 in the control arm and 418
in the intervention arm) and a further 261 at the 16-month follow-up (99 in the control arm and 162 in
the intervention arm). A total of 675 residents were included in the final cross-sectional sample (287 in the
control arm and 388 in the intervention arm) used for the primary analysis: 414 from the original sample
and 261 who were recruited at 16 months.
Primary outcomes
Care home residents in the intervention-arm care homes did not demonstrate any clinically meaningful or
statistically significant reduction in agitation compared with control-arm residents.
Secondary outcomes
There were no clinically meaningful or statistically significant differences in BSC, QoL or PRN use of
prescription medications for care home residents with dementia at either the 6- or the 16-month follow-up.
However, trends for BSC and mood (depression/apathy) were found to be in favour of the intervention arm
at 16 months in the closed cohort. The prescription rates of PRN medications were low across both arms at
all time points and this, alongside the wide CIs within the secondary analyses, makes the results difficult to
interpret. The quality of staff interactions did not differ between arms at either time point.
Given the poor return rates for staff outcome measures, we were unable to evaluate any potential impact
of DCM on staff health-related QoL (GHQ-12) or feelings of confidence in caring for people with dementia
(SCIDS).
Economic evaluation
We conducted an economic evaluation alongside a clinical trial adhering, where possible, to the NICE
reference case for technology appraisals.143 The primary analysis was a cost–utility (cost per QALY) evaluation
and the secondary analysis was a cost-effectiveness (cost per unit improvement in CMAI score) evaluation.
Costs for the intervention per person were £421.07. This depended on a number of assumptions, including
the number of staff involved, the number of cycles implemented and the number of residents who might
benefit. In general, our assumptions regarding these costs were conservative. We also conducted a sensitivity
analysis that accounted for the different costs incurred by care homes as a result of their compliance with the
intervention.
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The costs of resource use were substantially higher in the intervention arm, and this was driven by higher
secondary (hospital) care costs. This resulted from the presence of several high-cost individuals in the
intervention arm (six residents in the intervention arm had higher costs than the highest cost individual in
the control arm). We conducted sensitivity analyses in which we removed these six individuals (in a CCA
and prior to conducting MIs for an analysis using MI data) to examine the impact of these outliers on our
cost–utility estimates.
Regardless of the utility measure used and the analytical approach adopted, QoL appeared to be higher
in the intervention arm than in the control arm at 16 months. Although QoL declined over 16 months,
in general this decline was lower in the active treatment arm.
The base-case ICER was £60,627 and, being substantially over the NICE threshold of £20,000, this suggests
that DCM would not be an efficient use of health/social service resources. The sensitivity analyses were
consistent in finding that the intervention was more costly, but also more clinically effective, than the
control. With the exception of the analyses that excluded the high-cost individuals, ICERs from the sensitivity
analyses ranged from £24,139 to £57,509.
The analyses that excluded high-cost individuals in the intervention arm yielded ICERs that were either
below (£10,975/QALY for the CCA) or closer to (£36,371/QALY for the MI analysis) the NICE threshold.
When we examined the data on comorbidities and the reason for hospital admission for the six high-cost
individuals, it was not possible to conclude that these higher secondary care costs could have been the
result of chance rather than attributable to the intervention. Therefore, there was no reasonable justification
for removing these individuals from the main analyses. ICERs from analyses adjusting for baseline costs or
including only more compliant care homes also approached cost-effectiveness. However, these estimates
were based on reduced samples and are considered less robust.
Consistent with the main cost-effectiveness analysis, the net-benefit regression analyses indicated that
DCM did not represent value for money when compared with usual care. Furthermore, the net-benefit
regression and CACE analyses also showed no indication that intervention compliance may have had a
mediating effect. This was despite the likelihood that these analyses were biased by the failure to control
for (unobserved) factors related to potential differences in care home quality (which might be positively
related to the likelihood of compliance and to resident QoL).
We found the cost per unit improvement in CMAI score to be between £67 and £289, depending on the
analysis. This lower figure, although not our base case, is roughly in line with previously generated estimates
of comparable interventions.161,162
Safety
Undertaking DCM was not detrimental to care home residents. No unexpected SAEs occurred in the trial
and the majority of residents did not have any hospital admissions over the trial period, with admissions
figures and length of stay similar across the intervention and control arms.
Comparison with other trials of Dementia Care Mapping in
care home settings
The efficacy of DCM has been evaluated in three previous exploratory cluster RCTs63,93,94 and one
quasi-experimental trial.92 The RCT conducted by Chenoweth et al.63 found that researcher-led cycles of
DCM led to significant reductions in agitation and falls for care home residents with dementia compared
with those in the usual-care control. Likewise, the Norwegian study carried out by Rokstad et al.93 found a
significant reduction in overall BSC, agitation and psychosis and a significant improvement in QoL for care
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
94
home residents with dementia in the DCM intervention arm, compared with the usual-care control. This
study also used researcher-led cycles of DCM implementation. Conversely, the cluster RCT conducted by
van de Ven et al.,94 with cycles of DCM led by care home staff, found no significant difference in agitation
between the DCM intervention arm and the usual-care control. This trial did find a significant improvement
in staff emotional reactions towards people with dementia in the DCM intervention arm compared with the
control. The quasi-experimental trial conducted by Dichter et al.92 adopted cycles of DCM led by care home
staff and also found no significant benefits of the DCM intervention in comparison with the control as
regards resident QoL or BSC.
The DCM EPIC trial is the only pragmatic, explanatory trial conducted on the clinical effectiveness and
cost-effectiveness of DCM to date. It did not replicate the findings of the exploratory trials conducted by
Chenoweth et al.63 or Rokstad et al.,93 in which significant benefits of DCM over usual-care controls as
regards resident agitation, falls and QoL were indicated. It did support the findings of the exploratory trial
by van de Ven et al.94 and the quasi-experimental trial of Dichter et al.,92 in which no significant benefits of
DCM were found for agitation, BSC or QoL in comparison with the control. Unlike the economic evaluation
of DCM conducted by van de Ven et al.,163 which found that DCM was cost neutral, the DCM EPIC trial
found that DCM was not cost-effective. The costliness of DCM as an intervention was also identified by
Chenoweth et al.,63 who found that the costs of DCM per CMAI point averted in usual care were markedly
higher than those in PCCT. Owing to poor return rates on staff measures, we were unable to assess any
potential effects of DCM on staff outcomes in the DCM EPIC trial.
The comparison between the outcomes of the DCM EPIC trial and those of previous trials requires caution,
given the pragmatic, explanatory design of this trial compared with the exploratory designs of the previous
studies. Likewise, this is the only trial to have been conducted in the UK and thus the care home resident
population, care systems and costs differ from those of previous trials. Nevertheless, a common feature
emerges in that all trials adopting cycles of DCM led by care home staff, even with support from a DCM
expert or lead, recorded implementation challenges and no significant benefits of DCM over usual-care
controls. In the two trials in which significant benefits of DCM were reported over the control, DCM was
led by researchers and few implementation challenges were identified. This indicates that consideration
needs to be given to the model of DCM implementation and leadership, with all trials to date adopting
cycles led by care home staff failing to find any clinical effectiveness of the intervention over the control,
in contrast with the trials in which efficacy was found through external- or researcher-led cycles.
The potential benefits of externally supported interventions is confirmed by other intervention trials
in care home settings. The WHELD (Improving Wellbeing and Health for People with Dementia) trial,76
which combined staff training with support from a WHELD therapist who provided coaching, supervision
and regular review over a 9-month period, found that the intervention had statistically significant benefits
as regards QoL, agitation and neuropsychiatric symptoms and positive care interactions, compared with
treatment as usual. The benefits were greater for those with moderately severe dementia.
This trial is the first randomised controlled study of DCM in the UK and it reflects the largely practice-led
development and evolution of the method in the UK. Although the current eighth edition of DCM was
produced following a thorough review process, only the revised observational tool was evaluated using
formal research methods, with the additional guidance on DCM implementation developed through a
series of working groups involving practitioners.109 A recent systematic review96 of the published research
evidence on the process of DCM implementation, when used as a practice development methodology,
found only 12 papers representing nine research studies that reported on this area. Only six papers used
formal research methods to gather data and all were published from 2014 onwards, indicating that there
has been limited published research in this area to date, despite DCM’s use in practice for over 20 years.
The review concluded that more research is required.
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The formal process evaluation that is reported as part of this trial is the largest study of DCM implementation
to be conducted to date internationally. Therefore, in addition to the process-evaluation results reported earlier,
a number of in-depth papers discussing DCM implementation from the perspective of mappers, care home
staff, care home managers and expert mappers are being prepared to contribute to this body of evidence.
Strengths and limitations of the study
The DCM EPIC trial is the largest and only definitive trial of the clinical effectiveness and cost-effectiveness
of DCM to date (worldwide). It successfully recruited on time and to target, adding to the relatively limited
body of research on the conduct of pragmatic, cluster RCT studies in care home settings. Our use of random
sampling to approach care homes within specific geographical regions permitted recruitment of a number
of care homes that had not participated in research previously. This has increased the pool of care homes
that have been exposed to research and in particular to clinical trials and thus the numbers of homes that
may be considered ‘research ready’. The EPIC trial gave care home staff and managers an opportunity to
participate in research, and a number of the staff members who trained as mappers discussed the value
they placed on being able to access this training for their own professional development. Some of the care
homes have expressed a desire to be involved in future research projects with the local recruitment hubs.
The DCM EPIC trial has also provided a valuable opportunity to increase the number of researchers with
expertise in conducting dementia research within care home settings, across a range of trial roles. Some
research assistants employed on the trial have taken up permanent PhD or post-doctoral positions in
dementia research or are commencing clinical psychology training, ensuring their expertise is retained
within the field.
Study design
The EPIC trial followed the Medical Research Council guidance on evaluating a complex intervention.
A cluster RCT design was utilised, appropriate outcome measures were selected, a full economic evaluation
was conducted and a full, integrated process evaluation was undertaken.
However, loss to follow-up was larger than had been anticipated (close to 50%, in comparison with
the estimated 25–30%), owing mainly to resident deaths because of the frailty of this population, and
this resulted in the need to implement a design change and to adopt an open-cohort design mid-trial.
This is not an established design for cluster RCT studies and three of the co-applicants (RW, AF and CS)
have been successful in gaining additional funding to conduct methodological research on the use of
open-cohort designs.
Cluster blinding to allocation was not feasible within the trial, as care home staff were responsible for
intervention delivery. Therefore, this could have led to reporting bias. Independent observational measures
of agitation (PAS and CMAI-O) were therefore collected by an independent, blinded researcher to permit
analysis of potential reporting bias by arm. However, observational measures do not capture agitation that
may occur outside public areas, for example during personal care, and the set observation days and time
meant that agitation that occurred outside the observational hours could not be assessed, for example
during the evening and night-time, and over more than 2.5 days during a week. Therefore, the comparison
between observational and proxy-reported measures must be considered with some caution.
Researchers were all blinded to cluster allocation and were not permitted to collect data in homes to which
they became unblinded. This required flexibility within the research teams and some cross-working between
research hubs to provide cover when researchers became unblinded. The independent researcher who collected
observational PAS, CMAI-O and QUIS data was both blinded and independent, and so had collected no other
data in the care home apart from these observational measures. Independent researchers and researcher
blinding to the cluster allocation of homes in which they collected data were maintained throughout the trial.
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Owing to the variability in the ability of care home residents with dementia to self-report on measures of
BSC and QoL, the primary and secondary analyses were conducted using staff proxy-completed measures.
It was not possible to use relative or supporter proxy measures, as many residents did not have a proxy
informant recruited, either because their relatives/supporters were visiting less frequently than was required
for the measures used (at least once a fortnight) or because relatives/supporters did not wish to take part.
Proxy-completed measures are reported to have some but not full correlation with self-report164 and
therefore it is a limitation of this study that outcomes are reliant on proxy views. Although we attempted
to use the same staff proxy respondent at each time point, this was not always feasible owing to staff
turnover, sickness and annual leave. There is no reason to conclude that these issues affected one arm of
the trial more than or differently from the other. However, the issues associated with use of staff proxy
informants in both arms of the trial must be considered when interpreting the results.
The poor intervention adherence beyond the first expert-supported cycle of DCM is a further limitation.
Given the pragmatic trial design aiming to implement DCM in ‘real world’ conditions, the findings are
important for highlighting implementation challenges and for informing future use in such settings.
Health economic analysis
The health economic analysis has a number of limitations. The number of missing data was large and the
evaluation was heavily reliant on imputation. Given the difficulties in incorporating the cross-sectional
cohort approach in the economic evaluation framework, in particular the requirement to have baseline
data to calculate changes in costs and QALYs, it was not possible to fully capitalise on the increased
sample size in a robust way.
The adoption of a health and social care perspective meant that some societal costs were not accounted
for in the analysis (e.g. informal care); however, it is highly unlikely that these would have had a substantial
impact on total costs and collecting such data would have presented significant challenges.
Additional consideration is needed regarding how to deal with high-cost outliers165 and when it may be
appropriate to exclude them from analyses. Research should identify the most appropriate way to measure
and combine QoL estimates in this group.
Finally, future research should explore the maintenance of the health benefits of the DCM intervention
identified here.
Generalisability and sources of bias
Random selection of care homes from the large pool of eligible homes from three geographically wide
recruitment hub areas ensured a good representation of different care home settings and thus good
generalisability of the trial across care home settings in England. This helped to minimise selection bias.
Our exclusion of care homes that were subject to admissions bans, supportive input or other improvement
measures, due to issues or concerns regarding care quality means that a small proportion (c. 3%)166 of the
care home sector was not represented in the trial. Following randomisation, the characteristics of the
clusters were found to be balanced. No clusters were lost during the trial. There was a higher variation in
cluster sizes in the control than in the intervention arm; however, the median cluster size was similar in
both arms and in both cohorts.
The recruitment of residents was carefully designed to minimise selection bias at various levels. Resident
recruitment commenced following the recruitment of care homes but prior to their randomisation. All residents
who were identified as eligible and who consented to take part in the trial were recruited. Following the
change in design, the recruitment at 16 months of all eligible residents with dementia who were not already
participating in the trial or who had previously declined to take part contributed to a minimisation of selection
bias. Researchers independent of the care home were involved in resident recruitment. Characteristics of the
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screened and registered residents were well balanced across arms and cohorts, demonstrating a lack of
selection bias in resident recruitment.
Allocation concealment during the researchers’ visits to care homes was not always successful; however,
every effort was made to ensure that researchers collected no further data in care homes to whose
allocation they were unblinded. Research blinding to the allocation of care homes in which they collected
data was able to be maintained throughout the trial.
Implementation of a complex intervention
As a pragmatic trial, the DCM intervention was implemented as it would usually be in UK care home
settings, with some components enhanced from standard practice, but still within the scope of what
would be feasible in usual practice. This included (1) selection of care homes on the basis of criteria
that would ensure that there were no setting conditions that were likely to reduce their ability to engage
with the trial (e.g. quality concerns or competing research studies), (2) selection of mappers using criteria
of required qualities and skills, (3) provision of a standard 4-day DCM training course with assessment,
(4) provision of support for the first cycle of DCM from an expert mapper, (5) provision of standardised
documentation for DCM implementation (e.g. a report template and an action plan template), (6) ongoing
telephone and e-mail support from the DCM intervention lead and (7) prompts to conduct mapping cycles
at the required intervals sent to mappers by SMS and through the post.
Dementia Care Mapping training was provided at standard training locations (Bradford and London) for
‘open’ DCM courses (those open to any trainees and not purchased by a single provider organisation for
their own staff). However, evidence gathered during the mapper recruitment phase, subsequent efforts to
recruit further mappers to replace those who had withdrawn and the process evaluation all indicated that
this was difficult for many care home staff and thus restricted who could be recruited as a mapper. For the
majority of those recruited as mappers, the 4-day training course had to be completed on a residential
basis or it required significant daily travel. Some of those identified as potential mappers indicated that
they would be unable to attend the training because of child care or other responsibilities, whereas others
did not wish to or were concerned about travelling and/or attending the training on a residential basis.
Although overall commencement of DCM training within the planned 2 months after randomisation was
adequate, 29% of homes (n = 9) experienced delays in training mappers and one home failed to train any
mappers during the trial period. Mapper withdrawal was also high, with over half of homes having one
or more mappers withdraw during the trial period and one-third of homes having no trained mappers in
post by the 16-month follow-up. Reasons for withdrawal were mainly personal (leaving the organisation,
ill-health, maternity leave or change of role within the home). Finding suitable replacement mappers who
could be trained during the trial period was not possible in the majority of homes. These issues had an
impact on the care home’s ability to implement DCM over the trial period and they raise questions
regarding the long-term sustainability of DCM as an intervention within care home settings.
Given that DCM is an established intervention, piloting of its implementation was not considered a
requirement within this trial. However, given the lack of robust evidence on the implementation of DCM
that was available at the time of trail design and the subsequent implementation challenges identified, it
may have been beneficial to undertake some feasibility work to assess intervention adherence in care home
settings and potential barriers to and facilitators of this. Published and practitioner evidence regarding best
practice in DCM implementation was consulted in designing the study, and experts in the use of DCM were
involved in the trial design and delivery. DCM implementation within the trial included the range of supports
and prompts for mapping described earlier, which are over and above what would normally be received by a
mapper following completion of DCM training. Nevertheless, considerable DCM implementation difficulties
and problems with compliance were still encountered.
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Intervention compliance
Dementia Care Mapping implementation was poorer than expected and, even with DCM expert mapper
support, 10% of intervention care homes failed to undertake any DCM activity and 23% did not complete
one full cycle. A further 52% of homes completed only their first expert mapper-supported cycle, leaving just
over one-quarter of homes (26%) that completed more than one cycle and only 13% (n = 4) that completed
the three full, per-protocol cycles to an acceptable level. This was despite a range of methods for tracking and
supporting intervention compliance being implemented during the trial. Tracking intervention compliance was
challenging and it required considerable effort. Despite this, there was missing documentation, particularly in
terms of that associated with briefing and feedback sessions, and assumptions had to be made that previous
components of the cycle had been completed if documented evidence for later components was submitted
(e.g. we assumed that a briefing session had occurred if there was documented evidence of mapping
observations having taken place).
Two homes withdrew from the DCM intervention during the trial period, one because it was felt that DCM
was not of value and the other because it was unable to identify any suitable mappers following withdrawal
of the trained mappers for personal reasons. The poor intervention compliance was disappointing given
our adoption of established DCM training and implementation processes and the introduction of enhanced
support for the trained care home mappers, which was above what would be expected in usual DCM
practice. This has implications for considering the implementation of DCM in the future, in particular in
considering models of implementation that are not reliant on care home staff.
Integral process evaluation (separate papers in preparation)
An integral process evaluation was conducted within the DCM EPIC trial. It investigated the perceptions
of DCM implementation and impacts from the perspective of mappers, care home managers and staff,
care home residents with dementia, their relatives and friends, and the DCM expert mappers. The process
evaluation results have provided a valuable context within which to understand and interpret the DCM
EPIC trial findings and will be presented in detail in additional papers that are currently in preparation.
Interpretation of results
The results of this trial may potentially be attributed to poor intervention compliance. Although DCM
implementation was successful in a number of sites and the process evaluation was able to identify factors
associated with successful implementation, as well as barriers to this, the proportion of intervention homes
that failed to complete any, or more than, the initial expert-supported cycle was disappointing. This
indicates that, although DCM was a well-used intervention within care homes prior to this trial and it
was assumed, therefore, to be acceptable and feasible to use in these settings, this may not be the case.
Although the exploratory CACE analyses indicated that the treatment effect may increase if care homes
complete at least two DCM cycles to an acceptable level, compared with completing only one cycle, and
are thus suggestive of a dose–response relationship, further research would need to be undertaken to
explore this potential relationship.
Economic evaluation
We estimated the mean resident cost of DCM to be £421.07 and the most costly components of this were
attendance at the DCM training session and DCM expert mapper support. Although there appeared to be
incremental health (QALY) benefits for the intervention over the control, these were relatively modest and
were outweighed by the additional costs. As such, DCM did not appear to represent value for money in
the cost–utility framework. Cost per reduction in CMAI cost-effectiveness values were generated and these
should be interpreted alongside previous studies reporting the same metric.
The results were largely driven by a small number of high-cost outliers in the intervention arm and
sensitivity analyses removing these reduced the ICER substantively. As we cannot definitively state that
these cost outliers were random and not associated with the intervention, they are retained in the main
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analysis. The conclusions were robust to sensitivity analyses. However, efforts to reduce the cost of the
intervention and to improve compliance may improve estimates of value for money. However, given the
DCM implementation challenges identified in this study, it seems unlikely that greater adherence would
be feasible to achieve with DCM cycles led solely by care home staff. Therefore, the costs of potential
alternative models of delivery would need to be considered carefully in future research.
Overall evidence
Systematic reviews have identified DCM as clinically effective in reducing agitation immediately and at
6 months post randomisation in care home residents with dementia62 and in presenting benefits for
care home staff.167 However, the number of published studies is low, their outcomes are varied and robust
evidence to guide effective DCM implementation is extremely limited.96 Trials demonstrating the efficacy
of DCM have, to date, included only researcher-led cycles of DCM. The DCM EPIC trial sought to examine
whether or not DCM implemented within care home settings, following usual UK models of cycles led
by care home staff, was clinically effective and cost-effective. It is the largest and only explanatory trial
of DCM conducted internationally and the only UK-based trial. Recruiting 978 residents across 50 care
homes, and randomising 31 clusters to the DCM intervention arm, the DCM EPIC trial is the largest trial
of DCM conducted to date (the largest trial previous to this94 recruited 268 residents in 33 units across
14 care home locations and randomised 13 units in seven care homes to DCM). The DCM EPIC trial has
provided conclusive evidence that implementing cycles of DCM led by care home staff is not clinically
effective in reducing agitation, BSC or the use of PRN antipsychotic or other tranquillising medications,
or in improving QoL for care home residents with dementia compared with the control. Neither is it
cost-effective.
The findings of the process evaluation indicate that, despite a range of methods to support DCM
implementation within the trial, cycles of DCM led by care home staff result in poor intervention compliance,
with the vast majority of care homes (74%) failing to complete more than the first DCM expert-supported
cycle. Barriers to DCM implementation were found at the individual mapper level, the DCM intervention
level and the care home level. Additional barriers caused by the burdens of trial participation were also
identified. Considering these results alongside the findings from previous exploratory trials of DCM indicates
that externally led or supported implementation of DCM may provide a more beneficial and sustainable
format for DCM delivery. This aligns with the broader contextual challenges faced by care homes in
implementing complex interventions that are staff led. These include, but are not limited to, high staff
turnover rates; low staff literacy, numeracy, IT skills and confidence; and a lack of time and resources.
Future research will need to consider mechanisms for addressing these wider issues within the context of
intervention design and delivery. Utilising ‘bottom-up’ approaches to intervention design that involve care
home staff, managers and providers may provide a mechanism to identify and address potential challenges
within the development process.
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Chapter 7 Conclusions
This trial indicates that, as an intervention led by care home staff, DCM is not clinically effective orcost-effective in reducing agitation or improving QoL and care outcomes for residents with dementia
living in care home settings. This outcome may be associated with the poor DCM implementation we
experienced during the trial, despite efforts to support care home mappers in implementing the intervention.
Providing support for the first DCM cycle, in the form of an external expert mapper, enabled 77.4% of
intervention homes to complete that cycle; however, DCM implementation reduced greatly after the first
cycle when this support ended. Given the picture emerging from trials of DCM internationally, in which,
on the one hand, cycles of DCM led by care home staff have consistently produced negative trials results
and, on the other hand, researcher-led cycles have produced significant outcomes, further investigation is
warranted into models of DCM implementation that do not rely solely on care home staff to implement
them. The process evaluation revealed the challenges that care home staff faced when trying to implement
DCM. These included mappers not having the required skills and qualities to lead change or feeling
unconfident to do so; a lack of time, resources and management support; and difficulties in engaging
colleagues in supporting the change process. Staff turnover, sickness and other personal issues that affected
mappers’ ability to continue in the role were also challenging, with over half of the intervention homes
having at least one mapper withdraw during the study period. Nevertheless, one-quarter of intervention
care homes did complete two or more DCM cycles, and staff within the process evaluation reported a
range of benefits that they felt DCM had for residents and staff, as well as for care practices more broadly.
This trial suggests that the majority of care home settings may not provide the right setting conditions for a
costly intervention such as DCM and that externally led models may provide a more practical and resource-
effective method of implementation. However, further research is needed to evaluate this. Our findings
have implications for future complex intervention trials in care home settings. Future research should more
carefully consider the setting conditions needed for effective intervention implementation and thus the
most appropriate models for delivering these interventions given the available resources and cultural and
organisational contexts of care home settings.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101

Acknowledgements
General acknowledgements
We would like to thank all of the care homes, individuals with dementia, family members and care home
staff for taking part in this study and for freely giving their time.
We would like to thank the following people who contributed to the successful completion of this trial:
Chris Albertyn, Heather Blakey, Marie Crabbe, Elyse Couch, Cara Gates, Layla Hamadi, Stephanie Jones,
Baber Malik, Harriet Maunsell, Kirsty Nash, Sahdia Parveen, Luisa Rabanal, Bina Sharma, Victoria Simons,
Emily Smeaton, Alyma Somani, Emily Standell, Rebecca Thomas, Ingelin Testad and Miguel Vasconcelos
Da Silva, the researchers who collected the data; Robert Cicero, who supported the development
of the SAP; Kayleigh Burton, who undertook trial management; Madeline Harms, Alison Fergusson
and Laura Stubbs, who undertook data management; Benjamin Thorpe, who assisted with statistical
programming; Sharon Jones, Lisa Heller, Juniper West, Judith Farmer, Maria Scurfield and Lisa Breame,
who supported DCM intervention implementation activities; Jan Robins, Clare Mason and Lindsey Collins,
who delivered dementia awareness training; Barbara Carlton, Sandra Duggan, Jane Ward, Daniella Watson
and Connie Williams, who were members of the LAG; Sue Fortescue, who was a member of the Trial
Management Group and LAG; Ian Wheeler, who provided administrative support for the trial; and
Matt Murray from the Alzheimer’s Society, who provided oversight for the LAG. Graham Stokes would
like to acknowledge Bupa UK, his employing organisation during the majority of the study period. Jane Fossey
would like to acknowledge the NIHR Oxford Health Biomedical Research Centre, a partnership between
Oxford Health NHS Foundation Trust and the University of Oxford.
Contributions of authors
Claire A Surr (Professor of Dementia Studies and Director of the Centre for Dementia Research) conceived
and designed the study and was involved in the analysis of the qualitative data, interpretation of the data
and drafting of this paper (URL: www.leedsbeckett.ac.uk/school-of-health-and-community-studies/epic-trial/).
Ivana Holloway (Senior Medical Statistician) was involved in the analysis of the statistical data,
interpretation of the data and drafting of this paper.
Rebecca EA Walwyn (Principal Statistician) conceived and designed the study and was involved in the
analysis of the statistical data, interpretation of the data and drafting of this paper.
Alys W Griffiths (Research Fellow) was involved in the data acquisition, analysis of the qualitative data,
interpretation of the data and drafting of this paper.
David Meads (Associate Professor of Health Economics) helped design the study and was involved in the
analysis of the health economic data, interpretation of the data and drafting of this paper.
Rachael Kelley (Research Fellow) designed the process evaluation and was involved in the analysis of the
qualitative data, interpretation of the data and drafting of this paper.
Adam Martin (Senior Research Fellow in Health Economics) was involved in the analysis of the health
economic data, interpretation of the data and drafting of this paper.
Vicki McLellan (Senior Trial Co-ordinator) was involved in the data acquisition, management of the trial
and drafting of this paper.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
Clive Ballard (Pro-Vice-Chancellor of Exeter Medical School) helped design the study, was involved in the
data acquisition and commented on the draft of this paper.
Jane Fossey (Associate Director of Psychological Services) helped design the study, was involved in the
data acquisition and commented on the draft of this paper.
Natasha Burnley (Research Assistant) was involved in the data acquisition, analysis of the qualitative data
and interpretation of the data and commented on the draft of this paper.
Lynn Chenoweth (Professor of Nursing) helped design the study and commented on the draft of this
paper.
Byron Creese (Senior Research Fellow) was involved in the data acquisition and analysis of the qualitative
data and commented on the draft of this paper.
Murna Downs (Professor of Dementia Studies) helped design the study and commented on the draft of
this paper.
Lucy Garrod (Research Therapist) was involved in the data acquisition and analysis of the qualitative data
and commented on the draft of this paper.
Elizabeth H Graham (Trial Manager) helped design the study, was involved in the data acquisition and
commented on the draft of this paper.
Amanda Lilley-Kelley (Trial Manager) helped design the study, was involved in the data acquisition and
commented on the draft of this paper.
Joanne McDermid (Research Therapist) was involved in the data acquisition and analysis of the qualitative
data and commented on the draft of this paper.
Holly Millard (Assistant Psychologist) was involved in the data acquisition and analysis of the qualitative
data and commented on the draft of this paper.
Devon Perfect (Senior Clinical Research Assistant) was involved in the data acquisition and analysis of the
qualitative data and commented on the draft of this paper.
Louise Robinson (Director of the Newcastle University Institute for Ageing and Professor of Primary Care)
helped design the study and commented on the draft of this paper.
Olivia Robinson (Research Assistant) was involved in the data acquisition and analysis of the qualitative
data and commented on the draft of this paper.
Emily Shoesmith (Research Assistant) was involved in the data acquisition and analysis of the qualitative
data and commented on the draft of this paper.
Najma Siddiqi (Clinical Senior Lecturer in Psychiatry) helped design the study and commented on the draft
of this paper.
Graham Stokes (Director of Memory Care Services) helped design the study and commented on the draft
of this paper.
Daphne Wallace (Expert by Experience) helped design the study and commented on the draft of this paper.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
Amanda J Farrin (Professor of Clinical Trials and Evaluation of Complex Interventions and Director of the
Complex Interventions Division) conceived and designed the study and was involved in the interpretation
of the data and drafting of this paper.
Publications
Surr CA, Walwyn RE, Lilley-Kelley A, Cicero R, Meads D, Ballard C, et al. Evaluating the effectiveness and cost-
effectiveness of Dementia Care Mapping™ to enable person-centred care for people with dementia and their
carers (DCM-EPIC) in care homes: study protocol for a randomised controlled trial. Trials 2016;17:300.
Griffiths AW, Creese B, Garrod L, Chenoweth L, Surr C. The development and use of the assessment of
dementia awareness and person-centred care training tool in long-term care. Dementia 2018;18:3059–70.
Griffiths A, Kelley R, Garrod L, Perfect D, Robinson O, Shoesmith E, et al. Barriers and facilitators to
implementing Dementia Care Mapping in care homes: results from the DCM™ EPIC trial process evaluation.
BMC Geriatr 2019;19:37.
Griffiths AW, Albertyn CP, Burnley NL, Creese B, Walwyn R, Holloway I, et al. Development and validation
of an observational version of the Cohen-Mansfield Agitation Inventory [published online ahead of print
April 10 2019]. Int Psychogeriatr 2019.
Surr CA, Griffiths AW, Kelley R, Holloway I, Walwyn REA, Martin A, et al. The implementation of Dementia
Care Mapping™ in a randomised controlled trial in long-term care: results of a process evaluation. Am J
Alzheimers Dis Other Demen 2019;34:390–8.
Surr CA, Griffiths A, Woodward-Carlton B. Does DCM improve care in care homes? The EPIC trial. J Dementia
Care 2019;27:24–7.
Griffiths AW, Surr CA, Alldred DP, Baker J, Higham R, Spilsbury K, Thompson CA. Pro re nata prescribing
and administration for neuropsychiatric symptoms and pain in long-term care residents with dementia
and memory problems: a cross-sectional study [published online ahead of print July 24 2019]. Int J Clin
Pharm 2019;41:1814–22.
Martin A, Meads D, Griffiths A, Surr CA. How should we capture health state utility in dementia?
Comparison of DEMQOL-Proxy-U and of self- and proxy-completed EQ-5D-5L. Value Health
2019;22:1417–26.
Meads DM, Martin A, Griffiths A, Kelley R, Creese B, Robinson L, et al. Cost-effectiveness of Dementia
Care Mapping in care home settings – evaluation of a randomised controlled trial [published online ahead
of print November 8 2019]. Appl Health Econ Health Policy 2019.
Surr C, Griffiths A, Kelley R, Holloway I, Walwyn R, Martin A, et al. The implementation of Dementia Care
Mapping™ in a randomised controlled trial in long-term care: results of a process evaluation. Am J
Alzheimers Dis Other Dement 2019;34:390–8.
Surr CA, Shoesmith E, Griffiths AW, Kelley R, McDermid J, Fossey J. Exploring the role of external experts
in supporting staff to implement psychosocial interventions in care home settings: results from the process
evaluation of a randomized controlled trial. BMC Health Serv Res 2019;19:790.
Surr CA, Holloway I, Walwyn REA, Griffiths AW, Meads D, Martin A, et al. Effectiveness of Dementia Care
MappingTM to reduce agitation in care home residents with dementia: an open-cohort cluster randomised
controlled trial. Aging Ment Health 2020; in press.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
105
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to available
anonymised data may be granted following review.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
References
1. Prince M, Knapp M, Guerchet M, McCrone P, Prina M, Comas-Herrera A, et al. Dementia UK:
Update. London: Alzheimer’s Society; 2014.
2. Alzheimer’s Society. Low Expectations: Attitudes on Choice, Care and Community for People with
Dementia in Care Homes. London: Alzheimer’s Society; 2013.
3. Care Quality Commission. The State of Adult Social Care Services 2014 to 2017. Newcastle upon
Tyne: Care Quality Commission; 2017.
4. All-Party Parliamentary Group on Dementia. Always a Last Resort: Inquiry into the Prescription of
Antipsychotic Drugs to People with Dementia Living in Care Homes. London: The Stationery
Office; 2008.
5. Department of Health and Social Care (DHSC). Quality Outcomes for People with Dementia:
Building on the Work of the National Dementia Strategy. London: DHSC; 2010.
6. Department of Health and Social Care (DHSC). Living Well with Dementia: A National Dementia
Strategy. London: DHSC; 2009.
7. Department of Health and Social Care (DHSC). Prime Minister’s Challenge on Dementia:
Delivering Major Improvements in Dementia Care and Research by 2015. London: DHSC; 2012.
8. Department of Health and Social Care (DHSC). Prime Minister’s Challenge on Dementia 2020.
London: DHSC; 2015.
9. Ministerial Advisory Group on Dementia Research. The Ministerial Advisory Group on Dementia
Research: Headline Report. London: Department of Health and Social Care; 2011.
10. Bowie P, Mountain G. The relationship between patient behaviour and environmental quality for
the dementing. Int J Geriatr Psychiatry 1997;12:718–23. https://doi.org/10.1002/(SICI)1099-1166
(199707)12:7<718::AID-GPS608>3.0.CO;2-3
11. Ballard C, O’Brien J, James I, Mynt P, Lana M, Potkins D, et al. Quality of life for people with
dementia living in residential and nursing home care: the impact of performance on activities of
daily living, behavioral and psychological symptoms, language skills, and psychotropic drugs.
Int Psychogeriatr 2001;13:93–106. https://doi.org/10.1017/S1041610201007499
12. All-Party Parliamentary Group on Dementia. Prepared to Care. Challenging the Dementia Skills
Gap. London: The Stationery Office; 2009.
13. Kuske B, Hanns S, Luck T, Angermeyer MC, Behrens J, Riedel-Heller SG. Nursing home staff
training in dementia care: a systematic review of evaluated programs. Int Psychogeriatr
2007;19:818–41. https://doi.org/10.1017/S1041610206004352
14. Surr CA, Gates C, Irving D, Oyebode J, Smith SJ, Parveen S, et al. Effective dementia education
and training for the health and social care workforce: a systematic review of the literature.
Rev Educ Res 2017;87:966–1002. https://doi.org/10.3102/0034654317723305
15. Fossey J, Masson S, Stafford J, Lawrence V, Corbett A, Ballard C. The disconnect between evidence
and practice: a systematic review of person-centred interventions and training manuals for care
home staff working with people with dementia. Int J Geriatr Psychiatry 2014;29:797–807.
https://doi.org/10.1002/gps.4072
16. Bradford Dementia Group. Evaluating Dementia Care. The DCM Method. 7th edn. Bradford:
University of Bradford; 1997.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
107
17. Bradford Dementia Group. DCM 8 User’s Manual. Bradford: University of Bradford; 2005.
https://doi.org/10.1111/j.174-1617.1970.tb00694.x
18. Cox S. Developing Quality in Services. In Cantley C, editor. A Handbook of Dementia Care.
Buckingham: Open University Press; 2001. pp. 258–77.
19. Innes A. Dementia Care Mapping: Applications Across Cultures. Baltimore, MD: Health
Professions Press; 2003.
20. Bredin K, Kitwood T, Wattis J. Decline in quality of life for patients with severe dementia
following a ward merger. Int J Geriatr Psychiatry 1995;10:967–73. https://doi.org/10.1002/
gps.930101109
21. Brooker D. Auditing outcome of care in in-patient and day patient settings using Dementia Care
Mapping. Can it be done? PSIGE Newsletter 1994;51:18–22.
22. Brooker D, Foster N, Banner A, Payne M, Jackson L. The efficacy of Dementia Care Mapping as
an audit tool: report of a 3-year British NHS evaluation. Aging Ment Health 1998;2:60–70.
https://doi.org/10.1080/13607869856957
23. Clare M. Spreading DCM far and wide in Suffolk. J Dement Care 2006;14:10–11.
24. Edwards P, Brotherton S. DCM 8 in Cheshire. J Dement Care 2006;14:12.
25. Jacques I. Evaluating care services for people living with dementia. Elder Care 1996;8:10–13.
26. Martin GW, Younger D. Anti oppressive practice: a route to the empowerment of people with
dementia through communication and choice. J Psychiatr Ment Health Nurs 2000;7:59–67.
https://doi.org/10.1046/j.1365-2850.2000.00264.x
27. Martin GW, Younger D. Person-centred care for people with dementia: a quality audit approach.
J Psychiatr Ment Health Nurs 2001;8:443–8. https://doi.org/10.1046/j.1351-0126.2001.00427.x
28. Wilkinson AM. Dementia Care Mapping: a pilot study of its implementation in a psychogeriatric
service. Int J Geriatr Psychiatry 1993;8:1027–9. https://doi.org/10.1002/gps.930081211
29. Williams J, Rees J. The use of ‘dementia care mapping’ as a method of evaluating care received
by patients with dementia – an initiative to improve quality of life. J Adv Nurs 1997;25:316–23.
https://doi.org/10.1046/j.1365-2648.1997.1997025316.x
30. Ballard C, Corbett A. Management of neuropsychiatric symptoms in people with dementia.
CNS Drugs 2010;24:729–39. https://doi.org/10.2165/11319240-000000000-00000
31. Margallo-Lana M, Swann A, O’Brien J, Fairbairn A, Reichelt K, Potkins D, et al. Prevalence and
pharmacological management of behavioural and psychological symptoms amongst dementia
sufferers living in care environments. Int J Geriatr Psychiatry 2001;16:39–44. https://doi.org/
10.1002/1099-1166(200101)16:1<39::AID-GPS269>3.0.CO;2-F
32. Davison TE, Hudgson C, McCabe MP, George K, Buchanan G. An individualized psychosocial
approach for ‘treatment resistant’ behavioral symptoms of dementia among aged care residents.
Int Psychogeriatr 2007;19:859–73. https://doi.org/10.1017/S1041610206004224
33. Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P, et al. Quality of life in
dementia: more than just cognition. An analysis of associations with quality of life in dementia.
J Neurol Neurosurg Psychiatry 2006;77:146–8. https://doi.org/10.1136/jnnp.2005.072983
34. Liperoti R, Pedone C, Corsonello A. Antipsychotics for the treatment of behavioral and
psychological symptoms of dementia (BPSD). Curr Neuropharmacol 2008;6:117–24. https://doi.org/
10.2174/157015908784533860
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
108
35. Deudon A, Maubourguet N, Gervais X, Leone E, Brocker P, Carcaillon L, et al. Non-pharmacological
management of behavioural symptoms in nursing homes. Int J Geriatr Psychiatry 2009;24:1386–95.
https://doi.org/10.1002/gps.2275
36. Herrmann N, Lanctôt KL, Sambrook R, Lesnikova N, Hébert R, McCracken P, et al. The contribution
of neuropsychiatric symptoms to the cost of dementia care. Int J Geriatr Psychiatry 2006;21:972–6.
https://doi.org/10.1002/gps.1594
37. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J
Geriatr Psychiatry 2000;15(Suppl. 1):2–4. https://doi.org/10.1002/(SICI)1099-1166(200004)15:1
+<S2::AID-GPS159>3.0.CO;2-3
38. Majic T, Pluta JP, Mell T, Aichberger MC, Treusch Y, Gutzmann H, et al. The pharmacotherapy of
neuropsychiatric symptoms of dementia: a cross-sectional study in 18 homes for the elderly in
Berlin. Dtsch Arztebl Int 2010;107:320–7. https://doi.org/10.3238/arztebl.2010.0320
39. Tunis SL, Edell WS, Adams BE, Kennedy JS. Characterizing behavioral and psychological symptoms
of dementia (BPSD) among geropsychiatric inpatients. J Am Med Dir Assoc 2002;3:146–51.
https://doi.org/10.1016/S1525-8610(04)70457-0
40. Ballard CG, Margallo-Lana M, Fossey J, Reichelt K, Myint P, Potkins D, O’Brien J. A 1-year
follow-up study of behavioral and psychological symptoms in dementia among people in care
environments. J Clin Psychiatry 2001;62:631–6. https://doi.org/10.4088/JCP.v62n0810
41. Husebo BS, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce
behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical
trial. BMJ 2011;343:d4065. https://doi.org/10.1136/bmj.d4065
42. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home.
J Gerontol 1989;44:M77–84. https://doi.org/10.1093/geronj/44.3.M77
43. Cohen-Mansfield J. Instruction Manual for the Cohen-Mansfield Agitation Inventory (CMAI).
Rockville, MD: The Research Institute of the Hebrew Home of Greater Washington; 1991.
44. Hindley N, Gordon H. The elderly, dementia, aggression and risk assessment. Int J Geriatr
Psychiatry 2000;15:254–9. https://doi.org/10.1002/(SICI)1099-1166(200003)15:3<254::AID-
GPS103>3.0.CO;2-T
45. Burgio LD, Butler FR, Roth DL, Hardin JM, Hsu CC, Ung K. Agitation in nursing home residents:
the role of gender and social context. Int Psychogeriatr 2000;12:495–511. https://doi.org/
10.1017/S104161020000661X
46. Zuidema S, Koopmans R, Verhey F. Prevalence and predictors of neuropsychiatric symptoms in
cognitively impaired nursing home patients. J Geriatr Psychiatry Neurol 2007;20:41–9.
https://doi.org/10.1177/0891988706292762
47. Miyamoto Y, Tachimori H, Ito H. Formal caregiver burden in dementia: impact of behavioral and
psychological symptoms of dementia and activities of daily living. Geriatr Nurs 2010;31:246–53.
https://doi.org/10.1016/j.gerinurse.2010.01.002
48. Cohen-Mansfield J. Agitated behavior in persons with dementia: the relationship between type of
behavior, its frequency, and its disruptiveness. J Psychiatr Res 2008;43:64–9. https://doi.org/
10.1016/j.jpsychires.2008.02.003
49. Hughes J, Bagley H, Reilly S, Burns A, Challis D. Care staff working with people with dementia:
training, knowledge and confidence. Dementia 2008;7:227–38. https://doi.org/10.1177/
1471301208091159
50. Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action.
London: Department of Health and Social Care; 2009.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
109
51. Bishara D, Taylor D, Howard RJ, Abdel-Tawab R. Expert opinion on the management of
behavioural and psychological symptoms of dementia (BPSD) and investigation into prescribing
practices in the UK. Int J Geriatr Psychiatry 2009;24:944–54. https://doi.org/10.1002/gps.2200
52. Raju J, Sikdar S, Krishna T. What happened to patients with behavioural and psychological
symptoms of dementia (BPSD) after the Committee on Safety in Medicines (CSM) guidelines?
Int J Geriatr Psychiatry 2005;20:898–9. https://doi.org/10.1002/gps.1377
53. Cohen-Mansfield J, Werner P, Marx MS. The social environment of the agitated nursing home
resident. Int J Geriatr Psychiatry 1992;7:789–98. https://doi.org/10.1002/gps.930071104
54. Testad I, Auer S, Mittelman M, Ballard C, Fossey J, Donabauer Y, Aarsland D. Nursing home
structure and association with agitation and use of psychotropic drugs in nursing home residents
in three countries: Norway, Austria and England. Int J Geriatr Psychiatry 2010;25:725–31.
https://doi.org/10.1002/gps.2414
55. Stokes G. Challenging Behaviour: A Psychological Approach. In Woods RT, editor. Handbook of
the Clinical Psychology of Ageing. Chichester: Wiley; 1996. pp. 601–28.
56. Cohen-Mansfield J, Marx MS, Dakheel-Ali M, Regier NG, Thein K, Freedman L. Can agitated
behavior of nursing home residents with dementia be prevented with the use of standardized
stimuli? J Am Geriatr Soc 2010;58:1459–64. https://doi.org/10.1111/j.1532-5415.2010.02951.x
57. Brodaty H, Draper B, Saab D, Low LF, Richards V, Paton H, Lie D. Psychosis, depression and
behavioural disturbances in Sydney nursing home residents: prevalence and predictors. Int J
Geriatr Psychiatry 2001;16:504–12. https://doi.org/10.1002/gps.382
58. Weber K, Meiler-Mititelu C, Herrmann FR, Delaloye C, Giannakopoulos P, Canuto A. Longitudinal
assessment of psychotherapeutic day hospital treatment for neuropsychiatric symptoms in
dementia. Aging Ment Health 2009;13:92–8. https://doi.org/10.1080/13607860802154523
59. National Institute for Health and Care Excellence, Social Care Institute for Excellence. Dementia:
Supporting People with Dementia and Their Carers in Health and Social Care – NICE Clinical
Guideline 42. London: NICE; 2006.
60. Salzman C, Jeste DV, Meyer RE, Cohen-Mansfield J, Cummings J, Grossberg GT, et al. Elderly
patients with dementia-related symptoms of severe agitation and aggression: consensus
statement on treatment options, clinical trials methodology, and policy. J Clin Psychiatry
2008;69:889–98. https://doi.org/10.4088/JCP.v69n0602
61. Moniz-Cook E, Stokes G, Agar S. Difficult behaviour and dementia in nursing homes: five cases
of psychosocial intervention. Clin Psychol Psychother 2003;10:197–208. https://doi.org/10.1002/
cpp.370
62. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological
interventions for agitation in dementia: systematic review of randomised controlled trials.
Br J Psychiatry 2014;205:436–42. https://doi.org/10.1192/bjp.bp.113.141119
63. Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged
Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and
usual care in dementia: a cluster-randomised trial. Lancet Neurol 2009;8:317–25. https://doi.org/
10.1016/S1474-4422(09)70045-6
64. Brooker D. What is person centred care for people with dementia? Rev Clin Gerontol
2004;13:215–22. https://doi.org/10.1017/S095925980400108X
65. Chrzescijanski C, Moyle W, Creedy D. Reducing dementia-related aggression through a staff
education intervention. Dementia 2007;6:271–86. https://doi.org/10.1177/1471301207080369
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
110
66. Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, Howard R. Effect of enhanced
psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster
randomised trial. BMJ 2006;332:756–61. https://doi.org/10.1136/bmj.38782.575868.7C
67. Moniz-Cook E, Agar S, Silver M, Woods R, Wang M, Elston C, Win T. Can staff training reduce
behavioural problems in residential care for the elderly mentally ill? Int J Geriatr Psychiatry
1998;13:149–58. https://doi.org/10.1002/(SICI)1099-1166(199803)13:3<149::AID-GPS746>3.0.
CO;2-Q
68. Bird M, Llewellyn-Jones RH, Korten A. An evaluation of the effectiveness of a case-specific
approach to challenging behaviour associated with dementia. Aging Ment Health
2009;13:73–83. https://doi.org/10.1080/13607860802154499
69. Turner J, Snowdon J. An innovative approach to behavioral assessment and intervention in
residential care: a service evaluation. Clin Gerontol 2009;32:260–75. https://doi.org/10.1080/
07317110902895291
70. Bird M, Jones RH, Korten A, Smithers H. A controlled trial of a predominantly psychosocial
approach to BPSD: treating causality. Int Psychogeriatr 2007;19:874–91. https://doi.org/10.1017/
S1041610206004790
71. Skills for Care. Common Induction Standards (2010 ‘Refreshed’ Edition). Leeds: Skills for Care; 2010.
72. Care Quality Commission. Guidance about Compliance: Essential Standards of Quality and Safety.
London: Care Quality Commission; 2010.
73. Commission for Social Care Inspection. See Me, Not Just the Dementia: Understanding People’s
Experiences of Living in a Care Home. London: Commission for Social Care Inspection; 2008.
74. Furåker C, Nilsson A. The competence of certified nurse assistants caring for persons with
dementia diseases in residential facilities. J Psychiatr Ment Health Nurs 2009;16:146–52.
https://doi.org/10.1111/j.1365-2850.2008.01347.x
75. Lintern T, Woods RT, Phair L. Training is not enough to change care practice. J Dement Care
2000;8:15–16.
76. Ballard C, Corbett A, Orrell M, Williams G, Moniz-Cook E, Romeo R, et al. Impact of person-centred
care training and person-centred activities on quality of life, agitation, and antipsychotic use in
people with dementia living in nursing homes: a cluster-randomised controlled trial. PLOS Med
2018;15:e1002500. https://doi.org/10.1371/journal.pmed.1002500
77. Visser SM, McCabe MP, Hudgson C, Buchanan G, Davison TE, George K. Managing behavioural
symptoms of dementia: effectiveness of staff education and peer support. Aging Ment Health
2008;12:47–55. https://doi.org/10.1080/13607860701366012
78. Ballard C, Powell I, James I, Reichelt K, Myint P, Potkins D, et al. Can psychiatric liaison reduce
neuroleptic use and reduce health service utilization for dementia patients residing in care
facilities. Int J Geriatr Psychiatry 2002;17:140–5. https://doi.org/10.1002/gps.543
79. Andrews S, McInerney F, Robinson A. Realizing a palliative approach in dementia care: strategies
to facilitate aged care staff engagement in evidence-based practice. Int Psychogeriatr
2009;21(Suppl. 1):64–8. https://doi.org/10.1017/S1041610209008679
80. Brodribb W. Barriers to translating evidence-based breastfeeding information into practice.
Acta Paediatr 2011;100:486–90. https://doi.org/10.1111/j.1651-2227.2010.02108.x
81. Godley SH, Garner BR, Smith JE, Meyers RJ, Godley MD. A large-scale dissemination and
implementation model for evidence-based treatment and continuing care. Clin Psychol
2011;18:67–83. https://doi.org/10.1111/j.1468-2850.2011.01236.x
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
111
82. Brooker DJ, Latham I, Evans SC, Jacobson N, Perry W, Bray J, et al. FITS into practice: translating
research into practice in reducing the use of anti-psychotic medication for people with dementia
living in care homes. Aging Ment Health 2016;20:709–18. https://doi.org/10.1080/13607863.
2015.1063102
83. British Standards Institution (BSI). PAS 800:2010: Use of Dementia Care Mapping for Improved
Person-centred Care in a Care Provider Organization – Guide. London: BSI; 2010.
84. Innes A. Changing the Culture of Dementia Care: A Systematic Exploration of the Process of
Culture Change in Three Care Settings. Bradford: University of Bradford; 2000.
85. Innes A, Surr C. Measuring the well-being of people with dementia living in formal care settings:
the use of Dementia Care Mapping. Aging Ment Health 2001;5:258–68. https://doi.org/10.1080/
13607860120065023
86. Wylie K, Madjar I, Walton JA. Dementia Care Mapping. A person-centred, evidence-based
approach to improving the quality of care in residential care settings. Geriaction 2002;20:5–9.
87. Mansah M, Coulon L, Brown P. A mapper’s reflection on Dementia Care Mapping with older
residents living in a nursing home. Int J Older People Nurs 2008;3:113–20. https://doi.org/
10.1111/j.1748-3743.2007.00108.x
88. Beavis D, Simpson S, Graham I. A literature review of dementia care mapping: methodological
considerations and efficacy. J Psychiatr Ment Health Nurs 2002;9:725–36. https://doi.org/10.1046/
j.1365-2850.2002.00508.x
89. Brooker D. Dementia care mapping: a review of the research literature. Gerontologist
2005;45:11–18. https://doi.org/10.1093/geront/45.suppl_1.11
90. Chenoweth L, Jeon YH. Determining the efficacy of Dementia Care Mapping as an outcome
measure and a process for change: a pilot study. Aging Ment Health 2007;11:237–45.
https://doi.org/10.1080/13607860600844226
91. Kuiper D, Dijkstra GJ, Tuinstra J, Groothoff JW. [The influence of Dementia Care Mapping (DCM)
on behavioural problems of persons with dementia and the job satisfaction of caregivers: a pilot
study.] Tijdschr Gerontol Geriatr 2009;40:102–12. https://doi.org/10.1007/BF03079572
92. Dichter MN, Quasdorf T, Schwab CG, Trutschel D, Haastert B, Riesner C, et al. Dementia care
mapping: effects on residents’ quality of life and challenging behavior in German nursing homes.
A quasi-experimental trial. Int Psychogeriatr 2015;27:1875–92. https://doi.org/10.1017/
S1041610215000927
93. Rokstad AM, Røsvik J, Kirkevold Ø, Selbaek G, Saltyte Benth J, Engedal K. The effect of person-
centred dementia care to prevent agitation and other neuropsychiatric symptoms and enhance
quality of life in nursing home patients: a 10-month randomized controlled trial. Dement Geriatr
Cogn Disord 2013;36:340–53. https://doi.org/10.1159/000354366
94. van de Ven G, Draskovic I, Adang EM, Donders R, Zuidema SU, Koopmans RT, Vernooij-Dassen MJ.
Effects of dementia-care mapping on residents and staff of care homes: a pragmatic cluster-
randomised controlled trial. PLOS ONE 2013;8:e67325. https://doi.org/10.1371/journal.pone.
0067325
95. Jeon YH, Luscombe G, Chenoweth L, Stein-Parbury J, Brodaty H, King M, Haas M. Staff outcomes
from the caring for aged dementia care resident study (CADRES): a cluster randomised trial.
Int J Nurs Stud 2012;49:508–18. https://doi.org/10.1016/j.ijnurstu.2011.10.020
96. Surr CA, Griffiths AW, Kelley R. Implementing Dementia Care Mapping as a practice development
tool in dementia care services: a systematic review. Clin Interv Aging 2018;13:165–77. https://doi.org/
10.2147/CIA.S138836
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
112
97. Skills for Care. The State of the Adult Social Care Sector and Workforce in England. Leeds: Skills
for Care; 2017.
98. Surr CA, Walwyn RE, Lilley-Kelly A, Cicero R, Meads D, Ballard C, et al. Evaluating the
effectiveness and cost-effectiveness of Dementia Care Mapping™ to enable person-centred care
for people with dementia and their carers (DCM-EPIC) in care homes: study protocol for a
randomised controlled trial. Trials 2016;17:300. https://doi.org/10.1186/s13063-016-1416-z
99. Griffiths AW, Creese B, Garrod L, Chenoweth L, Surr C. The development and use of the
Assessment of Dementia Awareness and Person-centred Care Training (ADAPT) tool in long-term
care [published online ahead of print 9 April 2018]. Dementia 2018. https://doi.org/10.1177/
1471301218768165
100. Bupa. Person First ... Dementia Second: The Essentials Workbooks. Leeds: Bupa; 2010.
101. Care Quality Commission. The State of Health Care and Adult Social Care in England. An Overview
of Key Themes in Care 2009/10. London: The Stationery Office; 2010.
102. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653–9.
https://doi.org/10.1037/t08620-000
103. Great Britain. Mental Capacity Act 2005. London: The Stationery Office; 2005.
104. Medical Research Council. MRC Guidelines for Good Clinical Practice in Clinical Trials. London:
Medical Research Council; 1998.
105. Department of Health and Social Care, Welsh Assembly Government. Guidance on Nominating a
Consultee for Research Involving Adults Who Lack Capacity to Consent. London: Department of
Health and Social Care; 2008.
106. Medical Research Council. Medical Research Involving Adults Who Cannot Consent. London:
Medical Research Council; 2007.
107. Kuznetsova OM, Tymofyeyev Y. Preserving the allocation ratio at every allocation with biased coin
randomisation and minimisation in studies with unequal allocation. Stat Med 2012;31:702–23.
https://doi.org/10.1002/sim.4447
108. Brooker D, Surr C. Dementia Care Mapping: Principles and Practice. Bradford: University of
Bradford; 2005.
109. Brooker DJ, Surr C. Dementia Care Mapping (DCM): initial validation of DCM 8 in UK field trials.
Int J Geriatr Psychiatry 2006;21:1018–25. https://doi.org/10.1002/gps.1600
110. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc
1986;34:711–21. https://doi.org/10.1111/j.1532-5415.1986.tb04302.x
111. Shah A, Evans H, Parkash N. Evaluation of three aggression/agitation behaviour rating scales
for use on an acute admission and assessment psychogeriatric ward. Int J Geriatr Psychiatry
1998;13:415–20. https://doi.org/10.1002/(SICI)1099-1166(199806)13:6<415::AID-GPS788>3.0.
CO;2-A
112. Cohen-Mansfield J, Libin A. Assessment of agitation in elderly patients with dementia: correlations
between informant rating and direct observation. Int J Geriatr Psychiatry 2004;19:881–91.
https://doi.org/10.1002/gps.1171
113. Griffiths AW, Albertyn CP, Burnley NL, Creese B, Walwyn R, Holloway I, et al. Validation of the
Cohen-Mansfield Agitation Inventory Observational (CMAI-O) tool [published online ahead of
print 10 April 2019]. Int Psychogeriatr 2019. https://doi.org/10.1017/S1041610219000279
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
113
114. Rosen J, Burgio L, Kollar M, Cain M, Allison M, Fogleman M, et al. A user-friendly instrument
for rating agitation in dementia patients. Am J Geriatr Psychiatry 1994;2:52–9. https://doi.org/
10.1097/00019442-199400210-00008
115. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The
Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia.
Neurology 1994;44:2308–14. https://doi.org/10.1212/WNL.44.12.2308
116. Smith SC, Lamping DL, Banerjee S, Harwood RH, Foley B, Smith P, et al. Development of a new
measure of health-related quality of life for people with dementia: DEMQOL. Psychol Med
2007;37:737–46. https://doi.org/10.1017/S0033291706009469
117. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, et al. Measurement of
health-related quality of life for people with dementia: development of a new instrument
(DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005;9(10):1–93.
https://doi.org/10.3310/hta9100
118. Rowen D, Mulhern B, Banerjee S, Hout Bv, Young TA, Knapp M, et al. Estimating preference-
based single index measures for dementia using DEMQOL and DEMQOL-Proxy. Value Health
2012;15:346–56. https://doi.org/10.1016/j.jval.2011.10.016
119. The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life.
Health Policy 1990;16:199–208. https://doi.org/10.1016/0168-8510(90)90421-9
120. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36.
https://doi.org/10.1007/s11136-011-9903-x
121. Weiner MF, Martin-Cook K, Svetlik DA, Saine K, Foster B, Fontaine CS. The quality of life in
late-stage dementia (QUALID) scale. J Am Med Dir Assoc 2000;1:114–16. https://doi.org/10.1037/
t00432-000
122. Logsdon RG, Albert SM. Assessing quality of life in Alzheimer’s disease: conceptual and
methodological issues. J Ment Health Aging 1999;5:3–6.
123. Hoe J, Katona C, Roch B, Livingston G. Use of the QOL-AD for measuring quality of life in people
with severe dementia – the LASER-AD study. Age Ageing 2005;34:130–5. https://doi.org/
10.1093/ageing/afi030
124. Thorgrimsen L, Selwood A, Spector A, Royan L, de Madariaga Lopez M, Woods RT, Orrell M.
Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer’s
Disease (QoL-AD) scale. Alzheimer Dis Assoc Disord 2003;17:201–8. https://doi.org/10.1097/
00002093-200310000-00002
125. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Assessing quality of life in older adults with
cognitive impairment. Psychosom Med 2002;64:510–19. https://doi.org/10.1097/00006842-
200205000-00016
126. Edelman P, Fulton BR, Kuhn D, Chang CH. A comparison of three methods of measuring
dementia-specific quality of life: perspectives of residents, staff, and observers. Gerontologist
2005;45:27–36. https://doi.org/10.1093/geront/45.suppl_1.27
127. Siddiqi N, Cheater F, Collinson M, Farrin A, Forster A, George D, et al. The PiTSTOP study:
a feasibility cluster randomized trial of delirium prevention in care homes for older people.
Age Ageing 2016;45:652–61. https://doi.org/10.1093/ageing/afw091
128. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of
dementia. Br J Psychiatry 1982;140:566–72. https://doi.org/10.1192/bjp.140.6.566
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
114
129. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology
1993;43:2412–14. https://doi.org/10.1212/WNL.43.11.2412-a
130. Goldberg DP, Williams PA. User’s Guide to the General Health Questionnaire. Windsor:
NFER-Nelson; 1988.
131. Penninkilampi-Kerola V, Miettunen J, Ebeling H. A comparative assessment of the factor
structures and psychometric properties of the GHQ-12 and the GHQ-20 based on data from a
Finnish population-based sample. Scand J Psychol 2006;47:431–40. https://doi.org/10.1111/
j.1467-9450.2006.00551.x
132. Schepers AK, Orrell M, Shanahan N, Spector A. Sense of competence in dementia care staff
(SCIDS) scale: development, reliability, and validity. Int Psychogeriatr 2012;24:1153–62.
https://doi.org/10.1017/S104161021100247X
133. Dean R, Proudfoot R, Lindesay J. The Quality of Interactions Schedule (QUIS): development,
reliability and use in the evaluation of two domus units. Int J Geriatr Psychiatry 1993;8:819–26.
https://doi.org/10.1002/gps.930081004
134. Coates CJ. The Caring Efficacy Scale: nurses’ self-reports of caring in practice settings. Adv Pract
Nurs Q 1997;3:53–9.
135. Lindesay J, Skea D. Gender and interactions between care staff and elderly nursing home
residents with dementia. Int J Geriatr Psychiatry 1997;12:344–8. https://doi.org/10.1002/(SICI)
1099-1166(199703)12:3<344::AID-GPS504>3.0.CO;2-I
136. Smith R, Fleming R, Chenoweth L, Jeon YH, Stein-Parbury J, Brodaty H. Validation of the
Environmental Audit Tool in both purpose-built and non-purpose-built dementia care settings.
Australas J Ageing 2012;31:159–63. https://doi.org/10.1111/j.1741-6612.2011.00559.x
137. te Boekhorst S, Depla MF, Pot AM, de Lange J, Eefsting JA. The ideals of group living homes for
people with dementia: do they practice what they preach? Int Psychogeriatr 2011;23:1526–7.
https://doi.org/10.1017/S1041610211000858
138. Zuidema SU, Buursema AL, Gerritsen MG, Oosterwal KC, Smits MM, Koopmans RT, de Jonghe JF.
Assessing neuropsychiatric symptoms in nursing home patients with dementia: reliability and
Reliable Change Index of the Neuropsychiatric Inventory and the Cohen-Mansfield Agitation
Inventory. Int J Geriatr Psychiatry 2011;26:127–34. https://doi.org/10.1002/gps.2499
139. Staquet MJ, Hays RD, Fayers PM. Quality of Life Assessment in Clinical Trials: Methods and Practice.
Oxford: Oxford University Press; 1998.
140. Yan X, Lee S, Li N. Missing data handling methods in medical device clinical trials. J Biopharm Stat
2009;19:1085–98. https://doi.org/10.1080/10543400903243009
141. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of
interventions: Template for Intervention Description and Replication (TIDieR) checklist and guide.
BMJ 2014;348:g1687. https://doi.org/10.1136/bmj.g1687
142. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research:
conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–82.
https://doi.org/10.1037/0022-3514.51.6.1173
143. National Institute for Health and Care Excellence. Guide to the Methods of Technology Appraisal
2013. London: NICE; 2013.
144. Curtis L, Burns A. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services
Research Unit; 2016.
145. Department of Health and Social Care (DHSC). Drugs and Pharmaceutical Electronic Market
Information Tool (eMIT). London: DHSC; 2017.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
115
146. Department of Health and Social Care (DHSC). National Schedule of Reference Costs 2015–16.
London: DHSC; 2017.
147. Devlin N, Shah K, Feng Y, Mulhern B, van Hout B. Valuing Health-Related Quality of Life:
An EQ-5D-5L Value Set for England – OHE Research Paper 16/01. London: Office of Health
Economics; 2016. https://doi.org/10.1002/hec.3564
148. The EuroQol Group. EQ-5D-5L: Valuation – Crosswalk Index Value Calculator. Version 1.0.
URL: https://euroqol.org/eq-5d-instruments/eq-5d-5l-about/valuation-standard-value-sets/
crosswalk-index-value-calculator/ (accessed 19 October 17).
149. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness
analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70.
https://doi.org/10.1007/s40273-014-0193-3
150. Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York, NY: Wiley; 1987.
https://doi.org/10.1002/9780470316696
151. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness
acceptability curves. Health Econ 2001;10:779–87. https://doi.org/10.1002/hec.635
152. Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of
complex interventions: Medical Research Council guidance. BMJ 2015;350:h1258. https://doi.org/
10.1136/bmj.h1258
153. Linnan L, Steckler A. Process Evaluation for Public Health Interventions and Research.
San Francisco, CA: Jossey-Bass; 2002.
154. Smith J, Firth J. Qualitative data analysis: the framework approach. Nurse Res 2011;18:52–62.
https://doi.org/10.7748/nr2011.01.18.2.52.c8284
155. Walwyn R, Copas A, Farrin A, Surr C. Open Cohort Designs for Cluster Randomised Trials in
Institutional Settings: A Methodology Bolt-on to DCM-EPIC. London: Medical Research Council;
2019–21.
156. Department of Health and Social Care (DHSC). No Secrets: Guidance on Developing and
Implementing Multi-agency Policies and Procedures to Protect Vulnerable Adults from Abuse.
London: DHSC; 2000.
157. Meads DM, Martin A, Griffiths A, Kelley R, Creese B, Robinson L, et al. Cost-effectiveness of
Dementia Care Mapping in care home settings – evaluation of a randomised controlled trial
[published online ahead of print November 8 2019]. Appl Health Econ Health Policy 2019.
https://doi.org/10.1007/s40258-019-00531-1
158. Surr C, Griffiths A, Kelley R, Holloway I, Walwyn R, Martin A, et al. The implementation of
Dementia Care Mapping™ in a randomised controlled trial in long-term care: results of a
process evaluation. Am J Alzheimers Dis Other Dement 2019;34:390–8. https://doi.org/10.1177/
1533317519845725
159. University of Bradford. DCM™ for Realising Person Centred Care Booking Form 2017–18. Bradford:
University of Bradford; 2017. URL: www.bradford.ac.uk/health/dementia/training/training-courses/
dementia-care-mapping-for-realising-person-centred-care/ (accessed September 2017).
160. Griffiths AW, Kelley R, Garrod L, Perfect D, Robinson O, Shoesmith E, et al. Barriers and
facilitators to implementing dementia care mapping in care homes: results from the DCM™ EPIC
trial process evaluation. BMC Geriatr 2019;19:37. https://doi.org/10.1186/s12877-019-1045-y
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
116
161. Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. A systematic review of
the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural
interventions for managing agitation in older adults with dementia. Health Technol Assess
2014;18(39). https://doi.org/10.3310/hta18390
162. Zwijsen SA, Bosmans JE, Gerritsen DL, Pot AM, Hertogh CM, Smalbrugge M. The cost-
effectiveness of grip on challenging behaviour: an economic evaluation of a care programme
for managing challenging behaviour. Int J Geriatr Psychiatry 2016;31:567–74. https://doi.org/
10.1002/gps.4360
163. van de Ven G, Draskovic I, van Herpen E, Koopmans RT, Donders R, Zuidema SU, et al. The
economics of dementia-care mapping in nursing homes: a cluster-randomised controlled trial.
PLOS ONE 2014;9:e86662. https://doi.org/10.1371/journal.pone.0086662
164. Moyle W, Murfield JE, Griffiths SG, Venturato L. Assessing quality of life of older people with
dementia: a comparison of quantitative self-report and proxy accounts. J Adv Nurs
2012;68:2237–46. https://doi.org/10.1111/j.1365-2648.2011.05912.x
165. Wen YW, Tsai YW, Wu DB, Chen PF. The impact of outliers on net-benefit regression model in
cost-effectiveness analysis. PLOS ONE 2013;8:e65930. https://doi.org/10.1371/journal.pone.
0065930
166. Care Quality Commission. The State of Health Care and Adult Social Care in England 2016/17.
London: Care Quality Commission; 2017.
167. Barbosa A, Lord K, Blighe A, Mountain G. Dementia Care Mapping in long-term care settings:
a systematic review of the evidence. Int Psychogeriatr 2017;29:1609–18. https://doi.org/10.1017/
S1041610217001028
168. Curtis L, Burns A. Unit Costs of Health and Social Care 2012. Canterbury: PSSRU, University of
Kent; 2012.
169. Curtis L, Burns A. Unit Costs of Health and Social Care 2010. Canterbury: PSSRU, University of
Kent; 2010.
170. Curtis L, Burns A. Unit Costs of Health and Social Care 2015. Canterbury: PSSRU, University of
Kent; 2015.
DOI: 10.3310/hta24160 HEALTH TECHNOLOGY ASSESSMENT 2020 VOL. 24 NO. 16
© Queen’s Printer and Controller of HMSO 2020. This work was produced by Surr et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional
journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should
be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
117

Appendix 1 Supporting tables
Screening
TABLE 26 Resident original-cohort CONSORT, by hub
Residents, n (%)
Hub
Total
(50 care homes)
Yorkshire
(21 care homes)
London
(15 care homes)
Oxford
(14 care homes)
Screened 656 419 489 1564
Eligible (out of those screened) 451 (68.8) 297 (70.9) 321 (65.6) 1069 (68.4)
Not eligible (out of those screened) 205 (31.2) 122 (29.0) 168 (34.4) 495 (31.6)
Does not have formal diagnosis of dementia 133 (64.9) 67 (54.9) 98 (58.3) 298 (60.2)
Permanently bed-bound 27 (13.2) 32 (26.2) 30 (17.9) 89 (18.0)
Terminally ill 22 (10.7) 18 (14.8) 18 (10.7) 58 (11.7)
Not a permanent resident 38 (18.5) 2 (1.6) 21 (12.5) 61 (12.3)
Insufficient proficiency in English 2 (1.0) 6 (4.9) 4 (2.4) 12 (2.4)
Consented (out of those eligible) 366 (81.2) 199 (67.0) 216 (67.3) 781 (73.1)
Not consented (out of those eligible) 85 (18.8) 98 (33.0) 105 (32.7) 288 (26.9)
Consent refused 69 (81.2) 87 (88.8) 82 (78.1) 238 (82.6)
By resident 24 (66.7) 4 (11.1) 8 (22.2) 36 (15.1)
By Personal Consultee 33 (24.8) 37 (27.8) 63 (47.4) 133 (55.9)
By Nominated Consultee 12 (17.4) 46 (66.7) 11 (15.9) 69 (29.0)
Died 5 (5.9) 5 (5.1) 8 (7.6) 18 (6.3)
Unwilling to engage with researcher 4 (4.7) 2 (2.0) 5 (4.8) 11 (3.8)
Transferred elsewhere 7 (8.2) 2 (2.0) 7 (6.7) 16 (5.6)
No consultee available to consent 0 (0.0) 0 (0.0) 2 (1.9) 2 (0.7)
Other 1 (1.2) 2 (2.0) 2 (1.9) 5 (1.7)
Registered (out of those consented) 339 (92.6) 191 (96.0) 213 (98.6) 743 (95.1)
Not registered (out of those consented) 27 (7.4) 8 (4.0) 3 (1.4) 38 (4.9)
Died 16 (59.3) 7 (87.5) 3 (100.0) 26 (68.4)
Withdrew 1 (3.7) 0 (0.0) 0 (0.0) 1 (2.6)
No longer eligible 3 (11.1) 0 (0.0) 0 (0.0) 3 (7.9)
Moved out of care home 7 (25.9) 0 (0.0) 0 (0.0) 7 (18.4)
Other 1 (3.7) 1 (12.5) 0 (0.0) 2 (5.3)
Registered at randomisation (out of those
registered)
330 (97.3) 185 (96.9) 211 (99.1) 726 (97.7)
Died between registration and care home
randomisation (out of those registered)
9 (2.7) 6 (3.1) 2 (0.9) 17 (2.3)
The percentages of the reasons that residents were ‘not eligible’, ‘not consented’ and ‘not registered’ were calculated out
of the total number of residents who were ‘not eligible’, ‘not consented’ and ‘not registered’, respectively. The reasons for
residents being ‘not eligible’, ‘not consented’ and ‘not registered’ are not mutually exclusive.
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TABLE 27 Additional resident cohort screening, by hub
Residents, n (%)
Hub
Total care
homes
Yorkshire
care homes
London
care homes
Oxford
care homes
Screened 569 396 479 1444
Currently participating in the EPIC trial (out of
those screened)
185 (32.5) 109 (27.5) 131 (27.3) 425 (29.4)
Screened and not participating in the EPIC trial
(out of those screened)
384 (67.5) 287 (72.5) 348 (72.7) 1019 (70.6)
Screened at baseline but consent refused (out of
those screened and not participating in the EPIC trial)
43 (11.2) 57 (19.9) 42 (12.1) 142 (13.9)
Eligible (out of those screened) 189 (33.2) 90 (22.7) 142 (29.6) 421 (29.2)
Not eligible (out of those screened)a 152 (26.7) 140 (35.4) 164 (34.2) 456 (31.6)
Does not have formal diagnosis of dementia 93 (61.2) 57 (40.7) 103 (62.8) 253 (55.5)
Permanently bed-bound 9 (5.9) 38 (27.1) 7 (4.3) 54 (11.8)
Terminally ill 6 (3.9) 13 (9.3) 2 (1.2) 21 (4.6)
Not a permanent resident 19 (12.5) 1 (0.7) 8 (4.9) 28 (6.1)
Insufficient proficiency in English 1 (0.7) 4 (2.9) 2 (1.2) 7 (1.5)
Moved to the unit < 3 months ago 44 (28.9) 42 (30.0) 48 (29.3) 134 (29.4)
Missing information 1 (0.7) 0 (0.0) 0 (0.0) 1 (0.2)
Consented (out of those eligible) 120 (63.5) 47 (52.2) 99 (69.7) 266 (63.2)
Not consented (out of those eligible)a missing data 68 (36.0) 1 42 (46.7) 1 43 (30.3) 0 153 (36.3) 2
Consent refused 65 (95.6) 36 (85.7) 39 (90.7) 140 (91.5)
By resident 14 (21.5) 1 (2.8) 13 (33.3) 28 (20.0)
By Personal Consultee 19 (29.2) 10 (27.8) 14 (35.9) 43 (30.7)
By Nominated Consultee 32 (49.2) 25 (69.4) 12 (30.8) 69 (49.3)
Died 1 (1.5) 2 (4.8) 2 (4.7) 5 (3.3)
Unwilling to engage with researcher 1 (1.5) 1 (2.4) 1 (2.3) 3 (2.0)
No response from Personal Consultee 0 (0.0) 2 (4.8) 0 (0.0) 2 (1.3)
Transferred elsewhere 1 (1.5) 0 (0.0) 0 (0.0) 1 (0.7)
Other 1 (1.5) 1 (2.4) 1 (2.3) 3 (2.0)
Registered (out of those consented) 119 (99.2) 45 (95.7) 97 (98.0) 261 (98.1)
Not registered (out of those consented) missing data 1 (0.8) 0 2 (4.3) 0 1 (1.0) 1 4 (1.5) 1
Does not have formal diagnosis of dementia 0 (0.0) 1 (2.1) 0 (0.0) 1 (0.4)
Moved out of care home 1 (0.8) 0 (0.0) 0 (0.0) 1 (0.4)
Died 0 (0.0) 0 (0.0) 1 (0.8) 1 (0.4)
In hospital 0 (0.0) 1 (2.1) 0 (0.0) 1 (0.4)
a Categories are not mutually exclusive.
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TABLE 28 Residents screened in additional cohort, by treatment arm
Residents, n (%)
Control
(19 care homes)
Intervention
(31 care homes)
Total
(48 care homes)
Screened 494 950 1444
Currently participating in the EPIC trial (out of those
screened)
185 (37.4) 240 (25.3) 425 (29.4)
Screened and not participating in the EPIC trial
(out of those screened)
309 (62.6) 710 (74.7) 1019 (70.6)
Screened at baseline but consent refused (out of those
screened and not participating in the EPIC trial)
34 (11.0) 108 (15.2) 142 (13.9)
Eligible (out of those screened) 147 (29.8) 274 (28.8) 421 (29.2)
Not eligible (out of those screened)a 128 (25.9) 328 (34.5) 456 (31.6)
Does not have formal diagnosis of dementia 61 (47.7) 192 (58.5) 253 (55.5)
Moved to the unit < 3 months ago 15 (11.7) 39 (11.9) 54 (11.8)
Permanently bed-bound 6 (4.7) 15 (4.6) 21 (4.6)
Terminally ill 3 (2.3) 25 (7.6) 28 (6.1)
Not a permanent resident 3 (2.3) 4 (1.2) 7 (1.5)
Insufficient proficiency in English 51 (39.8) 83 (25.3) 134 (29.4)
Missing information 1 (0.8) 0 (0.0) 1 (0.2)
Consented (out of those eligible) 100 (68.0) 166 (60.6) 266 (63.2)
Not consented (out of those eligible)a missing data 46 (31.3) 1 107 (39.1) 1 153 (36.3) 2
Consent refuseda 40 (87.0) 100 (93.5) 140 (91.5)
By resident 9 (22.5) 19 (19.0) 28 (20.0)
By Personal Consultee 10 (25.0) 33 (33.0) 43 (30.7)
By Nominated Consultee 21 (52.5) 48 (48.0) 69 (49.3)
Died 2 (4.3) 3 (2.8) 5 (3.3)
Unwilling to engage with researcher 1 (2.2) 2 (1.9) 3 (2.0)
No response from Personal Consultee 2 (4.3) 0 (0.0) 2 (1.3)
Transferred elsewhere 1 (2.2) 0 (0.0) 1 (0.7)
Other 1 (2.2) 2 (1.9) 3 (2.0)
Registered (out of those consented) 99 (99.0) 162 (97.6) 261 (98.1)
Not registered (out of those consented) missing data 1 (1.0) 0 3 (1.8) 1 4 (1.5) 1
Does not have formal diagnosis of dementia 1 (1.0) 0 (0.0) 1 (0.4)
Moved out of care home 0 (0.0) 1 (0.6) 1 (0.4)
Died 0 (0.0) 1 (0.6) 1 (0.4)
In hospital 0 (0.0) 1 (0.6) 1 (0.4)
a Categories are not mutually exclusive.
The percentages of the reasons that residents were ‘not eligible’, ‘not consented’ and ‘not registered’ were calculated out
of the total number of residents who were ‘not eligible’, ‘not consented’ and ‘not registered’, respectively.
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TABLE 29 Screening data: original and additional cohort, by hub
Characteristic
Original cohort (N= 1564) Additional residents (N= 877)a
Yorkshire
(N= 656)
London
(N= 419)
Oxford
(N= 489)
Total
(N= 1564)
Yorkshire
(N= 341)
London
(N= 230)
Oxford
(N= 306)
Total
(N= 877)
Age at
registration
(years), mean
(SD)
85.3 (8.00) 84.7 (8.43) 85.1 (8.20) 85.1 (8.18) 85.0 (7.64) 84.2 (8.65) 86.0 (8.11) 85.1 (8.10)
Length of
stay in care
home (years),
mean (SD)
2.1 (2.29) 2.4 (2.44) 2.5 (2.70) 2.3 (2.48) 1.4 (1.79) 1.7 (2.63) 1.7 (2.17) 1.6 (2.17)
Sex, number
of females
(%)
483 (73.6) 301 (71.8) 356 (72.8) 1140 (72.9) 248 (72.7) 164 (71.3) 213 (69.6) 625 (71.3)
Ethnicity, n (%)
White 642 (97.9) 367 (87.6) 474 (96.9) 1483 (94.8) 338 (99.1) 208 (90.4) 300 (98.0) 846 (96.5)
Other 7 (1.1) 40 (9.5) 8 (1.6) 55 (3.5) 0 (0.0) 20 (8.7) 5 (1.6) 25 (2.9)
Missing 7 (1.1) 12 (2.9) 7 (1.4) 26 (1.7) 3 (0.9) 2 (0.9) 1 (0.3) 6 (0.7)
Funding type, n (%)
Local
Authority
297 (45.3) 179 (42.7) 265 (54.2) 741 (47.4) 145 (42.5) 92 (40.0) 167 (54.6) 404 (46.1)
Continuing
health care
58 (8.8) 35 (8.4) 22 (4.5) 115 (7.4) 4 (1.2) 16 (7.0) 1 (0.3) 21 (2.4)
Self-funded 226 (34.5) 141 (33.7) 188 (38.4) 555 (35.5) 116 (34.0) 80 (34.8) 122 (39.9) 318 (36.3)
Local Authority
and self-funded
59 (9.0) 1 (0.2) 9 (1.8) 69 (4.4) 57 (16.7) 7 (3.0) 4 (1.3) 68 (7.8)
Missing 16 (2.4) 63 (15.0) 5 (1.0) 84 (5.4) 19 (5.6) 35 (15.2) 12 (3.9) 66 (7.5)
a Excluding those already participating in the trial and those who were screened at baseline but refused consent.
TABLE 30 Type of consent of registered residents
Person who gave consent
Original cohort, n (%) Additional residents, n (%)
Total (N= 726) Control (N= 99) Intervention (N= 162) Total (N= 261)
Resident 145 (20.0) 22 (22.2) 36 (22.2) 58 (22.2)
Personal Consultee 263 (36.2) 34 (34.3) 39 (24.1) 73 (28.0)
Nominated Consultee 318 (43.8) 43 (43.4) 87 (53.7) 130 (49.8)
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Staff and relative/friend
TABLE 31 Staff measures: SCIDS scores (total number of staff members who completed at least one SCIDS item)
Staff measures
Baseline 6 months 16 months
Control
(n= 86)
Intervention
(n= 260)
Total
(n= 346)
Control
(n= 84)
Intervention
(n= 112)
Total
(n= 196)
Control
(n= 50)
Intervention
(n= 132)
Total
(n= 182)
Total SCIDS score, mean (SD) missing data 53.2 (8.96) 1 53.7 (9.24) 5 53.6 (9.16) 6 55 (8.64) 1 53.5 (8.56) 2 54.1 (8.6) 3 58.4 (7.97) 1 56.8 (8.3) 1 57.2 (8.22) 2
Professionalism 16.7 (2.61) 0 17 (2.75) 4 16.9 (2.72) 4 17.2 (2.72) 3 16.8 (2.52) 2 17 (2.6) 5 18 (2.17) 1 17.6 (2.4) 2 17.7 (2.34) 3
Building relationships 11.7 (2.37) 0 11.8 (2.36) 4 11.8 (2.36) 4 12.3 (2.24) 0 11.9 (2.18) 1 12.1 (2.21) 1 13 (2.39) 1 12.6 (2.24) 1 12.7 (2.28) 2
Core challenges 11.9 (2.84) 1 11.9 (2.9) 6 11.9 (2.88) 7 12.2 (2.71) 1 12 (2.63) 3 12.1 (2.66) 4 13.6 (2.51) 1 12.9 (2.61) 1 13.1 (2.59) 2
Sustaining personhood 12.9 (2.31) 0 13 (2.43) 5 13 (2.39) 5 13.4 (2.27) 2 12.8 (2.47) 1 13.1 (2.4) 3 13.8 (1.96) 1 13.6 (2.11) 2 13.6 (2.07) 3
Number of booklets circulated to staff 525 1143 1668 546 848 1394 526 1108 1634
Overall SCIDS scores ranged from 17 to 68, with higher scores indicative of more confidence in delivering care to those with dementia.
TABLE 32 The QUALID scale: completed by relative/friend (among those that were registered at each time point)
QUALID
relative/proxy
Baseline 6 months 16 months (original cohort) 16 months (cross-sectional cohort)
Control
(n= 96)
Intervention
(n= 101)
Total
(n= 197)
Control
(n= 85)
Intervention
(n= 85)
Total
(n= 170)
Control
(n= 63)
Intervention
(n= 55)
Total
(n= 118)
Control
(n= 64)
Intervention
(n= 55)
Total
(n= 119)
Mean (SD)
missing data
22.5 (7.49) 14 21.6 (6.86) 20 22 (7.18) 34 21.6 (7.18) 23 22.1 (8.89) 20 21.8 (8.07) 43 23 (6.24) 25 23.1 (8.41) 24 23 (7.24) 49 23 (6.15) 25 23.1 (8.41) 24 23 (7.18) 49
Median
(interquartile
range)
21 (17–28) 21 (17–25) 21 (17–26) 20.9 (15–25) 20 (14.3–30) 20.9 (15–27) 23 (18–26) 22 (16.5–29) 22 (18–28) 23 (18–26) 22 (16.5–29) 22.5 (18–28)
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Intervention
TABLE 33 Compliance with intervention, by care home (using documented evidence and expert opinion for cycle 1)
Hub Care home Cycle 1 Cycle 2 Cycle 3
Number of cycles
completed to at least
an acceptable level
Number of cycles
completed to at
least a partial level
Yorkshire 1 Acceptable None None One cycle One cycle
2 None None None No cycles No cycles
3 Acceptable Acceptable None Two cycles Two cycles
8 None None None No cycles No cycles
9 Acceptable Partial None One cycle Two cycles
17 Acceptable Partial Partial One cycle Three cycles
24 Acceptable None None One cycle One cycle
32 Acceptable Acceptable None Two cycles Two cycles
33 Partial None None No cycles One cycle
34 None None None No cycles No cycles
38 Partial None None No cycles One cycle
44 Acceptable None None One cycle One cycle
48 Acceptable Acceptable Acceptable Three cycles Three cycles
Oxford 4 Acceptable None None One cycle One cycle
5 Acceptable Partial None One cycle Two cycles
6 Acceptable None None One cycle One cycle
11 Acceptable None None One cycle One cycle
12 Partial None None No cycles One cycle
14 Partial None None No cycles One cycle
16 Acceptable Acceptable Acceptable Three cycles Three cycles
23 Acceptable Partial Partial One cycle Three cycles
25 Acceptable Acceptable None Two cycles Two cycles
London 10 Acceptable None None One cycle One cycle
19 Acceptable None None One cycle One cycle
20 Acceptable Partial Partial One cycle Three cycles
26 Acceptable None None One cycle One cycle
31 Acceptable Acceptable None Two cycles Two cycles
39 Acceptable None None One cycle One cycle
40 Acceptable Acceptable Acceptable Three cycles Three cycles
42 Acceptable None None One cycle One cycle
47 Acceptable Acceptable Acceptable Three cycles Three cycles
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Briefing
TABLE 34 Summary of briefing sessions as documented, by cycle
Characteristic Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Number of formal sessions, n (%)
1 9 (29.0) 7 (22.6) 3 (9.7)
2 4 (12.9) 1 (3.2) 1 (3.2)
3 2 (6.5) 1 (3.2) 1 (3.2)
Missing 16 (51.6) 22 (71.0) 26 (83.9)
Length of formal sessions (minutes)
Mean (SD) missing data 71.7 (61.72) 16 66.9 (34.94) 23 93.8 (41.31) 27
Median (range) 40 (20–240) 60 (30–140) 97.5 (45–135)
Total number of staff members who attended
Mean (SD) missing data 10.1 (4.52) 18 15.8 (7.44) 23 18.0 (8.19) 28
Median (range) 10 (3–20) 14.5 (8–28) 20 (9–25)
Number of direct care staff members who attended
Mean (SD) missing data 11.4 (6.23) 26 15.3 (6.08) 27 14.0 (5.29) 28
Median (range) 13.0 (3.0–17.0) 13.5 (10.0–24.0) 16.0 (8.0–18.0)
Time between formal session and randomisation (months)
Mean (SD) missing data 2.8 (0.98) 16 8.7 (2.79) 23 13.5 (1.19) 26
Median (range) 2.7 (1.0–4.9) 8.1 (4.4–13.0) 13.6 (12.4–15.3)
Informal briefing sessions held, n (%) missing data
Yes 15 (48.4) 15 10 (32.3) 20 3 (9.7) 26
No 1 (3.2) 0 1 (3.2) 0 2 (6.5) 0
Number of staff informally briefed
Mean (SD) missing data 10.5 (7.51) 17 13.1 (10.89) 23 19.3 (1.15) 28
Median (range) 8.5 (2.0–30.0) 7.0 (4.0–31.0) 20.0 (18.0–20.0)
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FIGURE 7 Time between care home randomisation and briefing sessions.
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Observation
TABLE 35 Summary of observations as documented, by cycle
Characteristic Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Number of mappers who made observations, n (%)
1 1 (3.2) 1 (3.2) 1 (3.2)
2 18 (58.1) 10 (32.3) 4 (12.9)
Missing 12 (38.7) 20 (64.5) 26 (83.9)
Number of observation periods
Mean (SD) missing data 4.3 (2.05) 16 3.9 (1.89) 23 2.0 (0.00) 28
Median (range) 4 (2–8) 4 (2–8) 2 (2–2)
Time between first and last observation (days)
Mean (SD) missing data 3.0 (7.05) 13 4.5 (14.75) 20 0.0 (0.00) 26
Median (range) 0 (0–29) 0 (0–49) 0 (0–0)
Total mapping time (hours)
Mean (SD) missing data 8.9 (2.76) 16 9.4 (2.30) 23 7.8 (0.43) 28
Median (range) 9.2 (4.0–12.4) 9.9 (6.5–12.3) 8.0 (7.3–8.0)
Use of all codes, n (%) missing data
Yes 10 (32.3) 13 7 (22.6) 20 2 (6.5) 26
Total number of residents observed
Mean (SD) missing data 5.4 (1.79) 13 5.7 (2.41) 20 5.2 (1.79) 26
Median (range) 5 (2–8) 6 (2–10) 4 (4–8)
Number of residents observed with less than 3 hours of observations
Mean (SD) missing data 2.2 (1.72) 13 1.1 (2.39) 20 1.0 (1.41) 26
Median (range) 2 (0–5) 0 (0–8) 0 (0–3)
Number of residents observed with at least 3 hours of observations
Mean (SD) missing data 3.3 (1.81) 13 4.6 (2.06) 20 4.2 (1.48) 26
Median (range) 3 (0–6) 5 (2–8) 4 (2–6)
Percentage of residents observed with at least 3 hours of observations
Mean (SD) missing data 58.7 (33.75) 13 86.0 (25.13) 20 82.5 (24.37) 26
Median (range) 60 (0–100) 100 (20–100) 100 (50–100)
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TABLE 36 Observation quality, by cycle
Quality Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Two mappers completed at least 4 hours of observations over a 1-week period, n (%)
Yes, completed fully 13 (41.9) 7 (22.6) 3 (9.7)
Completed partially 6 (19.4) 4 (12.9) 2 (6.5)
Not completed 12 (38.7) 20 (64.5) 26 (83.9)
At least five residents observed in total with at least 3 hours of available data on each resident, n (%)
Yes, completed fully 2 (6.5) 4 (12.9) 1 (3.2)
Completed partially 16 (51.6) 7 (22.6) 4 (12.9)
Not completed 13 (41.9) 20 (64.5) 26 (83.9)
Mappers using all four of the coding frames and making at least minimal qualitative notes, n (%)
Yes, completed fully 9 (29.0) 5 (16.1) 2 (6.5)
Completed partially 9 (29.0) 6 (19.4) 3 (9.7)
Not completed 13 (41.9) 20 (64.5) 26 (83.9)
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Feedback
TABLE 37 Summary of feedback sessions as documented, by cycle
Characteristic Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Number of mappers participating in the feedback process, n (%)
1 1 (3.2) 2 (6.5) 0 (0)
2 13 (41.9) 7 (22.6) 3 (9.7)
Missing 17 (54.8) 22 (71.0) 28 (90.3)
Formal feedback sessions held, n (%) missing data
Yes 12 (38.7) 17 8 (25.8) 21 3 (9.7) 27
No 2 (6.5) 0 2 (6.5) 0 1 (3.2) 0
Total number of formal feedback sessions
Mean (SD) missing data 1.8 (0.83) 19 1.4 (0.79) 24 1.0 (0.00) 28
Median (range) 2 (1–3) 1 (1–3) 1 (1–1)
Total length of formal feedback sessions (hours)
Mean (SD) missing data 2.0 (2.26) 20 1.2 (0.67) 25 0.8 (0.29) 28
Median (range) 1.2 (0.5–8.4) 1.0 (0.5–2.3) 1.0 (0.5–1.0)
Time between first and last feedback session (days)
Mean (SD) missing data 2.8 (5.75) 19 1.3 (2.98) 24 0.0 (0.00) 28
Median (range) 0 (0–20) 0 (0–8) 0 (0–0)
Total number of staff members who attended formal feedback sessions
Mean (SD) missing data 9.6 (4.56) 19 12.3 (4.46) 25 12.3 (4.51) 28
Median (range) 9.0 (2–17) 11.5 (7–18) 12.0 (8–17)
Total number of direct care staff members who attended formal feedback sessions
Mean (SD) missing data 8.0 (2.65) 28 8.5 (2.12) 29 12.0 (–) 30
Median (range) 9 (5–10) 8.5 (7–10) 12 (12–12)
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TABLE 38 Care home and residents’ feedback points, by cycle
Characteristic Cycle 1 (n= 31) Cycle 2 (n= 31) Cycle 3 (n= 31)
Number of care home feedback points
Mean (SD) missing data 5.0 (3.06) 21 3.7 (1.21) 25 6.0 (5.72) 27
Median (range) 4.5 (2–13) 3 (3–6) 5.5 (0–13)
Total number of residents with feedback points
Mean (SD) missing data 4.4 (1.78) 19 4.2 (2.23) 25 3.5 (1.73) 27
Median (range) 4.5 (1–7) 5 (1–6) 4 (1–5)
Number of resident feedback points
Mean (SD) missing data 3.2 (2.12) 20 2.5 (0.93) 25 2.3 (0.96) 27
Median (range) 2.8 (0.8–7.8) 2.9 (1.0–3.3) 2.4 (1.3–3.3)
Cycle 1 to cycle 2 Cycle 2 to cycle 3
Percentage of achieved resident action plans set in previous cycle
Mean (SD) missing data 51.6 (41.75) 22 73.8 (43.38) 26
Median (range) 64.7 (0–100) 100.0 (0–100)
Percentage of achieved care home action plans set in previous cycle
Mean (SD) missing data 54.8 (44.72) 22 79.2 (25.00) 27
Median (range) 60.0 (0–100) 83.3 (50–100)
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Action-planning
TABLE 40 Action-planning quality, by cycle
Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Standard care home template used, n (%) missing data
Yes 13 (41.9) 18 6 (19.4) 25 3 (9.7) 27
No 0 (0) 0 (0) 1 (3.2)
Standard resident template used, n (%) missing data
Yes 12 (38.7) 18 6 (19.4) 25 2 (6.5) 28
No 1 (3.2) 0 (0) 1 (3.2)
At least one action point per observed resident, n (%) missing data
Yes 5 (16.1) 18 4 (12.9) 25 1 (3.2) 28
No 8 (25.8) 2 (6.5) 2 (6.5)
TABLE 39 Summary of action-planning as documented, by cycle
Characteristic Cycle 1 (N= 31) Cycle 2 (N= 31) Cycle 3 (N= 31)
Care home action plan received, n (%) missing data
Yes 13 (41.9) 12 6 (19.4) 20 4 (12.9) 26
No 6 (19.4) 5 (16.1) 1 (3.2)
Number of care home action points
Mean (SD) 4.9 (3.20) 18 5.2 (4.83) 25 5.0 (2.16) 27
Median (range) 4 (2–14) 3 (3–15) 4.5 (3–8)
Resident action plans received, n (%) missing data
Yes 13 (41.9) 12 6 (19.4) 20 3 (9.7) 26
No 6 (19.4) 5 (16.1) 2 (6.5)
Total number of residents with action points
Mean (SD) 5.5 (1.85) 18 5.8 (2.86) 25 4.7 (1.15)
Median (range) 5 (3–8) 5.5 (2–10) 4 (4–6)
Number of resident action points
Mean (SD) 2.0 (1.95) 18 2.0 (1.24) 25 1.8 (1.77) 28
Median (range) 1.6 (0.1–7.8) 2.2 (0.1–3.3) 1.3 (0.3–3.8)
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Resident deaths
TABLE 41 Resident deaths, by treatment arm
Deaths Control (N= 308) Intervention (N= 418) Total (N= 726)
Died, n (%) 111 (36.0) 161 (38.5) 272 (37.5)
Place of death, n (%)
Care home 89 (80.2) 135 (83.9) 224 (82.4)
Hospital 22 (19.8) 26 (16.1) 48 (17.6)
Percentage of deaths per care home at 16 months
Mean (SD) 36 (12.3) 39 (14.0) 37 (13.4)
Median (range) 41 (7–60) 36 (10–75) 36 (7–75)
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TABLE 42 Unadjusted CMAI-Oa and PASb summaries by time point: closed cohort
a.m., mean (SD) number completed p.m., mean (SD) number completed
Control (n= 308) Intervention (n= 418) Total (n= 726) Control (n= 308) Intervention (n= 418) Total (n= 726)
Baseline CMAI-O total score 31.1 (3.1) 184 30.5 (2.7) 266 30.8 (2.9) 450 32.0 (3.7) 198 31.5 (3.8) 272 31.7 (3.8) 470
Subscales
Aggressive behaviour 9.2 (0.6) 185 9.1 (0.5) 266 9.1 (0.6) 451 9.4 (1.1) 198 9.3 (1.0) 272 9.3 (1.1) 470
Physically non-aggressive 7.2 (1.8) 184 6.9 (1.7) 265 7.0 (1.8) 449 7.6 (2.1) 198 7.3 (2.0) 272 7.4 (2.0) 470
Verbally agitated 5.5 (1.3) 184 5.3 (0.9) 266 5.4 (1.1) 450 5.6 (1.4) 198 5.6 (1.6) 272 5.6 (1.6) 470
Other 9.3 (0.9) 184 9.2 (0.7) 266 9.2 (0.8) 450 9.4 (1.1) 198 9.3 (0.8) 272 9.3 (0.9) 470
6-month CMAI-O total score 31.1 (4) 159 31.3 (3.6) 209 31.2 (3.8) 368 31.6 (3.6) 151 32.0 (3.9) 206 31.8 (3.8) 357
Subscales
Aggressive behaviour 9.3 (1.0) 159 9.2 (0.6) 209 9.2 (0.8) 368 9.3 (0.9) 151 9.3 (0.8) 206 9.3 (0.9) 357
Physically non-aggressive 6.8 (1.8) 159 6.9 (1.8) 209 6.9 (1.8) 368 7.1 (2.0) 151 7.4 (2.0) 206 7.3 (2.0) 357
Verbally agitated 5.7 (1.7) 159 5.6 (1.7) 209 5.6 (1.7) 368 5.8 (1.7) 151 5.8 (1.9) 206 5.8 (1.8) 357
Other 9.4 (1.0) 159 9.6 (1.2) 209 9.5 (1.1) 368 9.4 (1.0) 151 9.5 (1.1) 206 9.5 (1.1) 357
16-month CMAI-O total score 31.2 (3.8) 102 30.4 (3.2) 129 30.7 (3.5) 231 31.3 (4.1) 97 31 (3.9) 124 31.1 (4.0) 221
Subscales
Aggressive behaviour 9.3 (1.1) 102 9.3 (1.0) 129 9.3 (1.0) 231 9.3 (1.2) 97 9.4 (1.3) 124 9.4 (1.3) 221
Physically non-aggressive 6.7 (1.5) 102 6.5 (1.5) 129 6.6 (1.5) 231 6.8 (1.5) 97 6.7 (1.9) 124 6.8 (1.8) 221
Verbally agitated 5.8 (2.2) 102 5.4 (1.4) 129 5.6 (1.8) 231 5.8 (2.0) 97 5.5 (1.5) 124 5.6 (1.7) 221
Other 9.4 (1.0) 102 9.2 (0.7) 129 9.3 (0.8) 231 9.4 (1.0) 97 9.3 (1.0) 124 9.4 (1.0) 221
Baseline PAS score 1.0 (1.5) 185 0.8 (1.5) 266 0.8 (1.5) 451 1.3 (1.6) 197 1.3 (2.2) 271 1.3 (2.0) 468
6-month PAS score 0.9 (1.9) 159 0.9 (1.4) 209 0.9 (1.7) 368 1.1 (1.9) 151 1.2 (1.8) 204 1.2 (1.8) 355
16-month PAS score 1.0 (1.8) 102 0.7 (1.6) 129 0.9 (1.7) 231 1.2 (2.1) 97 0.9 (1.9) 123 1.0 (2.0) 220
a CMAI-O score overall range: 29–116. A higher score indicates more frequent agitated behaviour.
b PAS score range: 0–16. A higher score represents higher levels of agitation.
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FIGURE 8 Graphical depiction of change in average CMAI scores in care homes (cross-sectional), by treatment arm
(16 months–baseline).
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FIGURE 9 Graphical depiction of change in CMAI scores (closed cohort), by treatment arm: (a) 16 months–baseline;
and (b) 6 months–baseline.
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TABLE 43 The CMAI-O and PAS summaries: unadjusted scores
Baseline, mean (SD) n 6 months, mean (SD) n 16 months (original cohort), mean (SD) n 16 months (cross-sectional cohort), mean (SD) n
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 287)
Intervention
(N= 388)
Total
(N= 675)
Total CMAI-O
score (a.m.) 31.1 (3.1) 184 30.5 (2.7) 266 30.8 (2.9) 450 31.1 (4) 159 31.3 (3.6) 209 31.2 (3.8) 368 31.2 (3.8) 102 30.4 (3.2) 129 30.7 (3.5) 231 31.1 (3.8) 156 30.5 (3.3) 209 30.8 (3.5) 365
CMAI-O subscales (a.m.)
Verbally agitated 5.5 (1.3) 184 5.3 (0.9) 266 5.4 (1.1) 450 5.7 (1.7) 159 5.6 (1.7) 209 5.6 (1.7) 368 5.8 (2.2) 102 5.4 (1.4) 129 5.6 (1.8) 231 5.8 (2.2) 156 5.5 (1.5) 209 5.6 (1.8) 365
Physically
non-aggressive
7.2 (1.8) 184 6.9 (1.7) 265 7 (1.8) 449 6.8 (1.8) 159 6.9 (1.8) 209 6.9 (1.8) 368 6.7 (1.5) 102 6.5 (1.5) 129 6.6 (1.5) 231 6.7 (1.4) 156 6.5 (1.5) 209 6.6 (1.4) 365
Other 9.3 (0.9) 184 9.2 (0.7) 266 9.2 (0.8) 450 9.4 (1) 159 9.6 (1.2) 209 9.5 (1.1) 368 9.4 (1) 102 9.2 (0.7) 129 9.3 (0.8) 231 9.3 (1) 156 9.2 (0.7) 209 9.2 (0.8) 365
Aggressive
behaviour
9.2 (0.6) 185 9.1 (0.5) 266 9.1 (0.6) 451 9.3 (1) 159 9.2 (0.6) 209 9.2 (0.8) 368 9.3 (1.1) 102 9.3 (1) 129 9.3 (1) 231 9.3 (0.9) 156 9.3 (1) 209 9.3 (1) 365
Total CMAI-O
score (p.m.) 32 (3.7) 198 31.5 (3.8) 272 31.7 (3.8) 470 31.6 (3.6) 151 32 (3.9) 206 31.8 (3.8) 357 31.3 (4.1) 97 31 (3.9) 124 31.1 (4) 221 31.4 (3.8) 148 31.1 (3.9) 206 31.2 (3.9) 354
Median
(interquartile
range)
31 (29–34) 30 (29–32.6) 30 (29–33) 30 (29–33) 30 (29–34) 30 (29–33) 29 (29–32) 29 (29–32) 29 (29–32) 29 (29–32) 29 (29–32) 29 (29–32)
CMAI-O subscales (p.m.)
Verbally agitated 5.6 (1.4) 198 5.6 (1.6) 272 5.6 (1.6) 470 5.8 (1.7) 151 5.8 (1.9) 206 5.8 (1.8) 357 5.8 (2) 97 5.5 (1.5) 124 5.6 (1.7) 221 5.8 (1.9) 148 5.7 (1.7) 206 5.7 (1.8) 354
Physically
non-aggressive
7.6 (2.1) 198 7.3 (2) 272 7.4 (2) 470 7.1 (2) 151 7.4 (2) 206 7.3 (2) 357 6.8 (1.5) 97 6.7 (1.9) 124 6.8 (1.8) 221 6.9 (1.5) 148 6.8 (1.9) 206 6.9 (1.8) 354
Other 9.4 (1.1) 198 9.3 (0.8) 272 9.3 (0.9) 470 9.4 (1) 151 9.5 (1.1) 206 9.5 (1.1) 357 9.4 (1) 97 9.3 (1) 124 9.4 (1) 221 9.3 (0.9) 148 9.3 (0.9) 206 9.3 (0.9) 354
Aggressive
behaviour
9.4 (1.1) 198 9.3 (1) 272 9.3 (1.1) 470 9.3 (0.9) 151 9.3 (0.8) 206 9.3 (0.9) 357 9.3 (1.2) 97 9.4 (1.3) 124 9.4 (1.3) 221 9.3 (1.1) 148 9.3 (1.2) 206 9.3 (1.1) 354
Total PAS score
(a.m.) 1 (1.5) 185 0.8 (1.5) 266 0.8 (1.5) 451 0.9 (1.9) 159 0.9 (1.4) 209 0.9 (1.7) 368 1 (1.8) 102 0.7 (1.6) 129 0.9 (1.7) 231 1.1 (1.9) 156 0.8 (1.7) 209 0.9 (1.8) 365
Total PAS score
(p.m.) 1.3 (1.6) 197 1.3 (2.2) 271 1.3 (2) 468 1.1 (1.9) 151 1.2 (1.8) 204 1.2 (1.8) 355 1.2 (2.1) 97 0.9 (1.9) 123 1 (2) 220 1.2 (1.9) 148 0.9 (1.8) 205 1 (1.8) 353
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TABLE 44 Supportive analysis assuming that missing data are MAR: closed cohort
Analysis
Adjusted mean
in control
Adjusted mean
in intervention
Estimated mean
difference 95% CI p-value
Adjusted ICC for
intervention
Adjusted ICC
for control n
6 months
CMAI score 43.44 44.04 0.59 –1.98 to 3.17 0.653 0.049 0.001 726
CMAI-O score (a.m.) 31.40 31.86 0.46 –0.37 to 1.30 0.276 0.019 0.000 726
CMAI-O score (p.m.) 31.64 32.20 0.57 –0.27 to 1.40 0.182 0.023 0.001 726
PAS score (a.m.) 1.04 1.18 0.14 –0.24 to 0.52 0.473 0.022 0.001 726
PAS score (p.m.) 1.05 1.23 0.18 –0.20 to 0.57 0.350 0.021 0.001 726
16 months
CMAI-O score (a.m.) 30.90 30.50 –0.40 –1.27 to 0.46 0.361 0.014 0.001 726
CMAI-O score (p.m.) 31.17 31.05 –0.13 –1.09 to 0.84 0.795 0.012 0.001 726
PAS score (a.m.) 0.91 0.79 –0.12 –0.52 to 0.28 0.547 0.008 0.001 726
PAS score (p.m.) 1.08 0.91 –0.17 –0.67 to 0.33 0.502 0.018 0.001 726
Sensitivity analyses
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TABLE 45 Primary and sensitivity analyses: complete cases, cross-section
Analysis
Estimated
mean in
control
Estimated
mean in
intervention
Estimated
mean
difference 95% CI p-value
Unadjusted ICC
for intervention
arm
Unadjusted
ICC for
control arm
Adjusted ICC
for intervention
arm
Adjusted
ICC for
control arm n
Primary analysis 45.52 43.33 –2.19 –4.81 to 0.43 0.099 0.0546 0.0002 0 0 666
Sensitivity analyses
Key sensitivity analysis 46.01 43.73 –2.28 –4.98 to 0.42 0.095 0.0497 0.007 666
1. Adjusting for before–after
eligibility change
44.85 42.65 –2.2 –4.82 to 0.43 0.099 0.0546 0.0002 0 0 666
2. Care home size as a
continuous variable
45.48 43.16 –2.32 –5.03 to 0.38 0.090 0.0546 0.0002 0 0 661
3. Assuming homogeneous
clustering across arms
45.45 43.30 –2.16 –4.75 to 0.43 0.100 0.0497 0 666
TABLE 46 Sensitivity analyses (4–5): CMAI, PAS and CMAI-O scores at 16 months – closed cohort, complete cases
Analysis
Estimated
mean in
control
Estimated
mean in
intervention
Estimated
mean
difference 95% CI p-value
Unadjusted ICC
for intervention
Unadjusted
ICC for
control
Adjusted ICC
for intervention
Adjusted
ICC for
control n
CMAI score 46.00 42.44 –3.57 –6.65 to –0.48 0.025 0.0779 0.0003 0.0261 0.002 400
PAS score (a.m.) 1.10 0.66 –0.44 –1.04 to 0.15 0.140 0.0882 0.0012 0.0031 0.0024 170
PAS score (p.m.) 1.40 0.75 –0.65 –1.4 to 0.09 0.084 0.2394 0.0108 0.2265 0.0151 174
CMAI-O score (a.m.) 31.08 30.04 –1.04 –2.25 to 0.17 0.089 0.1189 0.0009 0.0251 0.0079 169
CMAI-O score (p.m.) 31.42 30.71 –0.72 –2.12 to 0.69 0.310 0.0985 0.0003 0.0272 0.0018 176
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TABLE 47 The CMAI, CMAI-O and PAS scores at 6 months: closed cohort, complete cases
Analysis
Estimated
mean in
control
Estimated
mean in
intervention
Estimated
mean
difference 95% CI p-value
Unadjusted ICC
for intervention
Unadjusted
ICC for
control
Adjusted ICC
for intervention
Adjusted
ICC for
control n
CMAI score 43.32 43.73 0.41 –2.6 to 3.42 0.784 0.1356 0.011 0.0892 0 572
CMAI-O score (a.m.) 31.41 31.79 0.38 –0.66 to 1.42 0.468 0.09 0.0001 0.0418 0.0006 270
CMAI-O score (p.m.) 31.79 32.34 0.55 –0.73 to 1.83 0.393 0.121 0.0127 0.1445 0.0353 278
PAS score (a.m.) 0.90 1.08 0.18 –0.29 to 0.66 0.446 0.112 0.0018 0.0862 0.0022 268
PAS score (p.m.) 1.09 1.23 0.14 –0.42 to 0.7 0.621 0.1001 0 0.0779 0.0077 275
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TABLE 48 Sensitivity analysis (5): CMAI score at 16 months, closed-cohort (deaths and withdrawals assumed to be MNAR – two-way tipping point analysis)
Treatment-
effect
p-values
Deaths shifted by
–40 –35 –30 –25 –20 –15 –10 –5 0 5 10 15 20 25 30 35 40
Withdrawals and moves shifted by
–40 0.028* 0.025* 0.023* 0.022* 0.02* 0.019* 0.019* 0.018* 0.018* 0.018* 0.018* 0.019* 0.02* 0.021* 0.023* 0.025* 0.028*
–35 0.029* 0.027* 0.025* 0.023* 0.021* 0.02* 0.02* 0.019* 0.019* 0.019* 0.019* 0.02* 0.021* 0.022* 0.024* 0.026* 0.029*
–30 0.03* 0.028* 0.026* 0.024* 0.023* 0.022* 0.021* 0.02* 0.02* 0.02* 0.021* 0.021* 0.022* 0.024* 0.026* 0.028* 0.03*
–25 0.032* 0.03* 0.027* 0.026* 0.024* 0.023* 0.022* 0.022* 0.021* 0.021* 0.022* 0.023* 0.024* 0.025* 0.027* 0.029* 0.032*
–20 0.034* 0.031* 0.029* 0.027* 0.026* 0.024* 0.024* 0.023* 0.023* 0.023* 0.023* 0.024* 0.025* 0.027* 0.029* 0.031* 0.034*
–15 0.036* 0.033* 0.031* 0.029* 0.027* 0.026* 0.025* 0.025* 0.025* 0.025* 0.025* 0.026* 0.027* 0.029* 0.031* 0.033* 0.036*
–10 0.038* 0.036* 0.033* 0.031* 0.03* 0.028* 0.027* 0.027* 0.027* 0.027* 0.027* 0.028* 0.029* 0.031* 0.033* 0.036* 0.039*
–5 0.041* 0.038* 0.036* 0.034* 0.032* 0.031* 0.03* 0.029* 0.029* 0.029* 0.029* 0.03* 0.032* 0.033* 0.036* 0.038* 0.041*
0 0.044* 0.041* 0.038* 0.036* 0.034* 0.033* 0.032* 0.032* 0.031* 0.031* 0.032* 0.033* 0.034* 0.036* 0.038* 0.041* 0.044*
5 0.047* 0.044* 0.041* 0.039* 0.037* 0.036* 0.035* 0.034* 0.034* 0.034* 0.035* 0.036* 0.037* 0.039* 0.041* 0.044* 0.048*
10 0.05* 0.047* 0.045* 0.042* 0.04* 0.039* 0.038* 0.037* 0.037* 0.037* 0.038* 0.039* 0.041* 0.042* 0.045* 0.048* 0.051
15 0.054 0.051 0.048* 0.046* 0.044* 0.042* 0.041* 0.041* 0.041* 0.041* 0.041* 0.043* 0.044* 0.046* 0.049* 0.052 0.055
20 0.058 0.055 0.052 0.05* 0.048* 0.046* 0.045* 0.045* 0.044* 0.045* 0.045* 0.046* 0.048* 0.05* 0.053 0.056 0.06
25 0.062 0.059 0.056 0.054 0.052 0.05* 0.049* 0.049* 0.048* 0.049* 0.049* 0.051 0.052 0.055 0.057 0.061 0.065
30 0.067 0.064 0.061 0.058 0.056 0.055 0.054 0.053 0.053 0.053 0.054 0.055 0.057 0.059 0.062 0.066 0.07
35 0.072 0.069 0.066 0.063 0.061 0.06 0.058 0.058 0.058 0.058 0.059 0.06 0.062 0.064 0.067 0.071 0.075
40 0.077 0.074 0.071 0.068 0.066 0.065 0.064 0.063 0.063 0.063 0.064 0.065 0.067 0.07 0.073 0.077 0.081
*p < 0.05.
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TABLE 49 The NPI-NH scores at baseline: unadjusted scores
Scores
Number experiencing the behaviour, n (%)
number completed
Mean (SD) missing data
Frequency score Severity score Caregiver distress score Total domain score
Control
(N= 308)
DCM™
intervention
(N= 418) Total (N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Total score 308 (100) 417 (99.8) 725 (99.9) 3.4 (4.72) 0 3.2 (4.37) 0 3.3 (4.52) 0 13 (13.95) 0 11.7 (12.35) 0 12.2 (13.06) 0
Subscales
Delusions 59 (19.2) 308 69 (16.5) 417 128 (17.7) 725 2.7 (1.12) 0 2.7 (1.13) 2 2.7 (1.12) 2 1.8 (0.71) 0 1.8 (0.68) 2 1.8 (0.69) 2 1.9 (1.28) 1 1.5 (1.41) 3 1.7 (1.35) 4 5.3 (3.41) 0 4.9 (3.04) 2 5.1 (3.21) 2
Hallucinations 47 (15.3) 307 59 (14.2) 416 106 (14.7) 723 2.6 (1.04) 0 2.6 (1.04) 1 2.6 (1.04) 1 1.4 (0.58) 0 1.5 (0.63) 1 1.5 (0.61) 1 0.8 (0.91) 0 1.2 (1.25) 1 1 (1.13) 1 3.8 (2.46) 0 4.2 (2.83) 1 4 (2.66) 1
Agitation/
aggression
145 (47.1) 308 192 (46) 417 337 (46.5) 725 3 (0.95) 1 2.9 (0.94) 0 2.9 (0.95) 1 1.6 (0.67) 1 1.6 (0.69) 0 1.6 (0.68) 1 1.7 (1.23) 0 1.8 (1.28) 1 1.7 (1.25) 1 5 (2.85) 2 4.7 (2.86) 0 4.8 (2.85) 2
Depression/
dysphoria
92 (30) 307 129 (30.9) 418 221 (30.5) 725 2.6 (0.94) 0 2.3 (1.01) 1 2.4 (0.98) 1 1.5 (0.67) 0 1.4 (0.6) 2 1.5 (0.63) 2 1.3 (1.04) 0 1.1 (1.14) 1 1.2 (1.1) 1 4.1 (2.77) 0 3.6 (2.63) 2 3.8 (2.7) 2
Anxiety 80 (26) 308 98 (23.5) 417 178 (24.6) 725 2.8 (0.94) 2 2.6 (0.96) 3 2.7 (0.96) 5 1.7 (0.71) 2 1.5 (0.6) 3 1.6 (0.66) 5 1.6 (1.19) 2 1.5 (1.25) 3 1.6 (1.23) 5 5.2 (3.16) 2 3.9 (2.32) 3 4.5 (2.8) 5
Elation/
euphoria
25 (8.1) 308 34 (8.2) 416 59 (8.1) 724 2.6 (0.96) 0 2.8 (1.07) 0 2.7 (1.02) 0 1.3 (0.44) 1 1.5 (0.62) 0 1.4 (0.56) 1 0.4 (1) 0 0.7 (1.04) 0 0.6 (1.02) 0 3.4 (2.16) 1 4.4 (2.81) 0 4 (2.59) 1
Apathy/
indifference
91 (29.5) 308 130 (31.2) 417 221 (30.5) 725 3.1 (0.89) 1 3.1 (0.9) 1 3.1 (0.89) 2 1.6 (0.69) 1 1.6 (0.67) 1 1.6 (0.67) 2 0.8 (1.03) 1 0.8 (0.99) 1 0.8 (1.01) 2 5.4 (3.3) 1 5.2 (3.07) 1 5.3 (3.16) 2
Disinhibition 51 (16.6) 308 65 (15.6) 416 116 (16) 724 2.8 (1.05) 0 2.6 (0.94) 0 2.7 (0.99) 0 1.7 (0.71) 0 1.4 (0.61) 0 1.5 (0.67) 0 1.5 (1.3) 1 1.2 (1.15) 0 1.3 (1.22) 1 5 (3.29) 0 3.8 (2.62) 0 4.3 (2.97) 0
Irritability/
lability
117 (38) 308 153 (36.7) 417 270 (37.2) 725 2.9 (1.04) 3 2.7 (0.92) 0 2.8 (0.98) 3 1.7 (0.67) 3 1.5 (0.65) 0 1.6 (0.66) 3 1.7 (1.21) 4 1.3 (1.23) 0 1.5 (1.23) 4 5.3 (3.16) 3 4.4 (2.85) 0 4.8 (3.01) 3
Aberrant
motor
behaviour
94 (30.5) 308 135 (32.5) 416 229 (31.6) 724 3.6 (0.73) 0 3.4 (0.77) 0 3.5 (0.76) 0 1.6 (0.68) 0 1.6 (0.7) 0 1.6 (0.69) 0 1.1 (1.21) 0 1.1 (1.31) 0 1.1 (1.27) 0 5.9 (3) 0 5.7 (3.04) 0 5.8 (3.02) 0
Sleep and
night-time
behaviour
disorders
48 (15.6) 307 77 (18.4) 418 125 (17.2) 725 3.1 (0.78) 0 2.9 (0.95) 5 3 (0.89) 5 1.5 (0.65) 0 1.7 (0.74) 5 1.6 (0.71) 5 1.8 (1.39) 0 2 (1.43) 5 1.9 (1.42) 5 4.9 (2.64) 0 5 (2.73) 5 5 (2.68) 5
Appetite and
eating
changes
57 (18.5) 308 98 (23.6) 415 155 (21.4) 723 3.3 (0.85) 3 3.3 (0.79) 4 3.3 (0.81) 7 1.9 (0.63) 2 1.8 (0.72) 4 1.8 (0.69) 6 1.3 (1.18) 2 1.3 (1.19) 4 1.3 (1.18) 6 6.4 (2.92) 3 6.1 (3.26) 4 6.2 (3.13) 7
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TABLE 50 The NPI-NH scores at 6 months: unadjusted scores
Scores
Number experiencing the behaviour, n (%)
number completed
Mean (SD) missing data
Frequency score Severity score Caregiver distress score Total domain score
Control
(N= 308)
DCM™
intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Total score 244 (79.2) 320 (76.6) 564 (77.7) 3 (4.03) 0 2.4 (3.26) 0 2.6 (3.62) 0 11.3 (12.35) 0 9.7 (10.14) 0 10.4 (11.17) 0
Subscales
Delusions 33 (13.5) 245 42 (13.2) 319 75 (13.3) 564 2.5 (1) 2 2.4 (1.01) 0 2.4 (1) 2 1.7 (0.68) 2 1.7 (0.67) 0 1.7 (0.67) 2 1.7 (1.19) 2 1.6 (1.19) 0 1.6 (1.19) 2 4.7 (3.07) 2 4.3 (2.99) 0 4.4 (3.01) 2
Hallucinations 26 (10.6) 245 29 (9.1) 319 55 (9.8) 564 2.8 (0.88) 0 2.6 (0.98) 0 2.7 (0.94) 0 1.5 (0.71) 0 1.4 (0.57) 0 1.5 (0.63) 0 1.2 (1.12) 0 0.7 (0.84) 0 0.9 (1) 0 4.5 (2.72) 0 3.7 (1.91) 0 4.1 (2.34) 0
Agitation/
aggression
120 (49) 245 125 (39.2) 319 245 (43.4) 564 2.9 (0.89) 0 2.6 (0.94) 0 2.8 (0.93) 0 1.8 (0.71) 0 1.6 (0.66) 0 1.7 (0.69) 0 1.8 (1.17) 0 1.7 (1.2) 0 1.7 (1.18) 0 5.4 (3.24) 0 4.4 (2.62) 0 4.9 (2.98) 0
Depression/
dysphoria
63 (26) 242 101 (31.6) 320 164 (29.2) 562 2.4 (1.01) 0 2.4 (0.97) 1 2.4 (0.98) 1 1.4 (0.59) 0 1.4 (0.57) 1 1.4 (0.57) 1 1.2 (1.17) 0 0.9 (0.9) 1 1 (1.02) 1 3.7 (2.66) 0 3.5 (2.35) 1 3.6 (2.47) 1
Anxiety 47 (19.3) 244 57 (17.9) 319 104 (18.5) 563 2.7 (0.99) 2 2.5 (0.87) 1 2.6 (0.93) 3 1.6 (0.74) 2 1.5 (0.66) 1 1.6 (0.7) 3 1.6 (1.2) 2 1.2 (1.06) 1 1.4 (1.13) 3 4.6 (2.92) 2 4 (2.71) 1 4.3 (2.81) 3
Elation/
euphoria
15 (6.1) 244 19 (6) 319 34 (6) 563 2.8 (1.01) 0 2.4 (0.9) 0 2.6 (0.96) 0 1.4 (0.63) 0 1.3 (0.67) 0 1.4 (0.65) 0 0.3 (0.8) 0 0.3 (0.58) 0 0.3 (0.68) 0 4.3 (3.27) 0 3.4 (2.81) 0 3.8 (3.01) 0
Apathy/
indifference
73 (29.9) 244 116 (36.3) 320 189 (33.5) 564 3.1 (0.87) 1 2.8 (0.98) 1 2.9 (0.95) 2 1.7 (0.77) 1 1.5 (0.62) 1 1.6 (0.7) 2 0.7 (0.93) 1 0.7 (0.91) 1 0.7 (0.91) 2 5.7 (3.39) 1 4.3 (2.91) 1 4.9 (3.16) 2
Disinhibition 35 (14.3) 244 30 (9.4) 320 65 (11.5) 564 2.7 (1.07) 0 2.9 (0.88) 0 2.8 (0.99) 0 1.7 (0.67) 0 1.7 (0.83) 0 1.7 (0.74) 0 1.7 (1.39) 0 1.6 (1.45) 0 1.6 (1.41) 0 4.9 (3.08) 0 5.3 (3.44) 0 5.1 (3.23) 0
Irritability/
lability
83 (33.9) 245 99 (30.9) 320 182 (32.2) 565 2.6 (0.92) 0 2.7 (0.88) 0 2.7 (0.9) 0 1.6 (0.66) 0 1.6 (0.69) 0 1.6 (0.68) 0 1.5 (1.14) 0 1.3 (1.18) 1 1.4 (1.17) 1 4.5 (3.12) 0 4.4 (2.89) 0 4.5 (2.99) 0
Aberrant
motor
behaviour
71 (29.1) 244 90 (28.2) 319 161 (28.6) 563 3.4 (0.73) 0 3.4 (0.69) 0 3.4 (0.7) 0 1.6 (0.62) 0 1.7 (0.67) 0 1.7 (0.65) 0 1.1 (0.98) 0 1.1 (1.12) 0 1.1 (1.06) 0 5.6 (2.58) 0 6 (2.98) 0 5.8 (2.81) 0
Sleep and
night-time
behaviour
disorders
39 (15.9) 245 51 (16) 319 90 (16) 564 3 (1) 0 2.9 (0.97) 0 3 (0.98) 0 1.5 (0.79) 0 1.6 (0.66) 0 1.6 (0.72) 0 1.7 (1.28) 0 2 (1.26) 0 1.8 (1.27) 0 4.9 (3.55) 0 5 (3.01) 0 5 (3.24) 0
Appetite and
eating
changes
48 (19.6) 245 46 (14.4) 319 94 (16.7) 564 3.3 (0.7) 1 3.2 (0.88) 1 3.3 (0.79) 2 1.9 (0.62) 1 1.8 (0.63) 1 1.8 (0.62) 2 1.4 (1.21) 1 1.6 (1.3) 1 1.5 (1.25) 2 6.3 (2.87) 1 5.8 (2.71) 1 6 (2.79) 2
A
PPEN
D
IX
1
N
IH
R
Journals
Library
w
w
w
.journalslibrary.nihr.ac.uk
140
TABLE 51 The NPI-NH scores at 16 months, original cohort: unadjusted scores
Scores
Number experiencing the behaviour,
n (%) number completed
Mean (SD) missing data
Frequency score Severity score Caregiver distress score Total domain score
Control
(N= 308)
DCM™
(N= 418) (N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Control
(N= 308)
DCM
(N= 418)
Total
(N= 726)
Total score 185 (60.1) 222 (53.1) 407 (56.1) 1.8 (3.12) 0 1.6 (2.79) 0 1.7 (2.94) 0 10.4 (9.25) 0 7.7 (9.36) 0 8.9 (9.4) 0
Subscales
Delusions 18 (9.7) 185 20 (9) 222 38 (9.3) 407 2.8 (1.26) 0 2.6 (1.1) 0 2.7 (1.16) 0 1.7 (0.57) 0 1.5 (0.51) 0 1.6 (0.55) 0 0.9 (1.16) 0 1.5 (1.07) 1 1.2 (1.13) 1 5.2 (3.03) 0 3.9 (2.28) 0 4.5 (2.71) 0
Hallucinations 15 (8.1) 185 20 (9) 222 35 (8.6) 407 2.3 (1.18) 0 3 (1.08) 0 2.7 (1.15) 0 1.4 (0.63) 0 1.3 (0.44) 0 1.3 (0.53) 0 0.2 (0.41) 0 0.6 (0.82) 0 0.4 (0.7) 0 3.3 (2.32) 0 3.8 (1.99) 0 3.6 (2.12) 0
Agitation/
aggression
82 (44.3) 185 76 (34.2) 222 158 (38.8) 407 3 (0.92) 0 2.8 (1.02) 0 2.9 (0.97) 0 1.5 (0.55) 0 1.5 (0.64) 0 1.5 (0.59) 0 1.4 (1.17) 0 1.6 (1.17) 0 1.4 (1.17) 0 4.5 (2.3) 0 4.5 (3) 0 4.5 (2.65) 0
Depression/
dysphoria
63 (34.1) 185 55 (24.8) 222 118 (29) 407 2.6 (0.9) 1 2.5 (0.95) 1 2.5 (0.92) 2 1.3 (0.49) 1 1.2 (0.49) 1 1.3 (0.49) 2 0.6 (0.94) 1 0.6 (0.77) 1 0.6 (0.86) 2 3.5 (2.09) 1 3.1 (1.87) 1 3.3 (1.99) 2
Anxiety 29 (15.7) 185 34 (15.3) 222 63 (15.5) 407 2.9 (0.84) 0 2.7 (0.94) 1 2.8 (0.9) 1 1.5 (0.51) 0 1.5 (0.67) 1 1.5 (0.59) 1 1 (0.98) 0 1 (1.16) 1 1 (1.07) 1 4.5 (2.28) 0 4.4 (2.83) 1 4.4 (2.56) 1
Elation/
euphoria
7 (3.8) 185 14 (6.3) 222 21 (5.2) 407 3.1 (0.9) 0 2.6 (1.02) 0 2.8 (1) 0 1.3 (0.49) 0 1.2 (0.43) 0 1.2 (0.44) 0 0 (0) 0 0.2 (0.58) 0 0.1 (0.48) 0 4.1 (2.19) 0 3.3 (2.09) 0 3.6 (2.11) 0
Apathy/
indifference
73 (39.5) 185 62 (27.9) 222 135 (33.2) 407 3.3 (1.01) 0 3 (1) 0 3.2 (1.01) 0 1.6 (0.69) 0 1.6 (0.73) 0 1.6 (0.71) 0 0.4 (0.63) 0 0.5 (0.88) 0 0.4 (0.76) 0 5.5 (3.33) 0 5.2 (3.4) 0 5.3 (3.36) 0
Disinhibition 24 (13) 185 24 (10.8) 222 48 (11.8) 407 2.5 (1.04) 1 2.5 (1.14) 0 2.5 (1.08) 1 1.3 (0.47) 1 1.3 (0.56) 0 1.3 (0.52) 1 0.8 (1.03) 1 1.3 (1.3) 0 1.1 (1.19) 1 3.6 (2.43) 1 3.6 (2.59) 0 3.6 (2.48) 1
Irritability/
lability
65 (35.1) 185 66 (29.7) 222 131 (32.2) 407 3 (0.76) 0 2.6 (1.04) 0 2.8 (0.92) 0 1.5 (0.56) 0 1.4 (0.61) 0 1.5 (0.59) 0 1.2 (1.09) 0 1 (1.1) 0 1.1 (1.1) 0 4.5 (2.3) 0 4 (2.83) 0 4.2 (2.58) 0
Aberrant
motor
behaviour
54 (29.2) 185 38 (17.1) 222 92 (22.6) 407 3.4 (0.74) 0 3.5 (0.73) 1 3.4 (0.73) 1 1.4 (0.56) 0 1.5 (0.56) 2 1.4 (0.56) 2 0.5 (0.84) 0 0.9 (1.15) 2 0.7 (0.98) 2 4.7 (2.41) 0 5.2 (2.35) 2 4.9 (2.38) 2
Sleep and
night-time
behaviour
disorders
22 (11.9) 185 27 (12.2) 222 49 (12) 407 2.7 (1.08) 0 2.8 (1.03) 4 2.8 (1.04) 4 1.1 (0.35) 0 1.4 (0.59) 4 1.3 (0.51) 4 0.8 (1.01) 0 1.7 (1.47) 4 1.2 (1.32) 4 3.1 (1.58) 0 4 (2.1) 4 3.6 (1.9) 4
Appetite and
eating
changes
30 (16.2) 185 25 (11.3) 222 55 (13.5) 407 3 (0.96) 4 3.2 (0.77) 4 3.1 (0.88) 8 1.8 (0.61) 4 1.7 (0.78) 4 1.8 (0.69) 8 1.2 (1.23) 4 1.5 (0.93) 4 1.3 (1.11) 8 5.9 (2.96) 4 5.8 (3.22) 4 5.8 (3.05) 8
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intervention Total
TABLE 52 The NPI-NH scores at 16 months, cross-sectional cohort: unadjusted scores
Scores
Number experiencing the behaviour, n (%)
number completed
Mean (SD) missing data
Frequency score Severity score Caregiver distress score Total domain score
Control
(N= 287)
DCM™
intervention
(N= 388)
Total
(N= 675)
Control
(N= 287)
DCM
(N= 388)
Total
(N= 675)
Control
(N= 287)
DCM
(N= 388)
Total
(N= 675)
Control
(N= 287)
DCM
(N= 388)
Total
(N= 675)
Control
(N= 287)
DCM
(N= 388)
Total
(N= 675)
Total score 284 (99) 384 (99) 668 (99) 1.6 (2.86) 0 2 (3.77) 0 1.9 (3.41) 0 10 (10.46) 0 8.4 (10.25) 0 9.1 (10.36) 0
Subscales
Delusions 24 (8.5) 284 50 (13) 384 74 (11.1) 668 2.9 (1.26) 0 2.6 (1.13) 1 2.7 (1.17) 1 1.7 (0.62) 0 1.5 (0.62) 1 1.6 (0.62) 1 0.8 (1.1) 0 1.5 (1.15) 2 1.3 (1.17) 2 5.3 (3.28) 0 4 (2.66) 1 4.5 (2.92) 1
Hallucinations 29 (10.2) 284 37 (9.6) 384 66 (9.9) 668 2.5 (1.09) 0 2.8 (1.12) 0 2.7 (1.11) 0 1.5 (0.69) 0 1.3 (0.53) 0 1.4 (0.6) 0 0.4 (0.78) 0 0.8 (0.95) 0 0.6 (0.89) 0 3.9 (3) 0 3.8 (2.38) 0 3.8 (2.65) 0
Agitation/
aggression
116 (40.8) 284 141 (36.7) 384 257 (38.5) 668 3 (0.92) 0 2.9 (0.95) 2 2.9 (0.94) 2 1.5 (0.57) 0 1.5 (0.58) 1 1.5 (0.57) 1 1.3 (1.14) 0 1.6 (1.22) 2 1.4 (1.19) 2 4.7 (2.48) 0 4.7 (2.67) 2 4.7 (2.58) 2
Depression/
dysphoria
95 (33.5) 284 105 (27.3) 384 200 (29.9) 668 2.5 (0.94) 2 2.4 (0.96) 1 2.5 (0.95) 3 1.3 (0.53) 2 1.3 (0.52) 1 1.3 (0.52) 3 0.6 (0.92) 2 0.8 (1) 1 0.7 (0.96) 3 3.5 (2.35) 2 3.2 (2.03) 1 3.3 (2.19) 3
Anxiety 48 (17) 283 72 (18.8) 384 120 (18) 667 2.6 (0.98) 0 2.6 (0.95) 2 2.6 (0.96) 2 1.5 (0.62) 0 1.5 (0.61) 2 1.5 (0.61) 2 0.7 (0.96) 0 1.1 (1.22) 2 1 (1.14) 2 4 (2.45) 0 4 (2.57) 2 4 (2.51) 2
Elation/
euphoria
13 (4.6) 283 22 (5.7) 384 35 (5.2) 667 2.8 (0.93) 0 2.6 (0.9) 0 2.7 (0.9) 0 1.4 (0.51) 0 1.3 (0.55) 0 1.3 (0.53) 0 0 (0) 0 0.2 (0.5) 0 0.1 (0.4) 0 3.8 (1.88) 0 3.6 (2.61) 0 3.7 (2.34) 0
Apathy/
indifference
95 (33.5) 284 108 (28.1) 384 203 (30.4) 668 3.3 (1) 0 2.9 (1) 0 3.1 (1.01) 0 1.6 (0.71) 0 1.5 (0.65) 0 1.5 (0.68) 0 0.3 (0.63) 0 0.5 (0.85) 0 0.4 (0.76) 0 5.5 (3.41) 0 4.6 (3.06) 0 5 (3.25) 0
Disinhibition 35 (12.3) 284 42 (10.9) 384 77 (11.5) 668 2.7 (1.09) 1 2.6 (1.03) 0 2.6 (1.05) 1 1.3 (0.53) 1 1.5 (0.71) 0 1.4 (0.64) 1 0.7 (0.93) 1 1.5 (1.38) 0 1.2 (1.26) 1 3.8 (2.7) 1 4.4 (3.22) 0 4.1 (2.99) 1
Irritability/
lability
94 (33.1) 284 127 (33.1) 384 221 (33.1) 668 3 (0.84) 0 2.6 (0.96) 1 2.8 (0.93) 1 1.5 (0.58) 0 1.4 (0.57) 1 1.5 (0.58) 1 1.1 (1.05) 0 1.1 (1.13) 1 1.1 (1.09) 1 4.5 (2.44) 0 4 (2.66) 1 4.2 (2.58) 1
Aberrant
motor
behaviour
83 (29.2) 284 74 (19.3) 384 157 (23.5) 668 3.4 (0.8) 0 3.4 (0.72) 1 3.4 (0.76) 1 1.4 (0.59) 0 1.5 (0.58) 2 1.5 (0.58) 2 0.5 (0.85) 0 0.9 (1.15) 2 0.7 (1.01) 2 4.9 (2.53) 0 5.2 (2.54) 2 5.1 (2.53) 2
Sleep and
night-time
behaviour
disorders
28 (9.9) 284 49 (12.8) 384 77 (11.5) 668 2.9 (1.07) 1 2.8 (0.94) 5 2.9 (0.98) 6 1.2 (0.42) 1 1.5 (0.59) 5 1.4 (0.55) 6 0.8 (0.97) 1 1.7 (1.49) 5 1.4 (1.38) 6 3.7 (2.11) 1 4.3 (2.14) 5 4 (2.13) 6
Appetite and
eating
changes
41 (14.4) 284 44 (11.5) 384 85 (12.7) 668 3.1 (1.01) 7 3.3 (0.74) 4 3.2 (0.88) 11 1.9 (0.69) 7 1.6 (0.67) 4 1.7 (0.69) 11 1.1 (1.23) 7 1.4 (1.03) 4 1.3 (1.12) 11 6.1 (3.39) 7 5.3 (2.75) 4 5.7 (3.07) 11
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TABLE 53 Behaviours that staff may find challenging to support, medications and mood (based on NPI domains) at
6 months, closed cohort
Analyses Logistic regression models
Treatment odds
ratio (treated
control) 95% CI p-value n
BSC Complete cases only 0.941 0.598 to 1.479 0.7921 558
Missing data imputed assuming they are MAR 0.95 0.612 to 1.476 0.8196 726
Cluster specific – complete cases only 0.939 0.561 to 1.57 0.8088 558
Cluster specific – missing data imputed assuming
they are MAR
0.951 0.584 to 1.547 0.8381 726
PRN
antipsychotic
medication
Complete cases only 0.454 0.114 to 1.815 0.2640 581
Missing data imputed assuming they are MAR 0.455 0.093 to 2.236 0.3314 726
Complete cases only without hub 0.494 0.093 to 2.629 0.4084 581
Missing data imputed assuming they are MAR
without hub
0.533 0.095 to 2.997 0.4743 726
Mood
Depression/
dysphoria
Complete cases only 1.34 0.862 to 2.082 0.1932 558
Missing data imputed assuming they are MAR 1.32 0.872 to 1.999 0.1895 726
Anxiety Complete cases only 1.023 0.59 to 1.774 0.9343 558
Missing data imputed assuming they are MAR 1.011 0.617 to 1.656 0.9668 726
Apathy/
indifference
Complete cases only 1.319 0.79 to 2.2 0.2897 559
Missing data imputed assuming they are MAR 1.33 0.853 to 2.073 0.2075 726
TABLE 54 Behaviours that staff may find challenging to support, medications and mood (based on NPI domains) at
16 months, closed cohort
Analyses Logistic regression models
Treatment odds
ratio (treated
control) 95% CI p-value n
BSC Complete cases only 0.605 0.339 to 1.079 0.0886 403
Missing data imputed assuming they are MAR 0.57 0.343 to 0.948 0.0305 726
Cluster specific – complete cases only 0.591 0.308 to 1.133 0.1131 403
Cluster specific – missing data imputed assuming
they are MAR
0.577 0.334 to 0.996 0.0484 726
PRN
antipsychotic
medication
Complete cases only without hub 0.766 0.132 to 4.457 0.7666 406
Missing data imputed assuming they are MAR
without hub
0.783 0.114 to 5.368 0.8019 726
Mood
Depression/
dysphoria
Complete cases only 0.614 0.345 to 1.094 0.0980 404
Missing data imputed assuming they are MAR 0.592 0.369 to 0.95 0.0298 726
Anxiety Complete cases only 1.027 0.51 to 2.069 0.9395 403
Missing data imputed assuming they are MAR 1.037 0.588 to 1.83 0.9004 726
Apathy/
indifference
Complete cases only 0.601 0.322 to 1.124 0.1109 403
Missing data imputed assuming they are MAR 0.601 0.38 to 0.952 0.0302 726
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TABLE 55 Behaviours that staff may find challenging to support, medications and mood (based on NPI domains) at
16 months, cross-sectional sample
Analyses Logistic regression models
Treatment odds
ratio (treated
control) 95% CI p-value n
BSC Complete cases only 0.723 0.481 to 1.088 0.1198 668
Missing data imputed assuming they are MAR 0.720 0.479 to 1.083 0.1146 675
Cluster specific – complete cases only 0.683 0.4 to 1.166 0.1619 668
Cluster specific – missing data imputed assuming
they are MAR
0.681 0.4 to 1.158 0.1561 675
PRN
antipsychotic
medication
Complete cases only 1.166 0.127 to 10.688 0.892 413
Missing data imputed assuming they are MAR 1.28 0.153 to 10.685 0.8189 675
Mood
Depression/
dysphoria
Complete cases only 0.757 0.51 to 1.123 0.1666 668
Missing data imputed assuming they are MAR 0.757 0.511 to 1.123 0.1672 675
Anxiety Complete cases only 1.134 0.667 to 1.928 0.6422 667
Missing data imputed assuming they are MAR 1.133 0.67 to 1.916 0.6423 675
Apathy/
indifference
Complete cases only 0.81 0.525 to 1.249 0.3402 668
Missing data imputed assuming they are MAR 0.81 0.525 to 1.249 0.3403 675
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TABLE 56 Quality-of-life analysis: QUALID (relative/friend and staff), closed cohort
Analysis
Estimated mean
difference 95% CI p-value
Unadjusted ICC
for intervention
Unadjusted ICC
for control
Adjusted ICC
for intervention
Adjusted ICC
for control n
6 months
QUALID (staff) – complete cases only –0.62 –1.91 to 0.67 0.334 0.1357 0.0173 0.0627 0.0001 560
QUALID (staff) – missing data imputed
assuming they are MAR
–0.74 –1.91 to 0.43 0.214 0.129 0.005 0.035 0.001 726
16 months
QUALID (staff) – complete cases only –0.04 –1.24 to 1.16 0.948 0.0838 0.0064 0 0 404
QUALID (staff) – missing data imputed
assuming they are MAR
–0.07 –1.26 to 1.11 0.902 0.07 0.004 0.004 0 726
TABLE 57 Quality-of-life analysis: QUALID (relative/friend and staff), cross-sectional sample
Analysis at 16 months
Estimated mean
difference 95% CI p-value
Unadjusted ICC
for intervention
Unadjusted ICC
for control
Adjusted ICC
for intervention
Adjusted ICC
for control n
QUALID (staff) – complete cases only –0.06 –1.14 to 1.02 0.910 0.0788 0.0089 0.0119 0.0015 668
QUALID (staff) – missing data imputed
assuming they are MAR
–0.05 –1.12 to 1.02 0.922 0.082 0.01 0.015 0.002 675
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TABLE 58 Prescription of regular medications: closed-cohort at baseline and at 6 months
Medication
Baseline, n (% sample) 6 months, n (% sample)
Control (N= 308) Intervention (N= 418) Total (N= 726) Control (N= 308) Intervention (N= 418) Total (N= 726)
Antipsychotic medication 44 (14.3) 51 (12.2) 95 (13.1) 35 (11.4) 37 (8.9) 72 (9.9)
Benzodiazepine medication 20 (6.5) 21 (5.0) 41 (5.6) 14 (4.5) 14 (3.3) 28 (3.9)
Non-benzodiazepine anxiolytic medication 0 (0) 4 (1.0) 4 (0.6) 0 (0.0) 0 (0.0) 0 (0.0)
Non-benzodiazepine hypnotic medication 22 (7.1) 14 (3.3) 37 (5.1) 20 (6.5) 15 (3.6) 35 (4.8)
Memantine medication 26 (8.4) 28 (6.7) 54 (7.4) 21 (6.8) 27 (6.5) 48 (6.6)
Antidepressant medication 127 (41.2) 135 (32.3) 262 (36.1) 107 (34.7) 113 (27.0) 220 (30.3)
Cholinesterase inhibitor medication 47 (15.3) 61 (14.6) 108 (14.9) 40 (13.0) 54 (12.9) 94 (12.9)
Anticonvulsant medication 14 (4.5) 20 (4.8) 34 (4.6) 13 (4.2) 17 (4.1) 30 (4.1)
Mood stabiliser medication 1 (0.3) 2 (0.5) 3 (0.4) 1 (0.3) 4 (1.0) 5 (0.7)
Pain relief medication 143 (46.4) 213 (51.0) 356 (49.0) 105 (34.1) 160 (38.3) 265 (36.5)
Total number of medications prescribed on the medication record administration chart over the reporting period
Mean (SD) number taken/month 8.7 (4.3) 304 8.7 (4.01) 414 8.7 (4.13) 718 8.5 (3.73) 240 9.2 (4.4) 336 8.9 (4.15) 576
Median (Q1, Q3) 8 (6, 11) 8 (6, 11) 8 (6, 11) 8.5 (6, 11) 9 (6, 12) 9 (6, 12)
Frequencies are given out of those in the samples, assuming that the missing data reflect no prescriptions.
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TABLE 59 Prescription of regular medications: closed cohort and cross-sectional cohort at 16 months
Medication
Original cohort, n (% sample) Cross-sectional cohort, n (% sample)
Control (N= 308) Intervention (N= 418) Total (N= 726) Control (N= 287) Intervention (N= 388) Total (N= 675)
Antipsychotic medication 29 (9.4) 27 (6.5) 56 (7.7) 41 (14.3) 46 (11.9) 87 (12.9)
Benzodiazepine medication 11 (3.6) 9 (2.2) 20 (2.8) 18 (6.3) 14 (3.6) 32 (4.7)
Non-benzodiazepine anxiolytic medication 0 (0.0) 1 (0.2) 1 (0.1) 0 (0.0) 1 (0.3) 1 (0.1)
Non-benzodiazepine hypnotic medication 14 (4.5) 12 (2.9) 26 (3.6) 21 (7.3) 22 (5.7) 43 (6.4)
Memantine medication 17 (5.5) 21 (5.0) 38 (5.2) 31 (10.8) 44 (11.3) 75 (11.1)
Antidepressant medication 80 (26.0) 68 (16.3) 148 (20.4) 119 (41.5) 131 (33.8) 250 (37.0)
Cholinesterase inhibitor medication 28 (9.1) 33 (7.9) 61 (8.4) 50 (17.4) 71 (18.3) 121 (17.9)
Anticonvulsant medication 9 (2.9) 10 (2.4) 19 (2.6) 9 (3.1) 15 (3.9) 24 (3.6)
Mood stabiliser medication 1 (0.3) 0 (0.0) 1 (0.1) 2 (0.7) 0 (0.0) 2 (0.3)
Pain relief medication 84 (27.3) 121 (28.9) 205 (28.2) 140 (48.8) 201 (51.8) 341 (50.5)
Total number of medications prescribed on the MAR over the reporting period
Mean (SD) number taken/month 8.9 (3.82) 165 8.9 (4.61) 214 8.9 (4.28) 379 8.7 (3.71) 260 8.8 (4.74) 368 8.7 (4.34) 628
Median (Q1, Q3) 9 (6, 11) 8 (6, 12) 9 (6, 12) 9 (6, 11) 8 (5, 11) 8 (6, 11)
Frequencies are given out of those in the samples, assuming that the missing data reflect no prescriptions.
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TABLE 60 Administration of PRN medications by cohort and time point
Medication
Baseline, n (% sample) 6 months, n (% sample)
16 months (original cohort),
n (% sample)
16 months (cross-sectional cohort),
n (% sample)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 287)
Intervention
(N= 388)
Total
(N= 675)
Antipsychotic
medication
1 (0.3) 1 (0.2) 2 (0.3) 2 (0.6) 1 (0.2) 3 (0.4) 1 (0.3) 0 (0.0) 1 (0.1) 1 (0.3) 1 (0.3) 2 (0.3)
Benzodiazepine
medication
9 (2.9) 8 (1.9) 17 (2.3) 9 (2.9) 9 (2.2) 18 (2.5) 4 (1.3) 2 (0.5) 6 (0.8) 10 (3.5) 6 (1.5) 16 (2.4)
Non-benzodiazepine
anxiolytic medication
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Non-benzodiazepine
hypnotic medication
2 (0.6) 3 (0.7) 5 (0.7) 1 (0.3) 1 (0.2) 2 (0.3) 4 (1.3) 1 (0.2) 5 (0.7) 6 (2.1) 1 (0.3) 7 (1.0)
Anticonvulsant
medication
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mood stabiliser
medication
0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Pain relief medication 67 (21.8) 69 (16.5) 136 (18.7) 74 (24) 93 (22.2) 167 (23.0) 48 (15.6) 40 (9.6) 88 (12.1) 71 (24.7) 67 (17.3) 138 (20.4)
Frequencies are given out of those in the samples, assuming that the missing data reflect no administrations.
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TABLE 61 The QUIS summaries: unadjusted
All interactions (% positive)
missing data
Baseline 6 months 16 months
Control
(n= 19)
Intervention
(n= 31)
Total
(n= 50)
Control
(n= 19)
Intervention
(n= 31)
Total
(n= 50)
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
a.m. 0–15 minute interval 255 (75.3) 0 297 (83.8) 2 552 (79.9) 2 268 (89.2) 0 283 (91.9) 0 551 (90.6) 0 180 (86.7) 0 376 (83.5) 0 556 (84.5) 0
15–30 minute interval 288 (71.9) 0 334 (88.9) 2 622 (81) 2 250 (84) 0 271 (89.7) 0 521 (86.9) 0 165 (86.1) 0 254 (85.4) 0 419 (85.7) 0
30–45 minute interval 213 (68.5) 0 296 (85.1) 1 509 (78.2) 1 224 (88.4) 0 280 (88.6) 0 504 (88.5) 0 204 (86.3) 0 285 (81.8) 1 489 (83.6) 1
45–60 minute interval 264 (83.7) 0 303 (87.1) 1 567 (85.5) 1 258 (85.7) 0 226 (81.9) 0 484 (83.9) 0 231 (84) 0 276 (81.2) 1 507 (82.4) 1
p.m. 0–15 minute interval 298 (81.2) 0 317 (79.5) 2 615 (80.3) 2 217 (78.3) 0 341 (90) 0 558 (85.5) 0 211 (80.6) 0 324 (83) 0 535 (82.1) 0
15–30 minute interval 264 (75.4) 0 312 (76.9) 2 576 (76.2) 2 168 (81.5) 0 272 (86.8) 0 440 (84.8) 0 216 (80.6) 0 316 (81) 0 532 (80.8) 0
30–45 minute interval 246 (72.4) 0 291 (74.9) 1 537 (73.7) 1 188 (69.7) 0 319 (89.7) 0 507 (82.2) 0 200 (83) 0 256 (86.3) 0 456 (84.9) 0
45–60 minute interval 237 (67.9) 0 255 (76.1) 1 492 (72.2) 1 193 (70.5) 0 299 (88.6) 0 492 (81.5) 0 171 (83) 0 233 (89.3) 0 404 (86.6) 0
Both a.m.
and p.m.
0–15 minute interval 553 (78.5) 0 614 (81.6) 4 1167 (80.1) 4 485 (84.3) 0 624 (90.9) 0 1109 (88) 0 391 (83.4) 0 700 (83.3) 0 1091 (83.3) 0
15–30 minute interval 552 (73.6) 0 646 (83.1) 4 1198 (78.7) 4 418 (83) 0 543 (88.2) 0 961 (86) 0 381 (82.9) 0 570 (83) 0 951 (83) 0
30–45 minute interval 459 (70.6) 0 587 (80.1) 2 1046 (75.9) 2 412 (79.9) 0 599 (89.1) 0 1011 (85.4) 0 404 (84.7) 0 541 (83.9) 1 945 (84.2) 1
45–60 minute interval 501 (76.2) 0 558 (82.1) 2 1059 (79.3) 2 451 (79.2) 0 525 (85.7) 0 976 (82.7) 0 402 (83.6) 0 509 (84.9) 1 911 (84.3) 1
All interactions 2065 (74.9) 0 2405 (81.7) 1 4470 (78.6) 1 1766 (81.7) 0 2291 (88.6) 0 4057 (85.6) 0 1578 (83.7) 0 2320 (83.7) 0 3898 (83.7) 0
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TABLE 62 Care home CDR summaries
Scores
Baseline 6 months 16 months (original cohort) 16 months (cross-sectional cohort)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 308)
Intervention
(N= 418)
Total
(N= 726)
Control
(N= 287)
Intervention
(N= 388)
Total
(N= 675)
Global CDR score categories, n (%)
0 1 (0.3) 2 (0.5) 3 (0.4) 0 (0.0) 1 (0.2) 1 (0.1) 0 (0.0) 1 (0.2) 1 (0.1) 0 (0.0) 1 (0.3) 1 (0.1)
0.5 17 (5.5) 23 (5.5) 40 (5.5) 6 (1.9) 7 (1.7) 13 (1.8) 5 (1.6) 0 (0.0) 5 (0.7) 11 (3.8) 6 (1.5) 17 (2.5)
1 79 (25.6) 101 (24.2) 180 (24.8) 37 (12.0) 77 (18.4) 114 (15.7) 27 (8.8) 49 (11.7) 76 (10.5) 55 (19.2) 101 (26.0) 156 (23.1)
2 111 (36.0) 160 (38.3) 271 (37.3) 110 (35.7) 145 (34.7) 255 (35.1) 54 (17.5) 89 (21.3) 143 (19.7) 90 (31.4) 151 (38.9) 241 (35.7)
3 98 (31.8) 130 (31.1) 228 (31.4) 92 (29.9) 92 (22.0) 184 (25.3) 99 (32.1) 83 (19.9) 182 (25.1) 128 (44.6) 125 (32.2) 253 (37.5)
Missing 2 (0.6) 2 (0.5) 4 (0.6) 63 (20.5) 96 (23.0) 159 (21.9) 123 (39.9) 196 (46.9) 319 (43.9) 3 (1.0) 4 (1.0) 7 (1.0)
Global CDR score
Mean (SD)
missing data
1.97 (0.85) 2 1.98 (0.84) 2 1.98 (0.84) 4 2.19 (0.74) 63 2.01 (0.77) 96 2.09 (0.76) 159 2.35 (0.79) 123 2.14 (0.77) 196 2.24 (0.79) 319 2.2 (0.83) 3 2.03 (0.8) 4 2.1 (0.82) 7
Median
(interquartile
range)
2 (1–3) 2 (1–3) 2 (1–3) 2 (2–3) 2 (1–3) 2 (2–3) 3 (2–3) 2 (2–3) 2 (2–3) 2 (2–3) 2 (1–3) 2 (1–3)
Subscales, mean (SD) missing data
Memory (primary
category)
1.95 (0.81) 2 1.91 (0.84) 2 1.93 (0.83) 4 2.23 (0.73) 63 2.03 (0.75) 96 2.12 (0.75) 159 2.34 (0.7) 123 2.14 (0.76) 196 2.23 (0.74) 319 2.21 (0.78) 3 2.04 (0.79) 4 2.11 (0.79) 7
Orientation 1.98 (0.86) 1 1.87 (0.93) 3 1.92 (0.9) 4 2.17 (0.78) 63 1.96 (0.86) 95 2.05 (0.83) 158 2.32 (0.79) 124 2.12 (0.82) 196 2.21 (0.81) 320 2.2 (0.85) 4 2.02 (0.86) 4 2.1 (0.86) 8
Judgement and
problem solving
1.85 (0.91) 2 1.89 (0.95) 3 1.88 (0.93) 5 2.12 (0.83) 63 1.95 (0.87) 92 2.03 (0.86) 155 2.29 (0.83) 123 2.12 (0.84) 196 2.2 (0.84) 319 2.14 (0.88) 3 1.98 (0.87) 4 2.05 (0.87) 7
Community
affairs
1.86 (0.76) 0 1.9 (0.78) 2 1.88 (0.77) 2 2.04 (0.64) 64 1.95 (0.68) 90 1.99 (0.66) 154 2.17 (0.67) 123 2.09 (0.69) 196 2.13 (0.68) 319 2.07 (0.69) 3 2 (0.72) 4 2.03 (0.71) 7
Home and
hobbies
1.79 (0.87) 0 1.86 (0.85) 3 1.83 (0.86) 3 2.09 (0.75) 63 1.94 (0.77) 90 2 (0.77) 153 2.15 (0.82) 123 2.04 (0.76) 196 2.09 (0.79) 319 2.02 (0.84) 3 1.92 (0.79) 4 1.96 (0.81) 7
Personal care 2.29 (0.86) 2 2.3 (0.83) 1 2.3 (0.84) 3 2.36 (0.8) 63 2.45 (0.72) 90 2.41 (0.76) 153 2.59 (0.74) 123 2.55 (0.68) 196 2.57 (0.71) 319 2.41 (0.9) 3 2.39 (0.82) 5 2.4 (0.85) 8
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TABLE 63 Care home EAT summaries
Total EAT score (%)
Baseline 6 months 16 months
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Mean (SD) missing data 53.5 (9.17) 1 53 (10.26) 2 53.2 (9.76) 3 58.9 (6.04) 4 52.9 (8.57) 3 55 (8.22) 7 54.7 (9.28) 3 55.3 (8.52) 4 55.1 (8.7) 7
Median (interquartile range) 53.2 (47.2–62.3) 52.5 (46–61) 52.9 (46.1–62.3) 61.5 (56.5–63.3) 52.1 (46.6–61) 56.5 (48.2–62.5) 55.2 (48.4–62.3) 55.8 (51.3–60.7) 55.8 (49.8–60.7)
Subscales, mean (SD) missing data
Safety 47.8 (13.83) 0 48.4 (16.08) 1 48.2 (15.1) 1 52.8 (16.68) 0 57.9 (13.56) 0 56 (14.86) 0 59.3 (14.58) 0 56.2 (16.28) 0 57.4 (15.57) 0
Size 30.7 (23.74) 0 23.9 (24.64) 1 26.5 (24.28) 1 29.8 (21.93) 0 19.9 (26.67) 0 23.7 (25.22) 0 33.3 (27.78) 0 22.8 (27.85) 1 26.9 (28.02) 1
Visual access features 23.1 (11.52) 0 25.4 (12.88) 1 24.5 (12.3) 1 19.6 (12.13) 1 21.2 (13.41) 1 20.6 (12.84) 2 17.6 (12.38) 0 24.1 (15.55) 0 21.6 (14.65) 0
Highlighting useful stimuli 91.8 (13.65) 0 86.3 (13.59) 1 88.4 (13.74) 1 89.5 (13.97) 0 89.1 (11.52) 0 89.2 (12.37) 0 91.3 (10.8) 0 93 (9.02) 0 92.4 (9.66) 0
Wandering 48.5 (35.95) 0 45.6 (38.08) 1 46.7 (36.92) 1 66 (32.27) 2 43.1 (38.02) 2 51.6 (37.34) 4 52.3 (33.05) 2 53.9 (30.81) 0 53.4 (31.27) 2
Familiarity 71.1 (16.74) 0 74.4 (24.44) 1 73.2 (21.65) 1 73.5 (16.09) 0 80.2 (12.82) 0 77.7 (14.38) 0 70.4 (18.87) 0 79.6 (16.02) 1 76 (17.58) 1
Privacy and community 76.6 (19.13) 0 81.5 (14.25) 1 79.6 (16.3) 1 77.1 (20) 0 75.8 (18.83) 0 76.3 (19.09) 0 76.8 (23.54) 0 72.2 (18.17) 0 73.9 (20.27) 0
Community links 51.3 (48.93) 0 48.3 (49.97) 1 49.5 (49.08) 1 69.4 (42.49) 1 46.8 (49.89) 0 55.1 (48.14) 1 36.8 (46.67) 0 46.7 (50.74) 1 42.9 (48.95) 1
Domestic activity 35 (9.36) 1 33.2 (11.43) 2 33.9 (10.62) 3 35.9 (11.62) 0 32.5 (11.46) 0 33.8 (11.52) 0 34.9 (10.22) 0 33.1 (10.19) 0 33.8 (10.14) 0
TABLE 64 The GLHC summaries
Total GLHC score
Baseline 6 months 16 months
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Control
(n= 19)
Intervention
(n= 31) Total (n= 50)
Mean (SD) missing data 32.2 (4.09) 0 31.1 (4.19) 2 31.5 (4.14) 2 29.9 (5.13) 0 30.2 (5.25) 0 30.1 (5.15) 0 29.9 (3.91) 0 30.8 (4.29) 0 30.4 (4.13) 0
Median (interquartile range) 31 (28.5–36) 31 (28–33) 31 (28–35.2) 29 (26–34) 30 (27–33) 29.5 (26.5–33) 29 (27–34) 31 (27–34) 31 (27–34)
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Health economic analysis
TABLE 65 Resource use: complete-case samplea
Health-care
resource item Month
Intervention Control
n Mean SD Minimum Maximum n Mean SD Minimum Maximum
Primary care
GP face-to-face visit 0 214 1.61 2.17 0 12 175 1.54 1.63 0 8
6 214 1.31 2.10 0 13 175 1.46 1.69 0 8
16 214 0.84 1.43 0 8 175 0.93 1.69 0 9
GP telephone call 0 214 0.72 1.62 0 12 175 0.71 1.24 0 6
6 214 0.49 0.99 0 5 175 0.39 0.92 0 7
16 214 0.36 0.89 0 5 175 0.29 0.71 0 4
District nurse visit 0 214 1.22 7.02 0 90 175 1.79 5.29 0 43
6 214 0.36 1.24 0 13 175 1.53 4.88 0 41
16 214 0.75 3.44 0 39 175 0.57 2.68 0 27
District nurse
telephone call
0 214 0.08 0.44 0 3 175 0.13 0.44 0 2
6 214 0.03 0.19 0 2 175 0.14 0.53 0 4
16 214 0.03 0.24 0 2 175 0.13 1.25 0 16
Secondary care
Nights spent in
hospital
0 214 0.72 4.06 0 43 175 0.66 3.81 0 37
6 214 0.64 3.02 0 28 175 0.29 1.58 0 15
16 214 0.14 1.14 0 12 175 0.01 0.08 0 1
Hospital day centre
visit
0 214 0.01 0.10 0 1 175 0.02 0.13 0 1
6 214 0.00 0.07 0 1 175 0.00 0.00 0 0
16 214 0.00 0.07 0 1 175 0.03 0.20 0 2
Hospital outpatient
clinic visit
0 214 0.14 0.61 0 7 175 0.14 0.46 0 4
6 214 0.08 0.27 0 1 175 0.06 0.31 0 3
16 214 0.07 0.35 0 3 175 0.01 0.15 0 2
Hospital A&E visit 0 214 0.15 0.83 0 11 175 0.10 0.39 0 2
6 214 0.07 0.27 0 2 175 0.06 0.29 0 2
16 214 0.01 0.12 0 1 175 0.01 0.08 0 1
a Values represent resource use in the previous month only and are extrapolated for the whole trial period.
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TABLE 66 Maina unit costs
Resource item Unit cost (£) Assumptions and source
Advanced nurse practitioner 77.24 Reference Costs 2015–16146
Advanced nurse practitioner (telephone) 33.08 Reference Costs 2015–16146
Counsellor 62.03 PSSRU 2011/12168
District nurse 37.98 Reference Costs 2015–16146
District nurse (telephone) 16.16 Reference Costs 2015–16146
GP 132.69 PSSRU 2009/10169
GP (telephone) 28.39 PSSRU 2014/15170
Health visitor 64.81 Reference Costs 2015–16146
Health visitor (telephone) 26.38 Reference Costs 2015–16146
Hospital A&E 137.74 Reference Costs 2015–16146
Hospital outpatient clinic 136.79 Reference Costs 2015–16146
Hospital overnight stay 464.83 Reference Costs 2015–16146
Member of community health team 43.00 PSSRU 2015/16144
Physiotherapist 48.94 Reference Costs 2015–16146
Psychiatrist or psychologist 142.98 PSSRU 2011/12168
Social worker 39.50 PSSRU 2015/16144
Speech and language therapist 88.02 Reference Costs 2015–16146
a Main resource use items only. The unit costs for resources that are used less frequently are available on request.
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Appendix 2 Summary of substantial amendments
Summary of substantial amendments to trial
Substantial amendment 1: approved 10 January 2014
Collection of data from medical records/the Health and Social Care Information Centre
(now NHS Digital)
The proposed plan for collection of resource use data (prescription medication usage and repeat hospital
attendances/admissions/safety data) was to obtain all of the required information from a review of each
resident’s care home records. Having undertaken some consultation with other researchers doing care home
research and collecting similar data, we have been informed that these data are often incomplete/ambiguous
and so further clarification needs to be sought from residents’ medical records.
To minimise missing data and to ensure a meaningful data set is obtained, we therefore propose to amend
section 13.5.5 of the protocol and the following participant information and consent/declaration forms to
include consent for researchers to access residents’ medical records [either via direct searching or remotely,
via the Health and Social Care Information Centre (now NHS Digital)]:
l resident information sheet
l short form of resident information sheet
l resident consent form
l Personal Consultee declaration form
l Nominated Consultee declaration form.
Full NHS research and development permissions will be obtained from the relevant trusts and the study
researchers will apply for research passports and approval to access these notes.
Substantial amendment 2: approved 22 April 2014
Changes to the care home information sheet
The care home information sheet has been amended to incorporate comments following the PPI review.
The content has also been updated to correct inaccuracies and to provide additional information and
clarification regarding trial processes.
Amendments to the approved document are highlighted using tracked changes. The following is a brief
summary of the key changes:
l clarification of the abbreviated title – ‘The EPIC trial’
l the addition of the trade mark (DCM™) throughout
l clarification of ‘What will happen in the study’
¢ care home selection
¢ confirming care home eligibility
¢ participant consent
¢ care home allocation
¢ DCM training
¢ data collection – researcher interview/questionnaires
l clarification of ‘What do I do if I am interested in taking part?’.
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Substantial amendment 3: approved 26 June 2014
Protocol amendments
Updated care home selection process
The proposed plan for care home selection has been revised during consultations with the statistical team
and researchers who are experienced in recruitment in the care home setting to minimise the burden on
care home staff. To maximise response rates while retaining a representative sample of care homes in an
attempt to maximise the generalisability of trial results, we propose to amend section 7.2 of the protocol
to incorporate the following key changes:
l Care homes within the hub catchment area are screened for eligibility and randomly ordered for
subsequent contact.
l Invitation information is sent to ordered samples of eligible care homes.
l Researchers contact all of the invited care homes (via telephone) to determine their interest –
the care home reply slip is no longer required.
l If interested care homes will complete the eligibility assessments via researcher interview, the eligibility
screening questionnaire is no longer required.
Eligibility criteria
English proficiency Following discussions with the TMG and the TSC, we intend to update the eligibility
criteria for residents, staff (completing staff measures only) and residents’ relatives/friends to include the
following: ‘Has sufficient proficiency in English to contribute to the data collection required for the research.’
We propose this change for staff completing staff measures, as this questionnaire will be self-completed by
members of staff with no assistance from trial researchers. Therefore, to ensure that staff understand the
questions being asked, they must have sufficient proficiency in written English. Validated translations of
assessments are also not available; therefore, the TMG agreed that it was not appropriate to use translated
versions because of the potential impact on the validity of the data collected. Consultation with care home
managers and staff suggested that the majority of staff working within UK care homes should have
sufficient English proficiency as a requirement for employment.
The proposed change has been suggested for residents and their relatives/friends (if applicable), as
assessments are completed via researcher interview; therefore, sufficient English proficiency is required to
develop a meaningful dialogue. It was deemed infeasible by the TMG/TSC for translated discussions to be
both available and accurate.
Proxy informant As outlined in the protocol, the primary outcome for analysis is based on completion of
the CMAI by a proxy informant (staff member). Therefore, we propose to update section 8 of the protocol
to incorporate the following inclusion criteria for residents: ‘Has an allocated member of staff willing to
provide proxy data.’
Screening questionnaires Proxy informants (staff and relatives/friends) were initially required to
demonstrate their willingness to participate by completing and returning a screening questionnaire.
However, following a review of the process, the TMG have confirmed that it would be more appropriate
to collect proxy informant data via researcher interview. It is hoped that this will decrease the burden on
proxy informants and increase responses. We therefore propose to amend the relevant section of the
protocol (sections 10.1–10.2).
Mutually exclusive roles The protocol outlines roles that staff members can undertake within the trial
and highlights any that are mutually exclusive (e.g. a mapper cannot act as a proxy informant). However,
to clarify this further, we propose to update the exclusion criteria by role to ensure that eligibility is assessed
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ahead of consent. This update will also clarify that a Nominated Consultee (staff member) cannot actively
participate in the trial in any way (e.g. providing staff or proxy measures).
Translation of trial documentation (information sheets/questionnaires)
Following consultation with the TMG and suggested updates regarding sufficient English proficiency, the
TMG agreed that translation of trial documentation would no longer be required. Discussions regarding
the variety of translations required by region (hub) also suggested that this process would not be feasible.
Therefore, references to translation of materials have been removed from the protocol.
Data collection/assessments
Assessments We propose to amend data collection assessments used within the trial, following a review
with the TMG, as summarised below:
l DEMQOL is to be replaced with QOL-AD: the TMG agreed that this was more appropriate to the
trial population.
l Caring Efficacy Scale is to be replaced with SCIDS: the TMG agreed that this was more appropriate to
the trial population.
l Bristol Activities of Daily Living Scale is to be removed: TMG agreed that it is not appropriate to collect
this in the trial population.
The overall quantity of data to be collected, and therefore the perceived participant burden, remain the same.
Completion of assessments (Pittsburgh Agitation Scale/Quality of Interactions Schedule)
The proposed plan for collection of independent assessments (PAS/QUIS) suggested that the PAS and
QUIS would be completed on a random 25% of registered residents. However, as these assessments are
completed following observations made within communal areas, the TMG agreed that it would not be
appropriate to restrict observations to a random sample of residents, because if they were not available
within communal areas at the time of observation, the data collection could not be completed, affecting
the integrity of the data for analysis. Thus, it was agreed that PAS/QUIS data would be collected for all
registered residents. The protocol has been updated to incorporate these changes.
Monitoring: recording sessions
Dementia Care Mapping intervention: feedback sessions The protocol outlines the recording
sessions planned for DCM feedback sessions within a sample (a minimum of 10 care homes) of randomised
care homes (n = 30). Following discussions with DCM experts, it was agreed that the feasibility and
accuracy of a standardised review would not be sufficiently robust and therefore it should not be
undertaken. Therefore, we propose to update section 12.7 of the protocol to remove references to
audio recording.
Withdrawal
Proxy informant: relative/friend We propose to amend the planned process for data collection
following relative/friend withdrawal. The protocol currently suggests that, in the event of a relative/friend
withdrawing, researchers would encourage the continuation of a subset of assessments. However,
following a review with the statistical team, discussions concluded that this process would not be feasible
and does not have a significant impact on the validity of the data for analysis. Therefore, we propose to
amend section 12.12 of the protocol to outline that, in the event of a relative/friend withdrawing, a new
proxy informant will be identified to complete all assessment measures.
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Resident safety Following consultation with the trial DMEC, we propose changes to the protocol to
ensure that sufficient safety data are collected for ongoing safety monitoring. The proposed changes
include:
l proactive (monthly) reporting of adverse events that fulfil the SAE criteria (i.e. hospitalisation)
l an annual summary of hospitalisations for registered residents collected from the Health and Social
Care Information Centre.
Suggested amendments to safety reporting have been reviewed by external experts (DMEC/TSC) to ensure
that reporting is commensurate with the risk for this population in the context of this trial.
Data Monitoring Ethics Committee
In accordance with guidance from the trial funder (NIHR HTA programme), a trial DMEC has been established
and responsibilities have been agreed. We therefore propose changes to the protocol to incorporate the DMEC.
Participant information sheet and informed consent form amendments
Study title
Following consultation with PPI groups and experts by experience, the TMG have agreed to amend the
study title in publicly available information to remove the acronym ‘DCM’ (Dementia Care Mapping).
We therefore include information sheets and consent forms with the title amended throughout.
Participant consent
Mapper We propose to add an additional statement to the mapper consent form to reference the DCM
training course schedule, to make it clear to mappers that we are asking them to be available for training,
as follows: ‘I agree to attend the next scheduled DCM training course if my care home is randomly
allocated to DCM + UC. <Insert course date>‘. As the DCM training course is a publicly available course,
dates are scheduled in advance and cannot be changed, so we need to be sure that mappers are able to
attend on specified dates. This will reflect the implementation of the intervention in practice.
Staff proxy The proposed plan for staff proxy informant consent was vague in the protocol, with no
previous staff proxy informant consent form being submitted for REC approval. Therefore, in accordance
with the proposed protocol update that removes references to the screening questionnaire (implied
consent following return of data), a staff proxy informant consent form has been produced and is
submitted for approval. This document will be version 4.0 (dated 30 May 2014) to match existing
documentation following approval of this amendment.
Residents (including Nominated and Personal Consultees) As data on residents and on residents’
relatives/friends are not used as part of the primary analysis, the TMG have agreed that consent to obtain
information from residents and their relatives/friends can be optional. We therefore propose to update the
relevant information sheets to incorporate these optional statements.
Short form of participant information sheet
Following consultation with PPI groups and experts by experience, we have developed shortened versions
of the information sheets for staff (measures), staff proxies and relative/friend proxies. These short versions
summarise the key information from the existing information sheets in a simple to understand format. It is
intended that these information sheets will be used in addition to existing participant information to
ensure that informed consent is obtained.
The existing short form of the resident information sheet has also been amended to reflect the format of
the new short-form information sheets. These documents will be version 4.0 (dated 30 May 2014) to
reflect existing documentation following approval of this amendment.
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Substantial amendment 4: approved 10 September 2014
Protocol amendments
Submission of a new document for approval (Personal Consultee introductory letter)
The protocol (version 4.0) states in section 8.3.2, ‘Consent for those (residents) without capacity’, that, if
an identified potential Personal Consultee is not present within the care home during participant (resident)
recruitment, they may be sent information in the post regarding taking part (acting as a Personal Consultee)
by the care home. We therefore enclose a proposed introductory letter template to be sent by care homes
with the relevant (REC-approved) information sheets. As this letter is designed to be sent by the care home,
it will be used as a template and added to where appropriate by the care home to personalise it for the
person in question.
Submission of a new document for approval (Personal Consultee reminder letter)
The protocol (version 4.0) states in section 8.3.2, ‘Consent for those (residents) without capacity’, that a
reminder will be sent to a potential Personal Consultee within 1 week of being approached to complete the
relevant (REC-approved) declaration form. We therefore enclose a proposed reminder letter template for
researchers to send within 1 week of initial approach (if required). As this letter is designed to be sent after initial
discussions with the researcher, it will be used as a template and added to where appropriate by the researcher.
Submission of a new document for approval (relative/friend proxy informant
introductory letter)
The protocol (version 4.0) states in section 10.1, ‘Relative/friend and informants’, that, if an identified
potential relative/friend is not present in the care home during participant recruitment, information
regarding taking part can be sent to them in the post (by the care home). We therefore enclose a
proposed introductory letter template to be sent by the care home with the relevant (REC-approved)
information sheets. As this letter is designed to be sent by the care home, it will be used as a template
and added to where appropriate by the care home to personalise it for the relative/friend.
Substantial amendment 5: approved 15 January 2015
Participant information sheet and informed consent form amendments
Submission of a new document for approval (general practitioner letter)
The protocol (version 4.0) states in section 12.1, ‘Intervention details – usual care’, that all GPs that deliver
care in a consenting care home will be provided with current best-practice guidelines for managing BSC.
We therefore enclose a proposed GP letter template to be sent to GP practices with a copy of current
antipsychotic prescribing guidance (Alzheimer’s Society). Please note that, in accordance with the protocol,
this information will not give details of residents currently participating in the study.
Substantial amendment 6: approved 15 January 2015
Protocol amendments
Change of sponsor
Following acceptance of a professorship role at Leeds Beckett University, Claire Surr, DCM EPIC chief
investigator, will be transferring from the University of Bradford to Leeds Beckett University in February 2015.
Therefore, the study sponsor will be transferred to reflect this move.
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The following documents have therefore been updated:
l NHS research and development and REC form
¢ A3–1. Chief investigator
¢ A4. Sponsor contact
¢ A64. Details of research sponsor
¢ A76. Insurance and/or indemnity
l Protocol (version 5.0) section 20.4, ‘Clinical governance issues’
l Protocol (version 5.0) section 23, ‘Statement of indemnity’
l Protocol (version 5.0) section 24, ‘Trial organisational structure’.
Care home eligibility criteria
Based on experience from ‘pilot’ care home recruitment and consultation with the trial oversight committees
(TMG/TSC), we propose to amend the care home eligibility criteria to clarify the requirements for having a
sufficient population of permanent residents living with dementia to recruit (register), namely a minimum of
10 residents. This wording will reduce the exclusion of care homes that would otherwise be eligible but do
not achieve the criteria as currently worded.
The protocol has also been updated to clarify the minimum and maximum resident recruitment limits. As
previously stated, a minimum of 10 registered (eligible, consented and complete-data) residents is required
per care home. In line with the experiences of care home recruitment to date, the trial team have also
investigated whether a maximum recruitment limit is required. However, after a review of the impact of
cluster size variability on the power calculations for analysis with the trial oversight committees (TMG/TSC),
they have confirmed that no maximum limit for resident recruitment is required.
Therefore, the protocol (version 5.0, section 7.1, ‘Care home eligibility’) has been updated to reflect the
suggested changes summarised above.
Resident eligibility criteria
During care home screening, it became apparent that the potential for co-enrolment to other studies is
relevant not only to care homes, but also to residents. For example, a trial may be recruiting a large
number of homes within the DCM EPIC hub catchment areas (London, Oxford and West Yorkshire),
but may be recruiting only a small proportion of residents in the participating care home. Therefore,
it would not be appropriate to exclude the care home, owing to the associated impact on care home
recruitment, but it would be appropriate to exclude the resident, owing to the potential for confounding
factors and the associated participant burden and research fatigue.
Therefore, the protocol (version 5.0, section 8.1) has been updated to include the following: ‘involvement
in another trial that conflicts with DCM or with the data collection during the course of their involvement
in the EPIC study’.
Randomisation
Following randomisation of the first two ‘pilot’ homes, the team has reviewed the stratification factors
[external factors (other than the intervention) that could have an impact on the trial outcome] for care home
randomisation with the trial oversight committees (TMG/TSC). It was noted that the four current stratification
factors do not include stratification by hub (London, Oxford and West Yorkshire). However, it was noted that
‘previous use of DCM’ might vary by hub, as Oxford care homes have introduced DCM at a local level.
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Therefore, the team concluded, in consultation with the trial oversight committees, that the care home
randomisation stratification factors should be updated, with ‘previous use of DCM’ replaced by ‘recruiting hub’.
Protocol version 5.0, section 11.2, has been updated to reflect the suggested changes summarised above.
Substantial amendment 7: approved 22 October 2015
Protocol amendments
Witnessing consent
Recently, we have had a few instances in which we have had resident signatures that are almost illegible –
some can pass for a signature; others are more of a mark. We have discussed this with the chief investigator,
who is happy that any form of signature stands as informed consent, and notes that we must respect
residents’ dignity by not asking for a witness countersignature just because their handwriting is not clear.
In the current version of the protocol (section 8.3.1) we say:
Residents who are able to give informed consent will sign the trial consent form. Where a resident is
unable to sign his/her name, s/he will be asked to make a mark on a consent form that will be
witnessed by an independent observer (staff member, relative or friend).
However, on checking Health Research Authority guidance and the clinical trials toolkit, it seems that any
form of mark is acceptable and that we would expect to need a witness only when a participant cannot
write at all.
After verbal confirmation from the REC manager that following the Health Research Authority guidance on
this issue is acceptable, we have removed this statement from the protocol and clarified that witnessing by
an independent observer is required only when a resident is unable to make any kind of mark on the form.
Therefore, section 8.3.1 has been updated as follows:
Residents who are able to give informed consent will sign or make a mark on the trial consent form.
Where a resident is unable to sign, or make a mark, s/he will be asked to indicate his/her consent
verbally. This will be witnessed by an independent observer (staff member, relative or friend) and
recorded on the trial consent form.
Text messages to mappers
To assist the mappers in planning subsequent cycles, ahead of each of the three DCM mapping cycles,
we will send a short text message to each mapper. The standard wording for these text messages can be
found in the attached document (Mapper Text Reminders_V1.0_28/09/2015).
The following statement has been added to section 12.2.3 to reflect this process: ‘Ahead of each mapping
cycle the CTRU will contact each mapper via SMS to remind them of the upcoming cycle’.
Participant information sheet and informed consent form amendments
The table below summarises the substantial amendments made to the participant information sheets,
consent forms and covering letters. All amendments can be reviewed in the tracked change versions of the
relevant documents.
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Document Amendment details
Relative/friend proxy informant introductory
letter for Personal Consultees
We have drafted a new letter to be used in instances in which the Personal
Consultee is also invited to act as the relative/friend proxy informant for
the resident. The current relative/friend proxy informant covering letters
previously approved by the REC are aimed at relatives/friends who have no
prior knowledge of the EPIC study, and so are not appropriate in these
circumstances
Personal Consultee reminder letter –
postal template (approach by care home
manager)
The current Personal Consultee reminder letter previously approved by the REC
is aimed at Personal Consultees who have previously spoken with the researcher
at the care home regarding the EPIC study. In some instances, the potential
Personal Consultee is approached via post as opposed to face to face in the
care home (i.e. in cases in which their visits do not coincide with the researcher’s
time in the care home) and, therefore, the wording of the current letter is not
appropriate. This new letter is aimed at Personal Consultees who have had no
prior contact with the researcher and, therefore, the initial approach would be
by the care home manager/research lead
Personal Consultee reminder letter –
postal template (approach by researcher)
This letter will be used for circumstances similar to the one outlined above;
however, this letter will be for cases in which a potential Personal Consultee
has already given consent to be contacted by the researcher directly and
therefore the letter is from the researcher, rather than the care home
manager/research lead
Relative/friend proxy consent form Updated to include date of birth (for identification purposes).
Address and telephone number of relative/friend proxy added and a
sentence regarding why this is collected added to page 2
Personal Consultee declaration form Optional consent questions amended from initials to ‘Y’ or ‘N’ to aid
completion
There had been some confusion highlighted by the researchers over question
12; therefore, an additional question (Q12) has been added for clarification.
The additional question confirms if the Personal Consultee is happy to be
asked questions about their relative/friend (i.e. acting as a proxy)
Owing to the addition of Q12, Q13 has been reworded to confirm that, if
the Personal Consultee is not willing to be a relative/friend proxy, they are
happy for other relatives/friends to take on this role
Address and telephone number of Personal Consultee added and a sentence
regarding why this is collected added to page 2
Substantial amendment 8: approved 4 January 2016
Protocol amendments
Process evaluation
More detail has been added to the protocol on how the process evaluation associated with the trial will
work in practice. The design of the process evaluation remains the same (integrating data from the main
trial data set/documentation with qualitative data from interviews and focus groups), but we have simply
provided more detail on the participant information sheets and consent forms, data collection methods,
sampling and data analysis that will be used.
Summaries of the extra detail provided are as follows.
Data collection More detail has been provided on the data that will be extracted from the main trial
data set and trial documentation. Topic guides have been developed to indicate the kinds of questions
that will be asked of participants during the qualitative data collection. The topic guides are enclosed with
this amendment application.
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Sampling To explore the implementation of the intervention with sufficient depth, we plan to conduct
the qualitative data collection in a subset of homes. Homes will be primarily selected according to the
degree of intervention implementation so that the factors affecting implementation can be thoroughly
explored. More details on the sampling strategy are included in the amended protocol. A more basic
evaluation of implementation (utilising data from the main trial data set and trial documentation) will still
take place across all homes.
Data analysis More detail is provided on the approach to the qualitative data analysis (framework
analysis) and how the qualitative and quantitative analyses will be integrated.
Staff measures booklet
There has been a poor return rate for the staff measures booklet, despite multiple efforts to increase
compliance. Following consultation and discussion with the DMEC and the TSC, it has been agreed that
persistence in relation to staff data is important because DCM (the intervention) is designed to effect a
‘whole home’ change. To try and increase compliance, the TSC has suggested reducing the length and
the identifiable nature of the staff booklet. To this end, we are proposing to remove the GHQ-12 and the
request for personal data from the booklet. We would also like to improve the aesthetics of the booklet
to ensure that it is as easy as possible for staff to complete.
Relative/friend informants
There has been poor trial participation by relatives/friends despite efforts to encourage uptake. It has been
agreed by the oversight committees that the low percentage of data received will not be sufficient for
quantitative analyses. Therefore, new relative/friend informants will not be identified at any follow-up time
points, as this would utilise significant researcher resources but would be unlikely to result in much additional
uptake or data. However, we will continue to request follow-up data for relative/friends who provided data
at baseline because data from different time points could still be usefully analysed (e.g. to allow an analysis
to be undertaken of the agreement between staff, resident and relative/friend completed measures and to
augment the process evaluation). Relatives/friends who completed these baseline measures also indicated
that they valued the opportunity to share their experiences and so would be likely to continue to take part.
It seems unethical to exclude their data because of poor participation from other relatives.
Participant information sheet and informed consent form amendments
We have developed new participant information leaflets and consent forms for the three groups that will
be asked to participate in the process evaluation: staff, residents and relatives. The information leaflets and
consent forms have been developed with PPI input.
Substantial amendment 9: approved 15 April 2016
Protocol amendments
Design change
We propose a change to the design of the EPIC trial, such that additional residents will be recruited at the
16-month follow-up time point from each care home, in order to minimise bias (owing to higher than
anticipated loss to follow-up) and to maintain the power and validity of the trial. The trial conduct will be
affected in the following ways:
l additional resident screening, recruitment and registration will be needed
l new staff proxies will need to be identified
l additional data collection from staff proxies will be needed
l data management will be affected
l statistical analyses will be affected.
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Therefore, the relevant sections of the protocol have been updated and the following new supporting
documents have been produced to support the recruitment process:
l 16M Resident Information Sheet_SHORT_v1.0 18 March 2016
l 16M Resident Information Sheet_v1.0 18 March 2016
l 16M Resident Consent Form_v1.0 18 March 2016
l 16M Personal Consultee Introductory Letter_v1.0 18 March 2016
l 16M Personal Consultee Declaration Form_v1.0 18 March 2016.
Staff proxy informant consent
We propose an alternative method of documenting staff agreement to provide data about the resident
they know well. In a similar trial in care homes run by the CTRU, the REC has agreed that provision of
information to staff proxies followed by verbal consent to take on the role is sufficient. Staff agreement to
keep their name on record for follow-up purposes is documented by the researcher in the data-collection
booklets. It is felt that this process is fit for purpose, given that we are not collecting any other personal
data relating to the staff member.
We propose that this process be adopted for the involvement of all staff proxies recruited at 16 months in
the EPIC trial, and we will adjust the data-collection booklets accordingly.
Care home indemnity
We propose to remove the statement ‘Possession of the appropriate insurance will be checked at point
of recruitment of the care home to the study.’ This is in line with new guidance received following the
change of the study sponsor. The sponsor has advised that this statement be removed, as EPIC is a trial of
a low-risk intervention, with care home employees delivering the intervention. Therefore, it is appropriate
to assume that standard care home insurance will cover the activities of the employees and additional
checks are not required.
Staff measures data collection
Following a review of the data collection process, we have amended the trial protocol (section 9, ‘Staff
roles, eligibility, recruitment and consent’) to include collection of the ‘current pattern of work’. This
information will be used to determine the impact of shift patterns on staff training and exposure to the
trial intervention.
Process evaluation: relative/friend recruitment
We propose to introduce a new document, ‘RF Introductory Letter – PE’, to support postal invitations
sent to relatives/friends to ask them to participate in the process evaluation. This document would be sent
with a copy of the relevant information sheet and consent form to relatives/friends currently participating
in the main trial that are not available in the care home during researcher visits. EPIC researchers would
confirm with the care home manager (or delegate) that postal contact is appropriate, prior to contacting
the relative/friend.
In addition to the new introductory letter, we also propose to amend the relative/friend consent form so
that those completing and returning it by post can outline their availability for discussions. This information
would be useful, as it would help researchers to schedule their time and ensure availability for relative/
friend feedback.
Following comments from the trial funder, we also propose to amend the number of residents and staff
members approached to participate in the process evaluation. We had originally planned to include two
or three residents and eight members of staff; however, we now propose to recruit up to 5 residents
and up to 10 members of staff. This amendment will allow for flexibility in homes that have limited
numbers of residents; it could also result in the emergence of key themes from fewer interviews.
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General practitioner information for residents recruited at 16 months
We propose to update the protocol (section 12) to clarify that we will be sending generic best-practice
guidance to GPs only for residents recruited at baseline and not for those additional residents recruited at
16 months (associated with the design change summarised above). This is because of the timelines for
circulation of information to GPs and the potential confusion regarding active care home participation in
the project, which ceases after the 16-month data collection. The guidance information would therefore
also have a limited impact on trial outcomes at this stage (i.e. supporting person-centred care).
Personal Consultee capacity
Following a review of trial processes, we propose to update the protocol (section 8.1.2, ‘Consent for those
without capacity’) to clarify the process for confirming the ongoing capacity of Personal Consultees. As a
Personal Consultee is not required to visit a care home with any frequency, and has the ability to provide
postal ascent for trial participation, trial researchers may never have face-to-face contact with a Personal
Consultee. Therefore, it is not feasible to determine any changes in capacity over time in accordance with
the Mental Capacity Act.103 In these instances, it is essential to obtain input from care home staff, who may
have more frequent interactions with the Personal Consultee and may be best placed to identify changes in
capacity over time.
Substantial amendment 10: approved 25 July 2016
Protocol amendments
Process evaluation: participant demographics
We are proposing an additional data collection of participant demographics (age/gender) for those
consented to participate in the process evaluation to aide with summarising the population sampled at
analysis. As participants in the process evaluation are not required to have taken part in the main trial
(as the intervention affects the entire care home irrespective of individual trial participation), we are not
able to summarise demographics as a subset of the main trial population. Therefore, we have amended
the relevant sections of the EPIC protocol (section 14, ‘Process evaluation’).
We have also updated the topic guides to include prompts to confirm participant details (identification,
role) at the start of the interview to assist with identification of recordings, as is best practice for qualitative
interviews. Any personal identifiers (e.g. name) will be removed from all transcriptions.
Text messages to mappers
We propose to introduce an additional text message to be sent to staff members acting as DCM mappers
to highlight the mutually exclusive roles in the EPIC trial ahead of follow-up (at 6 and 16 months). In the EPIC
trial, researchers completing follow-up data collection (at 6 and 16 months post randomisation) are blinded
to care home allocation and are therefore not aware of any changes to staff members delivering the trial
intervention [researchers recruit staff to act as mappers at baseline in all homes (n = 50); however, owing to
high staff turnover, these often change during the course of the trial for those homes randomised to deliver
the intervention (n = 31)]. This has therefore led to instances of inappropriate members of staff (i.e. mappers –
those delivering the trial intervention) providing data (staff proxy informant) for participating residents.
We would therefore like to circulate the following text message ahead of follow-up (at 6 and 16 months)
to staff currently acting as a consented mapper:
EPIC researchers will be visiting your home shortly to collect some more data. Please remember not to
provide data on behalf of any residents during this visit. Do not tell the researcher you are acting as a
DCM mapper. Regards, the EPIC team!
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The following statement has been added to the protocol (section 9, ‘Staff roles, eligibility, recruitment and
consent’):
A text message will be sent to trained DCM mappers ahead of data collection (6 and 16 months post
randomisation) to remind mappers not to provide proxy data relating to residents.
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Appendix 3 Rationale for design change
Health Technology Assessment programme extension application
11/13/15: the EPIC trial (March 2016)
Justification
In our original sample size estimation, we anticipated a 25% loss to follow-up rate of residents at 16 months
(our primary outcome) following care home randomisation, to detect a clinically important difference of
3 points (SD 7.5) in agitation using the CMAI. If loss to follow-up was higher than anticipated (but no greater
than 35%), our sample size of 750 residents would still provide more than 85% power at a two-sided 5%
significance level to detect the moderate effect size, equating to 0.4 SDs.
By monitoring loss to follow-up within the trial, we are now confident that the rate will exceed our lower
limit of 25%. Using data from care homes randomised into the trial up to 27 November 2015, we predict
that loss to follow-up at 16 months will be within the range of 32.4% to 48.1%. As such, continuation of
the trial as currently planned is unlikely to provide sufficient power for statistical analysis of the primary end
point and so an amendment is required to ensure that the results of the trial are robust and generalisable.
Therefore, based on consideration of all the available options, we propose recruiting more residents at
follow-up (i.e. move to an ‘open-cohort’ design).
As of 27 November 2015, there were 42 care homes randomised, with 638 registered residents. Residents
are registered before care home randomisation. Overall, there were 11 residents lost before the care homes
were randomised, so, at the point of randomisation, 627 residents were included in the trial. None of the
care homes had reached the 16-month follow-up time point and there were two care homes currently at
13 months following randomisation.
Loss to follow-up rates were estimated using the number of residents who died or moved care home
between randomisation and 27 November 2015. The rate was then extrapolated to 16 months. Figure 10
summarises the actual and predicted loss to follow-up rates by number of months since randomisation.
The same information is displayed graphically in the Kaplan–Meier curve in Figure 11.
To provide a robust evaluation of the trial, we propose to move to an open-cohort design in which all
eligible residents who (1) have resided in the care home for 3 months or more, 16 months after care home
randomisation and (2) are not already taking part in the trial or have not already declined to take part
will be approached to provide consent for trial participation at the 16-month follow-up visit. All those
consenting to take part (residents already participating in the trial and consented at baseline, as well as
additional residents consenting at 16 months) will provide data at 16 months.
The key impact of this option will be an increase in the size of the cohort at follow-up, which will maintain
the power of the trial and its ability to detect the effect size of 0.4 with 90% power.
Sample size calculations
With a current estimated 48.2% loss to follow-up, we expect to lose 360 residents before the 16-month
follow-up, meaning that we will have data at all three time points from 388 residents. All of the other
parameters – significance level, two-sided test and ICC of 0.1 – are the same. We have done sample size
calculations for three different scenarios of additional recruitment and all provide sufficient power to
detect the effect size of 0.4.
If we recruit, on average, an additional three residents per care home at the 16-month follow-up (from the
remaining 48 care homes) the sample size will be 388+ (48 × 3) = 532 residents (i.e. 10.64 residents/care home).
The design effect will be 1+ (10.64 – 1) × 0.1 = 1.964. We will achieve 89% power to detect the effect size of 0.4.
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FIGURE 10 Predicted loss to follow-up. The x-axis represents the number of months that care homes have been randomised; the numbers lost to follow-up are grouped by
care home and month.
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By replacing residents with 35% recruited residents, the overall number of residents available for the
analysis would be 388 + 254 (additional recruits) = 642. The mean number of residents/care home (cluster
size) would be 12.8. The design effect is now 1 + (12.8 – 1) × 0.1 = 2.18. The power to detect the effect
size of 0.4 would be 91% (or with 90% power, we can detect a smaller effect size of 0.39).
By replacing residents with 25% recruited residents, the overall number of residents available for the
analysis would be 388 + 182 (additional recruits) = 570. The mean number of care home residents/care
home (cluster size) will be 11.4. The design effect is now 1 + (11.4 – 1) × 0.1 = 2.04. The power to detect
the effect size of 0.4 would be 90%.
All scenarios will achieve the desired effect size with sufficient power. The message to researchers should
still be to recruit as many residents as possible to minimise bias. We will need to monitor recruitment to
ensure that we have at least three extra residents from each remaining care home.
The benefits of this design change are:
l We will be able to detect intervention effects at the care home level (as the intervention is aimed at the
whole care home).
l Our conclusions can be generalised to a broader population of residents (i.e. not just to those still
residing in the care home 16 months after randomisation).
l We will be able to conduct analyses based on both a cross-sectional (i.e. open-cohort) and a closed-cohort
(longitudinal) design.
l We will minimise selection bias by providing an objective criterion for inclusion (all eligible
consenting residents).
l Our recruitment process will be resource-effective, as all eligible residents can be approached to
participate at a single time point.
l We will be less reliant on assumptions regarding missing data mechanisms.
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FIGURE 11 Kaplan–Meier survival curve stratified by the length of time the care home has been in the trial. Number
of residents at risk at care home randomisation and at 3, 6, 9 and 12 months. Note that 16 months is 487 days’
‘survival’.
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Consideration was given to recruiting only a proportion of eligible residents at each home at 16 months
(to increase resident numbers to 75% baseline recruits, in line with originally predicted loss to follow-up
rates). However, the team and oversight committees (the TSC and the DMEC) agreed that such an option
would be open to selection bias and that statistical power and the ability to generalise could be limited
by including a limit to the number of residents recruited at baseline. Recruitment processes could also
be protracted by virtue of allowing time for Personal Consultee response (i.e. should this be negative,
further resident–consultee dyads would then need to be approached, thus considerably lengthening the
recruitment process and adding to researcher workload and thus cost).
As well as maintaining power and increasing generalisability, this design change incurs minimal additional
cost compared, for example, with recruiting additional clusters.
This application for extension and the included options have been discussed in detail at the DMEC and
TSC meetings in November and December 2015, respectively, based on the figures presented here. Those
committee members supported the open-cohort design, with the DMEC recommending it, provided that
we address the risk of selection bias. It should be noted that, as of the beginning of January 2016, we have
met our target of randomising 50 care homes but the patterns of loss to follow-up remain unchanged.
We believe that approaching all eligible residents best addresses the potential threat of selection bias.
With the additional recruitment of eligible residents, we will be able to achieve a power of over 90%,
even if loss to follow-up in the original sample of residents was 50%. Moving to an open-cohort design
will require additional funding and time to complete the trial – we are requesting an additional 3-month
extension to the trial (to the end of December 2017) to allow for the additional analysis and write-up time
that will be needed if the design change is approved. We are not requesting additional funding for all
co-applicants and trial staff for this period.
Impact if approved
The design change involves recruiting additional residents only from care homes that are already
randomised and aware of the requirements of the trial. We envisage that additional trial processes will
result in minimal additional burden on care homes.
Researchers will be able to combine 16-month follow-up visits to existing care homes (to see existing
residents) with recruitment and data collection for newly eligible residents. This reduces researcher burden
(when compared with recruiting entirely new care homes), although it does involve additional time at each
care home.
By implementing an open-cohort design, we will be able to generalise trial results to a broader group of
dementia residents and complete the trial robustly with sufficient power.
Impact if not approved
If the request is not approved, high attrition rates may decrease the statistical power, introduce bias in trial
reporting and pose a threat to the validity and generalisability of the trial.
If we continue with the trial with its current design, based on current data, the anticipated proportion of
residents lost to follow-up (died or moved care home) would be at least 32%. However, only 17/42 (40.5%)
care homes have been randomised for more than 6 months. If only those randomised for more than
6 months were included in the estimation of overall loss to follow-up (as this would allow more precise
estimates), the predicted loss at 16 months would be 48%.
Loss of entire cluster(s) is also a realistic scenario if the request is not approved, with small clusters being
most likely to be lost. Loss of clusters in addition to loss of residents induces further bias, as loss of cluster(s)
as a unit of randomisation has a greater influence in cluster randomised trial analysis than loss of individual
residents.
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The design effect (due to clustering of resident outcomes within care homes) is lower, with higher loss to
follow-up because the available mean cluster size at follow-up is smaller. However, high losses to follow-up
with loss of entire clusters threaten the validity of the trial, introduce bias and affect generalisability.
TABLE 67 Effect size detected based on the number of residents at the end of recruitment (variable cluster size
with incorporated loss to follow-up)
Number of registered residents at randomisation 750
Loss to follow-up 32% 48%
Design effect 1.96 1.72
Power 90% 80% 90% 80%
Ability to detect the effect size 0.41 0.36 0.45 0.39
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